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ABSTRACT
Bryostatin 1 is a complex macrolactone natural product isolated from the marine 
bryozoan Bugula neritina. In recent years, bryostatin 1 has been studied in diseases like 
cancer, Alzheimer’s, stroke, and HIV. The anticancer activity of bryostatin 1 has led to 
many phase I and phase II clinical trials, and its ability to block the formation of plaques 
has led to phase II clinical trials for Alzheimer’s disease. Bryostatin 1 has been found to be 
a functional antagonist for protein kinase C mediated responses, and does not exhibit 
tumor-promoting properties that are associated with phorbol esters.
There is a necessity to produce additional amounts of the marine natural product 
bryostatin 1 because of it incredibly rich biological profile. One way to address supply 
issues is through chemical synthesis of bryostatin 1. The first total synthesis of bryostatin 
1 was accomplished in 30 longest linear steps and a total of 55 steps. This synthesis 
involved a highly convergent union of the A-ring and C-ring using the pyran annulation 
methodology developed by our group. The synthesis of bryostatin 1’s C-ring features a 
olefin/carbonyl metathesis reaction leading to a method to produce fully functionalized C- 
ring. Bryostatin 7 was also constructed using our synthetic route, and its biological profile 
was evaluated. Bryostatin 7 differs from bryostatin 1 at the C20 side chain and was found 
to not be a critical element of bryostatin 1 to obtain the biological responses typical of 
bryostatin 1.
Constructing simplified bryostatin analogs is another method to address the supply 
issues of bryostatin 1. Our group has prepared structurally simplified analogs of bryostatin
that rivaled or exceed the activity of bryostatin 1 itself. In 2008, we constructed a 
structurally simplified bryostatin analog Merle 23 that displayed ‘PMA-like’ activity in the 
U937 cell line. We later constructed Merle 28, an analog that resembles bryostatin 1 
closely, that displayed ‘bryo-like’ activity in the U937 cell line. With these results, we 
hypothesized that the northern half of bryostatin is not simply a spacer domain as suggested 
in the literature.
In order to understand the underlying mechanism of action of Merle 23 and Merle 
28, the design and synthesis of fluorescent analogs were accomplished using a fully 
functionalized C-ring in our pyran annulation reaction. Incorporation of a fluorescent tag 
at the C20 position did not have substantial effects on the biological profile (binding 
affinity for PKC, U937 cells, and Toledo cells). Merle 44 (fluorescent Merle 23) was found 
to be a functional analog of Merle 23 and Merle 45 (fluorescent Merle 28) was found to be 
a functional analog of Merle 28.
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CHAPTER 1
THE SYNTHESIS OF THE C-RING SUBUNIT OF BRYOSTATIN 1;
THE BIOLOGICAL EVALUATION OF BRYOSTATIN 7
Introduction
In the late 1950s the National Cancer Institute (NCI) instituted a comprehensive 
program designed to identify new anticancer leads from the extracts of animals, plants, and 
microorganisms. In the 1960s, Pettit and coworkers discovered that the extracts from the 
marine bryozoans Bugula neritina, found in the Gulf of Mexico, had anticancer properties 
towards murine P388 lymphocytic leukemia cells.1 After isolation, one of the active agents 
in the extracts was identified as bryostatin 1. The structure of bryostatin 1 was elucidated 
through a combination of analytical techniques that included 1H and 13C NMR, high 
resolution mass spectroscopy, and X-ray crystallography.2 Since the structural elucidation 
of bryostatin 1, 19 other bryostatins have been isolated (Figure 1.1).3
The bryostatins consist of a 20 membered macrocyclic lactone with 3 embedded 
highly functionalized pyran rings that are referred to as the A-ring, B-ring, and C-ring. The 
B-ring and C-ring both contain an a,^-unsaturated methyl ester at the 4 position of the 
pyran and are connected by a trans olefin adjacent to a gem-dimethyl group. The structure 
of bryostatin has a network of hydrogen bonds. There is a bifurcated hydrogen bond 
between the C3 hydroxyl proton and the A and B pyran oxygens, and a second structure of 
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Figure 1.1 The Bryostatin Family o f Natural Products
bond between the C3 hydroxyl proton and the A and B pyran oxygens, and a second 
hydrogen bond between the C3 oxygen and the C19 hydroxyl proton. Most of the 
differences between the bryostatins occur at the C20 and C7 positions where they have 
different combinations of ester groups and hydroxyl groups. Bryostatin 3, 16, 17, 18, and 
20 also contain additional structural differences on the C-ring portion of the molecule. 
While Bugula neritina was originally thought to produce the bryostatins, more recent 
literature suggest that a symbiotic bacteria actually produces the natural product.
Candidus endobugula sertula is the symbiotic bacterium that is believed to be 
responsible for producing the bryostatins.4 It is suggested that the bacteria produce these 
natural products to protect the bryozoan from predation and in return receive an 
environment in which to grow.5 Further studies have shown that eliminating the symbiotic 
bacteria E. sertula with the use of the antibiotic gentamicin resulted in a 98% reduction of 
bryostatins produced by the organism.6 The number of B. neritina colonies in nature 
producing detectable amounts of bryostatins was found to be very low. The amounts varied 
from different colonies, time of the year, depth, and geographic locations.7 Generally, 
isolation yields tend to range between 10-3 to 10-8 %.3 The largest isolation of a bryostatin 
was in 1991 where 18 g of bryostatin 1 was isolated from 10,000 gallons of wet B. neritina.8 
This large scale isolation was done in anticipation of many biological studies which 
included formulation studies, preclinical toxicology, and clinical trials in cancer patients. 
Since then, other viable means to obtain additional amounts of bryostatins have been 
investigated. This is due to potential environmental impact on B. neritina and other 
organisms that depend on its existence.
Aquaculture of B. neritina has been investigated as a way of producing more
3
bryostatin 1.9 Unfortunately the company investigating this, CalBioMarine Technologies, 
dissolved in May of 2004. More promising results have been found by the Haygood group 
and they have identified the bryA gene cluster.10 The Haygood group is exploring the 
possibility of expressing these genes in a suitable host, resulting in the production of 
bryostatin 0. Bryostatin 0 is a hypothetical compound that differs from bryostatin 1 at the 
C7, the C14, and the C20 positions. From this intermediate, it might be possible to obtain 
bryostatin natural products through synthetic manipulations.
The Biological Activity of Bryostatin 1 
The life extension assays in the murine leukemia cell line in mice demonstrated that 
the bryostatins were a collection of potent oncolytic agents (Table 1.1).11 During the initial 
biological evaluation of the bryostatins, it was realized that their response to P388, L1210, 
and KB cells mimicked the response shown by the extracts from euphorbiaceae and 
thymelaeaceae. These plants contain phorbol esters and since they are known PKC 
activators, it was hypothesized that the bryostatin natural products might be too. This was 
shown to be true in a study by Pettit and Blumberg in which binding affinity was measured 
by competitive binding assays using a mixture of PKC isozymes (Table 1.1).12 The binding 
affinity of bryostatins 1-11, which differ only at the C7 and C20 positions, revealed only a 
moderate change in affinity. Bryostatin 16 and 17 had 100 fold less binding affinity due to 
their simplified C-ring. Despite the immense interest in bryostatin 1, there is very little 
known about the biological profiles of the other bryostatins. This is most likely due to the 
scarcity of material for biological testing.
4
5Table 1.1. In vitro ED50 and Murine in vivo Life Extensions in P388 Leukemia Cells
K; for PKC (nM)
bryostatin ED50 (ng/mL) Life Extension(dose: mg/kg) (mixture o f  isozymes)
1 0.23 52-96% (10-70) 1.35
2 60% (30) 5.86
3 63% (30) 2.75
4 0.1-1.0 62% (46) 1.30
5 0.26-1.3 88% (185) 1.04
6 0.01 82% (185) 1.18
7 0.026 77% (92) 0.84
8 74% (110) 1.72
9 1.2 40% (80) 1.31
10 0.26 34% (10) 1.56
11 0.018 64% (92.5) 4.82







Bryostatin 1 and Cancer
Much of the literature suggests that PKC plays a key role in cancer. Bryostatin 1 
exerts its tumor suppressive ability by inhibiting cell growth, not by cytotoxic effects.13 
Bryostatin 1 was originally isolated for its ability to inhibit the growth of murine P388 
lymphocytic leukemia, but has since been found to be effective in other types of leukemia 
cells (Table 1.2).13-14 Additionally, bryostatin 1 demonstrates activity in human A549 lung 
carcinoma, murine 4T1 p53 null mammary, murine L10A B lymphoma, murine M5076 
reticulum carcinoma, and murine B16 melanoma cell lines.15 In vivo assays demonstrated 
that mice with P388 lymphocytic leukemia doubled their life expectancy when treated with 
bryostatin 1. It also cured mice with M5 ovary carcinoma and B16 melanoma.16
6Table 1.2. Bryostatin 1 in Human Leukemia Cell Lines 








In 1993, bryostatin 1 entered its first clinical trial as a single agent for cancer. It 
was used in a variety of phase I and II clinical trials in patients with carcinomas such as 
solid tumors (melanoma, renal, and ovarian) and leukemia.17 In these studies there were no 
consistent results observed in the patient populations and severe myalgia was dose limiting. 
Unfortunately, bryostatin 1 did not show promise as a single therapeutic reagent for cancer 
for these reasons, but has recently shown potential when combined with established 
anticancer agents.
In contrast to many oncolytic agents, bryostatin 1 stimulates the immune system. 
This is particularly impressive since anticancer agents target rapidly dividing cells, and 
thus often impact the immune system. Bryostatin 1 stimulated the production of 
inflammatory cytokines IL-ip, IL-6, Il-8 and tumor necrosis factor a (TNF- a).18 It also 
has been shown to activate T-cells and neutrophils.19 This remarkable activity has 
promoted research in immunotherapy, which uses the immune system to target and 
eliminate cancer cells. Drugs which have been used in combination with bryostatin 1 
include vincristine, paclitaxel, cisplatin, fluarabine, temsirolimus, and gemcitabine.17 Even 
through the responses in carcinomas were initially reported to be promising there is only a
7handful of current clinical trials using bryostatin 1 synergistically with other drugs. 
Whether or not additional trials will be conducted is largely unknown.
Bryostatin 1 and Neurodegenerative Diseases
In recent years, bryostatin 1 has shown promise in the treatment of CNS disorders 
such as stroke and Alzheimer’s disease (AD). It has shown remarkable results in animal 
models by inducing new synaptic growth, rescuing dying neurons, and normalizing of 
amyloid plaques. For example, treatment with bryostatin 1 resulted in curative 
neurogenesis, synaptogenesis, and cognitive improvement in mice with ischemia/hypoxia 
induced stroke.20 Bryostatin 1 has also been shown to reduce the formation of amyloid 
plaques in transgenic mice by activating the secretion of a-secretase via PKCs.21 In 2009, 
the FDA approved the use of bryostatin 1 in phase II clinical trials in the treatment of AD 
based on preclinical results. The Banchette Rockefeller Neurosciences Institute is the main 
institution studying bryostatin 1 as a therapy of AD under the guidance of Dr. Daniel Alkon 
and the results from these clinical trials have not been released as of today.
Bryostatin 1 and Human Immunodeficiency Virus (HIV)
One of the major problems in treating HIV with the standard treatments is that it 
does not address the latent form of the virus. These HIV latent reservoirs are located in T- 
cells and monocyte/macrophages, and remain latent until its transcription factors are 
unregulated.22 Noncarcinogenic PKC activators, like bryostatin 1, have been shown to 
reactivate latent HIV-1 by the PKC or ampK pathways, making them interesting 
therapeutic agents in the treatment of HIV.23 Bryostatin 1 seems to be ready for clinical
trials for the treatment of HIV but have been hampered by a limited supply. There has been 
a tremendous effort to produce additional synthetic bryostatin 1 or biologically equivalent 
simplified analogs. Bryostatin 1’s biological responses are linked to the observed binding 
affinity to the C1 domain of PKC (K; for PKC, 1.35 nM). Understanding the complex 
relationship between PKC and bryostatin 1 is vital to understanding how to mimic its 
biological profile.
Structure and Function of Protein Kinase C (PKC)
The dysfunction of the cellular pathways associated with protein kinase C has been 
linked to illnesses like cancer24 and neurological diseases25, making it an exciting 
therapeutic target. PKCs are enzymes that catalyze the phosphorylation of the amino acids 
serine and threonine. They are involved in many critical events such as intracellular signal 
transduction cascades, apoptosis, cell differentiation, and proliferation.26
PKCs consist of 2 major domains, the C-terminal catalytic domain and the N- 
terminal regulatory domain (Figure 1.2).27 The catalytic domain contains the ATP binding 
site, and is largely conserved amongst protein kinases. Small molecules inhibiting the 
catalytic domain, like ruboxistaurin28 and enzastaurin29 have been identified as PKCP 
isozyme selective inhibitors but did not make it past phase III clinical trials.30 The 
regulatory domain contains the pseudosubstrate, C2, and C1 segments. PKC can be 
modulated at the regulatory domain by endogenous 1,2-diacylglycerols (DAGs) and other 
small molecules like bryostatin 1 and phorbol esters that bind to the C1 domain.
The PKC family is divided into 3 categories according to the structure of the 
regulatory domain and cofactor requirements (Figure 1.2).27, 31 There are at least ten unique
8
9Figure 1.2. Schematic Representation of PKC Family
mammalian isozymes which are grouped into classical (cPKC), novel (nPKC), and atypical 
(aPKC) PKCs. The distribution of these subtypes varies among different tissues and cell 
types. All the isozymes are dependent on anionic phospholipids (Ptd-L-Ser) for activation. 
The cPKC isozymes (a, pi, piI, y) require both calcium and an endogenous a DAG ligand; 
nPKC isozymes (s, 5, n) only require DAG, whereas aPKC isozymes (Z, t ) do not require 
calcium or DAG.
PKCs are allosterically regulated by their pseudosubstrate.32 In PKCs inactive form, 
the pseudosubstrate is bound to the catalytic domain and the C1b region blocks the ATP 
binding site, rendering the enzyme inactive.33 In order to be activated cPKC and nPKC, 
they must bind to endogenous DAGs. The primary mechanism of DAG is to interact with 
the C1 domain of PKC.34 The inactive form of PKC binds to DAG in the cytosol, resulting 
in a conformational change in the enzyme, removing the pseudosubstrate from the ATP- 
binding site. The activated PKC then translocates to the cell membrane where it finds ATP 
and various cofactors.33 Once fully initiated, PKC then phosphorylates specific protein
10
substrates, giving its biological activity. PKCs active form is vulnerable to cleavage at the 
hinge region by calpain and caspase.35 The result can either be down regulation of PKC 
through its breakdown or induction of other activities caused by the liberated catalytic and 
regulatory domains.34
Tumor-Promoting Natural Products that Target the C1 Domain
Phorbol-12-myristate-13-acetate (PMA) represents the most studied member of the 
phorbol ester family (Figure 1.3). It was originally isolated from the shrub Croton tiglium.36 
PMA was found to be a potent tumor-promoter of mouse skin carcinogenesis and was later 
found to target the C1 domain of PKC (K;= 0.55 nM).37 A crystal structure of the C1b 
domain of PKCpiI with PMA has been reported.38 Its function as a tumor-promoter is 
currently being evaluated as a differentiation agent where it forces cancer cells into 
maturation in use with other therapeutic agents.39
The aplysiatoxins are a family of spiroketals that were isolated from the sea hare 
Stylocheilus longicauda (Figure 1.3).40 Aplysiatoxin has a measured K; value of 3.0 nM 
for PKCS, but it is a tumor-promoter.41 Indolactams are another PKC C1 domain ligand 
that was isolated from Streptomyces mediocicus.42 Similarly to phorbol esters, indolactams 
are thought to interact with PKC through hydrogen bonds using the C11 amide and C14 
alcohol.43 Indolactam V is the simplest of the family and shows a K  value of 80 nM. Like 
Aplysiatoxin, it too is a tumor-promoter.44
11
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Figure 1.3. The Structures o f  Tumor-Promoting PKC Ligands
Nontumor-Promoting Natural Products that Target the C1 Domain
Several natural products are currently in or are approaching clinical trials (Figure 
1.4). 12-deoxy-phorbol 13-aceate (prostatin) was first isolated from the plant Homalanthus 
nutans 45 This compound was found to have an identical skeletal backbone to the phorbol 
esters but lacked the C12 hydroxyl/acyl group. Like phorbol esters, prostatin binds to PKC 
and show a Ki value of 12.5 nM for PKC. They show a modest decrease in affinity when 
compared to PMA. The deletion of the C20 group also changes the biological activity. This 
small difference in structure makes this ligand nontumor-promoting and has been 
suggested to be an effective therapy to address latent HIV.46
The ingenols are another class of natural products that are closely related to phorbol 
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Figure 1.4. The Structures o f  Nontumor Promoting PKC Ligands
Euphorbia peplus L.47 PEP005 has a very high binding affinity to PKC, 0.1-0.4 nM 
depending on the isozyme.48 PEP005 is another example of a nontumor-promoting PKC 
activator that was FDA approved for the treatment of actinic keratosis in 2012. Bryostatin
1 is another natural product that binds to the C1 domain with high affinity and does not 
demonstrate tumor-promoting activity. A need for additional amounts of the bryostatins 
for biological testing has led to extensive research in the area of total synthesis.
13
Previous Total Syntheses of the Bryostatins 
The bryostatins have been immensely important targets for the last 30 years in the 
area of natural product synthesis. Their rarity coupled with remarkable biological activity 
has led to intense research to construct these molecules, with each researcher tackling 
unique challenges in constructing their skeletons. The first synthesis of a bryostatin was 
the synthesis of bryostatin 7 by the Masamune group in 1990.49 Since then, Evans50, 
Yamamura51, Trost 52, Keck53, Wender54, and Krische55 have produced their own synthesis 
of different bryostatins. The general strategy to construct these complex natural products 
and how the southern portions of these molecules were constructed is evaluated in the 
following segments.
Masamune’s Total Synthesis of Bryostatin 749
In 1990, the Masamune group reported the first synthesis of bryostatin 7 which was 
the first synthesis of any bryostatin. The synthetic strategy involved the union of 2 very 
complex pieces: the A-B portion and functionalized C-ring (Figure 1.5). The key 
disconnection in this synthesis was the C16-C17 double bond, which was envisioned to be 
constructed through a Julia olefination reaction and a macrolactonization of the seco acid. 
The C-ring pyran 1.2 was envisioned to be constructed through a cyclization of the 
corresponding keto alcohol 1.1. The intermediate 1.3 would be divided into 2 portions and 
put together through an organometallic addition of iodide 1.5 into the C20 aldehyde 1.4.
Masamune’s synthesis of bryostatin 7 has been heavily reviewed, so an abbreviated 
scheme for the construction of sulfone 1.2 is shown in Figure 1.6. Aldehyde 1.4 started 
from commercially available 2,2-dimethylpropane-1,3-diol and was made in 15 steps.
14
PhS— v pDMPM
Figure 1.5. Masamune's Retrosynthesis of Bryosatin 7
Vinyl iodide 1.5 was constructed from L-threonine in 14 steps. Lithium halogen exchange 
of the vinyl iodide, followed by a chelation controlled addition into aldehyde 1.4 produced 
alcohol 1.7 as a 6:1 dr. The C20 alcohol 1.7 was protected as the TES ether, the DMPM 
ether was removed, and C19 alcohol was oxidized using Albright-Goldman conditions to 
give ketone 1.8. The phenyl sulfide was oxidized to the sulfone and the PMB ether was 
removed using DDQ producing a hemiketal intermediate. Methyl ketal formation was 
accomplished using TESOTf/TMSOMe and completed the synthesis of sulfone 1.2. The 
C17-C27 segment was constructed in 36 total steps (22 longest linear).
15
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Figure 1.6. Synthesis of C-ring Sulfone
Evans’ Total Synthesis of Bryostatin 250
The Evans group completed the first total synthesis of bryostatin 2 in 1999. The 
retrosynthetic plan involved dividing the molecule into 3 almost equally complex pieces. 
Like Masamune’s synthesis, the B-ring and C-ring would be joined through a Julia 
olefination reaction installing the C16-C17 trans double bond (Figure 1.7). The A-ring and 
B-ring would be connected through a displacement reaction of the triflate, shown in Figure 
1.8. The A-ring and C-ring would be connected at the O25 and C1 lactone bond, leading 
to the macrolactone. Dividing bryostatin 2 into 3 parts gives flexibility when coupling the 
rings together, but in the end B+C^BC+A^ABC was found to be the best sequence for 
coupling these pieces.
16
Figure 1.7. Evans' Retrosynthesis of Bryostatin 2
The construction of the C-ring of bryostatin 2 is shown in Figure 1.8. Commercially 
available 2,2-dimethyl-1,3-propanediol was monotosylated, displaced by phenyl sulfide, 
and then oxidized to give the sulfone intermediate. The alcohol was oxidized to the 
aldehyde 1.12, which was reacted with the Grignard reagent derived from 5-bromo-1- 
pentene. Oxidation of the resulting alcohol, followed by oxidative cleavage of the terminal 
alkene provided keto aldehyde 1.13. An aldol reaction between aldehyde 1.13 and ketone 
1.14 was successfully accomplished through a (-)-DIPCl (Ipc2BCl or 
Chlorodiisopinocamphenylborane) mediated double stereo differentiation, resulting in the 
P-hydroxy ketone 1.15 with a 13:3 dr. The C25 ketone was reduced using Evans- 
Tishchenko conditions, giving the diol monoester 1.16 as a single diastereoisomer. The 
C20 alcohol in 1.16 was protected as the TBS ether followed by hydrolysis of the C23 
nitrobenzoate ester with LiOH. Hydroxyketone 1.17 was cyclized under acidic conditions 
resulting in the formation of glycal 1.11. Unfortunately, installing the C19, C20 and C21 
functionality proved to be incompatible with the Julia olefination reaction. The C17-C27 
segment was constructed in 13 longest linear steps (LLS) and a total of 16 steps.
17
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Figure 1.8. Synthesis of the C-ring Glycal 1.11
Yamamura’s Total Synthesis of Bryostatin 351
Bryostatin 3 is the most complex member of its family due to an additional 
stereocenter at the C22 inside the pryan-butenolide structure (Figure 1.9). Its total synthesis 
was accomplished by the Yamamura group in 2000. Similarly to the 2 previous syntheses, 
a Julia reaction was planned to connect the B-ring and C-ring. This reaction would result 
in the formation of the C16-C17 trans olefin and an esterification reaction would complete 
the 20-membered macrolactone. The C-ring was envisioned to be constructed through an 
acid catalyzed cyclization of the corresponding keto alcohol 1.21. This intermediate would 
come from 2 separate portions that would be coupled through an addition of iodide 1.23 





Figure 1.9. Yamamura's Retrosynthesis o f Bryostatin 3
A summarized scheme of Yamamura’s construction of the C17- C27 subunit is 
shown in Figure 1.10. The C-ring is divided into 2 major portions. The left half of the 
molecule 1.23 was made in 16 steps from 2-dimethylpropane-1,3-diol and the right half 
1.22 was made from glucose in 11 steps. The union between the 2 pieces was accomplished 
using lithium halogen exchange on 1.23 and reaction with aldehyde 1.22, affording a 3:1 
mixture of diastereomers. The C20 and C22 alcohols were protected as TBS ethers, the 
sulfide was oxidized to the sulfone, and the PMB ether was removed to give alcohol 1.24. 
Oxidation of the C19 alcohol to the ketone, removal of the C23 BOM ether, and a 
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Figure 1.10. Synthesis of C-Ring Sulfone
A removal of all the silyl protecting groups and a reprotection as TES ethers was 
perfomered leading to the C17-C27 fragment 1.20. Yamaura’s group was able to construct 
the C-ring in 25 LLS and a total of 35 steps.
Wender’s Total Synthesis of Bryostatin 954
More recently in 2011, the Wender group completed the first total synthesis of 
bryostatin 9, which differs from bryostatin 7 only at the C20 ester position. A different 
approach was taken in this synthesis which applied a pyran annulation reaction56, not the 
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Figure 1.11. Wender's Retrosynthesis of Bryostatin 9
retrosynthetic approach had previously been shown to be a very convergent way to 
construct the bryostatin core and was first demonstrated on various bryostatin analogs.57 
The C26 and C25 stereocenters of C-ring 1.26 were to be set through a Sharpless 
asymmetric dihydroxylation from the corresponding olefin. The enal 1.27 was envisioned 
to be constructed through a Horner-Wadsworth-Emmons reaction and the C27 methyl 
group would be incorporated through a Takai olefination. The glycal 1.28 would be formed
through an acid mediated dehydrative cyclization reaction. Finally, the keto-alcohol 1.29 
would be synthesized by a Grignard addition and catalytic asymmetric allylation.
The synthesis of C-ring 1.26 started with the monoprotection of 2- 
dimethylpropane-1,3-diol, followed by oxidation of the remaining alcohol to give aldehyde 
1.30 (Figure 1.12). The C19 aldehyde was then reacted with the Grignard reagent derived 
from 4-chloro-1-butanol. The C19 alcohol was oxidized and the subsequent aldehyde was 
subjected to Keck’s asymmetric allylation conditions, giving homoallylic alcohol 1.29 with 
92% ee. Dehydrative cyclization of keto-alcohol 1.29 with catalytic TsOH gave the glycal 
intermediate, followed by epoxidation and methanolysis with MMPP in MeOH. The 
resulting a-hydroxyl ketal was oxidized using TPAP/NMO to give C20 ketone 1.28. The 
C26 methyl was then incorporated by oxidative cleavage with ozone, followed by Takai 
olefination to give olefin 1.31 as a 93:7 (Z:E) geometric mixture. Aldol condensation 
installed the C34 enoate using methyl glyoxylate and K2CO3 in MeOH. The C20 ketone 
was reduced using Luche conditions followed by esterification with butyric anhydride to 
give 1.32 as a single diastereoisomer at the C20 position. Desilylation, oxidation, and 
homologation with a vinyl zincate gave enal 1.27. At this stage, the C26 and C25 alcohols 
were installed using Sharpless asymmetric dihydroxylation giving the diol 1.33 with a 4:1 
dr. The methyl ketal was hydrolyzed using TsOH and the C26 alcohol was selectively 
silylated giving TBS ether 1.26. The Wender group was able to construct the C-ring in a 
total of 19 linear steps, providing the shortest overall route to a functionalized C-ring. The 
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Figure 1.12. Synthesis o f  Functionalized C-ring
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Krische’s Total Synthesis of Bryostatin 755
In 2011, the Krische group synthesized bryostatin 7. This was the most concise 
synthesis of a member of the bryostatin family to date due to the application of their C-C 
bond hydrogenation methodology to the construction of the A-ring portion 1.34 (10 
steps).55, 58 A convergent union between the A-ring 1.34 and C-ring 1.35 using the Keck 
pyran annulation reaction was envisioned followed by a Yamaguchi macrolactonization 
reaction to complete the 20-membered macrolactone (Figure 1.13). The P-hydroxyallyl 
silane 1.36 was proposed to be incorporated through a Keck asymmetric allylation reaction. 
Intermediate 1.37 would be constructed through a convergent hydrogen mediated reductive 
coupling between glyoxal 1.38 and enyne 1.39.
OH
TMS
Figure 1.13. Krische's Retrosynthesis o f Bryostatin 7
The synthesis of glyoxal 1.38 began with the hydroxymethylation of 3-methyl- 
butanone followed by a Swern oxidation of the resulting C17 alcohol to give ketoaldehyde 
1.41 (Figure 1.14). A Horner-Wadsworth-Emmons reaction using 
triethylphosphosphonoacetate then gave the C16-C17 a,P-unsaturated ester. The C19 
ketone was transformed into the silyl enol ether and a same pot reduction of the ethyl ester 
with LAH provided allylic alcohol 1.45. The C15 alcohol was then protected, as the TBS 
ether, and again in the same pot the enol ether was converted to the a-bromoketone with 
NBS. A Kornblum oxidation of the C20 completed the synthesis of glyoxal 1.38.
Enyne 1.39 was derived from the dihydroxylation of crotononitrile giving the C25- 
C26 diol 1.44 in 86% enantiomeric excess. The diol was then protected as the acetonide 
and the nitrile was reduced to the aldehyde using DIBAL-H. A 1,3 chelation controlled 
reaction with propargyl zinc gave the C23 alcohol 1.45 as a 5:1 mixture of isomers. The 
C23 homopropargylic alcohol was protected as the BPS ether, followed by a Sonogashira 
reaction between the alkyne in 1.45 and vinyl bromide, giving enyne 1.39.
The 1,3-enyne and glyoxal were coupled under hydrogen mediated reductive 
coupling to give C20 a-hydroxyketone 1.46 as a 7:1 mixture of diastereomers. These 
conditions proved to be very mild and did not over reduce the olefins in the desired 
product. The C20 acetate was then installed using acetic anhydride, the C15 silyl ether was 
removed, and the resulting alcohol was oxidized to give enal 1.37. This aldehyde was 
reacted with trimethyl(2-((tributylstannyl)methyl)allyl)silane under modified Keck 
asymmetric allylation conditions to give C15 P-hydroxyallyl silane 1.36 as a single 
diastereomer by NMR.59 The Krische group was able to construct the C-ring in 11 steps 
(LLS) and a total of 17 steps, showing a large improvement in making bryostatins C-ring.
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Figure 1.14. Synthesis o f  P-hydroxyallyl Silane 1.36
Results and Discussion 
The Pyran Annulation Methodology
In 2002, an exceptionally facile enantioselective synthesis of 2,6-cis-disubstituted- 
4-methylenetetrahydropyran systems was reported in the effort toward the synthesis of 
bryostatin 1. In this paper, constructing P-hydroxyallyl silane 1.49 by a catalytic 
asymmetric allylation reaction of aldehyde 1.47 and trimethylsilyl methylallylstannane 
1.48 is described (Figure 1.15).56 Dr. Covel found that treatment of a silane such as 1.49 
and aldehyde 1.50 with TMSOTf results in the formation of the 2,6-cis-disubstituted 4- 
methylene pyran 1.52 as a single cis isomer. The stereochemical outcome is in accord with 
a chair like transition state 1.51 where the alkyl groups are equatorially disposed.
Since this methodology’s development, it has been used to construct many 
bryostatin analogs (Figure 1.15). In Merle 23, the pyran annulation was used to construct 
both the A-ring and B-ring, establishing the exomethylene pyrans present in this analog.5713, 
60 These exocyclic olefins were oxidatively cleaved to ketones, reduced, and then esterified 
to give analog Merle 34.61 Analogs resembling bryostatin 1, like Merle 30, were made 
using the pyran annulation and a late stage Horner-Wadsworth-Emmons reaction to give 
the a, P- unsaturated ester at the C13 position.62 The pyran annulation methodology has 
also been successfully utilized by other groups such as the Wender group during the 
synthesis of bryostatin 9 54 and bryostatin analogs,63 and the Krische group during the 
synthesis of bryostatin 7.55
It was this versatile methodology which we thought would be the most convergent 
and useful way to construct bryostatin 1. Our first generation retrosynthesis of bryostatin
1 is shown in Figure 1.16. The C-ring and B-ring would be functionalized from bryopyran
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Figure 1.16. Retrosynthetic Analysis of Bryostatin 1
core 1.53 to give bryostatin 1. The B-ring of the tricycle was envisioned to be constructed 
from a pyran annulation between the A-ring aldehyde 1.55 and C-ring silane 1.54 using 
pyran annulation methodology. The 20 membered macrolactone would be completed using 
a Yamguchi macrolactonization.
The Problems with Late Stage C-ring Functionalization
Late stage functionalization of the C-ring was shown to very difficult during the 
synthesis of bryostatin analogs by Dr. Poudel (Figure 1.17, part A). The aldol condensation 
between 1.56 and methyl glyoxylate at the C20 ketone could not be conducted selectively 
in the presence of the C7 acetate. This reaction provided a disappointing ratio of almost 
1:1 desired to undesired aldol products 1.57 and 1.58 (Figure 1.17, part B). Additionally, 
the Luche reduction of the C20 ketone in macrolactone 1.61 gave a somewhat less selective 
reaction (dr= 4:1) then had previously been observed. The Luche reduction on just the C- 
ring compound 1.59 was reported as a single diastereoisomer by our group.64
The Established C-ring Route and Associated Problems
The route shown in Figure 1.18 was developed by Dr. Anh Truong and was the 
standard method of producing the C-ring portion for our analog program.65 The C27-C15 
portion utilizes (R)-(+)-isobutyl lactate to set the stereochemistry of the C23 and C25 by 
chelation- controlled allylations to access 1.67 (Figure 1.18). The synthesis commenced 
with the BOM protection of alcohol 1.65 and a DIBAL-H half reduction of the C25 ester 
to give the aldehyde 1.64. A 1,2-chelation controlled allylation reaction with allyltributyltin 
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Figure 1.18. Synthesis o f  Glycal 1.73 MeO OMe
homoallylic C25 alcohol was PMB protected, followed by oxidative cleavage using 
ozonolysis to furnish aldehyde 1.66. A second allylation reaction using MgBr2»Et2O gave 
1.67 as a 7:1 mixture of diastereomers. The synthesis of homoallylic alcohol 1.67 
accomplished setting 2 stereocenters based on substrate control in 6 steps and was 
applicable to multigram-scale synthesis.
The homoallylic alcohol was further elaborated by a very practical synthesis shown 
in Figure 1.18.65 The C23 homoallylic alcohol 1.67 was protected as the TBS ether. A one 
carbon homologation using Rh(acac)(CO)2  and phosphite ligand 1.68 under a CO/H2 
atmosphere provided aldehyde 1.69 in 95% yield. Treatment of C19 aldehyde 1.72 with a 
prenyl indium reagent delivered the alcohol in 95% yield. The hindered alcohol was then 
oxidized with a combination of PCC and NaOAc to give ketone 1.70. Ozonolysis of the 
terminal olefin delivered the aldehyde, which was then subjected to a Horner-Wadsworth- 
Emmons conditions reaction to give the desired a,P-unsaturated thiol ester 1.71. 
Deprotection of the TBS ether using HF*py was followed by cyclization to give the desired 
glycal 1.72 in 89% yield. Finally, a half reduction using DIBAL-H would give us the 
desired enal 1.73. The C-ring was constructed in a total of 15 steps and was comparable in 
length to the Evans’ C-ring synthesis (16 steps). This route would allow for the convergent 
connection between the C- ring and A-ring while forming the B-ring through a pyran 
annulation reaction, but it does not incorporate the C-ring functionality at the C19, C20, 
and C21 positions.
Attempts at a fully functionalized C-ring aldehyde are summarized in Figure 1.19. 
Setting the C19 stereocenter and oxidizing the C20 alcohol were accomplished by 


















Figure 1.19. Problems Functionalizing the C-ring
anomeric a-hydroxyl ketal 1.75. Unfortunately a major side product 1.74 was formed by a 
Michael addition of the resulting C19 alcohol to the a, ^-unsaturated thioester.66 A full 
reduction of this thioester and protection of resulting alcohol was attempted to circumvent 
this side reaction, but a 4:1 ratio of products 1.76 and 1.77 was observed.62a Attempts to 
elongate hindered aldehyde 1.78 with various nucleophiles like a vinyl zincate65 or cross 
metathesis of olefin 1.81 were unsuccessful, potentially due to the steric hindrance caused 
by the gem-dimethyl group.62a
The Retrosynthetic Analysis of Bryostatin 1
The use of fully functionalized C-ring 1.83 would allow us to avoid the late stage 
problematic steps and would make the synthesis much more convergent. Additionally, this 
would eliminate the linear nature of the original retrosynthetic analysis. Our synthetic plan 
would combine the A-ring 1.82 and C-ring 1.83, which are almost equal in complexity, 
through a pyran annulation and a Yamaguchi macrolactonization (Figure 1.20).
A Convergent Route to the C-ring53
Although glycal 1.73 could be prepared on a gram scale, frequent requirement of 
this material in multigram quantities for all bryostatin projects demanded a more concise 
synthesis. The drawbacks of the route to glycal 1.73 were its linear nature and the 
earlyinstallment of the a, P- unsaturated thioester. Thus, a simple improvement to this route 
would be to make it more convergent and to unmask the C15-C17 a, P- unsaturated 
aldehyde only prior to pyran annulation. This cyclic enol ether 1.86 was envisioned to be 









Figure 1.20. Retrosynthetic Analysis o f Bryostatin 1
been used successfully during the synthesis of various natural products such as brevenal67 
and gambierol.68
The retrosynthetic analysis of the C-ring is shown in Figure 1.21. The C-ring 
exocyclic enoate could be incorporated from ketone 1.85 via an aldol condensation with 
methyl glyoxylate, which was previously described by the Wender and Evans groups.50b’ 
69 A reduction of this ketone from the less hindered face would establish the stereocenter 
at the C20 position. The C19 stereocenter would be set by an oxidation of the enol ether 
and subsequent methanolysis, giving a a-hydroxyl ketal from the dihydropyran 1.86. The 
cyclic enol ether 1.86 was to be constructed using a Rainier metathesis reaction. Ester 
precursor 1.87 was to be made through a convergent union of carboxylic acid 1.88 and 
alcohol 1.89. The carboxylic acid piece 1.88 would be made from commercially available 
methyl isobutyrate (Figure 1.22).
Methyl isobutyrate was alkylated with allyl bromide to give ester 1.92. A Wohl- 
Zeigler bromination using benzoylperoxide and N- bromosuccinimide in CCU produced 
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Figure 1.21. Retrosynthesis o f  the C-ring
silanol gave silyl ether 1.93. Finally, careful hydrolysis of the methyl ester at 0 °C delivered 
carboxylic acid 1.88 in 93% yield in the presence of the terminal TBS ether.
At this point, an investigation into constructing alcohol 1.89 was conducted. 
Aldehyde 1.66 was synthesized on a multigram scale according to the previously described 
route.65 Asymmetric induction using a 1,3-chelation controlled Grignard addition to an 
aldehyde are previously reported in the literature, but they are not common. Our group has 
observed that the removal of THF from vinyl magnesium bromide under high vacuum and 
replacing the solvent with CH2O 2 increases diastereoselectivity of Lewis acid mediated 
Grignard additions.71 This was further emphasized by Dr. Rudra’s discovery of a 1,3-
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Figure 1.22. Synthesis o f  Acid Subunit
chelation controlled addition of vinyl magnesium bromide into a 1,3-PMB ether aldehyde 
with Me2AlCl in toluene, giving a 10:1 dr.61a Subjecting aldehyde 1.66 to alkyl Grignard 
addition under various Lewis acid conditions (Figure 1.23) resulted in only modest 
selectivity for the addition, with the highest diastereoselectivity (dr ~2:1) seen when using 
MgBr2»Et2O in THF, toluene, or CH2O 2 . With these disappointing results, other options 
were explored.
An alternative method is shown in Figure 1.24. Subjecting aldehyde 1.64 to a 1,2 
chelation controlled Mukaiyama aldol addition using TMS enol ether 1.95 gave ketone 
1.96 as a 11:1 mixture of diastereomers. The next step was to reduce the P-hydroxy ketone 
using the Evans-Tishchenko reaction with SmI2 to provide anti 1,3-diol, but unfortunately 
this reduction did not work even with stoichiometric amounts of SmI2 . A similar lack of 
reactivity was observed by the Evans group on a S-benzoxy-P-hydroxy ketone.72
Our inability to produce 1.89 led us to homologate the olefin after esterification 
(Figure 1.25). Alcohol 1.67 was synthesized on a multigram scale utilizing a previously 
developed procedure.65 With both fragments in hand, carboxylic acid 1.88 and alcohol 1.67
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Figure 1.23. Grignard Addition Conditions
were coupled using a Steglich esterification with EDCI and DMAP to give the desired ester 
1.98. Initially this reaction gave poor results; carboxylic acid 1.88 was being converted to 
the N-acyl urea by-product. The use of DMAP-HCl under highly concentrated conditions 
suppressed the formation of the by-product, giving ester 1.87 in an 87% yield. One carbon 
homologation of olefin 1.98 began with hydroboration /oxidation. Reaction of the olefin 
with borane/dimethylsulfide proved to be unselective between the C20 and C16-
39
Figure 1.24. Evans-Tishchenko Reduction
C17 olefins and 9-BBN was unreactive under normal conditions. Fortunately, applying 
ultrasound to the 9-BBN reaction resulted in a rapid conversion, giving the C20 primary 
alcohol 1.99 in a 74% yield after oxidation with H2O2 and NaOH.73 The resulting alcohol 
was oxidized using Parikh-Doering conditions, and Wittig olefination gave the desired one 
carbon extended olefin 1.87 in good yields.
The Rainier titanium-induced ring closing metathesis (RCM) reaction conditions 
smoothly delivered cyclic enol ether 1.86 in an 80% yield (Figure 1.26).74 It is postulated 
that this reaction works so well because the gem-dimethyl group is located adjacent to the 
carbonyl group creating an unfavorable steric interaction with the titanium ethylidene. This 
eliminates the undesired acyclic product 1.102 and gives us only cyclic enol ether 1.86. 
Functionalizing the C-ring began with setting the C19 stereocenter by epoxidation of enol 
ether 1.86 with MMPP in MeOH, giving the anomeric a-hydroxyl ketal (Figure 1.27 ).75 
This was immediately oxidized, without column chromatography, using Ley conditions to 
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Figure 1.25. Synthesis of Glycal 1.86
prepared methyl glyoxylate in the presence of K2CO3 delivered the C21 E-enoate 1.103 
with an 82% yield. A Luche reduction from the less hindered face of the C20 ketone 
afforded the alcohol intermediate, which was quickly esterified with acetic anhydride to 
provide ester 1.104 in an 84% yield over 2 steps.
This newly formed ester group would serve as a protecting group during the 
synthesis of bryostatin 1. We hypothesized that the C20 acetate would be more 
electrophilic and less sterically hindered than the C7 ester, which would allow us to remove
41
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Figure 1.26. Cyclic vs. Acyclic Pathway for Rainier RCM
one in the presence of the other to introduce the bryostatin 1 side chain later on in the 
synthesis. 60 In order to couple the C-ring with the A-ring through a pyran annulation, the 
TBS ether was removed using HFpy and the resulting allylic alcohol was oxidized using 
Ley conditions furnishing enal 1.84. The result of this newly described synthesis provided 
the most convergent and concise way to construct a highly functionalized C-ring at the 
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Figure 1.27. Synthesis of Fully Functionalized C-ring
The Construction of the A-ring76
Our A-ring synthesis was developed by Dr. Welch, and is based on chelation 
controlled allylations guided by a stereocenter set by a Keck asymmetric allylation reaction 
(Figure 1.28).76 It was envisioned that the A-ring would be constructed through a 
cyclization reaction of hydroxyketone 1.106. This acyclic precursor was to be constructed 
using our Lewis acid mediated 1,3-addition of stannane 1.107 into aldehyde 1.108, which 
would set the C7 stereocenter. Prenyl stannane 1.107 would be prepared from
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Figure 1.28. Retrosynthesis o f  A-ring Aldehyde
commercially available ethyl 2, 2-dimethyl acrylate. The C3 stereocenter in 1.108 was 
planned to be established using a chelation controlled Mukaiyama addition of thioketene 
acetal into aldehyde 1.109, which in turn would be prepared using a CAA (catalytic 
asymmetric allylation) reaction to set the C5 stereocenter.
The construction of prenyl stannane 1.107 started from commercially available 
acrylate 1.110 (Figure 1.29, part A). The sequence began with a vinylogous alkylation of 
the enolate using TBS ether protected 2-iodoethanol, providing 1.111. Migration of the 
olefin using potassium tert-butoxide gave the thermodynamically favored a,P-unsaturated 
ester 1.112. The ethyl ester was reduced to alcohol 1.112, which was then mesylated, 
followed by an in situ displacement with tributyltinlithiate to give prenyl stannane 1.107.
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Figure 1.29. Synthesis of Prenyl Stannane 1.107 (A) 
and A-ring Aldehyde 1.108 (B)
The synthesis of aldehyde 1.108 (Figure 1.29, part B) began with a catalytic 
asymmetric allylation of aldehyde 1.113, giving homoallylic alcohol 1.114 with a 93% ee. 
The C5 alcohol was then protected as the PMB ether, which was chosen to facilitate a 1,3- 
chelation controlled allylation. The BPS ether was removed using TBAF and the resulting 
alcohol was oxidized using Parikh-Doering conditions to give aldehyde 1.109. After 
scrupulous optimization, the use of 2.5 equiv of TiCh(O/Pr)2 afforded a 95% yield of aldol 
product 1.116 as a 41:1 mixture of diastereomers. The C3 P-hydroxy thioester 1.116 was 
protected as the BPS ether and the terminal olefin was oxidatively cleaved to give aldehyde 
1.108.
With the prenyl stannane and aldehyde in hand, the critical chelation controlled 
addition reaction was attempted (Figure 1.30). Nucleophilic addition of stannane 1.107 
using excess Me2AlCl into aldehyde 1.108 delivered alcohol 1.106 as a single 
diastereoisomer in 86% yield. This crucial reaction manages to set the C7 stereocenter and 
installs the gem-dimethyl group. Acyclic intermediate 1.106 was acetylated at the C7 
hydroxyl and the C5 PMB ether was removed with DDQ providing intermediate 1.118. 
Ozonolysis gave lactol 1.119 as the sole product with no open chained keto-alcohol 
observed. Treatment of this lactol under acidic methanol conditions protected the hemiketal 
as the methylketal and simultaneously removed the TBS ether, providing the primary 
alcohol. Subsequent Parikh-Doering oxidation produced desired aldehyde 1.105.
At this point, Dr. Poudel investigated ways to incorporate the P-hydroxyallylsilane 
from aldehyde 1.105.77 Unfortunately, a catalytic asymmetric allylation reaction failed to 
produce any product even with high catalyst loading. Since a direct asymmetric 
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Figure 1.30. Synthesis o f A-ring Aldehyde 1.105
1.31). This approach started off with a thermal addition of trimethylsilyl 
methylallylstannane into aldehyde 1.105 to produce P-hydroxyallylsilane 1.120 as a 1:1 
mixture of diastereomers, followed by a Parikh-Doering oxidation affording ketone 1.121. 
After screening a short list of reducing agents, Luche conditions gave the desired P- 
hydroxyallylsilane 1.122 with a moderate 4:1 diastereoselectivity at the C11 center.
The Completion of Bryostatin 1 and Bryostatin 7 53, 78
Bryostatin 1 and 7 were both completed by Dr. Poudel, and are described in the 
following sections. With the fully functionalized C-ring aldehyde 1.84 and P- 




H'  ^OAc Bu3Sn TMS













OAc CeCI3, NaBH4 t m s  








Figure 1.31. Synthesis o f A-ring Silane 1.122
bryopyran core in 61% yield. Unfortunately, a major side product caused by an 
intramolecular cyclization at C9, producing a spirocyclic product, diminished the yield of 
the pyran annulation reaction. In order to remove the thioester, a combination of the 
removal of the C3 BPS ether with HF*py followed by LiOH/H2O2 was necessary to 
produce acid 1.125.79 Not removing the C3 BPS rendered the thioester 1.123 inactive under 
these same conditions.77 The C3 hydroxy group was protected as the TES ether, the PMB 
was removed using DDQ, and the macrolactone was completed using Yamaguchi 
conditions, giving 1.126.80 At this point, the basic structure of bryostatin 1 was intact, and 
only needed a few modifications on the C-ring and B-ring and a global deprotection to be 
complete.
The final steps and completion of bryostatin 1 are shown in Figure 1.33. The B­
ring was elaborated using Sharpless asymmetric dihydroxylation, followed by sodium 
periodate cleavage to furnish C13 ketone 1.127. A Horner-Wadsworth-Emmons reaction 
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Figure 1.33. Completion of Bryostatin 1
50
Z:E a,P-unsaturated methyl ester 1.129 favoring the desired isomer.50a A selective 
methanolysis of the C20 acetate afforded the C20 alcohol which was then esterified with 
(2E,4E)-octa-2,4-dienoic anhydride giving a protected version of bryostatin 1 (1.130). 
Global deprotection using LiBF4 in acetonitrile/H2O at 80 °C provided bryostatin 1 in 72% 
yield.
After the publication and the synthesis of bryostatin 1, remaining intermediate 
1.127 was used to construct bryostatin 7 (Figure 1.34). This molecule was simply made by 
unmasking 1.129 using our global deprotection conditions. The purpose of generating 
bryostatin 7 was to elucidate it biological profile.
The Biological Profile of Bryostatin 778
An important hypothesis concerning PKC ligands is that the overall lipophilicity of 
the compounds might play an important role in their biological activity. Prostatin has a 
phorbol ester backbone, but lacks the hydroxy/acyl group at the C12 carbon. This small 
difference renders this molecule a nontumor- promoter and a potentially effective
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Figure 1.34. Synthesis of Bryostatin 7
HIV therapy.46^  82 Interestingly, replacement of prostatin’s C13 acetate group with 
tetradecanoate, a much more lipophilic group, results in a restoration of the molecule’s 
tumor-promoting activity (Figure 1.35).83 PEP005 (ingenol 3-angelate) is another example 
of the drastic effects that lipophilicity can have on biology. This natural product has been 
FDA approved for actinic keratosis and nonmelanotic skin cancer. It is nontumor- 
promoting but when the lipophilicity increased, by adding more hydrocarbonto the C3 side 
chain, the derivatives such as ingenol 3-hexadecanoate turn out to be potent tumor- 
promoters.34, 83 The indolactams are another family of natural products that have been 
identified as potent activators of PKC.84 So far, this family has shown to be tumor- 
promoters, but an interesting trend between binding affinity and lipophilicity was observed. 
One analog of interest is n-octyl indolactam V, which binds 20 times better to PKC than 
indolactam V.
The bryostatins are another class of natural products that bind to PKC, but little is 
known about the effects of the C20 side chain on biological activity. Comparing bryostatin 
1 to bryostatin 7 provides exemplary juxtaposition of lipophilicity at this position to study 
the biological effects (Figure 1.35). Bryostatin 7 has the highest binding affinity among the 
bryostatin family for PKC (mixture of isozymes) with a K; value of 0.26 nM while 
bryostatin 1 has a K; value of 1.35 nM.85 This is in sharp contrast to that of the indolactams, 
where additional lipophilicity increases their binding affinity. A detailed biological profile 
of bryostatin 7 was deemed necessary to determine the significance of the C20 ester side 
chain.
The following biological studies were conducted by Dr. Blumberg and coworkers 


















Figure 1.35. Effects of Lipophilic Side Chains
binding affinities of bryostatin 1 and 7 were confirmed. Bryostatin 7 is a stronger binder to 
PKCa than bryostatin 1, although the difference was slightly less than reported since 
bryostatin 1’s affinity changed from 1.35 nM (mixture of isozymes) to 0.48 nM for PKCa 
(Table 1.3).85 The C1 domain of PKC is highly conserved amongst its isozymes. 
Experiments were conducted to confirm binding affinities and to evaluate potential 
isozyme selectivity of bryostatin 1, bryostatin 7, and PMA. Five PKC isozymes were 
evaluated: PKCa (mouse), PKCa (human), PKCpiI, PKCS, and PKCs. All five isozymes 
were exposed to various PKC ligands and it was confirmed that there is very little isozyme 
selectivity or variation in binding affinity with these five isozymes with PKC (Table 1.3).
Phorbol esters and bryostatin 1 exhibit differential responses in the U937 leukemia 
cell line. PMA inhibits cell growth and induces cellular attachment, while bryostatin 1 
shows a severely reduced response.86 When bryostatin 1 and PMA are co-administered, the 
response resembles that of bryostatin 1 alone, showing a dominate mechanism of action. 
When bryostatin 7 was subjected to the proliferation assay in the U937 cells, it was found
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0.28 ± 0.02 0.20 ± 0.0003 0.33 ± 0.08 0.22 ± 0.05
Bryostatin 1 
Ki, nM
0.48 ± 0.03 0.73 ± 0.05 0.42 ± 0.01 0.26 ± 0.02 0.24 ± 0.01
Bryostatin 7, 
Ki, nM
0.26 ± 0.06 0.44 ± 0.01 0.32 ± 0.01 0.21 ± 0.02 0.16 ± 0.01
to closely resemble bryostatin 1 and was dramatically different from PMA (Figure 1.36). 
The biological responses of U937 cells to PMA, bryostatin 1, and bryostatin 7 were 
measured after a treatment that indicated concentration of ligand for 60 h. Additionally, 
bryostatin 7 resembled bryostatin 1 by giving a dose-dependent biphasic pattern in its 
ability to inhibit cell growth. When bryostatin 7 and PMA were co-administered, bryostatin 
7 was able to suppress the growth inhibition induced by PMA in a dose-dependent manner. 
A similar result was obtained in the cell attachment assay. Bryostatin 7, like bryostatin 1, 
has a reduced level of cell attachment relative to PMA, as well as a dose dependent biphasic 
response. When co-administered, bryostatin 7 inhibits the attachment induced by PMA. 
When compared to each other, bryostatin 7 inhibited proliferation slightly more and 
induced slightly more attachment than bryostatin 1.
Another assay involving U937 cells evaluates the effect of bryostatin 1, bryostatin
7, and PMA on the secretion of tumor necrosis factor a  (TNFa). TNFa is an 
immunomodulating protein produced by immune cells and induces an inflammatory 
response. It has also been suggested to be an important contributor in PMA’s ability to 
induce apoptosis in U937 cells. After treatment with PMA for 60 h, the ligand induces a 
very high level of TNFa. Bryostatin 1 and bryostatin 7 induce a similar level of TNFa after 
treatment , but not as much as PMA (Figure 1.37).
Since binding affinity and biological response are not correlated for PKC, it is 
important to evaluate other phenomena such as the ligand’s ability to down regulate PKC. 
Down regulation is caused by binding of the C1 domain, and inducing a conformational 
change in the protein which ultimately leads to cleavage.34-35 Bryostatin 1, bryostatin 7, 
and PMA were evaluated in their ability to effect down regulation of PKCpiI, PKCS, and
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Figure 1.36. Proliferation and Attachment Assay of U937 Cells by Bryostatin 7
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Drug concentration (nM)
Figure 1.37. TNFa Secretion
PKCs. With PKCs, the bryostatins and PMA showed very little down regulation. In Figure 
1.38, which plots the % of a controlled amount of PKCpiI versus ligand concentration, 
bryostatin 1 (EC50 = 0.310 ± 0.005 nM) and bryostatin 7 (EC50 =0.97 ± 0.08 nM) induced 
similar levels of down regulation, while PMA induced less down regulation. With PKCS, 
bryostatin 7 had an EC50 of 0.22 ± 0.03 nM, while bryostatin 1 was 3 fold more potent with 
an EC50 of 0.083 ± 0.008 nM. PMA is less effective in its ability to down regulate PKCS 
while bryostatin 1 and bryostatin 7 give a biphasic dose-dependent response.
In the LNCaP prostate cancer cell line, PMA once again inhibits cellular 
proliferation, while bryostatin 1 and bryostatin 7 show very little inhibition of cell growth 
(Figure 1.39). When bryostatin 1 and 7 are co-administered with PMA, the bryostatins were 
able to block inhibition of proliferation of PMA. Bryostatin 1 and bryostatin 7 cause a 
nominal amount of secretion of TNFa and both inhibit the secretion induced by PMA 
(Figure 1.40).
The translocation of PKC can be monitored in real time using PKC-green
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Figure 1.38. Down Regulation of PKCpiI and PKCS in U937 Cells at 24 h
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Figure 1.39. Inhibition of Cell Growth in LNCaP Cells
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Figure 1.40. TNFa Secretion in LNCaP Cells
fluorescence protein (GFP) conjugates in response to bryostatin 1, bryostatin 7, and PMA. 
We wanted to evaluate the biological effect that the C20 side chain of bryostatin has on 
translocation using PKC-GFP. Blumberg and coworkers found that the pattern of 
translocation of PKCS varies depending on short, intermediate, or long chained phorbol 
esters which can be correlated to their tumor-promoting or nontumor-promoting abilities.87 
This indicates that the lipophilicity of the ligands might play a key role in their biological 
activity. Tumor-promoters such as PMA induce the translocation of PKCS mostly to the 
plasma membrane while nontumor-promoters, such as bryostatin 1, cause translocation 
mainly to the nuclear membrane.88
Using mouse PKCS tagged with GFP and transiently transduced into LNCaP cells, 
PMA induces translocation of GFP-PKCS to the plasma membrane while bryostatin 1 
induces translocationto the nuclear and internal membranes with minimal plasma 
membrane translocation (Figure 1.41). When the GFP mouse PKCS was exposed to 
bryostatin 7, there was no visual difference between the translocation patterns seen with 
bryostatin 1 and bryostatin 7. This was a disappointing result since it was hypothesized that 
the less lipophilic bryostatin 7 might induce less plasma membrane translocation than 
bryostatin 1. Using human PKCS, PMA translocated GFP-PKCS mostly to the plasma 
membrane with some translocationto the nuclear and internal membranes (Figure 1.42). 
Additionally there is translocation of PKC to the plasma membrane that is substantially 
less compared to PMA. Interestingly, GFP-PKCS only translocates to the nuclear and 
internal membranes by bryostatin 7 with no detectable plasma membrane translocation. 
This change in translocation correlates to the decrease in lipophilicity of bryostatin 7.
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Figure 1.41. Translocation of Mouse GFP-PKCS in LNCaP Cells
bryostatin 7 with GFP-PKCS, further examination was warranted. Yellow fluorescence 
protein (YFP)-PKCs in LNCaP cells were evaluated using confocal microscopy (Figure 
1.43). There was almost exclusive movement of YFP-PKCs to the plasma membrane and 
swift clearing in the cytoplasm when treated with PMA. Bryostatin 1 retained YFP-PKCs 
in the cytoplasm, and again resembled PMA in that there is plasma membrane 
translocation. Bryostatin 7 on the other hand does not induce detectable plasma membrane
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Figure 1.42. Translocation of Human GFP-PKCS in LNCaP Cells
translocation. Bryostatin 7 on the other hand does not induce detectable plasma membrane 
translocation and is concentrated in the internal membranes. So far, the results in both GFP- 
PKCS and YFP-PKCs are consistent with our original hypothesis that the less lipophilic 
bryostatin 7 would induce less plasma membrane translocation than bryostatin 1.
The 2 previously examined PKC isozymes, S and s, are independent of Ca2+ for 
activation, but are dependent on a C1 domain ligand. An examination of translocation of 
PKCa, which is an isozyme that is dependent on Ca2+, was evaluated. With mouse PKCa
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Figure 1.43. Translocation of Human YFP-PKCs in LNCaP Cells
tagged with GFP and transiently transduced into CHO (Chinese hamster ovary) cells, PMA 
causes translocation of GFP-PKCa to the plasma membrane (Figure 1.44).87-88 Bryostatin 
1 and bryostatin 7 induce a similar response in these cell lines when looking at translocation 
of GFP-PKCa. In these cases, there was translocation to the plasma and internal 
membranes with a high concentration around the nuclear membrane. There was no 
observed difference between bryostatin 1 and 7 in translocation of PKCa.
Another tool to evaluate the biological profile of PKC effectors is the unique pattern
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Figure 1.44. Translocation of Human YFP-PKCa in CHO Cells
of gene expression controlled by PKC isozymes. Phorbol esters are known to cause 
profound changes in gene transcription in LNCaP prostate cancer cells lines.89 A series of 
phorbol ester responsive genes were compared to PMA, bryostatin 1, and bryostatin 7 
(Figure 1.45).89 Changes in levels of mRNA when exposed to PMA were much greater 
than with bryostatin 1 or bryostatin 7. The levels of mRNA expression for bryostatin 1 and 
bryostatin 7 resemble one another in this study.
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Figure 1.45. Gene Induction in LNCaP Cells 
Conclusions
The first total synthesis of bryostatin 1 was accomplished in 30 LLS steps (55 total 
steps). Bryostatin 7 was determined to retain the biological pattern of bryostatin 1, and is 
synthetically more accessible using our synthetic route. The less lipophilic bryostatin 7 
shows differences in its ability to translocate PKC, but more experiments are required to 
determine the biological significance of these results in disease models. Overall, the C20 
side chain is not a critical element of bryostatin 1 to obtain the biological responses typical 
of bryostatin 1. The preparation of the C-ring aldehyde 1.84 using a carbonyl/olefin 
metathesis provided a novel route that produced ample amounts of this fragment and was 
completed in 18 linear steps. This route provided us a way to incorporate all of the 
functionality on the C-ring and allowed us to rapidly connect 2 complex pieces using the
pyran annulation. This route was successfully utilized by other members of the group and 
used to complete synthesis of bryostatin analogs Merle 34-38 shown in Figure 1.46.
Experimental Section 
General Experimental Procedures, Materials, and Instrumentation
Solvents were purified according to the guidelines in Purification o f Common 
Laboratory Chemicals (Perrin, Armarego, and Perrin, Pergamon: Oxford, 1966).90 
(iPr)2NH, (iPr)2NEt, pyridine, Et3N, EtOAc, CH2Cl2, and TMEDA were distilled from 
CaH2 . The titer of n-BuLi was determined by the method of Eastham and Watson91. Et2O 
and THF were distilled from Na under an atmosphere of N 2 . MeOH was distilled from dry 
Mg turnings. TiCU was distilled prior to use. Zn was activated with aqueous HCl solution 
prior to use. Ozone was generated using a Welsbach model T-816 generator. All other 
reagents were used without further purification. Yields were calculated for material judged 
homogenous by thin layer chromatography and nuclear magnetic resonance (NMR). Thin 
layer chromatography was performed on Merck Kieselgel 60 A F254 plates or Silicycle 60A 
F254 eluting with the solvent indicated, visualized by a 254 nm UV lamp, and stained with 
an ethanolic solution of 12-molybdophosphoric acid, 4-anisaldehyde, or an aqueous 
potassium permanganate solution. Flash column chromatography was performed with 
Silicycle flash silica gel 40 -  63 |im, slurry packed with hexanes in glass columns. 
Glassware for reactions was oven dried at 125 °C and cooled under a dry nitrogen 
atmosphere prior to use. Liquid reagents and solvents were introduced by oven dried 
syringes through septum-sealed flasks under a nitrogen atmosphere. Nuclear magnetic 
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Figure 1.46. Uses o f the C-ring Subunit
for proton nuclear magnetic resonance (1H NMR) spectra are reported in parts per million 
relative to the signal residual CDCb at 7.27 ppm. Chemicals shifts for carbon nuclear 
magnetic resonance (13C NMR and DEPT) spectra are reported in parts per million relative 
to the center line of the CDCb triplet at 77.23 ppm. Chemical shifts of the unprotonated 
carbons (‘C’) for DEPT spectra were obtained by comparison with the 13C NMR spectrum. 
The abbreviations s, d, apd, dd, ddd, dddd, t, td, tt, q, dq, and m stand for the resonance 
multiplicity singlet; doublet; apparent doublet; doublet of doublets; doublet of doublet of 
doublets; doublet of doublet of doublet of doublets; doublet of doublet of doublets of 
doublets; triplet; triplet of doublets; triplet of triplets; quartet; doublet of quartets; and 
multiplet, respectively. Optical rotations (Na D line) were obtained using a microcell with 
1 dm path length. Specific rotations ([a ]“ , Unit: °cm2/g) are based on the equation a  = 
(1 0 0 a )/( /c )  and are reported as unitless numbers where the concentration c is in g/l00 mL 
and the path length / is in decimeters. Mass spectrometry was performed at the mass 
spectrometry facility of the Department of Chemistry at The University of Utah on a double 
focusing high resolution mass spectrometer. Compounds were named using ChemDraw
12.0.0.
Experimental Procedures and Analytical Data for Homoallylic 
Alcohol 1.67
Compounds 1.64-1.67 were previously prepared by Dr. Anh Truong and are 
reported in her Ph.D. thesis92 and in the literature.65 These syntheses were repeated on a 
larger scale in order to access for use in the present work. A larger scale experimental
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procedure and analytical data for these compounds are reproduced here, for those who may 
need to repeat this work.
(K)-2-((benzyloxy)methoxy) propanal (1.64).65 To a stirring solution of (R)-(+)- 
isobutyl lactate (24.0 mL, 160.1 mmol, 1.0 equiv) and (z'Pr)2NEt (84.0 mL, 480.0 mmol,
3.0 equiv) at 0° C in a 250 ml rb flask, was added benzyl chloromethylether (44.5 mL,
320.0 mmol, 2.0 equiv) via syringe. The solution was stirred overnight during which it 
slowly returned to rt. The reaction mixture was quenched by the addition of aqueous HCl 
solution (50 mL of 1.0 M) and diluted with Et2O (200 mL). The phases were separated, 
and the aqueous phase was extracted with Et2O (2 x 200 mL). The combined organic 
phases were dried with anhydrous Na2SO4, filtered, and concentrated under reduced 
pressure to provide the crude ester. Purification was accomplished by flash column 
chromatography using an 10.0 x 19.0 cm silica gel column, eluting with 10% EtOAc/ 
hexanes, collecting 125 mL Erlenmeyer flask fractions. The product containing fractions 
(8-45) was concentrated under reduced pressure to yield impure ester as a clear colorless
To a stirring solution of impure ester in CH2Q 2 (450 mL) in a 1 L rb flask at -78° 
C, was added DIBAL-H (1.0 M in CH2O 2, 112.4 mL, 112.4 mmol, 1.2 equiv) via syringe
which time TLC analysis indicated complete consumption of the starting material. The 




pump at a rate of 22.4 mL/hr. The reaction was allowed to proceed for 1 h at -78 °C, after
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25 mL/hr. The reaction mixture was poured into a stirring saturated aqueous solution of 
sodium potassium tartrate (500 mL) and stirred at rt overnight. The phases were then 
separated and the aqueous phase was extracted with CH2Q 2 (500 mL x 2). The combined 
organic phases were dried with anhydrous Na2 SO4, filtered, and concentrated under 
reduced pressure. The aldehyde was purified by flash column chromatography using an
8.0 x 10.0 cm silica gel column, eluting with 15% EtOAc/ hexanes, collecting 125 mL 
Erlenmeyer flask fractions. The product containing fractions (8-38) was concentrated 
under reduced pressure to yield pure aldehyde 1.64 (24.2 g, 78%, 2 steps) as a colorless
oil: Rf = 0.51 (30 % EtOAc/Hex.); 500 MHz 1H NMR (CDCb) S 9.65 (d, J  = 1.6 Hz, 1H), 
7.41-7.28 (m, 5H), 4.88 (s, 2 H), 4.71 (d, J= 11.8 Hz, 1H), 4.65 (d, J  = 11.7 Hz, 1H), 4.12 
( dq, J  = 7.0, 1.5 Hz, 1H), 1.34 (d, J = 7.1, 3H); 125 MHz 13C NMR (CDCb) S 202.5,
137.4, 128.6, 127.9, 127.8, 94.2, 78.2, 70.0, 15.3.
(2^,3^)-2-((benzyloxy)methoxy)hex-5-en-3-ol (1.65).65 To a stirring solution of 
aldehyde 1.64 (13.7 g, 70.6 mmol, 1.0 equiv) in CH2Q 2 (600 mL) in a 1 L rb flask, was 
added MgBr2»Et2O (36.6 g, 141.3 mmol, 2.0 equiv). The solution was stirred at rt for 5 
min and then cooled to -15° C. Stirring continued for 15 min, and a solution of 
allyltributyltin (33.0 mL, 106.0 mmol, 1.5 equiv) in CH2Q 2 (80 mL) was added to the 
reaction mixture over 20 min via cannula. The solution was allowed to reach rt as stirring 
continued overnight. The reaction mixture was quenched by pouring the mixture into a 2 
L Erlenmeyer flask containing saturated aqueous NaHCO3 solution (250 mL), aqueous KF
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solution (250 mL), and CH2O 2 (250 mL). The mixture stirred at rt for 2 h and the phases 
were then separated. The aqueous phase was extracted with CH2Q 2 (300 mL x 3). The 
combined organic phases were washed with aqueous saturated brine solution (50 mL), 
dried with Na2SO4, filtered, and concentrated under reduced pressure. The crude alcohol 
was purified by flash column chromatography using a 10.0 x 14.0 cm silica gel column, 
eluting with 2-25% EtOAc/ hexanes, collecting 125 mL Erlenmeyer flask fractions. The 
product containing fractions (15-25) was concentrated under reduced pressure to yield 
homoallylic alcohol 1.65 (13.5 g, 81%) as a clear colorless oil: Rf = 0.40 (30 % 
EtOAc/Hex.); 500 MHz 1H NMR (CDCb) 5 7.40-7.29 (m, 5H), 5.91 (dddd, J  = 16.6, 9.8,
7.3, 6.3 Hz, 1H), 5.18-5.10 (m, 2H), 4.88 (d, J  = 6.8 Hz, 1H), 4.84 (d, J  = 6.8 Hz, 1H), 4.68 
(d, J  = 11.7 Hz, 1H), 4.64 (d, J  = 11.7 Hz, 1H), 3.68 (dq, J  = 6.4, 6.4 Hz, 1H), 3.56 (dddd, 
J  = 7.9, 5.9, 3.9, 3.9 Hz, 1H), 2.61 (d, J  = 3.9 Hz, 1H), 2.41-2.34 (m, 1H), 2.27-2.20 (m, 
1H), 1.23 (d, J  =6.4 Hz, 3H); 125 MHz 13C NMR (CDCb) 5 137.7, 134.9, 128.7, 128.1,
128.0, 117.7, 94.1, 77.3, 74.4, 70.0, 37.8, 16.9.
(3^,4^)-4-((benzyloxy)methoxy)-3-((4-methoxy benzyl) oxy)pentanal (1.66).65
To a stirring solution of KH (35% in mineral oil, 10.5 g, 91.5 mmol, 1.5 equiv) in THF 
(500 mL) in a 1L rb flask at 0° C, was added a solution of homoallylic alcohol 1.65 (14.4 
g, 61.0 mmol, 1.0 equiv) in THF (80 mL) dropwise via cannula. The flask was rinsed with 
an additional THF (10 mL) and slowly added to the reaction mixture. This was repeated 2 
more times. The mixture was stirred at 0° C for 5 min, and then PMB-Br (13.2 mL, 91.5
mmol, 1.5 equiv) was added dropwise via syringe. The reaction was allowed to proceed 
for 2 h at 0 °C, after which time TLC analysis indicated complete consumption of the 
starting material. The reaction mixture was quenched by adding a saturated aqueous 
solution of NH4Cl (200 mL). The mixture was diluted with Et2O (300 mL) and H2O (100 
mL) was added. The phases were separated, and the aqueous phase was extracted with Et2O 
(2 x 300 mL). The organic phases were combined, dried over Na2SO4 and concentrated 
under reduced pressure. Purification was accomplished by flash column chromatography 
using a 10.0 x 15.0 cm silica gel column, eluting with 20% EtOAc/ hexanes, collecting 125 
mL Erlenmeyer flask fractions. The product containing fractions (9-19) were combined 
and concentrated under reduced pressure to yield crude PMB ether as a clear oil with 
inseparable impurities.
To a stirring solution of impure alkene in CH2Q 2/ MeOH (4:1, 600 mL), was added 
NaHCO3 (51.3 g, 610.2 mmol, 10.0 equiv). The reaction mixture was cooled to -78° C and 
O3 was bubbled through the mixture until the solution developed a light blue color. The 
excess O3 was purged from the reaction mixture by bubbling O2 through it for 20 min. 
Dimethyl sulfide (44 ml, 598.0 mmol, 9.8 equiv) was added to the mixture dropwise via 
syringe. The solution was slowly allowed to reach rt overnight. The solid NaHCO3 was 
removed by filtration, and the solution was concentrated under reduced pressure. 
Purification was accomplished by flash column chromatography using a 10.0 x 15.0 cm 
silica gel column, eluting with 20% EtOAc/hexanes, collecting 125 mL Erlenmeyer flask 
fractions. The product containing fractions (13-30) were combined and concentrated under 
reduced pressure to yield aldehyde 1.66 (19.9 g, 96%) as clear colorless oil: Rf = 0.40 (30 
% EtOAc/Hex.); 500 MHz 1H NMR (CDCb) S 9.74 (dd, J  = 2.2, 1.3 Hz, 1H), 7.43-7.17
72
(m, 7H), 6.89-6.84 (m, 2H), 4.82 (d, J  = 7.3 Hz, 1H), 4.77 (d, J  = 7.0 Hz, 1H), 4.60 (s, 2H), 
4.55 (d, J  = 11.3 Hz, 1H), 4.51 (d, J  = 11.0 Hz, 1H), 4.08-3.96 (m, 2H), 3.80 (s, 3H), 2.67 
(ddd, J  = 4.3, 1.1, 1.1 Hz, 1H), 2.64 (ddd, J  = 7.7, 2.4, 0.9 Hz, 1H), 1.21 (d, J  = 6.5 Hz, 
3H); 125 MHz 13C NMR (CDCb) S 201.5, 159.5, 137.9, 130.2, 129.8, 128.7, 128.0, 128.0,
114.0, 93.7, 75.6, 73.1, 72.3, 69.9, 55.4, 44.4, 15.1.
HO,, / \ ^ O P M B  
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(4»S,6^,7^)-7-((benzyloxy)methoxy)-6-((4-methoxy benzyl)oxy)oct-1-en-4-ol 
(1.67).65 To a stirring solution of aldehyde 1.66 (19.7 g, 60.0 mmol, 1.0 equiv) in CH2Q 2 
(250 mL) in a 1 L rb flask, was added MgBr2»Et2O (28.4 g, 109.9 mmol, 2.0 equiv). The 
solution was stirred at rt for 5 min, and was then cooled to -15 °C where stirring continued 
for an additional 25 min. A solution of allyltributyltin (25.5 mL, 82.4 mmol, 1.5 equiv) in 
CH2Cl2 (50 mL) was added to the reaction mixture via cannula over a 30 min. The reaction 
was allowed to proceed for 60 h at -15 °C, after which time TLC analysis indicated 
complete consumption of the starting material. The reaction mixture was quenched by 
pouring the mixture into a 2 L Erlenmeyer flask containing a stirring solution of saturated 
aqueous NaHCO3 solution (150 mL) and aqueous KF solution (150 mL). The mixture was 
stirred for 3 h at room temperature. The phases were separated, and the aqueous phase was 
extracted with CH2Q 2 (400 mL x 3). The combined organic phases were dried with 
Na2SO4, filtered, and concentrated under reduced pressure. Purification was accomplished 
by flash column chromatography using a 10.0 x 12.0 cm silica gel column, eluting with 
10% EtOAc/hexanes, collecting 250 mL Erlenmeyer flask fractions. The product
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containing fractions (7-22) were combined and concentrated under reduced pressure to 
yield homoallylic alcohol 1.67 (21.2 g, 96%) as clear colorless oil, and as a 7:1 mixture of 
diastereomers as determined by 1H and 13C NMR: Rf = 0.29 (30 % EtOAc/Hex.); 500 
MHz 1H N M R  (CDCb) S 7.40-7.20 (m, 7H), 6.89-6.83 (m, 2H), 5.82 (dddd, J  = 16.6, 9.8, 
6.8, 6.8 Hz, 1H), 5.14-5.06 (m, 2H), 4.86 (d, J  = 6.8 Hz, 1H), 4.82 (d, J  = 6.8 Hz, 1H), 4.61 
(s, 2H), 4.61 (d, J  = 11.2 Hz, 1H), 4.51 (d, J  = 10.9 Hz, 1H), 4.01 (dq, J  = 6.3, 5.9 Hz, 1H), 
3.88-3.82 (m, 1H), 3.81 (s, 3H), 3.77-3.70 (m, 1H), 2.28 (d, J  = 4.4 Hz, 1H), 2.25-2.18 (m, 
2H), 1.68-1.64 (m, 2H), 1.20 (d, J  = 6.4 Hz, 3H); 125 MHz 13C NMR (CDCb) S 159.5,
138.1, 135.1, 130.7, 129.8, 128.7, 128.0, 127.9, 118.0, 114.0, 93.9, 78.4, 74.0, 72.7, 69.8,
67.9, 55.5, 42.6, 36.6, 15.6.
Experimental Procedures and Analytical Data for Fully Functionalized 
C-ring 1.103
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Methyl 2,2-dimethylpent-4-enoate (1.91).65 To a stirring solution of (z'Pr)2NH 
(36.7 mL, 260 mmol, 1.1 equiv) in THF (160 mL) in a 1 L rb flask at -78 °C, was added n- 
BuLi (2.6 M in hexanes, 100 mL, 260 mmol, 1.1 mmol). The solution was stirred at -78 
°C for 30 min and was then allowed to warm to 0 °C for 30 min. Methyl isobutyrate (30 
mL, 236 mmol, 1.0 equiv) in THF (100 mL) in a 250 ml rb flask, was added slowly via 
cannula over 30 min down the side of the flask to the resulting solution of LDA at -78 °C. 
An additional THF rinse (20 mL) was used to transfer remaining residue into the reaction 
flask via cannula. The resulting light-yellow reaction mixture was allowed to stir at -78 °C
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for 1 h and allyl bromide (24.0 mL, 260 mmol, 1.1 equiv) in THF (140 mL) was added 
slowly via cannula down the side of the flask. The reaction mixture stirred at -78 °C for 30 
min and was allowed to warm to rt. This solution was stirred for 2 h, then quenched by the 
addition of saturated aqueous NH4O  solution (150 mL) and diluted with pentane (500 mL). 
The phases were separated and the organic phase was washed with a saturated aqueous 
Na2S2O3 solution (100 mL), saturated aqueous NaHCO3 solution (100 mL), and brine (100 
mL), then dried over MgSO4, filtered, and concentrated under reduced pressure. 
Purification was accomplished using fractional distillation, collecting at 125 °C -  145 °C 
to yield olefin 1.91 (25 mL, 74%) as a colorless liquid: Rf = 0.40 (5 % EtOAc/Hex.); 500 
MHz 1H N M R (CDCb) 5 5.78-5.68 (m, 1H), 5.07-5.06 (m,1H), 5.05-5.02 (m, 1H), 3.67 (s, 
3H), 2.28 (dt, J  = 7.8, 1.0 Hz, 2H), 1.18 (s, 6H); 125 MHz 13C NMR (CDCb) 5 178.1,
134.4, 118.0, 51.8, 44.9, 42.5, 25.0; 125 MHz DEPT 13C NMR (CDCb) CH3 5 51.8, 25.0; 
CH2 5 118.0, 44.9; CH1 5 134.4; CH0 5 178.1, 42.5; IR (neat) 2960, 2925, 2872, 1731, 
1469, 1384, 1147 995, 914 cm-1; HRMS (ESI) calcd for C8H 15O2(M+H): 143.1072, found: 
143.1068.
(E)-methyl 5-bromo-2,2-dimethylpent-3-enoate (1.92). To a stirring solution of 
olefin 1.91 (12.0 g, 84.3 mmol, 1.0 equiv) in CCb (85 mL, 1.0 M) in a 250 ml rb flask, was 
added #-bromosuccidimide (16.5 g, 92.8 mmol, 1.1 equiv) followed by benzoyl peroxide 
(70% in H2O, 0.6 g, 1.7 mmol, 0.02 equiv). This solution was heated at reflux for 2 h and
Br
O
cooled to rt. An additional portion of #-bromosuccidimide (7.5 g, 42.2 mmol, 0.5 equiv) 
was added and the solution was again heated at reflux for 2 h. After cooling to rt, the 
solution was filtered with the aid of CH2Q 2 and the filtrate was concentrated under reduced 
pressure. Purification was accomplished by flash column chromatography using a 10.0 x
14.0 cm silica gel column, eluting with 5% EtOAc/ hexanes, collecting 125 mL fractions. 
The product containing fractions (8-26) were combined and concentrated under reduced 
pressure to yield bromide 1.92 (13.1 g, 70%) as a clear yellow oil: Rf = 0.44 (5% 
EtOAc/Hex.); 500 MHz 1H NMR (CDCb) 5 5.97 (dt, J  = 15.7, 1.0 Hz, 1H), 5.74 (dt, J  =
15.6, 7.3 Hz, 1H), 3.97 (dd, J  = 7.3, 1.0 Hz, 2H), 3.69 (s, 3H), 1.32 (s, 6H); 125 MHz 13C 
NMR (CDCb) 5176.4, 139.6, 125.0, 52.4, 44.3, 32.9, 25.0; 125 MHz DEPT 13C NMR 
(CDCb) CH3 5 52.4, 25.0; CH2 5 32.9; CH1 5 139.5, 125.0; CH0 5 176.4, 44.3; IR (neat) 
2978, 2951, 2875, 1731, 1469, 1432, 1262, 1145, 969 cm-1; HRMS (ESI) calcd for 
C8H 13NaO2Br (M+Na): 242.9997, found: 243.0014.
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(E)-methyl 5-((terf-butyldimethylsilyl)oxy)-2,2-dimethyl pent-3-enoate (1.93).
To a stirring solution of 2,6-di-tert-butyl-4-methylpyridine (17.7 g, 86.6 mmol, 1.5 equiv) 
in CH2Cl2 (120 mL) in a 500 ml rb flask at 0° C, was added silver triflate (17.8 g, 69.3 
mmol, 1.2 equiv) followed by TBSOH (13.6 mL, 86.6 mmol, 1.5 equiv). Stirring continued 
for 5 min, and a solution of allylbromide 1.92 (12.8 g, 57.7 mmol, 1.0 equiv), in CH2Q 2 
(50 mL) was added to the reaction mixture over 20 min via cannula. An additional CH2Q 2
rinse (10 mL) was used to transfer the remaining residue into the reaction flask via cannula. 
After stirring at 0° C for 30 min, the precipitate of AgBr solid was filtered off and washed 
with CH2Cl2 . The filtrate was concentrated under reduced pressure, then purified by flash 
column chromatography using a 10.0 x 12 cm silica gel column, eluting with 10% EtOAc/ 
hexanes, collecting 125 mL fractions. The product containing fractions (4-11) were 
combined and concentrated under reduced pressure to yield TBS ether 1.93 (13.3 g, 84%) 
as a clear yellow oil: Rf = 0.62 (10 % EtOAc/Hex.); 500 MHz 1H NMR (CDCb) S 5.84 
(dt, J  = 15.6, 1.5 Hz, 1H), 5.59 (dt, J  = 15.6, 4.3 Hz, 1H), 4.18 (dd, J  = 4.3, 1.5 Hz, 2H), 
3.68 (s, 3H), 1.31 (s, 6 H), 0.91 (s, 9H), 0.07 (s, 6 H); 125 MHz 13C NMR (CDCb) S 177.0,
134.7, 127.9, 63.9, 52.1, 44.0, 26.1, 25.1, 18.6, -5.0; 125 MHz DEPT 13C NMR (CDCb) 
CH3 S 52.1, 26.1, 25.1, -5.0; CH2 S 63.9; CH1 S 134.7, 127.9; CH0 S 177.0, 44.6, 18.6; IR 
(neat) 2955, 2931, 2857, 1732, 1471, 1256, 1141, 837, 776 cm-1; HRMS (ESI) calcd for 
C 14H28NaO3Si (M+Na): 295.1705, found: 295.1709.
.OTBS
M e " y L .O H
Me T  
O
(E)-5-((tert-butyldimethylsilyl)oxy)-2,2-dimethylpent-3-enoic acid (1.88). To a
stirring solution of ester 1.93 (16.8 g, 61.5 mmol, 1.0 equiv) in 3:1 EtOH/H2O (200 mL, 
0.3 M) in a 500 ml rb flask at 0° C, was added sodium hydroxide (12.3 g, 307 mmol, 5.0 
equiv). The reaction was allowed to proceed for 15 h at 5° C, after which time TLC analysis 
indicated complete consumption of the starting material. The reaction mixture was 
quenched by transfer into a 1 L separatory funnel that contained a mixture of a EtOAc (300
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mL) and pH 2 aqueous buffer (300 mL). The phases were separated and the aqueous phase 
was extracted with EtOAc (2 x 300 mL). The organic phases were combined, dried over 
Na2SO4 and concentrated under reduced pressure. Purification was accomplished by flash 
column chromatography using a 10.0 x 10.0 cm silica gel column, eluting with 15% 
EtOAc/ hexanes, collecting 125 mL fractions. The product containing fractions (5-16) 
were combined and concentrated under reduced pressure to yield acid 1.88 (15.3 g, 93%) 
as a clear yellow oil: Rf = 0.54 (50 % EtOAc/Hex.); 500 MHz 1H NMR (CDCb) S 5.87 
(dt, J  = 15.6, 1.5 Hz, 1H), 5.65 (dt, J  = 15.6, 4.9 Hz, 1H), 4.20 (dd, J  = 4.9, 1.5 Hz, 1H), 
1.34 (s, 6H), 0.91 (s, 9H), 0.07 (s, 6H); 125 MHz 13C NMR (CDCb) S 183.2, 134.2, 128.4,
63.9, 43.9, 26.1, 25.1, 24.9, 18.6, -5.0; 125 MHz DEPT 13C NMR (CDCb) CH3 S 26.1,
24.9, -5.0; CH2 S 63.9; CH1 S 134.2, 128.4; CH0 S 183.2, 43.9, 18.6; IR (neat) 2955, 2930, 
2858, 1705, 1472, 1255, 1104, 837, 777 cm-1; HRMS (ESI) calcd for C o ^ N a O sS i 
(M+Na): 281.1549, found: 281.1540.
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(E)-(4»S,6^,7^)-7-((benzyloxy)methoxy)-6-((4-methoxybenzyl)oxy)oct-1-en-4- 
yl 5-((terf-butyldimethylsilyl)oxy) -2,2-dimethyl pent-3-enoate (1.98). To a stirring 
solution of alcohol 1.67 (17.2 g, 42.8 mmol, 1.0 equiv) and acid 1.88 (14.0 g, 53.0 mmol,
1.2 equiv) in CH2Q 2 (40 mL) in a 250 ml rb flask at 0° C, was added DMAP (7.9 g, 64.3 
mmol, 1.5 equiv), DMAP'HCl (6.8 g, 42.8 mmol, 1.0 equiv) followed by 1-Ethyl-3-(3- 
dimethylaminopropyl)carbodiimide (20.0 g, 128.5 mmol, 3.0 equiv). The reaction was
allowed to proceed for 15 h at rt, after which time TLC analysis indicated complete 
consumption of the alcohol starting material. The reaction mixture was quenched by 
transfer into a 2 L separatory funnel that contained a mixture of a 20% EtOAc/Hex (400 
mL) and H2O (300 mL). The phases were separated, and the aqueous phase was extracted 
with 20% EtOAc/Hex (2 x 400 mL). The organic phases were combined, dried over 
Na2SO4 and concentrated under reduced pressure. Purification was accomplished by flash 
column chromatography using a 1 0 .0  x 1 2 .0  cm silica gel column, eluting with 1 0 % 
EtOAc/ hexanes, collecting 125 mL fractions. The product containing fractions (20-77) 
were combined and concentrated under reduced pressure to yield ester 1.98 (23.9 g, 87%)
as a clear yellow oil: Rf = 0.47 (30 % EtOAc/Hex.); [a]D = +30.8 (c = 1.0, CHCb); 500 
MHz 1H NMR (CDCb) 5 7.35-7.25 (m, 7H), 6.88-6.84 (m, 2H), 5.86 (ddd, J  = 16.2, 2.0,
2.0 Hz, 1H), 5.79 (dddd, J  = 17.1, 9.8, 6 .8 , 6 . 8  Hz, 1H), 5.75 (ddd, J  = 21.0, 5.4, 5.4 Hz, 
1H), 5.21 (dddd, J  = 6.7, 6.7, 6.7, 3.3 Hz, 1H), 5.07-5.04 (m, 1H), 5.04-5.25 (m, 1H), 4.82 
(d, J  = 6 . 8  Hz, 1H), 4.78 (d, J  = 6 . 8  Hz, 1H), 4.62 (ddd, J  = 11.7, 11.7, 11.7 Hz, 2H), 4.52 
(d, J  = 10.8 Hz, 1H), 4.36 (d, J  = 10.8 Hz, 1H), 4.16 (dd, J  = 4.9, 1.5 Hz, 2H), 3.95 (dq, J  
= 6 .8 , 6.4 Hz, 1H), 3.79 (s, 3H), 3.43 (ddd, J  = 10.3, 4.9, 2.0 Hz, 1H), 2.40-2.26 (m, 1H), 
1.84-1.77 (m, 1H), 1.70-1.62 (m, 2H), 1.30 (s, 3H), 1.29 (s, 3H), 1.18 (d, J  = 6.4 Hz, 3H), 
0.90 (s, 9H), 0.06 (s, 6 H); 125 MHz 13C NMR (CDCb) 5 175.9, 159.4, 138.0, 134.7, 133.6,
130.6, 129.9, 128.6, 128.1, 128.0, 127.9, 127.8, 118.0, 114.0, 93.4, 77.4, 73.2, 73.1, 70.4,
69.5, 63.9, 55.4, 44.1, 39.6, 34.4, 26.1, 25.3, 25.1, 15.3, -4.9; 125 MHz DEPT 13C NMR 
(CDCb) CH3 5 55.4, 26.1, 25.3, 25.1, 15.4, -4.9; CH2 5 118.0, 93.4, 73.1, 69.5, 64.0, 39.6, 
34.5; CH1 5 134.7, 133.6, 129.9, 128.6, 128.0, 127.9, 127.8, 113.9, 77.4, 73.4, 70.4; CH0 5
175.9, 159.4, 138.0, 130.6, 128.0, 44.1; IR (neat) 2954, 2857, 1727, 1514, 1469, 1385,
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octan-4-yl-5- ((terf-butyldimethylsilyl)oxy)-2,2-dimethyl pent-3-enoate (1.99). To a
stirring solution of olefin 1.98 (12.4 g, 18.9 mmol, 1.0 equiv) in THF (25 mL) under an 
argon atmosphere in a 250 ml rb flask, was added 9-borabicyclo[3.3.1]nonane (0.5 M in 
THF, 114 mL, 56.8 mmol, 3.0 equiv). Stirring continued for 10 min at rt, and then the 
solution was placed into a H 2O bath and sonicated at 60 Hz for 45 min. The solution was 
removed from the sonication bath and cooled to 0° C. A 2M aqueous NaOH solution (45 
mL) and a 30% aqueous H2O2 solution (18 mL) were added. Stirring continued for 1 h at 
0° C. The reaction mixture was quenched by transfer into a 1 L separatory funnel that 
contained a mixture of EtOAc (300 mL) and H2O (200 mL). The phases were separated, 
and the aqueous phase was extracted with EtOAc (2 x 200 mL). The combined organic 
phases were dried over Na2SO4 and concentrated under reduced pressure. Purification was 
accomplished by flash column chromatography using a 10.0 x 10.0 cm silica gel column, 
eluting with 30% EtOAc/ hexanes, collecting 125 mL fractions. The product containing 
fractions (9-45) were combined and concentrated under reduced pressure to yield alcohol
1.99 (9.20 g, 74%) as a clear oil: Rf = 0.21 (30 % EtOAc/Hex.); [a]D = +28.0 (c = 1.0,
CHCb); 500 MHz 1H NMR (CDCb) 5 7.38-7.22 (m, 7H), 6.88-6.83 (m, 2H), 5.86 (ddd, 
J  = 17.6, 2.0, 2.0 Hz, 1H), 5.61 (ddd, J  = 20.5, 4.9, 4.9 Hz, 1H), 5.17 (dddd, J  = 9.0, 6.1,
4.9, 4.9 Hz, 1H), 4.82 (d, J  = 6.8 Hz, 1H), 4.78 (d, J  = 6.8 Hz, 1H), 4.64 (d, J  = 11.7 Hz, 
2H), 4.60 (d, J  = 12.2 Hz, 1H), 4.52 (d, J  = 10.7 Hz, 1H), 4.36 (d, J  = 10.3 Hz, 1H), 4.17 
(dd, J  = 4.9, 1.5 Hz, 2H), 3.95 (dq, J  = 6.4, 4.9 Hz, 1H), 3.79 (s, 3H), 3.60 (t, J  = 6.4 Hz, 
2H), 3.42 (ddd, J  = 10.3, 4.9, 2.0 Hz, 1H), 1.85-1.79 (m, 1H), 1.79-1.68 (m, 1H), 1.60-1.51 
(m, 4H), 1.30 (s, 3H), 1.30 (s, 3H), 1.18 (d, J  = 6.4 Hz, 3H), 0.90 (s, 9H), 0.06 (s, 6H); 125 
MHz 13C NMR (CDCb) 5 176.2, 159.4, 138.0, 134.8, 130.6, 130.0, 128.6, 128.1, 127.9,
127.9, 114.0, 93.5, 77.6, 73.3, 73.1, 71.2, 69.6, 64.0, 62.6, 55.5, 44.2, 35.0, 31.4, 28.4, 26.1,
25.3, 25.1, 18.6, 15.3, -5.0 ; 125 MHz DEPT 13C NMR (CDCb) CH3 5 55.5, 26.2, 25.3,
25.1, 15.4, -4.9; CH2 5 93.5, 73.1, 69.6, 64.0, 62.6, 35.0, 31.4, 28.4; CH1 5 134.8, 130.0,
128.7, 128.1, 128.0, 127.9, 114.1, 77.6, 73.3, 71.3; CH0 5 176.2, 159.4, 138.0, 130.6, 44.2, 
18.6; IR (neat) 3478, 2951, 2858, 1723, 1613, 1513, 1464, 1385, 1148, 1039, 836, 777, 698 
cm-1; HRMS (ESI) calcd for Cs?H58NaO8NaSi (M+Na): 681.3799, found: 681.3802.
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(E)-(4»S,6^,7^)-7-((benzyloxy)methoxy)-6-((4-methoxybenzyl)oxy)-1- 
oxooctan-4-yl-5-((terf-butyldimethylsilyl)oxy)-2,2-dimethyl pent-3-enoate. To a
stirring solution of alcohol 1.99 (19.2 g, 29.1 mmol, 1.0 equiv) in CH2O 2 (150 mL) in a 
500 ml rb flask at -5° C, was added (z'Pr)2NEt (35 mL, 204.0 mmol, 7.0 equiv) and DMSO
(20 mL, 291.4 mmol, 10.0 equiv). Stirring continued for 10 min at -5° C, and then SO3*Py 
(18.6 g, 116.6 mmol, 4.0 equiv) was added in three portions over 15 min. The reaction was 
allowed to proceed for 1 h at -5 °C, after which time TLC analysis indicated complete 
consumption of the starting material. The reaction mixture was quenched with saturated 
aqueous NaHCO3 solution (150 mL). The phases were separated, and the aqueous phase 
was extracted with CH2Cl2 (3 x 200 mL). The organic phases were combined, dried over 
Na2SO4 and concentrated under reduced pressure. Purification was accomplished by flash 
column chromatography using a 10.0 x 15.0 cm silica gel column, eluting with 15% 
EtOAc/hexanes, collecting 125 mL fractions. The product containing fractions (29-86) 
were combined and concentrated under reduced pressure to yield aldehyde (17.9 g, 93%)
as a clear yellow oil: Rf = 0.54 (50 % EtOAc/Hex.); [afD = +24.0 (c = 1.0, CHCb); 500 
MHz 1H NMR (CDCb) S 9.23 (t, J  = 1.5 Hz, 1H), 7.39-7.24 (m, 7H), 6.88-6.84 (m, 2H), 
5.86 (ddd, J  = 15.6, 1.5, 1.5 Hz, 1H), 5.62 (ddd, J  = 15.6, 4.9, 4.9 Hz, 1H), 5.17 (m, 1H),
4.82 (d, J  = 6.8 Hz, 1H), 4.78 (d, J  = 6.8 Hz, 1H), 4.63 (d, J  = 11.7 Hz, 1H), 4.59 (d, J  =
12.2 Hz, 1H), 4.52 (d, J  = 10.3 Hz, 1H), 4.34 (d, J  = 10.3 Hz, 1H), 4.17 (dd, J  = 4.9, 1.5 
Hz, 2H), 3.96 (dq, J  = 6.4, 4.9 Hz, 1H), 3.79 (s, 3H), 3.42 (ddd, J  = 10.7, 4.9, 2.4 Hz, 1H), 
2.44 (t, J  = 7.8 Hz, 2H), 1.96 (dddd, J  = 12.2, 7.8, 7.8, 4.4 Hz, 1H), 1.89-1.77 (m, 2H), 
1.63-1.59 (m, 1H), 1.58-1.55 (m, 2H), 1.31 (s, 3H), 1.30 (s, 3H), 1.18 (d, J  = 6.4 Hz, 3H), 
0.90 (s, 9H), 0.06 (s, 6H); 125 MHz 13C NMR (CDCb) S 201.4, 176.1, 159.5, 138.0, 134.4,
130.5, 130.0, 128.6, 128.4, 127.9, 127.9, 114.0, 93.5, 77.5, 73.1, 73.0, 70.7, 69.6, 63.8,
55.5, 44.2, 39.9, 34.9, 27.5, 26.2, 25.4, 25.1, 18.6, 15.2, -4.9 ; 125 MHz DEPT 13C NMR 
(CDCb) CH3 S 55.5, 26.2, 25.4, 25.1, 15.2, -4.9; CH2 S 93.5, 73.1, 69.7, 63.9, 40.0, 34.9, 
27.5; CH1 S 201.4, 134.4, 130.0, 128.7, 128.4, 127.9, 127.9, 114.0, 77.5, 73.0, 70.7; CH0 S
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176.1, 159.5, 138.0, 130.5, 44.2, 18.6; IR (neat) 2931, 2857, 1725, 1514, 1464, 1386, 1249, 
1111, 1040, 836, 778 cm-1; HRMS (ESI) calcd for Cs?H56O8NaSi (M+Na): 679.3642, 
found: 679.3654.
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(E)-(5»S,7^,8^)-8-((benzyloxy)methoxy)-7-((4-methoxy benzyl)oxy) non-1-en-5-yl 
5-((ferf-butyldimethylsilyl)oxy)-2,2-dimethyl pent-3-enoate (1.87). To a stirring 
suspension of methyltriphenylphosphonium bromide (9.0 g, 25.4 mmol, 2.0 equiv) in THF 
(85 mL) in a 250 ml rb flask at -5 °C under argon, was added «-BuLi (1.8 M in hexanes, 
9.3 mL, 16.5 mmol, 1.3 equiv). The solution was stirred at rt for 30 min, which resulted in 
a yellow-orange colored solution of the Wittig reagent.
To a stirring solution of aldehyde (8.3 g, 12.7 mmol, 1.0 equiv) and THF (30 mL) in a 
50 mL at -5 °C, was added Wittig reagent dropwise via cannula over 30 min. The reaction 
was allowed to proceed for 5 min at -5 °C, after which time TLC analysis indicated 
complete consumption of the starting material. The reaction mixture was quenched by 
transfer into a 1 L separatory funnel that contained a mixture of a saturated aqueous pH 7 
buffer solution (200 mL) and 20% EtOAc/hexanes (350 mL). The phases were separated 
and the aqueous phase was extracted with 20% EtOAc/hexanes (2 x 200 mL). The organic 
phases were combined, dried over Na2SO4 and concentrated under reduced pressure. 
Purification was accomplished by flash column chromatography using a 10.0 x 16.0 cm
silica gel column, eluting with 5% EtOAc/hexanes, collecting 125 mL fractions. The 
product containing fractions (33-49) were combined and concentrated under reduced 
pressure to yield olefin 1.87 (6.2 g, 74%) as a clear oil: Rf = 0.52 (20 % EtOAc/Hex.);
[a]2° = +24.5 (c = 1.0, CHCb); 500 MHz 1H NMR (CDCb) S 7.39-7.25 (m, 7H), 6 .8 8 ­
6.83 (m, 2H), 5.88 (ddd, J  = 15.6, 1.5, 1.5 Hz, 1H), 5.76 (dddd, J  = 16.6, 10.3, 6.4, 6.4 Hz, 
1H), 5.62 (ddd, J  = 15.6, 4.9, 4.9 Hz, 1H), 5.18 (dddd, J  = 9.8, 6 .6 , 5.3, 2.9 Hz, 1H), 5.00 
(dddd, J  = 16.5, 1.6, 1.6, 1.6 Hz, 1H), 4.95 (dd, J  = 10.3, 2.0 Hz, 1H), 4.81 (d, J  = 7.1 Hz, 
1H), 4.78 (d, J  = 7.1 Hz, 1H), 4.65 (d, J  = 12.2 Hz, 1H), 4.59 (d, J  = 11.7 Hz, 1H), 4.52 (d, 
J  = 10.3 Hz, 1H), 4.37 (d, J  = 10.3 Hz, 1H), 4.17 (dd, J  = 4.9, 1.5 Hz, 2H), 3.94 (dq, J  =
6.4, 6.3 Hz, 1H), 3.80 (s, 3H), 3.41 (ddd, J  = 10.3, 4.9, 2.0 Hz, 1H), 2.09-2.01 (m, 2H), 
1.80 (ddd, J  = 14.2, 9.8, 2.0 Hz, 1H), 1.72-1.60 (m, 3H), 1.31 (s, 3H), 1.31 (s, 3H), 1.17 (d, 
J  = 6.4 Hz, 3H), 0.90 (s, 9H), 0.06 (s, 6 H); 125 MHz 13C NMR (CDCb) S 176.1, 159.4,
138.1, 138.1, 134.7, 130.7, 130.0, 128.6, 128.1, 128.0, 127.9, 115.0, 114.0, 93.5, 77.7, 73.4,
73.2, 71.2, 69.6, 64.0, 55.5, 44.2, 35.1, 34.5, 29.6, 26.2, 25.4, 25.2, 18.6, 15.3, -4.9; 125 
MHz DEPT 13C NMR (CDCb) CH3 S 55.5, 26.2, 25.4, 25.2, 15.4, -4.9; CH2 S 115.0, 93.5,
73.2, 69.6, 63.9, 35.1, 34.5, 29.5; CH1 S 138.1, 134.7, 130.0, 128.6, 128.1, 128.0, 127.9,
114.0, 77.7, 73.4, 71.2; CH0 S 176.1, 159.4, 138.1, 130.7, 44.2, 18.6; IR (neat) 2931, 2857, 
1725, 1514, 1413, 1464, 1249, 1147, 1105, 1042, 836, 777 cm-1; HRMS (ESI) calcd for 
C38H 58O7NaSi (M+Na): 677.3850, found: 677.3850.
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(((E)-4-((»V)-2-((2^,3^)-3-((benzyloxy)meth oxy) -2-((4-methoxybenzyl) 
oxy)butyl)-3,4-dihydro-2#-pyran-6-yl)-4-methylpent-2-en-1-yl) oxy)(tert-
butyl)dimethylsilane (1.86). To a stirring solution of titanium(IV) chloride (15.6 mL, 
141.8 mmol, 15.0 equiv) in CH2O 2 (600 mL) in a 2 L rb flask at 0 °C under argon, was 
added THF (80 mL) to give a golden yellow solution. The solution was stirred at 0 °C for 
10 min, then TMEDA (135.0 mL, 907.3 mmol, 96.0 equiv) was added dropwise, resulting 
in a color change to brown. The solution was stirred at rt for 30 min, then activated zinc 
(22.2 g, 340.2 mmol, 36.0 equiv) and lead(II) chloride (5.3 g, 18.9 mmol, 2.0 equiv) were 
added in one large portion. A series of color changes occured, ultimately resulting in a 
blue-green solution. A solution of olefin 1.87 (6.2 g, 9.5 mmol, 1.0 equiv) and 1,1- 
dibromoethane (13.8 mL, 151.2 mmol, 16.0 equiv) in CH2Q 2 (150 mL) was added slowly 
over 20 min via an addition funnel. The addition funnel was rinsed with additional CH2Q 2 
(10 mL) and slowly added to the reaction mixture. The addition funnel was removed and 
the mixture was heated at reflux for 2 h, then cooled to 0 °C and quenched by the addition 
of saturated aqueous potassium carbonate solution (110 mL). The resulting solution was 
stirred at 0 °C for 30 min, and was then filtered through a 3 cm alumina pad. The reaction 
flask was washed with CH2Q 2 (300 mL) and filtered. This procedure was repeated 2 more 
times. The filtrate was concentrated under reduced pressure, and the resulting solid was 
filtered and washed with 50% EtOAc/hexanes (500 mL) in order to remove salts prior to 
chromatography Purification was accomplished by flash column chromatography using a
10.0 x 10.0 cm silica gel column, eluting with 10% EtOAc/hexanes, collecting 125 mL 
fractions. The product containing fractions (3-18) were combined and concentrated under 
reduced pressure to yield cyclic enol ether 1.86 (4.7 g, 80%) as a clear yellow oil: Rf =
0.39 (5 % EtOAc/toluene); [a]D = +37.9 (c = 1.0, CHCb); 500 MHz 1H NMR (CDCb) 
5 7.38-7.23 (m, 7H), 6.88-6.84 (m, 2H), 5.75 (ddd, J  = 15.6, 1.5, 1.5 Hz, 1H), 5.52 (ddd, J  
= 15.6, 10.3, 5.4, 5.4 Hz, 1H), 4.85 (d, J  = 6 .8  Hz, 1H), 4.82 (d, J  = 7.3 Hz, 1H), 4.69-4.60 
(m, 3H), 4.55 (dd, J  = 4.4, 2.9 Hz, 1H), 4.52 (d, J  = 10.7 Hz, 1H), 4.14 (dd, J  = 5.4, 1.5 Hz, 
2H), 4.01 (dddd, J  = 9.8, 9.8, 2.0, 2.0 Hz, 1H), 3.95 (dq, J  = 6.4, 6.4 Hz, 1H), 3.83 (ddd, J  
= 10.7, 5.4, 2.5 Hz, 1H), 3.80 (s, 3H), 2.08 (dddd, J  = 17.1, 9.8, 6 .8 , 2.9 Hz, 1H), 2.02-1.84 
(m, 1H), 1.80 (ddd, J  = 14.2, 10.3, 2.0 Hz, 1H), 1.75 (ddd, J  = 13.7, 6 .8 , 3.4 Hz, 1H), 1.61 
(ddd, J  = 13.2, 10.7, 2.4 Hz, 1H), 1.36-1.25 (m, 1H), 1.20 (d, J  = 6.4 Hz, 3H), 1.17 (s, 3H), 
1.17 (s, 3H), 0.90 (s, 9H), 0.05 (s, 6 H); 125 MHz 13C NMR (CDCb) 5 159.3, 159.1, 138.7,
138.1, 131.1, 129.6, 128.6, 128.0, 127.8, 125.9, 114.0, 93.6, 93.2, 78.0, 74.1, 73.6, 71.6,
69.6, 64.6, 55.4, 40.5, 36.4, 28.4, 26.2, 26.1, 26.0, 20.6, 18.6, 15.8, -4.8; 125 MHz DEPT 
13C NMR (CDCb) CH3 5 55.4, 26.2, 26.1, 25.9, 15.8, -4.8; CH2 5 93.6, 73.6, 69.5, 64.6,
36.4, 28.3, 20.6; CH1 5 138.7, 129.6, 128.6, 128.0, 127.8, 125.9, 114.0, 93.2, 78.0, 74.1, 
71.7; CH0 5 159.3, 159.1, 138.1, 131.1, 40.5, 18.6; IR (neat) 2930, 2856, 1661, 1581, 1462, 





2-((E)-5-((terf-butyldimethyl silyl)oxy)-2-methylpent-3-en-2-yl)-2- methoxydihydro- 
2H- pyran-3(4H)-one (1.85). To a stirring solution of magnesium monoperoxyphthalic 
acid (80%, 12.7 g, 20.5 mmol, 2.0 equiv) and NaHCO3 (8.6 g, 102.4 mmol, 10.0 equiv) in 
CH2Ch/MeOH (1:1, 70 mL) in a 250 ml rb flask at 0° C, was added glycal 1.86 (6.4 g,
10.2 mmol, 1.0 equiv) in CH2O 2 (30 mL) dropwise via cannula. The flask was rinsed with 
an additional CH2Cl2 (5 mL) and slowly added to the reaction mixture. TLC analysis after 
3 h at 0° C indicated complete consumption of the enol ether starting material. The reaction 
mixture was quenched by transfer into a 1 L separatory funnel that contained a mixture of 
a saturated aqueous H2O (350 mL) and EtOAc (200 mL). The phases were separated, and 
the aqueous phase was extracted with EtOAc (3 x 200 mL). The organic phases were 
combined, dried over Na2SO4 and concentrated under reduced pressure to provide the crude 
intermediate alcohol as a clear light yellow oil. This material was carried onto the next step 
without further purification.
To a stirring solution of previously described crude alcohol in CH2O 2 (100 mL) in 
a 250 ml rb flask at rt, was added oven dried 4 A molecular sieves (13.0 g) and N- 
methylmorpholine-N-Oxide (3.6 g, 30.7 mmol, 3.0 equiv). Stirring continued for 10 min 
and then tetrapropylammonium perruthenate (358 mg, 1.0 mmol, 0.1 equiv) was added. 
Stirring continued for 1 h, then the reaction was filtered through a 4 cm pad of silica gel. 
The silica pad was washed with EtOAc (3 x 100 mL). The resulting solution was
concentrated under reduced pressure. Purification was accomplished by flash column 
chromatography using a 1 0 .0  x 1 0 .0  cm silica gel column, eluting with 1 0 % 
EtOAc/hexanes, collecting 125 mL Erlenmeyer flask fractions. The product containing 
fractions (25-41) were combined and concentrated under reduced pressure to yield ketone
1.85 (4.6 g, 6 6 % over 2 steps) as a clear yellow oil: Rf = 0.44 (30 % EtOAc/hexanes);
[a]D = +15.2 (c = 1.0, CHCb); 500 MHz 1H NMR (CDCb) 5 7.39-7.19 (m, 7H), 6.87­
6.82 (m, 2H), 5.50 (ddd, J  = 16.1, 1.5, 1.5 Hz, 1H), 5.50 (ddd, J  = 16.1, 5.4, 5.4 Hz, 1H),
4.85 (dd, J  = 10.3, 6 . 8  Hz, 1H), 4.66 (s, 2H), 4.63 (d, J  = 11.2 Hz, 1H), 4.44 (d, J  = 10.7 
Hz, 1H), 4.14 (dd, J  = 4.9, 1.5 Hz, 2H), 4.13-4.07 (m, 2H), 3.88 (dq, J  = 3.4, 2.0 Hz, 1H), 
3.79 (s, 3H), 3.23 (s, 3H), 2.43 (dd, J  = 8.3, 5.4 Hz, 2H), 2.00-1.83 (m, 3H), 1.80 (ddd, J  =
14.2, 10.3, 2.0 Hz, 1H), 1.68 (ddd, J  = 14.3, 10.3, 2.4 Hz, 1H), 1.21 (d, J  = 6.4 Hz, 3H), 
1.14 (s, 3H), 1.10 (s, 3H), 0.90 (s, 9H), 0.06 (s, 3H), 0.06 (s, 3H); 125 MHz 13C NMR 
(CDCb) 5 207.5, 159.3, 138.0, 136.1, 130.7, 129.4, 128.6, 127.9, 127.8, 127.7, 113.9,
104.2, 93.5, 77.3, 72.6, 72.1, 70.1, 69.6, 64.2, 55.4, 52.3, 44.1, 37.7, 36.4, 30.2, 26.1, 22.9,
22.2, 18.5, 14.9, -5.0; 125 MHz DEPT 13C NMR (CDCb) CH3 5 55.4, 52.3, 26.2, 22.9,
22.2, 14.9, -5.0; CH2 5 93.5, 72.2, 69.6, 64.2, 37.7, 36.4, 30.2; CH1 5 136.1, 129.4, 128.6,
128.0, 127.9, 127.8, 114.0, 77.3, 72.6, 70.1; CH0 5 207.5, 159.3, 138.0, 104.2, 44.1, 18.5; 
IR (neat) 2950, 2857, 1723, 1612, 1513, 1463, 1382, 1249, 1112, 837, 737, 698 cm 1; 





en-2-yl)-2-methoxy-3-oxodihydro-2#-pyran-4(3#)-ylidene) acetate (1.103). To a
stirring solution of the ketone 1.85 (3.72 g, 5.54 mmol, 1.0 equiv) in MeOH (55 mL) in a 
100 ml rb flask at rt, was added K2CO3 (2.30 g, 16.6 mmol, 3.0 equiv) followed by methyl 
glyoxylate (1.24 M in THF, 11.2 mL, 13.9 mmol, 2.5 equiv). The reaction was allowed to 
proceed for 1 h at rt, after which time TLC analysis indicated complete consumption of the 
ketone starting material. The reaction mixture was quenched with saturated aqueous 
NH4O  solution (10 mL). The mixture was diluted with H2O (150 mL) and Et2O (200 mL). 
The phases were separated, and the aqueous phase was extracted with Et2O (2 x 200 mL). 
The organic phases were combined, dried over Na2SO4, and concentrated under reduced 
pressure. Purification was accomplished by flash column chromatography using a 5.0 x
10.0 cm silica gel column, eluting with 15% EtOAc/hexanes, collecting 25 mL fractions. 
The product containing fractions (9-28) were combined and concentrated under reduced 
pressure to yield enoate 1.103 (3.36 g, 82%) as a bright yellow oil: Rf = 0.53 (4:5:1
CH2Cl2/hexanes/Et2O); [a]D = -28.1 (c = 1.0, CHCb); 500 MHz 1H NMR (CDCb) S 
7.40-7.15 (m, 7H), 6.84-6.79 (m, 2H), 6.53 (q, J  = 2.0 Hz, 1H), 5.81 (ddd, J  = 15.6, 1.5, 
1.5 Hz, 1H), 5.40 (ddd, J  = 16.1, 5.4, 5.4 Hz, 1H), 4.85 (dd, J  = 10.7, 6.8 Hz, 2H), 4.66 (s,
2H), 4.61 (d, J  = 10.7 Hz, 1H), 4.41 (d, J  = 11.2 Hz, 1H), 4.18-4.08 (m, 2H), 4.06 (ddd, J  
= 5.4, 3.9, 2.0 Hz, 2H), 3.89 (dq, J  = 3.4, 2.0 Hz, 1H), 3.78 (s, 3H), 3.75 (s, 3H), 3.31 (ddd, 
J  = 18.6, 2.0, 2.0 Hz, 1H), 3.20 (s, 3H), 2.85 (ddd, J  = 19.1, 12.7, 3.4 Hz, 1H), 1.96 (ddd, 
J  = 14.2, 8.8, 2.0 Hz, 1H), 1.75 (ddd, J  = 14.2, 10.3, 2.9 Hz, 1H), 1.21 (d, J  = 6.4 Hz, 3H), 
1.10 (s, 3H), 1.04 (s, 3H), 0.90 (s, 9H), 0.04 (s, 6H); 125 MHz 13C NMR (CDCb) 5 197.8,
166.2, 159.4, 148.2, 138.1, 134.8, 130.6, 129.3, 128.8, 128.7, 128.0, 127.9, 122.7, 114.0,
104.8, 93.6, 76.9, 72.4, 71.8, 69.7, 69.5, 64.1, 55.4, 52.2, 52.0, 44.7, 36.2, 36.1, 26.1, 22.5,
22.0, 18.5, 14.7, -5.0; 125 MHz DEPT 13C NMR (CDCb) CH3 5 55.4, 52.2, 51.9, 26.1,
22.5, 22.0, 14.7, -5.0; CH2 5 93.6, 71.8, 69.7, 64.1, 36.2, 36.1; CH1 5 134.8, 129.3, 128.8,
128.7, 128.1, 127.9, 122.7, 114.0, 76.9, 72.4, 69.5; CH0 5 197.8, 166.2, 159.4, 148.2, 138.1,
130.6, 104.8, 44.7, 18.5; IR (neat) 2952, 2886, 2856, 1724, 1706, 1514, 1250, 1109, 1043,
835, 777 cm 1; HRMS (ESI) calcd for C41H60NaO 10Si (M+Na) 763.3853, found 763.3856.
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(E)-methyl 2-((2^,3^,6^)-3-acetoxy-6-((2^,3^)-3-((benzyloxy)methoxy)-2-((4- 
methoxybenzyl)oxy)butyl)-2-((E)-5-((tert-butyldimethy lsilyl)oxy) -2-methylpent -3- 
en-2-yl )-2-methoxydihydro -2#-pyran-4(3#)-ylidene)acetate (1.84). To a stirring 
solution of the ketone 1.103 (2.23 g, 3.0 mmol, 1.0 equiv) in MeOH (74 mL) in a 500 ml 
rb flask at rt, was added CeCb7H2O (22.2 g, 60.2 mmol, 20.0 equiv). The mixture was 
stirred until all the CeCb7H2O was completely dissolved. The mixture was then cooled
90
to -40 °C and then NaBH4 (766 mg, 20.2 mmol, 10.0 equiv) was added in one portion. 
Stirring continued for 1 h at -40 °C, after which the reaction was quenched by slow addition 
of saturated aqueous NH4 Q  solution (100 mL) and diluted with 50% EtOAc/hexanes (200 
mL). The phases were separated, and the aqueous phase was extracted with 50% 
EtOAc/hexanes (2 x 10 mL). The combined organic phases were dried over Na2SO4, 
filtered and carefully concentrated under reduced pressure to provide the crude alcohol was 
used in the next step without purification.
To a stirring solution of crude alcohol and DMAP (367 mg, 3.00 mmol, 1.0 equiv) in 
CH2Cl2 (150 mL, 0.02 M) in a 250 mL rb flask at 0 °C, was added a mixture of acetic 
anhydride (1.4 mL, 15.0 mmol, 5.0 equiv) and pyridine (4.9 mL, 60.2 mol, 20.0 equiv) 
dropwise via syringe. The solution was stirred at 0 °C for 3 h. The reaction mixture was 
quenched with saturated aqueous NaHCO3 solution (50 mL) and stirred for 1 h. The phases 
were separated and the aqueous phase was extracted with 50% EtOAc/hexanes (2 x 100 
mL). The organic phases were combined, dried over Na2SO4, and concentrated under 
reduced pressure. Purification was accomplished by flash column chromatography using 
a 5.0 x 16.0 cm silica gel column, eluting with 15% EtOAc/hexanes, collecting 25 mL 
fractions. The product containing fractions (7-21) were combined and concentrated under 
reduced pressure to yield ester 1.84 (2.1 g, 87%) as a clear oil: Rf = 0.41 (30%
EtOAc/hexanes); [a]D = -1.1 (c = 1.0, CHCb); 500 MHz 1H NMR (CDCb) 5 7.40-7.14 
(m, 7H), 6.84-6.81 (m, 2H), 6.00 (ddd, J  = 15.6, 1.5, 1.5 Hz, 1H), 5.90-5.82 (m, 1H), 5.40 
(ddd, J  = 16.1, 5.3, 5.3 Hz, 1H), 5.37 (s, 2H), 4.87 (d, J  = 7.3 Hz, 1H), 4.84 (d, J  = 7.4 Hz, 
1H), 4.66 (d, J  = 1.9 Hz, 2H), 4.61 (d, J  = 10.7 Hz, 1H), 4.41 (d, J  = 10.7 Hz, 1H), 4.17­
4.09 (m, 2H), 4.03 (dddd, J  = 12.4, 9.2, 2.7, 2.7 Hz, 1H), 3.89 (dq, J  = 4.3, 1.9 Hz, 1H),
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3.78 (s, 3H), 3.68 (s, 3H), 3.51 (dd, J  = 15.6, 8.5 Hz, 1H), 3.23 (s, 3H), 2.29 (ddd, J  = 14.6,
12.1, 1.9 Hz, 1H), 2.03 (s, 3H), 1.92 (ddd, J  = 14.2, 10.2, 2.0 Hz, 1H), 1.73 (ddd, J  = 14.6,
10.2, 2.4 Hz, 1H), 1.22 (d, J  = 6.4 Hz, 3H), 1.10 (s, 6H), 0.89 (s, 9H), 0.05 (s, 6H); 125 
MHz 13C NMR (CDCb) S 169.0, 166.2, 159.0, 152.2, 138.0, 137.8, 130.3, 129.2, 128.3,
127.6, 127.5, 124.0, 117.3, 113.6, 102.5, 93.1, 76.6, 72.1, 71.8, 71.7, 69.3, 68.3, 64.3, 55.0,
51.4, 50.9, 45.6, 36.2, 32.3, 25.1, 24.6, 23.1, 21.1, 18.3, 14.5, -5.1; 125 MHz DEPT 13C 
NMR (CDCb) CH3 S 55.0, 51.4, 51.0, 25.9, 24.6, 23.1, 21.1, 14.5, -5.1; CH2 S 93.1, 71.7,
69.3, 64.3, 36.1, 32.3; CH S 138.1, 129.2, 128.3, 127.6, 127.5 124.1, 117.3, 113.7, 76.6,
72.1, 71.8, 68.3; CH0 S 169.0, 106.2, 159.0, 152.2, 137.8, 130.3, 102.5, 45.6, 18.3. IR 
(neat) 2952, 2886, 2856, 1747, 1720, 1613, 1514, 1462, 1373, 1249, 1158, 1107, 1043,
836, 777, 689 cm-1; HRMS (ESI) calcd for C43H64NaOnSi (M+Na) 807.4116, found 
807.4129.
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CHAPTER 2
THE SYNTHESIS AND THE BIOLOGICAL PROFILE OF FLUORESCENT
BRYOSTATIN ANALOGS
Introduction
The secondary messenger 1,2-diacylglycerol (DAG) is an important regulator of a 
wide range of cellular functions such as apoptosis, differentiation, cell growth, and tumor- 
promotion. The response to DAG is mediated by a superclass of receptors including protein 
kinase C (PKC), which is widely studied for its role in cell proliferation, differentiation, 
and apoptosis.1 There are 2 classes of DAG-sensitive isozymes of PKC, classic PKC 
isozymes (a, pi, PII, y) and calcium independent novel PKC isozymes (s, S, n). When DAG 
binds to PKC it activates the kinase and induces translocation to a subcellular compartment 
or membrane. This activated receptor may interact with different targeted proteins or 
phosphorylate substrates based on the localization of the PKC. While DAG is the 
endogenous activator of PKC, exogenous ligands such as phorbol esters and bryostatins 
can also activate the kinase. These particular ligands have a much higher binding affinity 
for PKC than do the DAGs.
Characterizing the translocation of PKC using PKCs labelled with green 
fluorescent proteins (GFPs) has proven to be a valuable tool in learning more about this 
event.2 The Blumberg lab has observed that the location of PKC and the rate of 
translocation differ when exposed to phorbol esters of varying lipophilicity. The more 
lipophilic phorbol esters induce initial translocation of GFP-PKCS to the plasma membrane
while the more hydrophilic esters resulted in initial translocationto the nuclear membrane.3 
The effect of varying ligands on the translocation of PKC is not yet well understood. A 
better understanding of factors driving PKCs translocation may explain why different C1 
domain binding ligands show selectivity in their activation of downstream cellular 
pathways while having similar in vitro binding affinities.4 The location and persistence of 
activated PKC may play a key role in determining its access to different substrates effecting 
activation of downstream cellular pathways. This knowledge is important to understand 
the DAG signaling pathway and facilitate the design of selective C1 domain binding drugs.
The Role of Phorbol Esters in the Translocation of PKC
In 2005, the Blumberg group and collaborators designed and constructed a series 
of brightly fluorescent phorbol ester derivatives with the purpose of observing the real time 
analysis of the pharmacokinetics and intracellular migration of these ligands. The synthesis 
of these derivatives is shown in Figure 2.1. Details of the reagents and yields were not 
disclosed in the published paper. A linker between the phorbol ester 2.1 and fluorescent 
tag was incorporated through an esterification reaction to give 2.3. The Fmoc carbamate 
was then removed using TBAF to produce the primary amine. Peptide coupling then 
introduced the BODIPY FL tags that varied in carbon chain length. Using acidic 
conditions, the triphenylmethyl ether was removed to produce fluorescent phorbol esters 
that varied in length (C2, C4, C10, and C15) 2.4.
The binding affinities of the fluorescent phorbol esters are shown in Table 2.1. The 
Ki values for all of the phorbol esters were measured for PKCa and PKC5, and found to 
range from 1.4-210 nM. The fluorescent phorbol esters were all less potent than [20-3#]
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1) Fluorescent reagents 
2) AcCI, MeOH
Figure 2.1. Synthesis o f Fluorescent Phorbol Esters
phorbol 12,13-dibutyrate (PDBu) and showed a decrease in binding affinity as the chain 
length on the ester increased from C2 to C15. The decrease in binding affinity was 
attributed to poor solubility of the fluorescent derivatives in aqueous media, so this 
measurement was assayed with an increased incubation time of 30 min. The K  values then 
became similar across different phorbol esters in PKCS. For example, PE-BDFL-C15 
(phorbol ester-BODIPY FL tag- C15) has a binding affinity for PKCS of 199 nM at 5 min, 
but after 30 min had an affinity of 31 nM.
Using both fluorescent phorbol esters and fluorescent PKC, the Blumberg group
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Table 2.1. Binding Properties o f Fluorecent Phorbol Esters
Ligand Receptor binding (Ki nmol/L)
PKCa, PKC 8, PKCS,
5-min 5-min 30-min
PDBu 0.30 ± 0.05 0.39 ± 0.004
PE-BDFL-C2 1.4 ±0.1 3.0 ± 0 .2 1.5 ±0.1
PE-BDFL-C4 6.0 ±0.3 4.8 ± 0.4 2.8 ± 0 .2
PE-BDFL-C10 16.0 ±0 .5 8.1 ± 0 .4 2.2 ± 0.0
PE-BDFL-C15 211 ± 17 199 ± 2 6 31.2 ± 0 .4
was able to simultaneously compare the distribution of ligand and receptor. This was 
accomplished using CHO (Chinese hamster ovary) cells that were transfected with 
plasmids expressing fusions of PKCa and PKCP to DsRed (red fluorescent protein). These 
cells were then treated with the BODIPY FL tagged phorbol esters and visualized in real 
time using laser scanning confocal microscopy. The results from the C2 and C10 phorbol 
esters with PKCa-DsRed are shown in Figure 2.2. A patchy translocation pattern of PKCa- 
DsRed to the plasma membrane was found regardless of the lipophilicity of the phorbol 
ester. The C2 phorbol ester (PE-BDFL-C2) showed very little colocalization with PKCa- 
DsRed and was located in the perinuclear area. In contrast, the duration of C10 phorbol 
ester (PE-BDFL-C2) colocalization with PKCa-DsRed in the plasma membrane increased 
significantly. The predominant location of the lipophilic phorbol esters ligands eventually 
shifted to the perinuclear membrane area, but at a lower rate.
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Figure 2.2. Visualization of Fluorescent Phorbol Esters with PKCa
PKCS-DsRed translocates similarly toPKCa-DsRed (Figure 2.3). Phorbol esters 
like PE-BDFL-C2 showed perinuclear colocalization with PKCS, whereas the more 
hydrophobic phorbol esters like PE-BDFL-C15 showed initial cytoplasmic membrane 
localization. Over time the PE- BDFL-C15 moved primarily to the nuclear membrane. The 
differences observed in translocation are thought to be due to the lipophilicity of the 








Figure 2.3. Visualization of Fluorescent Phorbol Esters with PKC5
The Proposed Pharmacophoric Elements of the Bryostatins
In 1988, a collaborative effort between the Wender, Blumberg and Petit groups led 
to the first series of structure activity relationship (SAR) studies of the bryostatins.5 These 
studies compared semisynthetic bryostatins and bryostatin natural products. Comparing the 
binding affinities across bryostatin 1-10, 16, 17, and 18, showed that changing the esters 
group at the C7 and C20 positions did not increase or decrease the binding affinity 
significantly. When bryostatin 5 and bryostatin 16 were compared, a significant loss in
binding affinity was observed (Figure 2.4). Bryostatin 16 lacks the C19-C20 oxidations, 
and as a result loses its internal hydrogen bonding network. Additional correlations 
between binding affinity and structure were gained from semi-synthetic bryostatins. Two 
analogs, 2.5 and 2.6, were obtained from the hydrogenation of bryostatin 1. Both analogs 
had a reduced C20 a,P,y,5-ester and C13 enoate. Analog 2.6 had an additional reduction of 
the C21 enoate bond causing a substantial decrease in binding affinity. Acetylation of the 
C26 alcohol of bryostatin 4 had the most dramatic effect, essentially eliminating the 
analogs binding affinity for PKC.
The Wender group also compared the structure of DAG, phorbol esters, and 
bryostatin using SAR and computational methods. From these comparisons a 
pharmacophore was proposed (Figure 2.5). It was proposed that all 3 PKC ligands shared 
a common binding motif, a heteroatom triad that interacts with the C1 domain of PKC 
through hydrogen bonds. It was suggested that the C1, C19, and C26 oxygens of bryostatin 
are the main pharmacophores responsible for binding to PKC. These atoms corresponded 
to the C4, C9, and C20 oxygen atoms in phorbol, respectively. From these studies 2 
hypotheses were developed. The first was that the southern portion of bryostatin is the 
region important for binding to PKC. The second was that the northern half of bryostatin 
serves as a ‘spacer domain’ that holds the pharmacophoric region in a rigid conformation 
providing proper orientation for binding.
Simplified Bryostatin Analogs 
In 2008, the Keck group prepared structurally simplified analogs of bryostatin that 
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Figure 2.5. PKC Ligand Binding Hypothesis
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bryostatin analog constructed by the Keck group was Merle 23 (Figure 2.6, part A).7 Merle 
23 differs from bryostatin 1 at 4 positions across the northern half. This analog omits the 
C9 alcohol, while replacing the C7 ester and the C13 enoate exocyclic methylenes, and 
removing the C8 gem-dimethyl. These simplifications do not affect the proposed 
pharmacophoric elements in the southern half of the molecule that are important for 
binding to PKC.8
The Synthesis of Merle 23
The synthetic approach to Merle 23 is shown on Figure 2.6, part B. The C21 




Figure 2.6. Structural Differences (A) and 
Retrosynthesis of Merle 23 (B)
the C20 ester would be established by a reduction and esterification of this ketone. The A- 
ring 2.9 and C-ring 2.10 would be combined using the previously developed pyran 
annulation9 and a Yamaguchi macrolactonization to give 2.8.
The pyran annulation between hydroxy allyl silane 2.9 and C-ring aldehyde 2.10 
provided the tricyclic macrolactone in an 82% isolated yield (Figure 2.7). The elaboration 
of the C1 BPS ether to carboxylic acid 2.12 was accomplished by a selective deprotection 
of the BPS group using TBAF buffered with AcOH 10, followed by sequential Parikh- 
Doering and Pinnick oxidations. The 20 membered macrolactone was completed by 
removing the C25 TBS group, followed by a Yamaguchi macrolactonization to afford the 
desired tricyclic macrolactone 2.8 in 87% isolated yield over 2 steps. The installation of 
the C21 enoate involved a 2-step procedure starting with the aldol reaction of methyl 
glyoxylate with ketone 2.8, followed by elimination with carbonyl diimidazole and Et3N. 
A Luche reduction of the resulting ketone gave the alcohol which was immediately 
acylated with (2E ,4E)-octa-2,4-dienoic anhydride to give protected versions of Merle 23 
2.13 as a 4:1 mixture of diastereomers at the C20 position. Global deprotection of the 
remaining protecting groups was accomplished in 2 steps. The C3 PMB ether was removed 
with DDQ, and the C26 BOM ether and C19 methyl ketal with LiBF4.11
The Biological Evaluation of Merle 23
Merle 23 (Ki = 0.70 ±0.01 nM) proved to have a higher binding affinity for PKC 
than does bryostatin 1 (Ki = 1.35 nM). However, the binding affinity for Merle 23 was 
measured using pure PKCa, whereas the 1.35 nM binding affinity for bryostatin1 had been 
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Figure 2.7. Synthesis of Merle 23
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determination of K  for bryostatin 1 gives a 0.48 ±0.03 nM for PKCa. Simply comparing 
binding affinities only characterizes the compounds as competent PKC ligands and does 
not determine if the analogs biologically mimic bryostatin. In a U937 leukemia cell assay, 
phorbol esters inhibit proliferation and induce attachment while bryostatin 1 fails to induce 
either effect.12 Additionally, bryostatin 1 antagonizes the response induced by PMA in a 
dose dependent manner. This experiment was suggested and performed by Blumberg and 
his group at the NIH as one assay to demonstrate whether or not an analog will be 
‘bryostatin like.’ When evaluated in this assay, Merle 23 displayed a PMA like behavior 
in that it both inhibits proliferation (Figure 2.8, part A) and induces attachment (Figure 2.8, 
part B). Merle 23 also does not antagonize the response to PMA like bryostatin 1 does. We 
concluded that the northern region must somehow be responsible for the PMA like activity 
of Merle 23 in the U937 cell line and is not simply a spacer domain as suggested in the 
literature.8
The Synthesis Merle 28
Due to the ‘PMA-like’ activity exhibited by Merle 23 in U937 cells, the functional 
groups on the northern half of the analog responsible for this switch were evaluated. It was 
hypothesized that one or more of the 4 changes (C7, C8, C9, and C13) in the molecule 
were responsible for this switch. In order to determine the substitution crucial for the shift, 
a systematic deletion of one group at a time, starting with the C30 ester, was undertaken 
(Figure 2.9).13 Synthetically, this would be the easiest analog to obtain with one of the 4 
deletions because it was accessible through previously developed routes to the A-ring 2.16 
and C-ring fragments 2.15.
112
Treatment for 72 hours
A
B




Figure 2.9. Structural Difference of Merle 28 (A) and 
Retrosynthesis of Merle 28 (B)
The retrosynthesis of Merle 28 is shown in Figure 2.9. Similarly to Merle 23, the 
C-ring of 2.14 would be functionalized after the A-ring and C-ring were joined together. 
The 20-membered macrolactone would be completed through a Yamaguchi 
macrolactonization to construct Merle 28. The P -hydroxyallyl silane 2.15 and aldehyde 
2.16 would be joined through a pyran annulation reaction.
The synthesis of the C-ring P-hydroxyallyl silane started from cyclic enol ether 
2.17.14 This aldehyde was reacted with trimethyl(2-((tributylstannyl)methyl)allyl)silane 
under asymmetric allylation conditions to give C15 P-hydroxyallyl silane 2.15 (Figure 
2.10). The synthesis of A-ring 2.16 was accomplished using a previously developed 
procedure.15 Both fragments were combined using TMSOTf to provide the desired tricyclic 
adduct 2.14 in a 58% yield. The functionalization of the C-ring began with the epoxidation 
of the glycal using MMPP and in situ opening by MeOH to provide the a-hydroxyl ketal. 
This alcohol was immediately oxidized using TPAP/NMO to afford C20 ketone 2.18. 
Installation of the a, y9-unsaturated methyl ester at the C21 position was accomplished using 
a 2-step process involving an aldol reaction of the ketone with methyl glyoxylate, followed 
by dehydration with CDI to deliver enoate 2.19. The relatively low yield of 47 % was due 
to a side reaction at the C7 acetate position.
A Luche reduction of the C20 ketone afforded the alcohol intermediate, which was 
quickly esterified by reaction with (2E ,4E)-octa-2,4-dienoic anhydride to provide ester 
2.20 (Figure 2.11). With all the necessary functional groups incorporated, the next step was 
to produce the seco acid for macrolactonization. This was achieved by the removal of the 
C3 BPS group followed by hydrolysis of the thioester. The resulting hydroxy acid was 
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Figure 2.11. Completion of C30-decarbomethoxy Bryostatin 1
macrolactonization afforded the macrolactone 2.21. Global deprotection using LiBF4 
hydrolyzed the 2 ketals, the C3 TES, and the C26 BOM ether to give the desired analog 
Merle 28.
The Biological Evaluation of Merle 28
Merle 28 was evaluated for PKC binding affinity and assayed for function in the 
U937 leukemia cell line. Merle 28 was shown to have a binding affinity of 0.52 ± 0.06 nM 
for PKCa. In the U937 cells, Merle 28 (numbered 12 in Figure 2.12) resembled bryostatin
1 rather than PMA. Merle 28 resembled bryostatin 1 by giving a dose-dependent biphasic 
pattern in its inhibition of cell growth. When co-administered, Merle 28 proved to be a 
functional antagonist of PMA and blocked the effect of the phorbol ester. A similar result 
was obtained in the cell attachment assay where Merle 28 had a reduced level of cell 
attachment, similar to bryostatin 1. When co-administered, Merle 28 inhibited the 
attachment induced by PMA. From this U937 cell line study of Merle 28, it was found that 
the absence of the C30 carbomethoxy group does not decrease the binding affinity for 
PKCa, and does not change the bryostatin like biological activity. From these experiments 
it was concluded that Merle 28 is a functional analogue of bryostatin 1.
Results and Discussion 
Merle 23 and Merle 28 differ from each other at only 3 positions (C7, C8, and C9), 
but have very different responses in U937 cells. Merle 23 acts ‘PMA like’ and Merle 28 
acts ‘bryo-like’ (Figure 2.13). We decided to investigate why these 2 structurally similar 
analogs have very different biological responses. Using a fluorescent version of
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Figure 2.12. Proliferation and Attachment of U937 Cells by Merle 28
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Figure 2.13. Bryostatin Analogs
these bryostatin analogs will help us understand the phenomena of PKC 
translocation,which is believed to be at least partially responsible for different biological 
responses observed with different PKC ligands. The localization of the fluorescent 
bryostatin analogs will be correlated to the localization of GFP-PKC isozymes. The uptake 
rate of the analogs by the cells may also have an effect on where PKC translocates. Since 
location and persistence of activated PKC plays a key role in downstream cellular 
pathways, these analogs might help explain what kind of cellular responses is key to ‘bryo- 
like’ activity. However, incorporating a tag may affect the binding affinity and biological 
responses of Merle 23 and Merle 28.
The Fluorescent Tag and the Position
The photo and chemical stability, solubility, narrow emission bands, high emission 
intensity, and visible excitation wavelength of BOPIPY fluorophores make it a popular tag 
for imaging applications. The initial studies involving BODIPY FL labeled phorbol esters 
used this tag to study PKC translocation.4 Typically a BODIPY adduct is constructed
through an esterification or peptide coupling reaction.
The location of the BODIPY tag was limited to a late stage installation since its 
stability during many chemical manipulations was questionable. In Merle 23 and Merle 28, 
shown in Figure 2.13, there are only 3 sites common for a late stage esterification reaction 
(C3, C20, and C26). Through semisynthetic bryostatin analogs, if the C26 alcohol is 
esterified the molecule loses binding affinity. It has also been observed that the C3 alcohol 
is very unreactive toward electrophiles due to the internal hydrogen bond network present 
in the bryostatin structure. Different ester groups at the C20 position on Merle 23 have 
been shown to have limited effects on binding and biological activity.8, 16 For these 
reasons, we chose the C20 position as the best location to install the BODIPY tag.
A computational study of bryostain 1 in the C1 domain of PKC was conducted by 
Dr. Megan Peach from the NIH (Figure 2.14).17 The model shows that bryostatin 1’s C20 
side chain sticks outside of the binding pocket. This model adds validity to the hypothesis 
that the BODIPY side chain should not have a large affect on binding affinity if placed on 
the C20 ester position.
The Retrosynthetic Analysis of Fluorescent Merle 23 (Merle 44)
Figure 2.15 shows the retrosynthetic plan for the synthesis of Merle 44 (fluorescent 
Merle 23). The BODIPY ester was to be constructed through a hydrolysis of protected 
intermediate 2.24. The main difference in this approach is the utilization of a fully 
functionalized C-ring 2.25 in the pyran annulation with A-ring 2.26. This synthetic 
approach would avoid difficult manipulations on complex substrates and reduces the 
number of steps from the longest linear sequence. The A-ring 2.26 would be constructed
120
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Figure 2.14: A Space Filling Model for the Docking of Bryostatin 1 
to the PKC C1 Domain
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Figure 2.15. Retrosynthesis o f Merle 44
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using a previously developed procedure by a pyran annulation between 2.27 and 2.28.6
The Synthesis of Macrolactone 2.2416
The A-ring intermediate 2.29 was prepared by Dr. Petersen using a pyran 
annulation reaction between the hydroxy allylsilane 2.27 and aldehyde 2.28 (Figure 2.16, 
part A).6 This material was utilized by the removal of the C13 TBS ether, which resulted 
in a mixture of the mono alcohol 2.30 and the C1 BPS deprotected diol. To circumvent this 
problem, HF*py was used to remove both the C1 and C13 silyl ethers, and then reprotected 
selectively using BPSCl, giving 2.30 as a single product. The C13 alcohol was then 
protected as the TMS ether 2.31 and a Bunnelle reaction18 was used to install the P- 
hydroxyallylsilane 2.26. The C-ring enal 2.25 was constructed by the removal of the TBS 
ether and oxidation of the resulting allylic alcohol to give 2.34 (Figure 2.16, part A). The 
C25 PMB ether was then swapped for a TBS ether, giving the desired alcohol 2.25.
A pyran annulation reaction between fully functionalized C-ring aldehyde 2.25 and 
P-hydroxyallylsilane 2.26 provided the tricyclic byropyran core 2.35 in 95% yield (Figure 
2.17). The macrolactonization of 2.35 follows the same steps that were reported during the 
synthesis of Merle 23. This sequence starts by a deprotection of the C1 BPS ether, followed 
by consecutive oxidations using Parikh-Doering and Pinnick reactions to give the C1 
carboxylic acid 2.37. The C25 TBS ether is then removed, followed by a Yamaguchi 
macrolactonization to afford the desired tricyclic macrolactone 2.24. This route shows a 
significant improvement in the methodology to construct bryostatin analogs by 
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Installation of the BOPDIY Tag
With intermediate 2.24 constructed, an investigation into installing the fluorescent 
tag commenced. The preparation of the BODIPY FL acid started from the commercially 
available pyrrole-2-carbaldehyde using a previously developed procedure (Figure 2.18).19 
A Horner-Wadsworth-Emmons reaction between aldehyde 2.38 and ethyl 
(triphenylphosphoranylidene)acetate followed by hydrogenation of the olefin gave pyrrole 
ester 2.39 in a 78% yield over 2 steps. A Vilsmeier-Haack reaction on 2,4-dimethyl-1#- 
pyrrole gave aldehyde 2.40. Pyrrole 2.39 and 2.40 were condensed using POCb, and then 
treated with BF3*OEt2 to produce BODIPY FL ester 2.41 in one pot. The ethyl ester was 
removed using aqueous hydrochloric acid to provide acid 2.42.
A model study was devised to install the BODIPY FL tag and to test the stability 
of the resulting ester (Figure 2.19). Removal of the C20 acetate through transesterification 
with K2CO3/MeOH produced the free alcohol that was immediately esterified with the
H 1) Ph3P '  C02Et 
V  /  Tol., A
'N 0  2) Pd-C, H2, MeOH, 

















Y ' % ' N/ \Me F F 
2.42
O.




H2, Pd(OH)2 C16-C17 reduction
1-Me-1,4-cyclohexadiene, C16-C17 reduction
Pd/C
BF3*OEt2, DMS C19-C20 elimination
Figure 2.19. BODIPY FL Model Study
BODIPY FL acid using Yamaguchi conditions to give the desired ester 2.43 in a 50% yield 
over 2 steps. Typically, the Keck group employs a global deprotection reaction using 
LiBF4 to remove the C26 BOM ether and any ketals present in the bryostatin analog. This 
tagged C-ring was then evaluated to see whether it would withstand these BOM 
deprotection conditions.
Using LiBF4 in CH3CN/H2O at 80°C failed to produce any of the desired product 
2.44. Other methods using hydrogenation and transfer hydrogenation did not affect the tag
and removed the BOM ether, but caused the reduction of the C16-C17 olefin. Using 
BF3*OEt2/DMS on model 2.43 resulted in elimination across the C19-C20 bond. Even 
though these conditions might work on an intermediate where the C19 participates in the 
hydrogen bond network of bryostatin, it was deemed too risky and an alternative approach 
to install the BODIPY tag was assessed.
Realizing that the BODIPY FL tag needed to be installed in the last step, we began 
to investigate an alternative reaction to esterification. A‘click reaction’ was thought to be 
the best way to install the BODIPY tag because these conditions are generally very 
selective, high yielding, and simple to perform.20 One of the most efficient ‘click reactions’ 
to date is the copper-catalyzed azide-alkyne cycloaddition. It was decided this reaction 
would be the best way to install the fluorescent side chain on an advanced substrate 
containing a plethora of different functional groups (Figure 2.20).
Azide 2.47 was synthesized following a procedure found in the literature (Figure 
2.21, part A).21 Reduction of ethyl ester 2.39 with LAH afforded the desired primary 
alcohol 2.48. The alcohol was then mesylated and subsequently displaced with sodium 
azide in DMF to give the azide intermediate. This compound was found to be unstable to 
column chromatography, so the crude reaction mixture was used in the next step. Pyrrole 
2.40 and 2.49 were condensed using POCb, and then treated with BF3*OEt2 providing 
BODIPY FL azide 2.47 in one pot with a 55% yield over 3 steps.
With the azide in hand, a suitable model for the click reaction was constructed 
(Figure 2.21, part B). Removal of the C20 acetate with K2CO3/MeOH gave the free alcohol, 
which was immediately esterified with commercially available 5-hexynoic acid under 





Figure 2.20. Click Reaction as a Possible Alternative to Esterification
130
OEt
LAH, Et20  
quant.
2.39
1) MsCI, Et3N, CH2CI2 

















Figure 2.21. Synthesis o f BODIPY FL Azide (A) and 
Model Study o f the Click Reaction (B)
cycloaddition between this alkyne and azide 2.47 worked smoothly to give the desired 
triazole 2.51 as the only observable product in an 85% yield. With these results, 
incorporating the BODPY FL tag would now be attempted as the final step in the synthesis 
of Merle 44.
The Completion of Merle 44
Confident in the installation of the BODIPY tag through a click reaction, the C20 
acetate was removed and the resultant alcohol was esterified with 5-hexynoic acid to give 
the desired ester 2.52 (Figure 2.22). The removal of this acetate took 1 h on the 
macrolactone versus 3 h on C-ring 2.32. The PMB ether was removed, and global 
deprotection gave bryopyran 2.46. Stirring this alkyne with azide 2.47 in the presence of 
copper(I) iodide afforded desired triazole or Merle 44 in an 80% yield.
Synthesis of Merle 45: The Installation of the B-hydroxyallyl Silane
The pyran annulation has been successfully used to construct bryostatin natural 
products and many bryostatin analogs. The joining of the C-ring and A-ring though this 
reaction can be approached from 2 different directions to form the B-ring. The first 
approach is comprised of the A-ring as the aldehyde and the C-ring as the B-hydroxyallyl 
silane. Previous research on a late stage installation of a B-hydroxyallyl silane on the C- 
ring is shown in Figure 2.23, part A. While constructing a bryostatin like tricyclic 
macrolactone, Dr. Truong found that a CAA reaction could be conducted on advanced C- 
ring enal 2.17 using a large excess of the BITIP reagent to give B-hydroxyallyl silane 
2.15.22 This reaction was later found to have poor reproducibility, so an alternative route
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Figure 2.23. Three Step Procedure (A) and a One Step 
Sequence to Install the P-hydroxyallyl Silane (B)
was developed. A 3 step procedure was established using the thermal addition of 
trimethyl(2-((tributylstannyl)methyl)allyl)silane, a Parikh-Doering oxidation, and a Corey- 
Bakshi-Shibata (CBS) reduction to give P-hydroxyallyl silane 2.15 as a single 
diastereoisomer.13 Another example of installing the P-hydroxyallyl silane on an advanced 
intermediate was done by the Krische group during the synthesis of bryostatin 7 (Figure 
2.23, part B).23 A modified Keck asymmetric allylation reaction gave the C15 P- 
hydroxyallyl silane 2.56 as a single diastereomer.24 This reaction was impressive since the 
substrate is highly oxygenated and did not affect the catalyst by competitive binding.
A potential retrosynthetic plan of fluorescent Merle 28 or Merle 45 uses a C-ring 
P-hydroxyallyl silane (Figure 2.24). When fully functionalized C-ring 2.25 was subjected 
to five equivalents of (R)-BITIP catalyst, no reaction was observed even with prolonged 
time. Also, subjecting cyclic 2.25 to the same conditions that the Krische group used on 
their acyclic C-ring was unsuccessful in producing P-hydroxyallyl silane 2.58.
In 1986, the Corey group developed (R,R)- and (S',5)-1,2-diamino-1,2- 
diphenylethane #,#-sulfonamides as effective chiral auxiliaries for aldol, Diels-Alder, and 
allylation reactions.25 Dr. Williams and his group at Indiana University recognized that 
these ligands can be reacted with boron tribromide to form a bromoborane intermediate 
that can be transmetalated with a variety of allylic stannanes to form chiral 
allyldiazaborolidines with a high degree of functional group compatibility.26 Various 
papers have reported using chiral allyldiazaborolidines in asymmetric allylations reactions 
of complex aldehydes to form allylic alcohols27, and used them en route to complex natural 
products.28 Applying Williams’ allylation conditions (Figure 2.24) to enal 2.25 using chiral 
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Figure 2.24. Asymmetric Allylation Conditions
Unfortunately, multiple experiments showed that the diastereomeric ratio was 2:1 by NMR 
and could not be improved using these conditions.
The second approach to the pyran annulation is comprised of the A-ring as the P- 
hydroxyallyl silane and the C-ring as the aldehyde. Examples of previous attempts to install 
the P-hydroxyallyl silane late stage are shown in Figure 2.25. As with the C-ring, attempted 
installation of the C11 homoallylic alcohol through an asymmetric allylation reaction using 
(S)-BITIP failed to produce 2.63.29 Lewis acid mediated allylations of aldehyde 2.16 were 
attempted, but were met with limited success.29-30 Once again, a 3 step procedure to 
produce P-hydroxyallyl silane 2.63 was developed, starting with the thermal addition of 
trimethyl(2-((tributylstannyl)methyl)allyl)silane and a Parikh-Doering oxidation of 
aldehyde 2.16 to give ketone 2.62. After an evaluation of many different reduction 
conditions, it was found that Luche conditions provided 2.63 in an 82% yield as a 4:1 
mixture of diastereomers; this reflects the stereoselectivity of the Luche reduction.31 
Another attempt to incorporate the P-hydroxyallyl silane late stage was done by Dr. 
Truong. It was found that using an excess of (S)-BITIP did in fact produce some product 
2.65, but this reaction could never be improved from a 20% yield.32
A potential retrosynthetic analysis of Merle 45, which has the A-ring as the P- 
hydroxyallyl silane, is shown in Figure 2.26. Subjecting A-ring 2.16 to five equivalents of 
(^)-BITIP catalyst or to Krische’s modified allylation conditions failed to produce any 
homoallylic alcohol 2.63. Fortunately, allyldiazaborolidine 2.68 successfully added into 
aldehyde 2.16 provides homoallylic alcohol 2.63 in an 87% yield and as a 10:1 mixture of 
diastereomers by NMR. It was confirmed that the major diastereomer possessed the desired 
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Figure 2.25. Late Stage Installation of the p-hydroxyallyl 
Silane on the A-ring
Williams allylation reaction procedure improves the synthesis of hydroxyallyl silane 2.63 
by eliminating 2 steps and improving the diastereoselectivity for the creation of the C11 
stereocenter from 4:1 to 10:1.
The Retrosynthetic Analysis of Fluorescent Merle 28 (Merle 45)
Figure 2.27 shows the retrosynthetic plan for the synthesis of Merle 45 (fluorescent 
Merle 28). Using the knowledge gained during the synthesis of Merle 44, the BODIPY FL 
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Figure 2.26. Asymmetric Allylation Conditions
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Figure 2.27. Retrosynthesis o f Merle 45
reaction of intermediate 2.57. The B-ring of 2.57 would be constructed via the pyran 
annulation of P-hydroxyallyl silane 2.67 and aldehyde 2.66. The macrolactone would be 
completed using a Yamaguchi esterification. Again, this route improves upon the original 
route to Merle 28 by utilizing a fully functionalized C-ring 2.66 in the pyran annulation.
The Coupling of the A-ring and the C-ring
With both fragments, A-ring hydroxyallylsilane 2.63 and C-ring aldehyde 2.25, in 
hand, these were subjected to the crucial pyran annulation conditions (Figure 2.28). This 
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consumed valuable A-ring 2.63 as the spirocyclic compound 2.69. An alternative method 
to produce the bryopyran structure was needed because this pyran annulation reaction was 
low yielding and consumed a significant amount of precious A-ring material.
At this point, an intramolecular pyran annulation was investigated. In the 
retrosynthetic analysis shown in Figure 2.27, this would entail performing the Yamaguchi 
esterification reaction first, followed by the pyran annulation. The synthesis and attempts 
are shown in Figure 2.29. Subjecting the thioester 2.16 to hydrolysis using NBS gave 
carboxylic acid 2.71.33 Reacting (S,S)-allylboronate 2.68 with aldehyde 2.71 led to 
homoallylic alcohol 2.67 in a 77% yield as a 6:1 mixture of diastereomers. Stirring 
compound 2.71 with TESCl protected both the alcohol and the carboxylic acid. However, 
upon workup and column chromatography the TES ester was converted back to the 
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Figure 2.29. Intramolecular Pyran Annulation Reaction
agreement with the same previously published compound 2.72.34 The C25 PMB group was 
removed using DDQ, and Yamguchi esterification joined the A-ring carboxylic acid 2.72 
and C-ring alcohol 2.66 to give ester 2.73 in a 74% yield. Previously developed conditions 
using a catalytic amount of PPTS in MeOH were found to facilitate the pyran annulation 
by first removing the C11 TES ether followed by cyclization to form a tricyclic 
macrolactone during the synthesis of bryostatin 9.34 These same conditions were then 
applied to aldehyde 2.73, but led to a different result from what was reported in the 
literature. The C11 TES ether was quickly removed and the C15 aldehyde was transformed 
into the acetal to give 2.74 as the sole product. No desired product from the 
macrocyclization was observed.
The pyran annulation reaction developed by the Wender group is shown in Figure 
2.30. When comparing compounds 2.29 and 2.73, there are only 3 functional differences. 
There is an acetate versus a butyrate at the C20 and BOM ether versus TBS ether at the 
C26 position. Additionally, the C19 exists as the hemiketal versus the methyl ketal. The 
C20 and C26 differences were thought to be minor changes that would not have any effect 
on the pyran annulation. The C19 alcohol was thought to have the most influence on this 
reaction since it might play a role in intamolecular hydrogen bonding.
The synthesis of the hemiketal substrate started with the removal of the PMB ether 
with DDQ and the methyl ketal using aqueous hydrofluoric acid to provide alcohol 2.77. 
Yamaguchi esterification of this alcohol and acid 2.72 produced ester 2.78 in an 82% yield. 
Subjecting this aldehyde to PPTS in MeOH overnight, macrocyclization occurred to give 
tricyclic macrolactone 2.79 in an 80% yield. It should be noted that no spirocyclic side 
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Figure 2.30. Wender's Pyran Annulation and 2nd Attempt
The necessity of the C19 alcohol is not fully understood, but it has shown to be crucial for 
the PPTS driven pyran annulation reaction. We suggest that the presence of this group 
establishes the requisite reaction conformations of the substrate (i.e., those that place the 
hydroxy allylsilane and the C15 aldehyde groups in spatial proximity to each other) by 
internal H-bonding, most likely to the C3 oxygen as is observed in the bryostatin internal 
H-bonding array.
The Completion of Merle 45
At this point, the alkyne needed to be introduced through hydrolysis and 
esterification. Dr. Poudel found when subjecting bisacetate 2.80 to K2CO3/MeOH, a 
selective methanolysis of the C20 acetate in the presence of the C7 acetate occurred in just 
45 min. It was immediately esterified with (2£,4£)-octa-2,4-dienoic anhydride providing 
protected bryostatin 1 2.81 (Figure 2.31). Applying these conditions using K2CO3/MeOH 
to the C19 hemiketal 2.79, followed by esterification with 5-hexynoic acid using 
Yamaguchi conditions failed to produce any of the desired product 2.80. The reaction 
resulted in a single spot with the same R/ value to the starting material but, when analyzed 
by NMR it was a complex mixture of multiple products. The instability of intermediate
2.79 was attributed to the C19 methyl ketal not being present in the molecule. Since the 
hydrolysis and esterification of the C20 was unsuccessful, an alternative route towards 
alkyne 2.80 was sought.
To circumvent this problem, an installation of the alkyne chain before pyran 
annulation was planned. The synthesis of macrolactone with the 5-hexynoate side chain is 
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Figure 2.31. Selective Hydrolysis of the C20 Acetate
O C02Me 
2.80
unmasked alcohol was oxidized and the C25 PMB was deprotected to produce enal 2.82. 
The C19 methyl ketal was removed with aqueous hydrofluoric acid, and then coupled to 
carboxylic acid 2.72 using a Yamaguchi esterification to provide ester 2.83 in a 70% yield 
over 2 steps. A PPTS mediated pyran annulation macrocyclization of 2.83 delivered 
tricyclic macrolactone 2.80 in a 70% yield. With the route to protected alkyne firmly 
established, Merle 45 would be completed by the deprotection and installation of the 
BODIPY tag (Figure 2.33). This started with a prolonged exposure of BPS ether 2.80 to 
HF*py followed by a global deprotection using LiBF4 to give alcohol 2.84 in a 66% yield 






















Figure 2.32. Synthesis of Macrolactone 2.80
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Figure 2.33. Synthesis o f Merle 45
(z'Pr)2NEt afforded the desired triazole or Merle 45 in an 80% yield.
Binding Affinity of Merle 44 and Merle 45
The determination of binding affinity was accomplished by a competitive binding 
assay of the ligand with the bound PDBu from isozyme PKCa. The values are an average 
of 3 experiments. Merle 44 was found to have a K, of 0.64 ± 0.08, which was essentially 
the same as that for Merle 23 (K, = 0.70 ±0.01 nM). Merle 45 was found to have a K, of 
0.32 ± 0.03, which was also similar to the binding affinity of Merle 28 (K, = 0.52 ± 0.06 
nM). Both Merle 44 and Merle 45 had a similar K, value for PKCa as does bryostatin 1 (K,
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= 0.43 ± 0.03 nM)
Evaluation of Merle 44 and Merle 45 in Toledo Cells
In Toledo cells, also known as human non-Hodgkin cells, bryostatin 1 (IC50 = 0.091 
± 0.026 nM) and PMA (IC50 = 0.565 ± 0.272 nM) behave similarly causing apoptosis of 
Toledo cells at low concentrations. Both Merle 23 (IC50= 0.331 ± 0.105 nM) and Merle 28 
(IC50 = 0.111 ± 0.009 nM) also cause apoptosis at low concentrations. Merle 44 and Merle 
45 were assayed in these cells to evaluate the potency of these analogs compared to PMA, 
bryostatin 1, Merle 23, and Merle 28 (Figure 2.34). Merle 45 (IC50= 0.334 ± 0.068 nM) 
was found to have similar inhibitory concentrations as PMA, bryostatin 1, and Merle 28 in 
the Toledo cells. Merle 44 (IC50 = 3.168 ± 0.672 nM) was the least potent of the group 
showing about a 10 fold decrease in potency from Merle 23. Nonetheless, this study 
showed that despite the incorporation of the large and complex C20 side chain, both Merle 
44 and Merle 45 were functional in living cells. This was a major relief as there was no 
guarantee that this would be the case.
Proliferation and Attachment Assays in U937 Cells
Merle 45 resembled bryostatin 1 and Merle 28 in the U937 proliferation assay by 
giving a dose-dependent biphasic pattern in its ability to inhibit cell growth (Figure 2.35). 
Merle 45 contrasts with PMA by being far less effective in inducing apoptosis of the U937 
cells. When co-administered, Merle 45 is a functional antagonist of PMA and blocks the 
effect of the phorbol ester (10 nM PMA+ 1000 nM Merle 45). Merle 28 and Merle 45 
behave similarly in their ability to block the effect of PMA. Merle 45 also resembled
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Figure 2.34. Proliferation Studies in Toledo Cells
bryostatin 1 and Merle 28 in the U937 attachment assay by showing a diminished amount 
of cell attachment when compared to PMA (Figure 2.36). Interestingly, Merle 45 induces 
less attachment than Merle 28 resulting in a pattern that appears even more bryostatin like. 
The biological results with Merle 45 reveal a distinctly bryo-like pattern of behavior in 
U937 cells.
In contrast to Merle 45, Merle 44 resembled PMA and Merle 23 by inhibiting 
proliferation. Merle 44 also does not antagonize the response to PMA as does bryostatin 1. 
In cell attachment, Merle 44 behaves similarly to Merle 23 and PMA by inducing 
a significant amount of cell attachment. Both Merle 44 and Merle 45 have significant 
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Figure 2.36. Attachment of U937 Cells
in the U937 cell line. Another interesting observation from these assays is that Merle 44 is 
‘PMA-like’ in these assays, but is slightly more ‘bryo-like’ than Merle 23. This suggests 
that the C20 ester side chain could possibly be altered, in a Merle 23-like analog, to switch 
the biological response to a more ‘bryo-like’ compound.
TNFa Secretion Assay in U937 Cells
Another assay involving U937 cells evaluates the effect of PMA, bryostatin 1, 
Merle 23, Merle 44, Merle 28, and Merle 45 on the secretion of tumor necrosis factor a  
(Figure 2.37). It is believed that TNFa is an important contributor in PMA’s ability to 
induce apoptosis in U937 cells. After treatment of the U937 cells with PMA for 60 h, the 
ligand induces a very high level of TNFa. Merle 23, and Merle 44 also induces a high level 
of TNFa secretion. Merle 44 has slightly less TNFa secretion than Merle 23. Bryostatin 1, 
Merle 28, and Merle 45 all induced a similar levels of TNFa .
Visualization of Merle 44 and Merle 45 in LNCaP Cells
Initial studies from the Blumberg group are shown in Figure 2.38. Red fluorescence 
protein (RFP)-PKCS, and green fluorescent Merle 44 and Merle 45 are currently being 
evaluated using confocal microscopy in LNCaP cells for cellular uptake and localization. 
Both Merle 44 and Merle 45 initially reside in the internal membranes when LNCaP cells 
are treated with 1000 nM of the ligand after 10 min. The yellow color comes from the 
overlay of (RFP)-PKCS and Merle 45. At this concentration, the drugs did not seem to 
colocalize with PKCS and did not cause translocation of the enzyme. Also, initial results 
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Figure 2.38. Distribution of Merle 44 (left) and Merle 45 (right)
Additional experiments are needed since these data are only from one experiment.
Conclusions
Merle 44 and Merle 45 were rapidly constructed using a fully functionalized C-ring 
and the pyran annulation. An investigation into installing the /?-hydroxyallylsilane led to a 
very mild and effective way of installing this functionality at a late stage on the A-ring. A 
highly selective intramolecular pyran annulation using PPTS, in the presence of fully 
functionalized A-ring, was found to be dependent on the C19 alcohol for success. 
Significant changes at the C20 ester by installing the BODIPY FL tag did not have a 
substantial effect on the biology of the new fluorescently labeled analogs. Merle 44 was 
found to be a functional analog of Merle 23 and Merle 45 was found to be a functional 
analog of Merle 28.
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Figure 2.39. Uptake of Merle 44 and Merle 45
Future Work
Further biological studies by the Blumberg group will be conducted on Merle 44 
and Merle 45. A measurement of the rate of uptake of the compounds and their distribution 
after uptake will be obtained using real time analysis similarly to the fluorescent phorbol 
ester studies (Figure 2.40, part A). A comparison of their kinetics and localization will be 
correlated to that of PKC isoform. The PKC isoforms will be labeled with mCherry, which 
is a red variant of PKC isoforms. The green fluorescent bryostatin analogs can then be 
compared to the red fluorescent PKC localization simultaneously. A phorbol ester 
containing the BODIPY FL tag through a click reaction will also be constructed. With these 
compounds, we can also potentially measure fluorescence resonance energy transfer
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Figure 2.40. Fluorescent Phorbol Ester (A) and 
SAR Studies Using the Click Reaction (B)
containing the BODIPY FL tag through a click reaction will also be constructed. With these 
compounds, we can also potentially measure fluorescence resonance energy transfer 
(FRET) between the fluorescent PKC and the fluorescent ligands to see if there is a 
conformational difference between Merle 44, Merle 45 and the fluorescent phorbol ester 
2.86.
The results from Merle 44 also suggest that we might potentially switch a Merle 
23-like analog to a bryo-like compound. This is because Merle 44 was found to be less
‘PMA-like’ than Merle 23. SAR studies could be conducted on the C20 side chain of Merle 
23 by changing the overall polarity of the molecule (Figure 2.40, part B). This could be 
quickly and efficiently accomplished using the click chemistry between a desired azide and 
alkyne 2.52.
Experimental Section 
General Experimental Procedures, Materials and Instrumentation
Solvents were purified according to the guidelines in Purification o f Common 
Laboratory Chemicals (Perrin, Armarego, and Perrin, Pergamon: Oxford, 1966).35 
(iPr)2NH, (iPr)2NEt, pyridine, Et3N, EtOAc, CH2O 2, and TMEDA were distilled from 
CaH2 . The titer of n-BuLi was determined by the method of Eastham and Watson36. Et2O 
and THF were distilled from Na under an atmosphere of N2. MeOH was distilled from dry 
Mg turnings. Ozone was generated using a Welsbach model T-816 generator. All other 
reagents were used without further purification. Yields were calculated for material judged 
homogenous by thin layer chromatography and nuclear magnetic resonance (NMR). Thin 
layer chromatography was performed on Merck Kieselgel 60 A F254 plates or Silicycle 60A 
F254 eluting with the solvent indicated, visualized by a 254 nm UV lamp, and stained with 
an ethanolic solution of 12-molybdophosphoric acid, 4-anisaldehyde, or an aqueous 
potassium permanganate solution. Flash column chromatography was performed with 
Silicycle flash silica gel 40 -  63 |im, slurry packed with hexanes in glass columns. 
Glassware for reactions was oven dried at 125 °C and cooled under a dry nitrogen 
atmosphere prior to use. Liquid reagents and solvents were introduced by oven dried 
syringes through septum-sealed flasks under a nitrogen atmosphere. Nuclear magnetic
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resonance spectra were acquired at 500 MHz for 1H and 125 MHz for 13C. Chemical shifts 
for proton nuclear magnetic resonance (1H NMR) spectra are reported in parts per million 
relative to the signal residual CDCb at 7.27 ppm. Chemicals shifts for carbon nuclear 
magnetic resonance (13C NMR and DEPT) spectra are reported in parts per million relative 
to the center line of the CDCb triplet at 77.23 ppm. Chemical shifts of the unprotonated 
carbons (‘C’) for DEPT spectra were obtained by comparison with the 13C NMR spectrum. 
The abbreviations s, d, apd, dd, ddd, dddd, t, td, tt, q, dq, and m stand for the resonance 
multiplicity singlet; doublet; apparent doublet; doublet of doublets; doublet of doublet of 
doublets; doublet of doublet of doublet of doublets; doublet of doublet of doublets of 
doublets; triplet; triplet of doublets; triplet of triplets; quartet; doublet of quartets; and 
multiplet, respectively. Optical rotations (Na D line) were obtained using a microcell with
1 dm path length. Specific rotations ([a]“ , Unit: °cm2/g) are based on the equation a  = 
(100a)/(/c) and are reported as unitless numbers where the concentration c is in g/l00 mL 
and the path length / is in decimeters. Mass spectrometry was performed at the mass 
spectrometry facility of the Department of Chemistry at The University of Utah on a double 
focusing high resolution mass spectrometer. Compounds were named using ChemDraw 
12.0.0.
Experimental Procedures and Analytical Data for A-ring 2.26
The compounds 2.30, 2.31, and 2.26 were previously prepared by Dr. Wei Li and 
are reported in his Ph.D. thesis and in the literature.6 These syntheses were repeated on a 
larger scale to assess these for use in the present work. Compound 2.30 was prepared using 
an alternative 2 step procedure to simplify its synthesis. The experimental procedure and
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analytical data for these compounds are reproduced here for the convenience of those who 
may need to repeat this work.
OPMB
(3^)-ethyl 4-(6-((»£)-4-((terf-butyldiphenylsilyl)oxy)-2-((4-methoxybenzyl) 
oxy)butyl)-4-methylenetetrahydro-2#-pyran-2-yl)-3-hydroxybutanoate (2.30).6 To a
stirring solution of the silyl ether 2.29 (1.35 g, 1.71 mmol, 1.0 equiv) in THF (17 mL) at 0 
°C in a 60 mL plastic bottle, was added HF*py (20% in pyridine, 4.3 mL). TLC analysis 
after 38 h at rt indicated complete consumption of the starting material. The mixture was 
quenched by pipetting into a stirring mixture of saturated aqueous NaHCO3 solution (50 
mL) and EtOAc (50 mL). The layers were separated and the aqueous layer was extracted 
with EtOAc (3 x 50 mL). The combined organic layers were dried over Na2SO4, filtered, 
and concentrated under reduced pressure. This material was carried onto the next step 
without further purification.
To a stirring solution of crude diol in CH2Q 2 (30 mL) in a 50 ml rb flask at 0 °C, 
was added Et3N (0.72 mL, 5.13 mmol, 3.0 equiv) followed by BPSCl (0.44 mL, 1.71 mmol, 
1.0 equiv) and DMAP (42 mg, 0.34 mmol, 0.2 equiv). The reaction was allowed to proceed 
for 3 h at 0 °C, then quenched by the addition of saturated aqueous NaHCO3 solution (10 
mL). The layers were separated and the aqueous layer was extracted with CH2Cl2 (3 x 20 
mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated 
under reduced pressure. Purification was accomplished by flash column chromatography
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using a 3.0 x 30.0 cm silica gel column, eluting with 15% EtOAc/hexanes, collecting 25 
mL fractions. The product containing fractions (15-30) were combined and concentrated 
under reduced pressure to yield alcohol 2.30 (1.02 g, 81%) as a clear oil: Rf = 0.30 (20% 
EtOAc/hexanes); 500 MHz 1H NMR (CDCb) 5 7.70-7.65 (m, 4H), 7.46-7.36 (m, 6H), 
7.19 (d, J  = 8.6 Hz, 2H), 6.85 (d, J  = 8.6 Hz, 2H), 4.71 (d, J  = 11.3 Hz, 2H), 4.39 (ABq, J  
= 10.9 Hz, Av = 41.2 Hz, 2H), 4.28-4.22 (m, 1H), 4.14 (ddd, J  = 14.2, 7.0, 2.0 Hz, 2H),
3.80 (s, 3H), 3.79-3.72 (m, 4H), 3.57-3.47 (m, 2H), 2.52 (dd, J  = 15.5, 7.4 Hz, 1H), 2.44 
(dd, J  = 15.7, 7.5 Hz, 1H), 2.22 (d, J  = 13.4 Hz, 1H), 2.16 (d, J  = 13.4 Hz, 1H), 1.99 (t, J  
= 12.0 Hz, 1H), 1.92 (t, J  = 12.0 Hz, 1H), 1.83-1.62 (m, 6H), 1.24 (t, J  = 6.9 Hz, 3H), 1.06 
(s, 9H). 125 MHz 13C NMR (CDCb) 5 179.5, 152.1, 134.9, 130.6, 130.0, 129.8, 129.7,
128.6, 123.4, 118.9, 115.4, 77.5, 45.6, 43.1, 33.8, 29.3, 25.9, 24.0.
(3^)-ethyl 4-(6-((»£)-4-((terf-butyldiphenylsilyl)oxy)-2-((4-methoxybenzyl) 
oxy)butyl)-4-methylenetetrahydro-2#-pyran-2-yl)-3-((trimethylsilyl)oxy)butanoate 
(2.31).6 To a stirring solution of alcohol 2.30 (940 mg, 1.26 mmol, 1.0 equiv) in CH2Q 2 
(25 mL) in a 50 ml rb flask at 0 °C, was added Et3N (0.53 mL, 3.78 mmol, 3.0 equiv) 
followed by TMSCl (0.32 mL, 2.52 mmol, 2.0 equiv). The reaction was allowed to proceed 
for 2 h at rt, after which time TLC analysis indicated complete consumption of the alcohol 
starting material. The reaction mixture was quenched by the addition of saturated aqueous 
NaHCO3 solution (10 mL), the phases were separated, and the aqueous layer was extracted
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with CH2Cl2 (3 x 10 mL). The combined organic layers were dried over Na2SO4, 
concentrated and purified by flash column chromatography using a 2.0 x 25.0 cm silica gel 
column, eluting with 10% EtOAc/hexanes, collecting 25 mL fractions. The product 
containing fractions (4-21) were concentrated to give silyl ether 2.31 (1.02 g, 98%) as a 
clear oil. Rf = 0.62 (20% EtOAc/hexanes); 500 MHz 1H NMR (CDCb) 5 7.71-7.66 (m, 
4H), 7.46-7.36 (m, 6H), 7.19 (d, J  = 8.5 Hz, 2H), 6.85 (d, J  = 8.5 Hz, 2H), 4.72 (d, J  = 11.1 
Hz, 2H), 4.42 (ABq, J  = 10.7 Hz, Av = 28.2 Hz, 2H), 4.36-4.32 (m, 1H), 4.15-4.00 (m, 
2H), 3.90 (dt, J  = 6.2, 5.7 Hz, 1H), 3.79-3.74 (m, 2H), 3.80 (s, 3H), 3.54-3.46 (m, 1H),
3.43-3.35 (m, 1H), 2.50 (d, J  =1.3 Hz, 1H), 2.49 (s, 1H), 2.26 (d, J  = 13.1 Hz, 1H), 2.16 
(d, J  = 13.1 Hz, 1H), 1.94 (q, J  = 12.7 Hz, 2H), 1.88-1.76 (m, 3H), 1.67-1.60 (m, 3H), 1.22 
(t, J  = 6.7 Hz, 3H), 1.08 (s, 9 H), 0.13 (s, 9H); 125 MHz 13C NMR (CDCb) 5 177.8, 159.3,
144.9, 135.9, 134.2, 131.4, 129.9, 129.6, 128.0, 114.1, 108.9, 75.2, 75.2, 72.9, 71.9, 66.9,





en-2-ol (2.26).6 Powdered CeCb*7 H2O (1.63 g, 4.37 mmol, 10 equiv) in a 25 ml rb flask, 
was dried at 170 °C under a vacuum of 0.2 mm of Hg for 18 h. The flask was cooled to rt, 
flushed with Ar, and THF (2 mL) was added. The suspension was stirred for 2 h. 
Separately, oven dried Mg turnings (110 mg, 4.37 mmol, 10.0 equiv) and a single crystal
of I2 in a 25 mL round bottom flask, was heated using a heat gun until I2 sublimed. THF 
(5 mL) and TMSCH2Q  (0.61 mL, 4.37 mmol, 10.0 equiv) were added and the mixture was 
brought to reflux using the heat gun. After 1.5 h, the TMSCH2MgCl solution was added 
dropwise to the CeCb suspension at -78 °C via cannula. This solution was stirred at -78 
°C for 1 h, then ethyl ester 2.x (327 mg, 0.44 mmol, 1.0 equiv) was added in THF (2.0 mL 
+ 0.5 mL rinse) via cannula. This solution was stirred at -78 °C for 2 h then allowed to 
reach rt as it stirred overnight. The mixture was transferred to a 125 mL Erlenmeyer flask, 
diluted with THF (40 mL), and cooled to -78 °C. To this vigorously stirred solution was 
added a 1 N aqueous HCl solution 5 drops at a time until only a single spot was observed 
by TLC. The reaction mixture was then transferred into a 250 mL separatory funnel that 
contained a mixture of a saturated aqueous NaHCO3 solution (30 mL) and CH2Q 2 (30 mL). 
The aqueous layer was extracted with CH2Q 2 (2 x 30 mL). The combined organic layers 
were dried over Na2SO4, filtered, and concentrated under reduced pressure. Purification 
was accomplished by flash column chromatography using a 2.0 x 30.0 cm silica gel 
column, eluting with 15% EtOAc/hexanes, collecting 10 mL fractions. The product 
containing fractions (15-31) were combined and concentrated under reduced pressure to 
yield /?-hydroxyallylsilane 2.26 (223 mg, 71%) as a clear oil: Rf = 0.61 (20% 
EtOAc/hexanes); 500 MHz 1H NMR (CDCb) 5 7.67-7.62 (m, 4H), 7.43-7.38 (m, 6H),
7.18 (d, J  = 8.5 Hz, 2H), 6.84 (d, J  = 8.5 Hz, 2H), 4.70 (dd, J  = 10.7, 1.4 Hz, 2H), 4.64 (d, 
J  = 15.5 Hz, 2H), 4.39 (Apq, J  = = 10.7 Hz, Av = 28.2 Hz, 2H), 3.98-3.92 (m, 1H), 3.79 
(s, 3H), 3.76-3.72 (m, 3H), 3.52-3.46 (m, 3H), 2.26-2.13 (m, 3H), 2.05 (dd, J  = 13.6, 6.6 
Hz, 1H), 1.99 (dd, J  = 12.1, 12.1 Hz, 1H), 1.80-1.78 (m, 2H), 1.72-1.58 (m, 4H), 1.55 (s, 
2H), 1.05 (s, 9H), 0.02 (s, 9H); 125 MHz 13C NMR (CDCb) 5 159.4, 144.8, 144.3, 135.9,
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134.2, 134.2, 131.3, 129.9, 129.8, 129.7, 128.0 114.1, 110.2, 109.2, 79.5, 75.7, 73.0, 71.7,
69.8, 60.7, 55.6, 46.8, 42.8, 42.1, 41.4, 41.3, 37.7, 27.3, 27.1, 19.5, -1.0.
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Experimental Procedures and Analytical Data for C-ring 2.34
The compounds 2.33 and 2.34 were previously prepared by Dr. Yam Poudel and 
are reported in his Ph.D. thesis and in the literature.31 These syntheses were repeated on a 
similar scale to assess these for use in the present work. Compound 2.34 was prepared 
using an alternative oxidation using activated MnO2 . The experimental procedure and 
analytical data for these compounds are reproduced here for the convenience of those who 
may need to repeat this work.
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dihydro-2#- pyran-4(3#)-ylidene)acetate (2.33).31 To a stirring solution of the TBS
ether 2.32 (620 mg, 0.790 mmol, 1.0 equiv) in THF (15 mL) at 0 °C in a plastic bottle, was 
added HF*Py (20 % in pyridine, 2.0 mL). TLC analysis after 3 h at 0 °C, indicated 
complete consumption of the starting material. The mixture was quenched by pipetting 
into a stirring mixture of saturated aqueous NaHCO3 solution (30 mL) and EtOAc (50 mL). 
The layers were separated and the aqueous layer was extracted with EtOAc (3 x 30 mL).
The combined organic layers were dried over Na2SO4, filtered, and concentrated under 
reduced pressure. Purification was accomplished by flash column chromatography using 
a 2.0 x 12.0 cm silica gel column, eluting with 30% EtOAc/hexanes, collecting 8 mL 
fractions. The product containing fractions (20-36) were combined and concentrated under 
reduced pressure to yield alcohol 2.33 (480 mg, 91%) as a white foam: Rf = 0.30 (50% 
EtOAc/hexanes); 500 MHz 1H NMR (CDCb) 5 7.39-7.28 (m, 5H), 7.23-7.18 (m, 2H),
6.86-6.82 (m, 2H), 5.98 (d, J  = 15.6 Hz, 1H), 5.88 (s, 1H), 5.50 (td, J  = 15.9, 5.9 Hz, 1H),
5.43 (s, 1H), 4.87 (d, J  = 6.8 Hz, 1H), 4.84 (d, J  = 6.8 Hz, 1H), 4.68 (s, 2H), 4.61 (d, J  = 
10.7 Hz, 1H), 4.41 (d, J  = 11.2 Hz, 1H), 4.14 (dddd, J  = 10.7, 6.4, 6.4, 4.4 Hz, 1H), 4.08­
4.01 (m, 2H), 3.90 (ddd, J  = 10.3, 4.4, 2.0 Hz, 1H), 3.79 (s, 3H), 3.70 (s, 3H), 3.45 (dd, J  
= 15.6, 2.4 Hz, 1H), 3.23 (s, 3H), 2.34 (ddd, J  = 14.2, 10.9, 1.5 Hz, 1H), 2.05 (s, 3H), 1.93 
(ddd, J  = 14.2, 9.8, 2.0 Hz, 1H), 1.73 (ddd, J  = 13.4, 10.3, 2.4 Hz, 1H), 1.45 (t, J  = 6.2 Hz, 
1H), 1.22 (d, J  = 6.4 Hz, 3H), 1.13 (s, 3H), 1.10 (s, 3H); 125 MHz 13C NMR (CDCb) 5
169.2, 166.3, 159.0, 152.1, 138.9, 137.7, 130.2, 129.1, 128.2, 126.6, 127.5, 124.6, 117.1,




(E)-methyl 2-((2^,3^,6^)-3-acetoxy-6-((2^,3^) -3-((benzyloxy)methoxy)-2-((4- 
methoxybenzyl)oxy)butyl)-2-methoxy-2-((E)-2-methyl-5-oxopent-3-en-2-yl)dihydro- 
2#-pyran-4(3#)-ylidene)acetate (2.34).31 To a stirring solution of the allylic alcohol 2.33 
(480 mg, 0.716 mmol, 1.0 equiv) in benzene (15 mL) at rt in a 25 ml rb flask, was added 
activated MnO2 (1.56 g, 17.9 mmol, 25.0 equiv). TLC analysis after 2 h indicated complete 
consumption of the allylic alcohol starting material. The reaction mixture was filtered over 
a pad of Celite® and washed with copious amounts of EtOAc. Purification was 
accomplished by flash column chromatography using a 2.0 x 13.0 cm silica gel column, 
eluting with 25% EtOAc/hexanes, collecting 8 mL fractions. The product containing 
fractions (14-24) were combined and concentrated under reduced pressure to yield 
aldehyde 2.34 (432 mg, 90%) as a white foam: Rf = 0.39 (40% EtOAc/hexanes); 500 MHz 
1H NMR (CDCb) 5 9.52 (d, J  = 7.3 Hz, 1H), 7.40-7.28 (m, 5H), 7.22-7.17 (m, 2H), 6.86­
6.82 (m, 2H), 5.93 (dd, J  = 16.1, 7.8 Hz, 1H), 5.89 (s, 1H), 5.39 (s, 1H), 4.87 (d, J  = 6.8 
Hz, 1H), 4.84 (d, J  = 6.8 Hz, 1H), 4.67 (s, 2H), 4.63 (d, J  = 10.8 Hz, 1H), 4.40 (d, J  = 11.2 
Hz, 1H), 4.17 (dddd, J  = 6.4, 6.4, 6.4, 4.4 Hz, 1H), 4.07 (dddd, J  = 12.7, 9.8, 2.9, 2.9 Hz, 
1H), 3.87 (ddd, J  = 10.3, 4.4, 2.0 Hz, 1H), 3.79 (s, 3H), 3.70 (s, 3H), 3.53(dd, J  = 16.1, 2.4 
Hz, 1H), 3.26 (s, 3H), 2.36 (ddd, J  = 14.1, 11.3, 1.4 Hz, 1H), 1.97 (ddd, J  = 14.1, 11.3, 2.0 
Hz, 1H), 1.91 (s, 3H), 1.78 (ddd, J  = 13.2, 10.3, 2.9 Hz, 1H), 1.23 (d, J  = 6.4 Hz, 3H), 1.16 
(s, 3H), 1.14 (s, 3H); 125 MHz 13C NMR (CDCb) 5 194.1, 168.4, 166.5, 165.9, 159.0,
151.1, 137.7, 130.1, 129.1, 128.2, 127.5, 127.4, 126.6, 117.6, 113.6, 102.2, 93.1, 76.2, 71.7,
71.2, 71.1, 69.2, 68.9, 55.0, 51.1, 51.0, 47.1, 35.8, 32.4, 23.6, 21.4, 20.9, 14.2.
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Experimental Procedures and Analytical Data for Macrolactone 2.24
The compounds 2.25, 2.35, 2.36, 2.37, and 2.24 were previously prepared by Dr. 
Mark Petersen and are reported in his Ph.D. thesis.16 These syntheses were repeated on a 
larger scale to assess these for use in the present work. The experimental procedure and 
analytical data for these compounds are reproduced here for the convenience of those who 
may need to repeat this work.
H ^ O
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yl)dihydro-2#-pyran-4(3#)-ylidene)acetate (2.25).16 To a stirring solution of PMB ether 
2.34 (240 mg, 0.359 mmol, 1.0 equiv) and H2O (70 ^L) in CH2Q 2 (7 mL) at 0 °C in a 25 
ml rb flask, was added DDQ (122 mg, 0.538 mmol, 1.5 equiv). TLC analysis after 2 h at 
0 °C indicated complete consumption of the PMB ether starting material. The mixture was 
quenched by the addition of saturated aqueous NaHCO3 solution (5 mL). The layers were 
separated and the aqueous layer was extracted with CH2O 2 (3 x 5 mL). The combined
organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure 
to yield the impure alcohol.
To a stirring solution of the crude alcohol and 2,6-lutidine (250 ^L, 2.15 mmol, 6.0 
equiv) in CH2O 2 (7 mL) in a 25 ml rb flask at 0 °C, was added TBSOTf (190 ^L, 1.08 
mmol, 3.0 equiv). TLC analysis after 1 h at 0 °C indicated complete consumption of the 
alcohol starting material. The mixture was quenched by the addition of saturated aqueous 
NaHCO3 solution (5 mL). The layers were separated and the aqueous layer was extracted 
with CH2Cl2 (3 x 5 mL). The combined organic layers were dried over Na2SO4, 
concentrated, and purified by flash column chromatography using a 2.0 x 15.0 cm silica 
gel column, eluting with 10% EtOAc/hexanes, collecting 10 x 7 5  mm test tube fractions. 
The product containing fractions (33-55) were combined and concentrated under reduced 
pressure to provide TBS ether 2.25 (190 mg, 80% over 2 steps) as a clear oil: Rf = 0.68 
(50% EtOAc/hexanes); 500 MHz 1H NMR (CDCb) 5 9.53 (d, J  = 7.8 Hz, 1H), 7.38-7.27 
(m, 4H), 5.94 (dd, J  = 16.1, 4.8 Hz, 1H), 5.91 (s, 1H), 5.50 (s, 1H), 4.80 (ABq, J  = 7.1 Hz, 
Av = 11.9 Hz, 2H), 4.64 (s, 2H), 4.14-4.07 (m, 2H), 3.85 (dt, J  = 10.9, 6.2 Hz, 2H), 3.70 
(s, 3H), 3.53 (dd, J  = 16.1, 2.5 Hz, 1H), 3.40 (s, 3H), 2.35 (ddd, J  = 15.1, 11.5, 1.2 Hz, 1H),
2.03 (ddd, J  = 14.1, 8 .8 , 2.2 Hz, 1H), 1.93 (s, 3H), 1.65 (ddd, J  = 14.0, 8.5, 2.8 Hz, 1H),
1.16 (d, J  = 6.5 Hz, 3H), 1.17 (s, 3H), 1.15 (s, 3H), 0.88 (s, 9H), 0.09 (s, 3H), 0.07 (s, 3H); 
125 MHz 13C NMR (CDCb) 5 194.9, 169.1, 167.2, 166.4, 151.6, 137.7, 128.7, 128.0,
127.1, 118.2, 102.5, 93.3, 75.1, 71.0, 70.3, 69.5, 69.1, 52.0, 51.5, 47.5, 38.7, 33.0, 26.1,







tetrahydro-2#-pyran-3-yl octanoate (2.35).16 To a stirring solution of aldehyde 2.25 
(148 mg, 0.222 mmol, 1.0 equiv) and silane 2.26 (174 mg, 0.224 mmol, 1.1 equiv) in Et2O 
(5 mL) in a 15 ml rb flask at -78 °C, was added TMSOTf (1.1 M in Et2O, 220 ^L, 0.244 
mmol, 1.1 equiv) via syringe. The reaction was allowed to proceed for 6 h at -78 °C, after 
which time TLC analysis indicated complete consumption of the aldehyde starting 
material. The reaction mixture was quenched by transfer into a 25 mL separatory funnel 
that contained a mixture of a saturated aqueous NaHCO3 solution (5 mL) and Et2O (5 mL). 
The layers were separated and the aqueous layer was extracted with Et2O (3 x 5 mL). The 
combined organic layers were dried over Na2SO4, concentrated, and purified by flash 
column chromatography using a 2.0 x 18.0 cm silica gel column, eluting with 10% 
EtOAc/hexanes, collecting 10 mL fractions. The product containing fractions (6-24) were 
concentrated to give bispyran 2.35 (210 mg, 73%) as a white foam. Rf = 0.46 (30% 
EtOAc/hexanes); 500 MHz 1H NMR (CDCb) 5 7.73-7.65 (m, 4H), 7.47-7.24 (m, 11H),
7.18 (d, J  = 7.8 Hz, 2H), 6.85 (d, J  = 7.8 Hz, 2H), 5.96 (d, J  = 16.1 Hz, 2H), 5.90 (s, 1H),
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5.56 (s, 1H), 5.41 (dd, J  = 16.0, 5.6 Hz, 1H), 4.80 (s, 1H), 4.72 (d, J  = 11.0 Hz, 2H), 4.64 
(s, 2H), 4.64 (s, 1H), 4.54 (s, 1H), 4.42 (ABq, J  = 10.3 Hz, Av = 35.7 Hz, 2H), 4.14-4.04 
(m, 2H), 3.96-3.90 (m, 1H), 3.89-3.68 (m, 2H), 3.79 (s, 3H), 3.77-3.71 (m, 2H), 3.69 (s, 
3H), 3.60-3.42 (m, 5H), 3.31 (s, 3H), 2.42-2.12 (m, 4H), 2.08 (s, 3H), 2.04-1.84 (m, 6H), 
1.82-1.73 (m, 2H), 1.69-1.55 (m, 3H), 1.18 (d, J  = 6.4 Hz, 3H), 1.11 (s, 3H), 1.10 (s, 3H),
1.06 (s, 9H), 0.88 (s, 9H), 0.09 (s, 3H), 0.07 (s, 3H); 125 MHz 13C NMR (CDCb) 5 169.5,
166.7, 159.3, 153.0, 145.0, 144.3, 138.3, 135.8, 134.1, 131.1, 129.8, 129.6, 128.5, 128.0,
127.9, 127.8, 127.0, 117.0, 114.0, 109.0, 108.7, 102.6, 93.2, 79.1, 77.4, 75.0, 75.0, 74.9,
72.8, 72.2, 71.7, 70.2, 69.6, 68.4, 60.5, 55.5, 51.6, 51.4, 46.1, 43.0, 42.5, 41.4, 41.1, 40.9,





2#-pyran-4(3#)-ylidene)acetate (2.36).16 A stock solution of 0.5 M TBAF/ AcOH was 
prepared by adding TBAF (1M in THF, 0.5 mL) to a stirring solution of AcOH (1M in 
DMF, 0.5 mL) in a 1 mL volumetric flask and stirred at rt for 10 min.
CC^Me
To a stirring solution of BPS ether 2.35 (92 mg, 0.067 mmol, 1.0 equiv) and DMF 
(3.0 mL) in a 10 ml rb flask at 0 °C, was added TBAF (0.5 M buffered with 100 mol% 
AcOH in DMF/THF, 264 ^L, 0.132 mmol, 1.0 equiv) via volume pipette. The reaction was 
allowed to proceed for 19 h at rt, after which time TLC analysis indicated complete 
consumption of the BPS ether starting material. The reaction mixture was quenched by 
transfer into a 25 mL separatory funnel that contained a mixture of a H 2O (10 mL) and 
25% EtOAc/hexanes (10 mL). The layers were separated and the aqueous layer was 
extracted with 25% EtOAc/hexanes (3 x 10 mL). The combined organic layers were dried 
over Na2SO4, filtered, and concentrated under reduced pressure. Purification was 
accomplished by flash column chromatography using a 2.0 x 16.0 cm silica gel column, 
eluting with 20% EtOAc/hexanes, collecting 10 mL fractions. The product containing 
fractions (30-79) were combined and concentrated under reduced pressure to yield alcohol 
2.36 (104 mg, 75%) as a clear oil: Rf = 0.46 (50% EtOAc/hexanes); 500 MHz 1H NMR 
(CDCb) 5 7.38-7.22 (m, 7H), 6.89 (d, J  = 8.4 Hz, 2H), 5.97 (d, J  = 16.4 Hz, 1H), 5.90 (s, 
1H), 5.54 (s, 1H), 5.41 (dd, J  = 15.8, 6.2 Hz, 1H), 4.80 (s, 2H), 4.73 (s, 2H), 4.66 (s, 1H), 
4.64 (s, 2H), 4.58 (s, 1H), 4.48 (ABq, J  = 10.4 Hz, Av = 24.5 Hz, 2H), 4.13-4.04 (m, 2H), 
3.93-3.82 (m, 2H), 3.80 (s, 3H), 3.76-3.70 (m, 2H), 3.69 (s, 3H), 3.56-3.40 (m, 4H), 3.32 
(s, 3H), 2.47-2.32 (m, 2H), 2.28-2.15 (m, 4H), 2.09 (s, 3H), 2.06-1.87 (m, 8H), 1.84-1.53 
(m, 6H), 1.17 (d, J  = 6.4 Hz, 3H), 1.10 (s, 3H), 1.09 (s, 3H), 0.88 (s, 9H), 0.08 (s, 3H), 0.06 
(s, 3H); 125 MHz 13C NMR (CDCb) 5 169.6, 166.7, 159.5, 153.0, 144.6, 144.3, 138.6,
138.1, 130.6, 129.7, 128.6, 128.0, 128.0, 127.9, 126.9, 117.0, 114.1, 109.1, 109.0, 102.6,
93.2, 79.4, 77.4, 75.4, 75.3, 75.0, 75.0, 74.9, 72.1, 71.6, 70.1, 69.5, 68.4, 60.4, 55.5, 51.6,
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51.4, 46.2, 42.9, 41.8, 41.4, 41.0, 40.9, 40.5, 38.6, 36.8, 33.4, 26.1, 24.2, 23.9, 21.5, 18.3,
13.9, -3.8, -4.5.
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yl)-3-((4-methoxybenzyl)oxy)butanoic acid (2.37).16 To a stirring solution of alcohol 
2.26 (100 mg, 0.095 mmol, 1.0 equiv) in CH2O 2 (2 mL) in a 10 ml rb flask at -5° C, was 
added (z'Pr)2NEt (116 |iL, 0.665 mmol, 7.0 equiv) and DMSO (68 |iL, 0.950 mmol, 10.0 
equiv). Stirring continued for 10 min at -5° C, and then SO3*Py (45 mg, 0.286 mmol, 3.0 
equiv) was added. The reaction was allowed to proceed for 1 h at -5° C, after which time 
TLC analysis indicated complete consumption of the alcohol starting material. The solution 
was quenched by the addition of saturated aqueous NaHCO3 solution (2 mL). The layers 
were separated and the aqueous layer was extracted with CH2Cl2 (3 x 5 mL). The 
combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced 
pressure. The crude alcohol was used in the next step without purification.
To a stirring solution of crude aldehyde in 2-methyl-2-butene (1.4 mL) and ffiuOH 
(1.4 mL) in a 10 ml rb flask at -15° C, was added aqueous KH2PO4 solution (1.25 M, 0.5 
mL) followed by NaClO2 (80%, 107 mg, 0.950 mmol, 10.0 equiv). The reaction was 
allowed to proceed for 4 h at -15° C. The solution was quenched by the addition of 
saturated aqueous NH4Q  solution (2 mL) and diluted with EtOAc (5 mL). The layers were 
separated and the aqueous layer was extracted with EtOAc (4 x 5 mL). The combined 
organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. 
Purification was accomplished by flash column chromatography using a 2.0 x 20.0 cm 
silica gel column, eluting with 3% MeOH/CH2Cl2, collecting 10 mL fractions. The product 
containing fractions (7-17) were combined and concentrated under reduced pressure to 
yield acid 2.37 (88 mg, 90%) as an oil: Rf = 0.30 (10% MeOH/CH2Ch); 500 MHz 1H 
NMR (CDCb) 5 7.44-7.20 (m, 7H), 6.88 (d, J  = 8.8 Hz, 2H), 5.99 (d, J  = 16.0 Hz, 1H), 
5.90 (s, 1H), 5.55 (s, 1H), 5.42 (dd, J  = 15.8, 6.1 Hz, 1H), 4.81 (s, 2H), 4.73 (s, 2H), 4.65 
(s, 2H), 4.59 (s, 1H), 4.51 (ABq, J  = 11.1 Hz, Av = 57.6 Hz, 2H), 4.15-4.03 (m, 2H), 3.89­
3.83 (m, 1H), 3.80 (s, 3H), 3.76-3.70 (m, 1H), 3.69 (s, 3H), 3.57-3.39 (m, 4H), 3.31 (s, 
3H), 2.62 (d, J  = 5.9, 5.9 Hz, 1H), 2.42-2.31 (m, 1H), 2.29-2.12 (m, 5H), 2.09 (s, 3H), 2.06­
1.84 (m, 8H), 1.82-1.49 (m, 4H), 1.17 (d, J  = 7.2 Hz, 3H), 1.11 (s, 3H), 1.10 (s, 3H), 0.87 
(s, 9H), 0.08 (s, 3H), 0.06 (s, 3H); 125 MHz 13C NMR (CDCb) 5 174.5, 169.7, 166.7,
159.5, 153.0, 144.4, 144.3, 138.8, 137.9, 130.2, 129.7, 128.6, 128.1, 128.0, 127.9, 126.9,
117.0, 114.1, 109.1, 102.6, 93.1, 79.5, 77.4, 75.1, 75.0, 74.9, 75.0, 73.1, 72.4, 71.7, 70.1,
69.5, 68.4, 55.5, 51.6, 51.4, 46.1, 42.9, 42.0, 41.2, 40.9, 40.8, 40.5, 40.2, 38.6, 33.5, 26.1,
24.3, 23.8, 21.5, 18.3, 13.9, -3.8, -4.5.
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(E)-methyl 2-((1JR,3S,7JR,m ,12S,15S, 17tf,21JR,23S,£)-12-acetoxy-17-((JR)-1- 
((benzyloxy)methoxy)ethyl)- 11-methoxy-21-((4-methoxybenzyl)oxy)-10,10-dimethyl-
5,25-dimethylene-19-oxo-18,27,28,29-tetra oxatetracyclo[21.3.1.13,7.111,15]nonacos-8- 
en-13-ylidene)acetate (2.24).16 To a stirring solution of the TBS ether 2.37 (65 mg, 0.0611 
mmol, 1.0 equiv) in THF (3 mL) at 0 °C in a 14 mL plastic bottle, was added HF*py (20 
% in pyridine, 1.5 mL). TLC analysis after 74 h at rt indicated complete consumption of 
the TBS ether starting material. The mixture was quenched by pipetting into a stirring 
mixture of saturated aqueous NaHCO3 solution (25 mL) and Et2O (25 mL). The layers 
were separated and the aqueous layer was extracted with Et2O (3 x 15 mL). The combined 
organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. 
The crude material was taken onto the next step without further purification
To a stirring solution of the seco acid in THF (3 mL) in a 10 ml rb flask at 0 °C, were 
added Et3N (51 |iL, 0.367 mmol, 6.0 equiv) and 2,4,6-trichlorobenzoyl chloride (29 |iL, 
0.183 mmol, 3.0 equiv) via syringe. After 10 min, the reaction mixture was warmed to rt 
and stirring was continued for an additional 3 h. The reaction mixture was then diluted 
with toluene (20 mL) and taken up into a 25 mL gas-tight syringe. This solution was added 
by syringe pump to a stirring solution of DMAP (52 mg, 0.444 mmol, 20.0 equiv) in toluene 
(40 mL) in a 250 ml rb flask at 40 °C, over 16 h. The residual contents of the syringe were
rinsed into the flask with toluene (2 x 2 mL) and stirring was continued for an additional 2 
h. The reaction mixture was cooled to rt, washed with saturated aqueous NaHCO3 solution 
(25 mL), the layers were separated, and the aqueous layer was extracted with Et2O (3 x 25 
mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated 
under reduced pressure. Purification was accomplished by flash column chromatography 
using a 2.0 x 15.0 cm silica gel column, eluting with 15% EtOAc/hexanes, collecting 10 
mL fractions. The product containing fractions (53-83) were combined and concentrated 
under reduced pressure to yield macrolactone 2.24 (40 mg, 70%) as a white foam: Rf =
0.39 (30% EtOAc/hexanes); 500 MHz 1H NMR (CDCb) 5 7.42-7.28 (m, 5H), 7.21 (d, J  =
8.3 Hz, 2H), 6.82 (d, J  = 8.3 Hz, 2H), 6.23 (d, J  = 15.8 Hz, 1H), 5.95 (s, 1H), 5.62-5.53 
(m, 1H), 5.34 (dd, J  = 15.6, 8.5 Hz, 1H), 5.16 (s, 1H), 4.82 (ABq, J  = 6.9 Hz, Av = 14.1 
Hz, 2H), 4.76 (s, 2H), 4.71 (s, 2H), 4.64 (ABq, J  = 11.9 Hz, Av = 24.7 Hz, 2H), 4.48 (s, 
2H), 4.22-4.14 (m, 1H), 4.00-3.92 (m, 2H), 3.74 (s, 3H), 3.73-3.70 (m, 2H), 3.69 (s, 3H), 
3.55-3.47 (m, 1H), 3.41-3.32 (m, 1H), 3.09 (s, 3H), 2.58 (dd, J  = 15.2, 1.5 Hz, 1H), 2.47 
(dd, J  = 15.6, 10.4 Hz, 2H), 2.31 (d, J  = 13.0 Hz, 1H), 2.22-2.08 (m, 4H), 2.05 (s, 3H),
2.03-1.82 (m, 5H), 1.79-1.66 (m, 2H), 1.56 (dd, J  = 13.8, 6.9 Hz, 1H), 1.50-1.39 (m, 2H), 
1.09 (s, 3H), 1.08 (s, 3H), 1.06 (d, J  = 6.8 Hz, 3H); 125 MHz 13C NMR (CDCb) 5 172.2,
169.3, 166.9, 159.3, 151.4, 144.5, 144.4, 141.8, 138.1, 130.9, 129.6, 128.6, 127.1, 127.8,
125.6, 119.5, 113.9, 109.1, 109.0, 103.3, 93.7, 81.5, 76.5, 76.4, 76.3, 75.3, 73.9, 73.1, 72.1,
70.7, 69.8, 67.3, 55.5, 52.8, 51.4, 45.2, 44.2, 43.1, 41.9, 41.5, 41.1, 40.9, 41.1, 34.6, 30.9,
29.9, 26.3, 21.6, 20.2, 15.2.
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Experimental Procedures and Analytical Data for BODIPY FL 
Tag 2.34 and 2.47
The compounds 2.39, 2.40, 2.41, and 2.34 were previously prepared and are 
reported in the literature.19 The synthesis of the BODIPY FL acid 2.34 was repeated on 
half the scale to assess these for use in the present work. The compounds 2.48 and 2.47 
were also previously prepared and are reported in the literature.21 The synthesis of the 
BODIPY FL azide 2.47 was repeated on a similar scale to assess these for use in the present 
work. The experimental procedure and analytical data for BODIPY FL acid 2.34 and 
BODIPY FL azide 2.47 are reproduced here for the convenience of those who may need 
to repeat this work.
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Ethyl 3-(1#-pyrrol-2-yl)propanoate (2.39).19 To a stirring solution of 1#-pyrrole-
2-carbaldehyde (5.20 g, 54.7 mmol, 1.0 equiv) in toluene (60 mL) in a 250 mL round 
bottom flask, was added ethyl 3-(triphenylphosphoranylidene)propanoate (21.0 g, 60.2 
mmol, 1.1 equiv). The reaction mixture was heated at 50 °C for 14 h, and then allowed to 
cool to rt. The mixture was filtered over a silica (3 x 9 cm) pad and washed with copious 
amounts of 50% EtOAc/hexanes. The filtrate was concentrated under reduced pressure to 
give the crude product as an orange oil. This material was carried onto the next step without 
further purification.
A 250 mL Parr bomb was charged with a magnetic stir bar, the crude olefin, palladium 
(10% on carbon, 10 g), and ethanol (50 mL). The gas inlet tube was attached to a hydrogen
source and hydrogen was introduced into the reaction vessel until the pressure gauge 
indicated 500 psi. The pressure was carefully released to 1 atm by opening the stop valve. 
This procedure was repeated 2 times, and finally hydrogen was pressurized to 500 psi. The 
reaction solution was stirred at rt for 26 h, during which time the hydrogen cylinder was 
kept connected. After the main valve of the hydrogen cylinder was closed, excess hydrogen 
in the reaction tube was carefully bled off, and the apparatus was disassembled. The 
reaction mixture was filtered through a Celite pad (3 x 8 cm), washed with copious amounts 
of 50% EtOAc/hexanes, and concentrated under reduced pressure. Purification was 
accomplished by flash column chromatography on a 12 x 14 cm column, eluting with 10% 
EtOAc/hexanes, collecting 125 mL fractions. The product containing fractions (10-24) 
were combined and concentrated under reduced pressure to give ester 2.39 (7.0 g, 78% 
yield) as a pale yellow oil: R/ = 0.65 (30% EtOAc/hexanes); 500 MHz 1H NMR (CDCb) 
5 8.59 (brs, 1H), 6.69 (d, J  = 1.0 Hz, 1H), 6.13 (dd, J  = 2.9, 2.4 Hz, 1H), 6.69 (d, J  = 1.0 
Hz, 1H), 4.19 (q, J  = 7.3 Hz, 2H), 2.66 (t, J  = 6.8 Hz, 2H), 2.66 (t, J  = 7.3 Hz, 3H); 125 
MHz 13C NMR (CDCb) 5 174.3, 131.2, 116.9, 108.1, 105.6, 60.9, 34.7, 32.7, 14.3.
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Me
3,5-dimethyl-1#-pyrrole-2-carbaldehyde (2.40).19 To a stirring solution of 
commercially available 2,4-dimethyl-1#-pyrrole (4.3 g, 45.2 mmol, 1.0 equiv) and DMF 
(30 mL) in a 100 mL round bottom flask at 0 °C, was added POCb (4.6 mL, 49.7 mmol,
1. 1 equiv) over 20 min via syringe. The reaction was allowed to proceed for 2 h at rt, after 
which time TLC analysis indicated complete consumption of the pyrrole starting material.
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The iminium salt was then quenched by pouring the reaction mixture into a stirring solution 
of aqueous NaOH solution (300 mL of 6M) and stirred for 30 min. The aqueous phase was 
extracted with CH2Q 2 (3 x 5 mL). The organic phases were combined, dried over Na2SO4 
and concentrated under reduced pressure. Purification was accomplished by filtration over 
a plug of alumina (5 x 15 cm). The plug was flushed with copious amounts of 30% 
EtOAc/hexanes. The filtrate was concentrated under reduced pressure to give pure product
2.40 (4.5 g, 80% yield) as a yellow solid: mp 80-81 °C; R / = 0.35 (30% EtOAc/hexanes);
500 MHz 1H NMR (CDCb) 5 10.44 (brs, 1H), 9.47 (s, 1H), 5.86 (s, 1H), 2.33 (s, 3H), 2.32 
(s, 3H); 125 MHz 13C NMR (CDCb) 5 176.1, 139.0, 135.1, 128.9, 13.3, 10.8.
3-(3-ethoxy-3-oxopropyl)-5,5-difluoro-7,9-di methyl-5#-dipyrrolo[1,2-c:2',1'- 
/)[1,3,2]diazaborinm-4-ium-5-uide (2.41).19 To a stirring solution of pyrrole 2.39 (603 
mg, 3.61 mmol, 1.0 equiv) and CH2O 2 (30 mL) in a 100 mL round bottom flask at 0 °C, 
was added aldehyde 2.40 (489 mg, 3.97 mmol, 1.1 equiv) followed by POCb (0.34 mL,
3.97 mmol, 1.1 equiv) via syringe. The reaction was allowed to proceed for 2 h at rt, after 
which time TLC analysis indicated complete consumption of the pyrrole 2.39 starting 
material. The solution was cooled to 0 °C, and (/Pr)2NEt (3.5 mL, 19.9 mmol, 5.0 equiv) 
and BF3*OEt2 (2.0 mL, 15.9 mmol, 4.0 equiv) were added dropwise via syringe. The 
solution was stirred for 16 h during which it slowly returned to rt. The solution was diluted 
with H2O (50 mL), the phases were separated, and the aqueous phase was extracted with
Me
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CH2Cl2 (2 x 50 mL). The organic phases were combined, dried over Na2SO4, and 
concentrated under reduced pressure. Purification was accomplished by flash column 
chromatography on a 5 x 15 cm column, eluting with 20% EtOAc/hexanes, collecting 8 
mL fractions. The product containing fractions (16-31) were combined and concentrated 
under reduced pressure to give 2.41 (720 mg, 62% yield) as a red solid: mp 76-77 °C; R/ 
= 0.34 (30% EtOAc/hexanes); 500 MHz 1H NMR (CDCb)5 7.08 (s, 1H), 6.88 (d, J  = 3.9 
Hz, 1H), 6.27 (d, J  = 3.9 Hz, 1H), 6.12 (s, 1H), 4.16 (q, J  = 7.3 Hz, 2H), 3.30 (t, J  = 7.3 
Hz, 2H), 2.76 (t, J  = 7.3 Hz, 2H), 2.57 (s, 3H), 2.24 (s, 3H), 1.26 (t, J  = 7.3 Hz, 2H); 125 
MHz 13C NMR (CDCb) 5 172.7, 160.5, 157.5, 144.0, 135.4, 133.5, 128.3, 124.0, 120.6,
116.9, 60.7, 33.6, 24.2, 15.1, 14.4, 11.5.
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3-(2-carboxyethyl)-5,5-difluoro-7,9-dimethyl-5#-dipyrrolo[1,2-c:2',r-/)[1,3,2] 
diazaborinin-4-ium-5-uide (2.42).19 To a stirring solution of ester 2.41 (610 mg, 1.91 
mmol, 1.0 equiv) and THF/H2O (3:2, 150 mL) in a 500 mL round bottom flask at rt, was 
added HCl (37% in H2O, 40 mL) via pipet. The reaction was allowed to proceed for 26 h 
at rt, after which time TLC analysis indicated complete consumption of the ester starting 
material. The solution was diluted with CH2O 2 (100 mL), the phases were separated, and 
the aqueous phase was extracted with CH2O 2 (3 x 100 mL). The organic phases were 
combined, dried over Na2SO4, and concentrated under reduced pressure. Purification was 
accomplished by flash column chromatography on a 5 x 12 cm column, eluting with 1%
179
MeOH/ CH2O 2, collecting 8 mL fractions. The product containing fractions (12-18) were 
combined and concentrated under reduced pressure to give 2.42 (360 mg, 65% yield) as a 
red solid: mp 179-181 °C; Rf = 0.40 (10% MeOH/ CH2Ch); 500 MHz 1H NMR (CDCb) 
5 9.07 (brs, 1H), 7.38 (s, 1H), 7.01 (d, J  = 3.9 Hz, 1H), 6.33 (d, J  = 3.9 Hz, 1H), 6.23 (s, 
1H), 3.15 (t, J  = 7.3 Hz, 2H), 2.71 (t, J  = 7.3 Hz, 2H), 2.51 (s, 3H), 2.26 (s, 3H); 125 MHz 
13C NMR (CDCb) 5 174.0, 161.6, 157.8, 146.1, 136.2, 134.2, 129.4, 125.9, 121.6, 117.3,
32.9, 24.6, 15.1, 11.4.
3-(1#-pyrrol-2-yl)propan-1-ol (2.48).21 To a stirring solution of ester 2.39 (3.17 g,
19.0 mmol, 1.00 equiv) in ether (150 mL) in a 500 ml rb flask at 0° C, was added lithium 
aluminum hydride (1.08 g, 28.4 mmol, 1.5 equiv) in 3 portions over 10 mins. The reaction 
was allowed to proceed for 4 h at rt, after which time TLC analysis indicated complete 
consumption of the starting material. The reaction mixture was quenched by the addition 
of H2O (1.1 mL), aqueous NaOH solution (1.1 mL of 15%), and then with an additional 
amount of H2O (3.3 mL). Stirring was continued for 1 h at rt. The solution was dried over 
MgSO4, stirred for 15 min, filtered, and concentrated under reduced pressure to give alcohol 
2.48 (2.38 g, 100% yield) as a clear yellow oil: Rf = 0.17 (50% EtOAc/hexanes); 500 MHz 
1H NMR (CDCb) 5 8.37 (brs, 1H), 6.70-6.68 (m, 1H), 6.17-6.14 (m, 1H), 5.98-5.94 (m, 
1H), 3.71 (t, J  = 5.9 Hz, 2H), 2.73 (t, J  = 7.2 Hz, 2H), 2.10 (brs, 1H), 1.89 (tt, J  = 6.8, 6.8 





diazaborinin-4-ium-5-uide (2.47).21 To a stirring solution of alcohol 2.48 (2.38 g, 19.0 
mmol, 1.0 equiv) and Et3N (5.3 mL, 38.0 mmol, 2.0 equiv) in CH2O 2 (50 mL) in a 100 ml 
rb flask at 0 °C, was added methanesulfonyl chloride (1.2 mL, 12.1 mmol, 1.0 equiv) via 
syringe. The reaction was allowed to proceed for 4h at rt, after which time TLC analysis 
indicated complete consumption of the alcohol starting material. The reaction mixture was 
quenched by transfer into a 100 mL separatory funnel that contained a mixture of a 
saturated aqueous NaHCO3 solution (25 mL) and CH2Q 2 (25 mL). The phases were 
separated and the aqueous layer was extracted with CH2Q 2 (2 x 25 mL). The combined 
organic layers were dried over Na2SO4 and concentrated under reduced pressure. This 
material was carried onto the next step without further purification.
To a stirring solution of the crude mesylate in DMF (50 mL) in a 100 ml rb flask, 
was added sodium azide (3.7 g, 57.0 mmol, 3.0 equiv). The reaction was allowed to 
proceed for 16 h at 70 °C, and then allowed to cool to rt. The solution was diluted with 
H2O (25 mL) and 30% EtOAc/hexanes (25 mL), the phases were separated, and the 
aqueous phase was extracted with 30% EtOAc/hexanes (2 x 25 mL). The combined 
organic layers were dried over Na2SO4 and concentrated under reduced pressure. This 
material was carried onto the next step without further purification.
To a stirring solution of crude pyrrole and CH2Q 2 (200 mL) in a 500 mL round 
bottom flask at 0 °C, was added 3,5-dimethyl-1#-pyrrole-2-carbaldehyde (2.3 g, 19.0
mmol, 1.0 equiv) followed by POCb (2.0 mL, 20.9 mmol, 1.1 equiv) via syringe. The 
reaction was allowed to proceed for 2 h at rt. The solution was cooled to 0 °C, and 
(z'Pr)2NEt (16.5 mL, 95.0 mmol, 5.0 equiv) followed by BF3*OEt2 (11.7 mL, 95.0 mmol,
5.0 equiv) were added dropwise via syringe. The solution was stirred for 18 h during which 
it slowly returned to rt. The reaction mixture was quenched slowly with H2O (100 mL), 
the phases were separated, and the aqueous layer was extracted with CH2Q 2 (2 x 100 mL). 
The organic phases were combined, dried over Na2SO4, and concentrated under reduced 
pressure. Purification was accomplished by flash column chromatography on a 4 x 35 cm 
column, eluting with 5% EtOAc/hexanes, collecting 25 mL fractions. The product 
containing fractions (22-44) were combined and concentrated under reduced pressure to 
give 2.47 (3.17 g, 55% yield, 3 steps) as a red solid: mp 49-50 °C; R / = 0.35 (30% 
EtOAc/hexanes); 500 MHz 1H NMR (CDCb) 5 7.09 (s, 1H), 6.91 (d, J  = 3.9 Hz, 1H),
6.28 (d, J  = 4.0 Hz, 1H), 6.12 (s, 1H), 3.39 (t, J  = 6.9 Hz, 2H), 3.05 (t, J  = 7.6 Hz, 2H),
2.57 (s, 3H), 2.25 (s, 3H), 2.04 (tt, J  = 7.9, 7.9 Hz, 2H); 125 MHz 13C NMR (CDCb) 5
160.4, 157.9, 143.9, 135.3, 133.4, 128.3, 123.9, 120.6, 116.8, 51.1, 28.3, 26.0, 15.1, 11.5.
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(2-methoxy-2-oxoethylidene)tetrahydro-2#-pyran-3-yl hex-5-ynoate (2.50). To a
stirring solution of acetate 2.32 (135 mg, 0.172 mmol, 1.0 equiv) in MeOH (10 mL) in a 
25 mL round bottom flask at rt, was added K2CO3 (237 mg, 1.72 mmol, 10.0 equiv). The 
reaction was allowed to proceed for 1 h, after which time TLC analysis indicated complete 
consumption of the starting material. The reaction mixture was quenched by transfer into 
a 100 mL separatory funnel that contained a mixture of saturated aqueous NH4O  solution 
(10 mL) and CH2Cl2 (50 mL). The layers were separated and the aqueous layer was 
extracted with CH2O 2 (2 x 15 mL). The organic layers were combined, dried over Na2SO4, 
and concentrated to give the crude alcohol that was taken directly onto the next reaction 
without further purification.
To a stirring solution of 5-hexynoic acid (36 ^L, 0.344 mmol, 2.0 equiv), Et3N (140 
|iL, 1.03 mmol, 6.0 equiv), and toluene (7 mL) in a 15 mL round bottom flask at rt, was 
added 2,4,6-trichlorobenzoyl chloride (54 ^L, 0.344 mmol, 2.0 equiv) via syringe. The 
reaction was allowed to proceed for 5 h at rt, after which time the solution was added to 
the neat crude alcohol in a 15 mL round bottom flask via cannula, followed by the addition
of DMAP (210 mg, 1.72 mmol, 10.0 equiv). The reaction was allowed to proceed for 1 h 
at rt. Purification was accomplished by directly loading the suspension onto a 2 x 17 cm 
silica gel flash column, rinsing with toluene, then eluting with 10% EtOAc/hexanes, 
collecting 8 mL fractions. The product containing fractions (20-41) were combined and 
concentrated under reduced pressure to yield alkyne 2.50 (118 mg, 82%) as a white foam: 
Rf = 0.51 (30% EtOAc/hexanes); [«]“  = -3.7 (c = 1.0, CHCb); 500 MHz 1H NMR
(CDCb) 5 7.43-7.19 (m, 7H), 6.89-6.81 (m, 2H), 6.00 (d, J  = 15.9 Hz, 1H), 5.89 (s, 1H), 
5.41 (s, 1H), 5.38 (ddd, J  = 9.6, 4.5, 4.5 Hz, 1H), 4.86 (d, J  = 3.0 Hz, 2H), 4.66 (s, 2H), 
4.63 (d, J  = 12.6 Hz, 1H), 4.43 (d, J  = 11.3 Hz, 1H), 4.17-4.10 (m, 3H), 4.05 (dddd, J  =
12.0, 10.1, 2.3, 2.3 Hz, 1H), 3.90 (ddd, J  = 9.6, 4.2, 1.3 Hz, 1H), 3.79 (s, 3H), 3.69 (s, 3H), 
3.53 (dd, J  = 15.7, 2.4 Hz, 1H), 3.24 (s, 3H), 2.44 (t, J  = 7.3 Hz, 2H), 2.33-2.22 (m, 2H),
1.98 (dd, J  = 2.6, 2.6 Hz, 1H), 1.92 (ddd, J  = 14.5, 10.2, 1.6 Hz, 1H), 1.87-1.78 (m, 2H), 
1.74 (ddd, J  = 13.0, 10.2, 2.1 Hz, 1H), 1.23 (d, J  = 6.6 Hz, 3H), 1.12 (s, 6H), 0.91 (s, 9H), 
0.06 (s, 6H); 125 MHz 13C NMR (CDCb) 5 171.5, 166.6, 159.3, 152.4, 138.0, 138.1,
130.7, 129.8, 129.4, 128.6, 128.0, 127.9, 117.7, 114.0, 102.8, 93.5, 83.2, 76.9, 72.5, 72.2,
72.1, 69.6, 69.6, 68.5, 55.4, 51.7, 51.3, 45.9, 36.4, 33.1, 32.6, 26.2, 24.6, 23.6, 23.4, 18.6,
17.9, -4.9; DEPT 13C NMR (CDCb) CH3 5 55.4, 51.7, 51.3, 26.2, 24.6, 23.6, -4.9; CH2 
5 93.5, 72.1, 69.6, 64.6, 36.4, 33.1, 32.6, 23.4, 17.9; CH 5 138.1, 129.8, 129.4, 128.6,
128.0, 127.9, 117.7, 114.0, 76.9, 72.5, 72.2, 69.6, 68.5; CH0 5 171.5, 166.6, 159.3, 152.4,
138.0, 130.7, 102.8, 83.2, 45.9, 18.6; IR (neat) 3304, 2952, 2856, 1742, 1720, 1612, 1513, 
1462, 1432, 1383, 1249, 1152, 1106, 1040, 836, 777 cm-1; HRMS (ESI) calcd for 
C4?H68NaOnSi (M+Na) 859.4429, found 859.4432.
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(1R,3S,7R,8E,11S,12S,13E,15S,17R, 21R,23S) -17-((R)-1- ((benzyloxy) 
methoxy)ethyl) -11-methoxy -13-(2-methoxy-2-oxo ethylidene) -21-((4- 
methoxybenzyl)oxy) -10,10 -dimethyl -5,25-dimethylene -19-oxo-18,27,28,29 -  
tetraoxatetracyclo [21.3.1.13,7.111,15] nonacos-8-en-12-yl hex-5-ynoate (2.52): To a
stirring solution of acetate 2.24 (8.9 mg, 0.0096 mmol, 1.0 equiv) in MeOH (2 mL) in a 4 
mL vial at rt, was added K2CO3 (13 mg, 0. 096 mmol, 10.0 equiv). The reaction was 
allowed to proceed for 45 min at rt, after which time TLC analysis indicated complete 
consumption of the ester starting material. The reaction mixture was transferred into a 25 
mL separatory funnel that contained a mixture of CH2O 2 (5 mL) and H2O (5 mL). The 
layers were separated and the aqueous layer was extracted with CH2O 2 (3 x 5 mL). The 
organic layers were combined, dried over Na2SO4, and concentrated. The crude alcohol 
was used without further purification.
To a stirring solution of 5-hexynoic acid (6 |iL, 0.055 mmol, 5.0 equiv), Et3N (15 
|iL, 0.110 mmol, 10.0 equiv), and toluene (1 mL) in a 4 mL vial at 0 °C, was added 2,4,6- 
trichlorobenzoyl chloride (9 ^L, 0.055 mmol, 5.0 equiv) via syringe. The reaction was 
allowed to proceed for 3 h at rt, after which time the solution was added to the neat crude 
alcohol in a 4 mL vial via cannula, followed by the addition of DMAP (13 mg, 0.110 mmol,
10.0 equiv). The reaction was allowed to proceed for 1 h at rt, after which time TLC
analysis indicated complete consumption of the alcohol starting material. Purification was 
accomplished by directly loading the suspension onto a 1.0 x 7.0 cm silica gel flash column, 
rinsing with toluene, then eluting with 30% EtOAc/hexanes, collecting 4 mL fractions. 
The product containing fractions (7-22) were combined and concentrated under reduced 
pressure to yield ester 2.52 (7.6 mg, 70%) as a clear film: Rf = 0.39 (30% EtOAc/hexanes); 
[o\2  = +29 (c = 0.3, CHCb); 500 MHz 1H NMR (CDCb) 5 7.41-7.28 (m, 5H), 7.21 (d, J  
= 8.6 Hz, 2H), 6.82 (d, J  = 8.0 Hz, 2H), 6.23 (d, J  = 15.5 Hz, 1H), 5.95 (s, 1H), 5.60-5.55 
(m, 1H), 5.34 (dd, J  = 15.8, 8.8 Hz, 1H), 5.18 (s, 1H), 4.82 (ABq, J  = 7.0 Hz, Av = 14.5 
Hz, 2H), 4.76 (s, 2H), 4.71 (s, 2H), 4.64 (ABq, J  = 11.9 Hz, Av = 24.2 Hz, 2H), 4.48 (s, 
2H), 4.22-4.15 (m, 1H), 4.00-3.92 (m, 2H), 3.75 (s, 3H), 3.73-3.71 (m, 2H), 3.69 (s, 3H), 
3.54-3.45 (m, 1H), 3.41-3.33 (m, 1H), 3.27-3.19 (m, 1H), 3.09 (s, 3H), 2.58 (dd, J  = 15.0,
2.6 Hz, 1H), 2.51-2.42 (m, 2H), 2.32 (d, J  = 12.4 Hz, 2H), 2.24 (td, J  = 7.8, 2.6 Hz, 2H),
2.18 (t, J  = 8.9 Hz, 2H), 2.15-2.02 (m, 2H), 2.00-1.92 (m, 4H), 1.91-1.79 (m, 4H), 1.77­
1.59 (m, 2H), 1.56 (dd, J  = 15.0, 7.8 Hz, 1H), 1.50-1.41 (m, 1H), 1.30-1.15 (m, 4H), 1.09 
(s, 3H), 1.08 (s, 3H), 1.06 (d, J  = 6.5 Hz, 3H), 0.92-0.83 (m, 1H); 125 MHz 13C NMR 
(CDCb) 5 173.3, 171.5, 167.0, 159.3, 151.3, 144.5, 144.4, 141.8, 138.1, 130.9, 129.6,
128.6, 128.1, 127.8, 125.7, 119.5, 113.9, 109.1, 109.0, 103.3, 93.7, 83.1, 81.5, 81.5, 77.4,
76.4, 75.3, 73.9, 73.2, 72.1, 70.7, 69.8, 69.5, 67.2, 55.4, 52.8, 51.4, 45.2, 44.2, 43.1, 41.9,
41.4, 41.1, 41.0, 40.9, 34.7, 33.3, 31.0, 29.9, 26.5, 23.3, 20.2, 17.9, 15.2, 14.3; 125 MHz 
DEPT 13C NMR (CDCb) CH3 5 54.4, 52.8, 26.5, 20.2, 15.2; CH2 5 109.1, 109.0, 93.7,
72.1, 69.8, 44.2, 43.1, 41.9, 41.9, 41.4, 41.1, 41.0, 40.9, 34.7, 33.3, 31.0, 29.9, 23.4, 17.9, 
14.3; CH 5 141.8, 129.6, 128.1, 127.8, 125.7, 119.6, 113.9, 83.1, 81.5, 77.4, 76.4, 75.3,
73.9, 73.2, 70.7, 69.5, 67.2; CH0 5 172.3, 171.5, 167.0, 159.3, 144.5, 144.4, 138.1, 130.9,
185
103.3, 81.5, 45.2; IR (neat) 3290, 2934, 1721, 1665, 1612, 1514, 1453, 1423, 1370, 1300, 
1247, 1148, 1089, 1042, 894, 820, 737, 698, 637 cm-1; HRMS (ESI) calcd for C5?H74NaO14 
(M+Na) 1005.4976, found 1005.4984.
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(1R,3S,7R,8E,11S,12S,13E,15S,17R, 21R,23S)-11,21-dihydroxy-17-((R)-1- 
hydroxyethyl)-13-(2-methoxy-2-oxoethylidene)-10,10 -dimethyl -5,25 -dimethylene - 
19-oxo -18,27,28,29 -tetraoxatetracyclo [21.3.1.13,7.111,15]nonacos-8-en-12-yl hex-5- 
ynoate (2.45): To a stirring solution of PMB ether 2.51 (6.4 mg, 0.0063 mmol, 1.0 equiv) 
in CH2O 2 (1 mL) and H2O (10 |iL) at 0 °C in a 4 mL vial, was added DDQ (3 mg, 0.0126 
mmol, 2.0 equiv). TLC analysis after 4 h at 0 °C indicated complete consumption of the 
PMB ether starting material. The reaction mixture was quenched by transfer into a 25 mL 
separatory funnel that contained a mixture of saturated NaHCO3 solution (2 mL) and 
CH2Cl2 (5 mL). The layers were separated and the aqueous layer was extracted with 
CH2Cl2 (3 x 5 mL). The combined organic layers were dried over Na2SO4, filtered, and 
concentrated under reduced pressure. The crude material was taken onto the next step 
without further purification
To a stirring solution of crude BOM ether in CH3CN/ H2O (25:1, 1 mL) in a 4 mL 
vial, was added LiBF4 (24 mg, 0.252 mmol, 40.0 equiv). The reaction vial, was sealed and
the mixture was allowed to stir at 80 °C for 16 h. The reaction mixture was cooled to rt, 
quenched by the addition of saturated aqueous NaHCO3 solution (2 mL) and diluted with 
Et2O (5 mL). The layers were separated and the aqueous layer was extracted with Et2O (3 
x 5 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated 
under reduced pressure. Purification was accomplished by flash column chromatography 
using a 1.0 x 7.0 cm silica gel column, eluting with 25% EtOAc/hexanes, collecting 4 mL 
fractions. The product containing fractions (4-10) were combined and concentrated under 
reduced pressure to yield macrolactone 2.45 (3.3 mg, 70%) as a white powder: Rf = 0.37 
(40% EtOAc/hexanes); [«]^0 = + 8  (c = 0.15, CHCb); 500 MHz 1H NMR (CDCb) 5 7.41­
7.28 (m, 5H), 7.21 (d, J  = 8.6 Hz, 2H), 6.82 (d, J  = 8.0 Hz, 2H), 6.23 (d, J  = 15.5 Hz, 1H), 
5.95 (s, 1H), 5.60-5.55 (m, 1H), 5.34 (dd, J  = 15.8, 8.8 Hz, 1H), 5.18 (s, 1H), 4.82 (ABq, 
J  = 7.0 Hz, Av = 14.5 Hz, 2H), 4.76 (s, 2H), 4.71 (s, 2H), 4.64 (ABq, J  = 11.9 Hz, Av =
24.2 Hz, 2H), 4.48 (s, 2H), 4.22-4.15 (m, 1H), 4.00-3.92 (m, 2H), 3.75 (s, 3H), 3.73-3.71 
(m, 2H), 3.69 (s, 3H), 3.54-3.45 (m, 1H), 3.41-3.33 (m, 1H), 3.27-3.19 (m, 1H), 3.09 (s, 
3H), 2.58 (dd, J  = 15.0, 2.6 Hz, 1H), 2.51-2.42 (m, 2H), 2.32 (d, J  = 12.4 Hz, 2H), 2.24 (td, 
J  = 7.8, 2.6 Hz, 2H), 2.18 (t, J  = 8.9 Hz, 2H), 2.15-2.02 (m, 2H), 2.00-1.92 (m, 4H), 1.91­
1.79 (m, 4H), 1.77-1.59 (m, 2H), 1.56 (dd, J  = 15.0, 7.8 Hz, 1H), 1.50-1.41 (m, 1H), 1.30­
1.15 (m, 4H), 1.09 (s, 3H), 1.08 (s, 3H), 1.06 (d, J  = 6.5 Hz, 3H), 0.92-0.83 (m, 1H); 125 
MHz 13C NMR (CDCb) 5 173.3, 171.5, 167.0, 159.3, 151.3, 144.5, 144.4, 141.8, 138.1,
130.9, 129.6, 128.6, 128.1, 127.8, 125.7, 119.5, 113.9, 109.1, 109.0, 103.3, 93.7, 83.1, 81.5,
77.4, 76.5, 76.4, 76.3, 75.3, 73.9, 73.2, 72.1, 70.7, 69.8, 69.5, 67.2, 55.4, 52.8, 51.4, 45.2,
44.2, 43.1, 41.9, 41.4, 41.1, 41.0, 40.9, 34.7, 33.3, 31.0, 29.9, 26.5, 23.3, 20.2, 17.9, 15.2; 
125 MHz DEPT 13C NMR (CDCb) CH3 5 54.4, 52.8, 26.5, 20.2, 15.2; CH2 5 109.1, 109.0,
187
93.7, 72.1, 69.8, 44.2, 43.1, 41.9, 41.9, 41.4, 41.1, 41.0, 40.9, 34.7, 33.3, 31.0, 29.9, 23.4, 
17.9; CH 5 141.8, 129.6, 128.1, 127.8, 125.7, 119.6, 113.9, 83.1, 81.5, 77.4, 76.5, 76.4,
76.3, 75.3, 73.9, 73.2, 70.7, 69.5, 67.2; CHo 5 172.3, 171.5, 167.0, 159.3, 144.5, 144.4,
138.1, 130.9, 103.3, 45.2; IR (neat) 2925, 1734, 1717, 1700, 1669, 1662, 1653, 1647, 1636, 
1569, 1540, 1506, 1457, 1419, 1374, 1289, 1231, 1156, 1104, 1077, 1009, 890 cm-1; 





dimethylene -19-oxo-18,27,28,29 -tetraoxa tetracyclo [21.3.1.13,7.111,15] nonacos-8-en- 
12-yl)oxy) -4-oxobutyl) -1#-1,2,3-triazol-1-yl)propyl) -5,5-difluoro -1,3-dimethyl-5#- 
dipyrrolo[1,2-c:2',r-/)[1,3,2]diazaborinin-4-ium-5-uide (Merle 44): To a stirring 
solution of alkyne 2.45 (2.7 mg, 0.0026 mmol, 1.0 equiv) and THF (1.0 mL) in a 4 mL 
reaction, was added freshly distilled (/Pr)2NEt (2 ^g, 0.013 mmol, 5.0 equiv) and copper(I) 
iodide (2.5 mg, 0.013 mmol, 5.0 equiv). Azide 2.47 (2.4 mg, 0.0078 mmol, 3.0 equiv) was 
added to the suspension, the reaction vial, was sealed, and the mixture was allowed to stir 
at 70 °C for 22 h. The reaction suspension was cooled to rt, filtered over a pad (4.0 x 0.5 
cm) of Celite®, washed with copious amounts of Et2O, and concentrated under reduced
pressure. Purification was accomplished by flash column chromatography using a 0.5 x
4.0 cm silica gel column, eluting with 1% MeOH/ CH2O 2, collecting 1 mL fractions. The 
product containing fractions (7-13) were combined and concentrated under reduced 
pressure to yield Merle 44 (2.1 mg, 80%) as a red foam: Rf = 0.39 (60% EtOAc/hexanes); 
[a]2° = +10 (c = 0.06, CHCb); 500 MHz 1H NMR (CDCb) 5 7.34 (s, 1H), 7.11 (s, 1H),
6.89 (d, J  = 3.9 Hz, 1H), 6.26 (d, J  = 3.9 Hz, 1H), 6.14 (s, 1H), 5.98 (d, J  = 2.0 Hz, 1H), 
5.78 (d, J  = 15.5 Hz, 1H), 5.32 (dd, J  = 15.7, 8.9 Hz, 1H), 5.27 (s, 1H), 5.21 (ddd, J  =
11.7, 8.6, 2.7 Hz, 1H), 5.14 (s, 1H), 4.76-4.67 (m, 4H), 4.47 (d, J  = 12.0 Hz, 1H), 4.41 (dd, 
J  = 6.9, 6.9 Hz, 1H), 4.21 (ddd, J  = 13.7, 11.6, 2.4 Hz, 1H), 4.08-3.98 (m, 2H), 3.80 (ddd, 
J  = 13.6, 7.7, 6.0 Hz, 1H), 3.71-3.69 (m, 1H), 3.68 (s, 3H), 3.56 (dd, J  = 10.0, 2.0 Hz, 1H), 
3.52-3.46 (m, 1H), 3.44-3.37 (m, 1H), 3.03 (d, J  = 7.4 Hz, 1H), 3.01 (d, J  = 7.4 Hz, 1H),
2.79-2.69 (m, 2H), 2.58 (s, 3H), 2.50 (dd, J  = 11.8, 2.2 Hz, 1H), 2.45 (dd, J  = 11.8 1H),
2.43-2.34 (m, 3H), 2.27 (s, 3H), 2.21-1.78 (m, 14H), 1.73-1.48 (m, 5H), 1.23 (d, J  = 6.5 
Hz, 3H), 1.12 (s, 3H), 1.00 (s, 3H); 125 MHz 13C NMR (CDCb) 5 172.5, 171.9, 167.2,
160.7, 157.0, 152.1, 144.0, 143.5, 138.9, 135.4, 130.2, 130.0, 128.4, 124.1, 120.7, 119.9,
117.0, 109.3, 108.8, 99.1, 80.2, 79.7, 77.8, 76.5, 74.5, 73.9, 70.6, 68.9, 64.7, 56.2, 51.3,
50.0, 45.0, 43.3, 42.8, 42.4, 41.5, 40.9, 40.3, 36.1, 34.1, 31.5, 29.9, 29.7, 29.6, 26.0, 24.6,
20.1, 15.2, 11.6; 125 MHz DEPT 13C NMR (CDCb) CH3 5 51.3, 29.6, 25.1, 20.1, 15.2,
11.6; CH2 5 109.3, 198.8, 50.0, 43.3, 42.8, 42.4, 41.5, 41.0, 40.9, 40.3, 36.1, 34.1, 31.5,
29.9, 29.7, 26.0, 24.6; CH 5 138.9, 130.0, 128.4, 124.1, 120.7, 119.9, 117.0, 80.2, 79.6,
68.9, 64.7; CH0 5 172.5 171.9, 167.2, 160.7, 157.0, 152.1, 144.0, 143.5, 133.4, 130.2, 99.1,
56.2, 45.0, 32.1; IR (neat) 3453, 3318, 2925, 2853, 1737, 1692, 1658, 1606, 1530, 1484,
189
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1440, 1378, 1256, 1140, 1078, 985, 890 cm-1; HRMS (ESI) calcd for C54H72BF2N5NaO12Si 
(M+Na) 1054.5136, found 1054.5155.
Experimental Procedures and Analytical Data for A-ring 2.16
Compound 2.16 was previously prepared by Dr. Dennie Welch and are reported in 
his Ph.D. thesis and in the literature.37 Since the compounds needed to construct 2.16 are 
not mentioned in this chapter, they are designated as 2.16.1-2.16.13. A larger scale 
experimental procedure and analytical data for these compounds are reproduced here for 
those who may need to repeat this work.
3-((ferf-butyldiphenylsilyl)oxy)propan-1-ol (2.16.1).37 To a stirring solution of
1,3-propanediol (78.0 mL, 1.08 mol, 4.4 equiv) and Et3N (150 mL, 1.08 mol, 4.4 equiv) in 
CH2Cl2 (1.1 L) in a 2 L rb flask at 0 °C, was added fert-butyl(chloro)diphenylsilane (63.0 
mL, 0.24 mol, 1.0 mmol). The solution was stirred at rt for 36 h. The reaction mixture 
was quenched by the addition of H2O (500 mL), the phases were separated, and the aqueous 
phase was extracted with 50% EtOAc/hexanes (2 x 500 mL) then dried over MgSO4, 
filtered, and concentrated under reduced pressure. Purification was accomplished by flash 
column chromatography using a 10.0 x 12.0 cm silica gel column, eluting with 10% 
EtOAc/hexanes, collecting 125 mL fractions. The product containing fractions (6-36) were 
combined and concentrated under reduced pressure to yield silyl ether 2.16.1 (72.3 g, 95%) 
as a clear yellow oil: Rf = 0.35 (30 % EtOAc/hexanes.); 500 MHz 1H NMR (CDCb) 
5 7.71-7.67 (m, 4H), 7.48-7.39 (m, 6H), 3.88-3.84 (m, 4H), 2.46 (t, J  = 5.4 Hz, 2H), 1.82
OH OBPS
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(quin, J  = 5.4 Hz, 2H), 1.07 (s, 9H); 125 MHz 13C NMR (CDCb) 5 135.6, 133.4, 129.9, 
127.9, 63.1, 61.6, 34.4, 27.0, 19.2.
3-((ferf-butyldiphenylsilyl)oxy)propanal (2.16.2).37 To a stirring solution of 
oxalyl chloride (30.0 mL, 350.0 mmol, 1.5 equiv) in CH2Q 2 (1 L) in a 2 L rb flask at -78 
°C, was added dimethyl sulfoxide (50.0 mL, 700 mmol, 3.0 equiv) slowly via an addition 
funnel. After 2 h at -78 °C, alcohol 2.16.1 (72.3 g, 233.3 mmol, 1.0 equiv) in CH2Q 2 (300 
mL) was added dropwise via an addition funnel. The addition funnel was rinsed with 
additional CH2Cl2 (10 mL) and slowly added to the reaction mixture. After 1 h at -78 °C, 
Et3N (163 mL, 1.17 mol, 5.0 equiv) was added to the reaction via an addition funnel. The 
solution was allowed to slowly reach rt over a 14 h period. The reaction mixture was then 
quenched by the addition of H2O (500 mL) and stirred for 20 min. The phases were 
separated and the aqueous phase was extracted with EtOAc (2 x 500 mL). The organic 
phases were combined, dried over MgSO4, and concentrated under reduced pressure. 
Purification was accomplished by flash column chromatography using a 10.0 x 15.0 cm 
silica gel column, eluting with 10% EtOAc/hexanes, collecting 125 mL fractions. The 
product containing fractions (12-31) were combined and concentrated under reduced 
pressure to yield aldehyde 2.16.2 (71.0 g, 97%) as a white solid: Rf = 0.60 (30 %
EtOAc/hexanes.); 500 MHz 1H NMR (CDCb) 5 9.83 (t, J  = 2.0 Hz, 1H), 7.74-7.65 (m, 
4H), 7.48-7.37 (m, 6H), 4.04 (t, J  = 5.9 Hz, 2H), 2.62 (dt, J  = 5.9, 2.0 Hz, 2H), 1.05 (s,
O OBPS




(»£)-1-((terf-butyldiphenylsilyl)oxy)hex-5-en-3-ol (2.16.3).37 To a stirring 
solution of oven dried 4 A molecular sieves (105 g) and (S)-BINOL (14.1 g, 49.1 mmol, 
0.22 equiv) in CH2Q 2 (480 mL) in a 2 L rb flask at rt, was added trifluoroacetic acid (90 
|iL, 0.9 mmol, 0.004 equiv) and Ti(O/Pr)4 (1M in CH2O 2, 25 mL, 24.6 mmol, 0.11 equiv) 
slowly via syringe. The reaction mixture was heated at reflux for 2 h, and then allowed to 
cool to rt. Aldehyde 2.16.2 (69.8 g, 223.4 mmol, 1.0 equiv) in CH2O 2 (100 mL) was added 
to the reaction flask via cannula. An additional CH2Cl2 (2 x 10 mL) rinse was used to 
transfer the remaining aldehyde residue into the reaction flask via cannula. Stirring 
continued for 30 min, then the solution was cooled to -78 °C and then allyltributyltin (90 
mL, 290.4 mmol, 1.3 equiv) was added dropwise via syringe. The reaction mixture was 
stirred for an additional 30 min at -78 °C and then transferred to a -30 °C freezer. After 4 
days, the reaction mixture was poured into a 3 L Erlenmeyer flask that contained an ice 
cold saturated aqueous NaHCO3 solution (800 mL) and stirred for 30 min. The reaction 
mixture was filtered over a pad of Celite® and washed with copious amounts of CH2O 2 . 
The phases were separated, and the organic phase was washed with brine (2 x 500 mL). 
The organic phases were combined, dried over MgSO4, and concentrated under reduced 
pressure. Purification was accomplished by flash column chromatography using a 10.0 x
15.0 cm silica gel column, eluting with 5% EtOAc/hexanes, collecting 125 mL fractions.
The product containing fractions (4-25) were combined and concentrated under reduced 
pressure. An additional purification was accomplished by flash column chromatography 
using a 10.0 x 10.0 cm silica gel column, eluting with 5% EtOAc/hexanes, collecting 125 
mL fractions. The product containing fractions (16-36) were combined and concentrated 
under reduced pressure to yield allyl alcohol 2.16.3 (71.7 g, 91%) as a clear oil: Rf = 0.50 
(30 % EtOAc/hexanes.); 500 MHz 1H NMR (CDCb) 5 7.71-7.67 (m, 4H), 7.48-7.39 (m, 
6H), 5.87 (dddd, J  = 17.6, 10.3, 7.3, 7.3 Hz, 1H), 5.16-5.08 (m, 2H), 4.01-3.95 (m, 1H), 
3.92-3.82 (m, 2H), 3.23 (d, J  = 2.5 Hz, 1H), 2.34-2.23 (m, 2H), 1.79-1.67 (m, 2H), 1.07 
(s, 9H); 125 MHz 13C NMR (CDCb) 5 135.7, 135.1, 133.1, 130.0, 130.0, 128.0, 117.6,
71.1, 63.5, 42.2, 38.1, 27.0, 19.2; Assay of enantiomeric excess: HPLC (Chiralcel OD-H 




(S)-3-((4-methoxybenzyl)oxy)hex-5-en-1-ol (2.16.4).37 To a stirring solution of 
alcohol 2.16.3 (61.9 g, 174.6 mmol, 1.0 equiv) and Sc(OTf)3 (837 mg, 1.7 mmol, 0.01 
equiv) in toluene (800 mL) in a 2L rb flask at 0° C, was added a solution of freshly prepared
4-methoxybenzyl trichloroacetimidate (74.0 g, 261.9 mmol, 1.5 equiv) in toluene (100 mL) 
dropwise via an addition funnel. The mixture was stirred at 0° C for 2 h then concentrated 
under reduced pressure. The reaction mixture was filtered over a pad of Celite®, washed 
with copious amounts of 10% EtOAc/hexanes, and then concentrated under reduced 
pressure. Purification was accomplished by flash column chromatography using a 10.0 x
15.0 cm silica gel column, eluting with 15% EtOAc/ hexanes, collecting 125 mL
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Erlenmeyer flask fractions. The product containing fractions (5-24) were combined and 
concentrated under reduced pressure to yield PMB ether as a clear yellow oil with 
inseparable impurities.
To a stirring solution of this crude PMB ether in THF (1.2 L) in a 2 L rb flask, was 
added tetrabutylammonium fluoride (1 M in THF, 230 mL, 227.0 mmol, 1.3 equiv). The 
reaction was allowed to proceed for 12 h at rt. The reaction mixture was quenched by 
transfer into a 2 L separatory funnel that contained a mixture of H2O (300 mL) and 50% 
EtOAc/hexanes (300 mL). The phases were separated and the aqueous phase was extracted 
with 50% EtOAc/hexanes (2 x 300 mL). The combined organic phases were dried over 
Na2SO4, and concentrated under reduced pressure. Purification was accomplished by flash 
column chromatography using a 10.0 x 12.0 cm silica gel column, eluting with 10% 
EtOAc/hexanes, collecting 125 mL Erlenmeyer flask fractions. The product containing 
fractions (7-21) were combined and concentrated under reduced pressure to yield alcohol 
2.16.4 (24.7 g, 60%) as clear colorless oil: Rf = 0.25 (40 % EtOAc/hexanes); 500 MHz 1H
NMR (CDCb) 5 7.29-7.25 (m, 2H), 6.90-6.87 (m, 2H), 5.82 (dddd, J  = 17.2, 10.2, 7.1, 7.1 
Hz, 1 H), 5.12-5.08 (m, 2H), 4.51 (ABq, J  = 11.2 Hz, Av = 87.4 Hz, 2H), 3.81 (s, 3 H),
3.79-3.67 (m, 3H), 2.50-2.26 (m, 2H), 1.86-1.71 (m, 2H); 125 MHz 13C NMR (CDCb)
(S)-3-((4-methoxybenzyl)oxy)hex-5-enal (2.16.5).37 To a stirring solution of 
alcohol 2.16.4 (24.7 g, 93.8 mmol, 1.0 equiv) in CH2Q 2 (1 L) in a 2 L rb flask at -5° C,
5 159.4, 134.4, 130.4, 129.6, 117.7, 114.0, 77.7, 70.8, 60.8, 55.4, 38.2, 36.1.
PMBO O
was added (z'Pr)2NEt (115 mL, 656.6 mmol, 7.0 equiv) and DMSO (67 mL, 938.1 mmol,
10.0 equiv). Stirring continued for 10 min at -5° C, then SO3*Py (59.7 g, 375.2 mmol, 4.0 
equiv) was added in three portions over 15 min. Stirring continued for 1 h at -5° C, then 
the reaction mixture was quenched by the addition of saturated aqueous NaHCO3 solution 
(300 mL). The phases were separated and the aqueous phase was extracted with 50% 
EtOAc/hexanes (2 x 500 mL). The organic phases were combined, dried over Na2SO4, 
and concentrated under reduced pressure. Purification was accomplished by flash column 
chromatography using a 10.0 x 15.0 cm silica gel column, eluting with 10% 
EtOAc/hexanes, collecting 125 mL fractions. The product containing fractions (10-25) 
were combined and concentrated under reduced pressure to yield aldehyde 2.16.5 (20.7 g, 
85%) as a clear yellow oil: Rf = 0.44 (50 % EtOAc/hexanes); 500 MHz 1H NMR (CDCb) 
5 9.77 (t, J  = 2.0 Hz, 1H), 7.28-7.23 (m, 2H), 6.91 -6.86 (m, 2H), 5.81 (dddd, J  = 16.8, 9.6,
7.3, 7.3 Hz, 1 H), 5.15-5.14 (m, 1H), 5.12 (s, 1H), 4.51 (ABq, J  = 8.2 Hz, Av = 49.0 Hz, 
2H), 4.02 (dddd, J= 7.8, 6.9, 4.9, 4.9 Hz, 1H), 3.81 (s, 3 H), 2.67 (ddd, J  = 16.6, 7.9, 2.5 
Hz, 1H), 2.56 (ddd, J  = 16.6, 4.5, 1.5 Hz, 1H), 2.48-2.41 (m, 1H), 2.40-2.33 (m, 1H); 125 




(3^,5»£)-»S-terf-butyl 3-hydroxy-5-((4-methoxy benzyl)oxy)oct-7-enethioate 
(2.16.6).37 To a stirring solution of aldehyde 2.16.5 (7.63 g, 31.9 mmol, 1.0 equiv) in
toluene (300 mL) in a 1 L round bottom flask under an atmosphere of Ar at -78 °C, was 
added a freshly prepared solution of TiCh(O/Pr)2 (1 M in toluene, 80.0 mL, 79.7 mmol,
2.5 equiv) dropwise via cannula. The resulting solution was allowed to stir for 15 min, 
then a solution of ((1-(fert-butylthio)vinyl)oxy)trimethylsilane (16.9 g, 82.9 mmol, 2.6 
equiv) in toluene (50 mL) was added dropwise via cannula over a 10 min period. After 4 
h at -78 °C, the reaction mixture was poured into a 2 L Erlenmeyer flask that contained 
aqueous pH 7 buffer solution (200 mL) and stirred for 20 min. The suspension was filtered 
over a pad o f  Celite® and washed with copious amounts o f  CH2Cl2. The layers were 
separated and the organic layer was washed with saturated aqueous NH4O  solution (200 
mL) and brine (200 mL). The organic phase was dried over Na2SO4 and concentrated 
under reduced pressure. Purification was accomplished by flash column chromatography 
using a 10.0 x 15.0 cm silica gel column, eluting with 15% EtOAc/hexanes, collecting 125 
mL fractions. The product containing fractions (6-21) were combined and concentrated 
under reduced pressure to yield alcohol 2.16.6 (11.0 g, 94%) as a clear yellow oil: Rf = 
0.45 (30 % EtOAc/hexanes); 500 MHz 1H NMR (CDCb) 5 7.30-7.25 (m, 2H), 6.91-6.86 
(m, 2H), 5.81 (dddd, J  = 17.3, 10.2, 7.2, 7.2 Hz, 1 H), 5.15 -5.06 (m, 2H), 4.51 (ABq, J  =
11.0 Hz, Av = 70.9 Hz, 2H), 4.33-4.26 (m, 1H), 3.81 (s, 3 H), 3.82-3.75 (m, 1H), 3.18 (d, 
J  = 4.1 Hz, 1H), 2.61 (d, J  = 2.5 Hz, 1H), 2.59 (s, 1H), 2.47-2.39 (m, 1H), 2.37-2.30 (m, 
1H), 1.70-1.55 (m, 2H), 1.47 (s, 9H); 125 MHz 13C NMR (CDCb) 5 200.0, 159.4, 134.4,




(3^,5»£)-»S-terf-butyl 3-((terf-butyldiphenylsilyl)oxy) -5-((4-methoxybenzyl) 
oxy)oct-7-enethioate (2.16.7).37 To a stirring solution of alcohol 2.16.6 (5.34 g, 14.6 
mmol, 1.0 equiv) and imidazole (2.98 g, 43.7 mol, 3.0 equiv) in DMF (40 mL) in a 100 ml 
rb flask at rt, was added fert-butyl(chloro)diphenylsilane (5.7 mL, 21.9 mmol, 1.5 equiv). 
The reaction was allowed to proceed for 36 h at rt, after which time TLC analysis indicated 
complete consumption of the alcohol starting material. The reaction mixture was quenched 
by transfer into a 250 mL separatory funnel that contained a mixture of saturated aqueous 
NaHCO3 solution (50 mL) and diluted with 50% EtOAc/hexanes (50 mL). The phases were 
separated, and the aqueous phase was extracted with 50% EtOAc/hexanes (2 x 50 mL), 
dried over Na2SO4, filtered, and concentrated under reduced pressure. Purification was 
accomplished by flash column chromatography using a 6.0 x 20.0 cm silica gel column, 
eluting with 5% EtOAc/hexanes, collecting 25 mL fractions. The product containing 
fractions (16-42) were combined and concentrated under reduced pressure to yield silyl 
ether 2.16.7 (7.9 g, 95%) as a clear oil: Rf = 0.49 (20 % EtOAc/hexanes); 500 MHz 1H 
NMR (CDCb) 5 7.76-7.66 (m, 4H), 7.44-7.34 (m, 6H), 7.14-7.09 (m, 2H), 6.84-6.81 (m, 
2H), 5.58 (dddd, J  = 14.2, 10.7, 7.3, 7.3 Hz, 1 H), 4.98-4.92 (m, 2H), 4.40 (tt, J  = 5.9, 5.9 
Hz, 1H), 4.30 (d, J  = 11.2 Hz, 1H), 4.02 (d, J  = 10.6 Hz, 1H), 3.81 (s, 3 H), 3.34 (dddd, J  
= 5.9, 5.9, 5.2, 5.2 Hz, 1 H), 2.71 (dd, J  = 14.7, 6.3 Hz, 1 H), 2.64 (dd, J  = 14.7, 5.9 Hz, 1 
H), 2.13-2.02 (m, 2H), 1.74 (ddd, J  = 14.2, 8.3, 5.9 Hz, 1 H), 1.65 (ddd, J  = 14.2, 6.4, 3.9 
Hz, 1 H), 1.43 (s, 9H), 1.04 (s, 9H); 125 MHz 13C NMR (CDCb) 5 198.0, 164.2, 136.2,
136.1, 134.0, 134.5, 134.2, 131.0, 129.9, 129.8, 127.8, 127.7, 117.3, 113.8, 75.7, 70.3, 69.2, 
55.5, 53.0, 48.1, 42.4, 38.6, 30.0, 27.2, 19.6.
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(3^,5^)-S-terf-butyl 3-((terf-butyldiphenylsilyl) oxy)-5-((4-methoxybenzyl)oxy)- 
7-oxoheptanethioate (2.16.8).37 To a stirring solution of olefin 2.16.7 (7.9 g, 13.1 mmol,
1.0 equiv) and 4-methylmorpholine-#-oxide (4.6 g, 39.2 mmol, 3.0 equiv) in THF/^- 
BuOH/H2O (4:4:1, 135 mL) in a 250 ml rb flask at rt, was added a solution of OsO4 (0.08 
M in THF, 16 mL, 1.3 mmol, 0.1 equiv) dropwise. The reaction was allowed to proceed 
for 14 h at rt, after which time TLC analysis indicated complete consumption of the olefin 
starting material. The reaction mixture was quenched by pouring the mixture into a 1 L 
Erlenmeyer flask that contained saturated aqueous Na2S2O3 solution (250 mL) and EtOAc 
(250 mL). The phases were separated, then the aqueous phase was extracted with EtOAc 
(2 x 200 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give 
the crude diol.
To a stirring solution of the crude diol in benzene (50 mL) was added lead(II) acetate 
(4.5 g, 13.7 mmol, 1.05 equiv). The suspension was stirred for 1.5 h and then filtered over 
a pad of Celite®, washing with copious amounts of hexanes. After concentration of the 
filtrate under reduced pressure, purification was accomplished by flash column 
chromatography using a 5.0 x 25.0 cm silica gel column, eluting with 10% EtOAc/hexanes, 
collecting 25 mL fractions. The product containing fractions (40-80) were combined and
concentrated under reduced pressure to yield aldehyde 2.16.8 (6.0 g, 76%) as clear 
colorless oil: Rf = 0.36 (20 % EtOAc/hexanes); 500 MHz 1H NMR (CDCb) 5 9.54 (t, J  =
2.0 Hz, 1 H), 7.73-7.76 (m, 4H), 7.48-7.34 (m, 6H), 7.12-7.06 (m, 2H), 6.86-6.80 (m, 2H), 
4.33 (tt, J  = 6.3, 5.9 Hz, 1H), 4.19 (ABq, J  = 10.7 Hz, Av = 41.8 Hz, 2H), 3.85-3.81 (m, 
1H), 3.80 (s, 3 H), 2.72 (dd, J  = 14.2, 5.9 Hz, 1 H), 2.62 (dd, J  = 14.7, 6.3 Hz, 1 H), 2.34 
(ddd, J  = 16.6, 6.8, 2.4 Hz, 1 H), 2.36 (ddd, J  = 16.1, 4.9, 2.0 Hz, 1 H), 1.96 (ddd, J  = 13.7,
7.3, 5.9 Hz, 1 H), 1.64 (ddd, J  = 14.2, 5.9, 5.9 Hz, 1 H), 1.43 (s, 9H), 1.05 (s, 9H); 125 
MHz 13C NMR (CDCb) 5 201.2, 197.7, 159.4, 136.1, 136.0, 133.6, 133.8, 130.4, 130.0,




(3R,5S,7S)-S-tert-butyl 11-((tert-buty\ dimethyl silyl)oxy)-3-((tert- 
butyldiphenylsilyl)oxy)-7-hydroxy-5-((4-methoxybenzyl) oxy)-8,8-di methyl-9- 
methyleneundecanethioate (2.16.9).37 To a stirring solution of aldehyde 2.16.8 (1.74 g, 
2.87 mmol, 1.0 equiv) in toluene (30 mL) in a 100 ml rb flask at -78 °C, was added a freshly 
prepared Me2AlCl (3 M in toluene, 6.7 mL, 20.1 mmol, 7.0 equiv) dropwise via syringe 
down the side of the flask. This was followed by an addition of fert-butyl-dimethyl-(3- 
methyl-tributyl-stannanyl-methyl-pent-enyloxy)-silane37 (2.08 g, 4.01 mmol, 1.4 equiv) in 
toluene (6 mL) via cannula down the inside of the reaction flask over a 10 min period. The 
reaction was allowed to proceed for 1 h at -78 °C, after which time TLC analysis indicated
complete consumption of the aldehyde starting material. The reaction mixture was 
quenched with saturated aqueous NaHCO3 solution (5 mL), and then poured into a 1 L 
Erlenmeyer flask that contained aqueous sodium potassium tartrate salt solution (200 mL) 
and 20% EtOAc/hexanes (200 mL). This mixture was stirred for 12 h. The phases were 
separated and the aqueous phase was extracted with 20% EtOAc/hexanes (2 x 200 mL). 
The organic phases were combined, dried over Na2SO4 and concentrated under reduced 
pressure. Purification was accomplished by flash column chromatography using a 3.0 x
13.0 cm silica gel column, eluting with 5% EtOAc/hexanes, collecting 8 mL fractions. The 
product containing fractions (16-42) were combined and concentrated under reduced 
pressure to yield alcohol 2.16.9 (2.0 g, 87%) as a clear yellow oil: Rf = 0.57 (30 % 
EtOAc/hexanes); 500 MHz 1H NMR (CDCb) 5 7.76-7.69 (m, 4H), 7.46-7.34 (m, 6H), 
7.12-7.16 (m, 2H), 6.86-6.81 (m, 2H), 4.99 (s, 1H), 4.92 (s, 1H), 4.33 (quin, J  = 5.9, 1H), 
4.23 (ABq, J  = 10.7 Hz, Av = 50.1 Hz, 2H), 3.81 (s, 3H), 3.80-3.76 (m, 2H), 3.70-3.65 (m, 
1H), 3.64-3.58 (m, 1H), 2.71 (dd, J  = 14.7, 6.4 Hz, 1H), 2.65 (dd, J  = 14.7, 5.9 Hz, 1H),
2.43 (d, J  = 2.9 Hz, 1H), 2.32-2.17 (m, 2H), 1.96 (ddd, J  = 14.2, 6.8, 6.8 Hz, 1H), 1.59 (td, 
J  = 13.7, 5.9 Hz, 1H), 1.46 (s, 9H), 1.27-1.14 (m, 2H), 1.06 (s, 9H), 0.97 (s, 3H), 0.95 (s, 
3H), 0.92 (s, 9H), 0.89 (s, 3H), 0.87 (s, 3H); 125 MHz 13C NMR (CDCb) 5 197.8, 159.2,
151.8, 136.2, 136.1, 134.0, 134.2, 133.9, 130.9, 129.9, 129.8, 129.6, 127.8, 127.8, 113.8,
111.3, 74.5, 71.6, 71.0, 68.9, 63.5, 55.4, 52.4, 48.1, 43.9, 42.6, 35.5, 34.0, 30.0, 27.1, 26.2,






disilaheptadecan-9-yl acetate (2.16.10).37 To a stirring solution of alcohol 2.16.9 (4.43 
g, 5.30 mmol, 1.0 equiv) and DMAP (61 mg, 0.50 mmol, 0.1 equiv) in CH2Q 2 (50 mL) in 
a 250 ml rb flask at 0 °C, was added a mixture of acetic anhydride (1.0 mL, 10.6 mmol,
2.0 equiv) and Et3N (2.2 mL, 15.9 mol, 3.0 equiv) dropwise via syringe. The solution was 
stirred at rt for 16 h. The reaction mixture was quenched by the addition of saturated 
aqueous NaHCO3 solution (50 mL) and stirred for 1 h. The phases were separated, and the 
aqueous phase was extracted with CH2Q 2 (2 x 50 mL) then dried over Na2SO4, filtered, 
and concentrated under reduced pressure. Purification was accomplished by flash column 
chromatography using a 5.0 x 15.0 cm silica gel column, eluting with 5% EtOAc/hexanes, 
collecting 25 mL fractions. The product containing fractions (36-65) were combined and 
concentrated under reduced pressure to yield ester 2.16.10 (4.6 g, 99%) as a clear oil: Rf 
= 0.54 (20 % EtOAc/hexanes); 500 MHz 1H NMR (CDCb) 5 7.74-7.66 (m, 4H), 7.46­
7.32 (m, 6H), 7.24-7.16 (m, 2H), 6.86-6.80 (m, 2H), 5.29 (d, J  = 8.9 Hz, 1H), 4.91 (s, 1H),
4.84 (s, 1H), 4.30-4.15 (m, 4H), 3.80 (s, 3H), 3.79-3.78 (m, 1H), 3.68 (t, J  = 7.3 Hz, 2H),
3.26-3.18 (m, 1H), 2.66 (dd, J  = 14.7, 6.4 Hz, 1H), 2.56 (dd, J  = 14.7, 2.9 Hz, 1H), 2.33­
2.17 (m, 2H), 2.00 (s, 3H), 1.96-1.90 (m, 1H), 1.33-1.17 (m, 2H), 1.46 (s, 9H), 1.36-1.20 
(m, 2H), 1.06 (s, 9H), 0.97 (s, 3H), 0.95 (s, 3H), 0.91 (s, 9H), 0.05 (s, 6H); 125 MHz 13C
NMR (CDCb) 5 197.7, 170.8, 159.1, 150.9, 136.1, 136.0, 133.9, 133.8, 131.1, 129.9,
129.8, 129.7, 127.8, 127.8, 113.8, 111.2, 74.6, 73.4, 71.3, 68.7, 63.3, 55.4, 52.3, 48.2, 43.4,





(2.16.11).37 To a stirring solution of the PMB ether 2.16.10 (4.61 g, 5.26 mmol, 1.0 equiv) 
in CH2O 2 (50 mL) in a 250 ml rb flask at rt, was added pH 7 phosphate buffer (20 mL). 
DDQ (2.40 g, 10.5 mmol, 2.0 equiv) was added in one portion and the mixture was stirred 
vigorously for 3 h. The reaction mixture was quenched by transfer into a 1 L separatory 
funnel that contained a mixture of 50% EtOAc/hexanes (300 mL) and saturated aqueous 
NaHCO3 solution (300 mL). The phases were separated, and the aqueous phase was 
extracted with 50% EtOAc/hexanes (2 x 300 mL), dried over Na2SO4, filtered, and 
concentrated under reduced pressure. Purification was accomplished by flash column 
chromatography using a 5.0 x 15.0 cm silica gel column, eluting with 10 % 
EtOAc/hexanes, collecting 25 mL fractions. The product containing fractions (12-24) were 
combined and concentrated under reduced pressure to yield alcohol 2.16.11 (3.57 g, 90%) 
as a clear oil: Rf = 0.55 (20 % EtOAc/hexanes); 500 MHz 1H NMR (CDCb) 5 7.74-7.66 
(m, 4H), 7.47-7.36 (m, 6H), 5.07 (dd, J  = 10.7, 1.0 Hz, 1H), 4.94 (s, 1H), 4.87 (s, 1H),
4.45-4.36 (m, 1H), 3.77-3.66 (m, 1H), 3.52-3.45 (m, 1H), 2.66-2.62 (m, 3H), 2.26 (t, J  =
7.3 Hz, 2H), 1.93 (s, 3H), 1.64-1.51 (m, 2H), 1.41 (s, 9H), 1.38-1.22 (m, 3H), 1.04 (s, 9H),
1.02 (s, 3H), 1.01 (s, 3H), 0.91 (s, 9H), 0.07 (s, 6H); 125 MHz 13C NMR (CDCb) 5 197.7,
172.2, 150.6, 136.1, 136.0, 133.8, 129.9(x2), 127.9, 127.8, 111.3, 75.2, 68.5, 63.8, 63.3,




(2S,4S,6S)-6-((K)-2-((terf-butyldiphenyl silyl) oxy)-4-(terf-butylthio)-4- 
oxobutyl)-2-(2-hydroxyethyl)-2-methoxy-3,3-dimethyl tetra hydro-2#-pyran -4-yl 
acetate (2.16.12).37 To a stirring solution of alkene 2.16.11 (3.57 g, 4.71 mmol, 1.0 equiv) 
in CH2Cl2 (50 mL) was added NaHCO3 (3.96 g, 47.2 mmol, 10.0 equiv). The reaction 
mixture was cooled to -78° C and O3 was bubbled through the mixture until the solution 
developed a light blue color. The excess O3 was purged from the reaction mixture by 
bubbling O2 through it for 20 min. Dimethyl sulfide (6.9 ml, 94.2 mmol, 20.0 equiv) was 
added to the mixture dropwise via syringe. The solution was slowly allowed to reach rt 
overnight. The solid NaHCO3 was removed by filtration, and the solution was concentrated 
under reduced pressure. Purification was accomplished by flash column chromatography 
using a 5.0 x 12.0 cm silica gel column, eluting with 5% EtOAc/hexanes, collecting 25 mL 
Erlenmeyer flask fractions. The product containing fractions (10-46) were combined and 
concentrated under reduced pressure to yield hemiketal 2.16.12 (2.94 g, 82%) as clear
colorless oil: Rf = 0.40 (10 % EtOAc/hexanes); 500 MHz 1H NMR (CDCb) 5 7.75-7.66 
(m, 4H), 7.47-7.35 (m, 6H), 5.23 (s, 1H), 5.09 (dd, J  = 11.7, 4.9 Hz, 1H), 4.28 (quin, J  =
5.9, 1H), 4.18 (t, J  = 10.3 Hz, 1H), 3.85-3.78 (m, 1H), 3.76-3.71 (m, 1H), 2.70 (d, J  = 5.9 
Hz, 2H), 2.68-2.63 (m, 1H), 2.02 (s, 3H), 1.94-1.84 (m, 1H), 1.73 (dt, J  = 14.2, 7.8 Hz, 
1H), 1.56-1.50 (m, 1H), 1.45 (s, 9H), 1.38-1.32 (m, 1H), 1.04 (s, 9H), 0.92 (s, 3H), 0.90 (s, 
9H), 0.83 (s, 3H), 0.10 (s, 6H),; 125 MHz 13C NMR (CDCb) 5 197.9, 170.5, 136.1(x2),
134.6, 134.4, 129.9, 129.7, 127.8, 127.7, 102.3, 73.4, 69.3, 64.7, 60.3, 34.1, 33.5, 30.0, 





oxobutyl)-2-(2-hydroxyethyl)-2-methoxy-3,3-dimethyltetra hydro-2#-pyran -4-yl 
acetate (2.16.13).37 To a stirring solution of TBS ether 2.16.12 (813 mg, 1.07 mmol, 1.0 
equiv) in MeOH (10 mL) in a 25 ml rb flask, was added (±)-camphor-10-sulfonic acid (62 
mg, 0.268 mmol, 0.25 equiv) at 0 ° C. Stirring continued for 2 h at 0 ° C, then the reaction 
was quenched by pipetting into a stirring saturated aqueous NaHCO3 solution (10 mL). 
The aqueous phase was extracted with CH2Q 2 (3 x 15 mL). The organic phases were 
combined, dried over Na2SO4, and concentrated under reduced pressure. Purification was 
accomplished by flash column chromatography using a 3.0 x 10.0 cm silica gel column, 
eluting with 15% EtOAc/hexanes, collecting 8 mL fractions. The product containing
fractions (30-55) were combined and concentrated under reduced pressure to yield alcohol 
2.16.13 (637 mg, 90%) as a clear oil: Rf = 0.33 (30 % EtOAc/hexanes); 500 MHz 1H 
NMR (CDCb) 5 7.72-7.62 (m, 4H), 7.45-7.35 (m, 6H), 5.05 (dd, J  = 11.7, 4.9 Hz, 1H),
4.28 (q, J  = 5.9, 1H), 3.68- 3.57 (m, 2H), 3.46 (dddd, J  = 11.7, 7.8, 4.4, 3.3 Hz, 1H), 2.96 
(s, 3H), 2.72 (dd, J  = 14.2, 5.9 Hz, 1H), 2.63 (dd, J  = 14.2, 5.9 Hz, 1H), 2.39 (s, 1H), 2.01 
(s, 3H), 1.99-1.95 (m, 1H), 1.84-1.72 (m, 1H), 1.53 -  1.45 (m, 2H), 1.14-1.02 (m, 10H),
1.04 (s, 9H), 0.90 (s, 3H), 0.82 (s, 3H); 125 MHz 13C NMR (CDCb) 5 197.9, 170.6, 136.1,
133.9, 130.0, 127.9, 104.9, 73.4, 68.7, 65.9, 59.6, 52.5, 48.6, 48.3, 43.8, 41.9, 34.7, 32.9,




(2»S,4»S,6»y)-6-((K)-2-((terf-butyldiphenylsilyl) oxy) -4-(terf-butylthio)-4- 
oxobutyl)-2-methoxy-3,3-dimethyl-2-(2-oxoethyl)tetra hydro-2#-pyran-4-yl acetate 
(2.16).37 To a stirring solution of alcohol 2.16.13 (637 mg, 0.967 mmol, 1.0 equiv) in 
CH2Cl2 (30 mL) in a 100 ml rb flask at -5° C, was added (z'Pr)2NEt (1.2 mL, 6.77 mmol,
7.0 equiv) and DMSO (0.7 mL, 9.67 mmol, 10.0 equiv). Stirring continued for 10 min at 
-5° C, and then SO3*Py (616 mg, 3.87 mmol, 4.0 equiv) was added in one portion. Stirring 
continued for 1 h at -5° C, then the reaction mixture was quenched by the addition of 
saturated aqueous NaHCO3 solution (20 mL). The phases were separated and the aqueous 
phase was extracted with CH2Cl2 (3 x 20 mL). The organic phases were combined, dried
over Na2SO4, and concentrated under reduced pressure. Purification was accomplished by 
flash column chromatography using a 3.0 x 12.0 cm silica gel column, eluting with 10% 
EtOAc/ hexanes, collecting 8 mL fractions. The product containing fractions (4-20) were 
combined and concentrated under reduced pressure to yield aldehyde 2.16 (522 mg, 82%) 
as a white foam: Rf = 0.45 (20 % EtOAc/Hex.); 500 MHz 1H NMR (CDCb) 5 9.65 (t, J  
= 2.9 Hz, 1H), 7.71-7.62 (m, 4H), 7.46-7.35 (m, 6H), 5.01 (dd, J  = 11.7, 4.9 Hz, 1H), 4.28 
(q, J  = 6.3, 1H), 3.41 (dddd, J  = 11.7, 7.8, 4.4, 3.4 Hz, 1H), 3.00 (s, 3H), 2.72 (dd, J  = 14.2, 
6.8 Hz, 1H), 2.63 (dd, J  = 14.2, 5.2 Hz, 1H), 2.52 (t, J  = 2.9 Hz, 2H), 2.01 (s, 3H), 1.77 
(ddd, J  = 14.6, 7.8, 6.8 Hz, 1H), 1.50 (ddd, J  = 14.2, 4.4, 4.4 Hz, 2H), 1.43 (s, 9H), 1.16­
1.06 (m, 1H), 1.03 (s, 9H), 0.87 (s, 3H), 0.82 (s, 3H); 125 MHz 13C NMR (CDCb) 
5 201.4, 197.9, 170.6, 136.1, 134.1, 130.0, 127.9, 104.0, 72.8, 69.1, 66.4, 53.0, 48.8, 48.3,
45.8, 43.5, 42.0, 32.8, 29.9, 27.1, 21.3, 20.8, 19.5, 17.4.




tetrahydro-2#-pyran-4-yl acetate (2.63).31 A 5 ml rb flask, was charged with N,N- 
((1S,2S)-1,2-diphenylethane-1,2-diyl)bis(4-methyl benzenesulfon amide) (373 mg, 0.717 
mmol, 3.0 equiv) and heated to 90 °C under 0.2 mm Hg vacuum. After 18 h, the dry powder
was cooled to rt, and the flask was flushed with Ar. CH2Q 2 (2 mL) was added via syringe 
and the suspension was cooled to 0 °C. Boron tribromide (68 |iL, 0.717 mmol, 3.0 equiv) 
was added dropwise via syringe and then stirred for 1 h at rt. The solvent was removed 
under high vacuum and the flask was then purged with Ar. A mixture of trimethyl(2- 
((tributyl stannyl )methyl) allyl)silane (299 mg, 0.717 mmol, 3.0 equiv) and 2,6-di-tert- 
butyl-4-methylpyridine (147 mg, 0.282 mmol, 3.0 equiv) and in CH2Q 2 (1.5 mL + 0.5 mL 
rinse) was added via cannula. Stirring continued for 16 h under Ar.
To a stirring solution of aldehyde 2.16 (157 mg, 0.239 mmol, 1.0 equiv) and CH2O 2 
(5 mL) at -78 °C in a 15 ml rb flask, was added the previously prepared solution of (4S,5S)-
4,5-diphenyl-1,3-ditosyl-2-(2-((trimethylsilyl)methyl)allyl)-1,3,2-diazaborolidine 
dropwise via cannula. TLC analysis after 2 h at -78 °C indicated complete consumption of 
the aldehyde starting material. The mixture was quenched by the addition of pH 7 aqueous 
buffer (10 mL). The layers were separated and the aqueous layer was extracted with EtOAc 
(3 x 100 mL). The organic phases were combined, dried over Na2SO4, and concentrated 
under reduced pressure. Et2O/ hexanes (15 mL of 2:1) was added, N,N'-((1S,2S)-1,2- 
diphenylethane-1,2-diyl)bis(4-methylbenzenesulfon amide) was recovered via filtration, 
and the solid was washed with copious amounts of 2:1 Et2O/hexanes. The filtrate was 
concentrated under reduced pressure and purification was accomplished by flash column 
chromatography using a 3.0 x 16.0 cm silica gel column, eluting with 5% EtOAc/ hexanes, 
collecting 8 mL fractions. The product containing fractions (31-43) were combined and 
concentrated under reduced pressure to yield silane 2.63 (167 mg, 89%) as a 10:1 mixture 
of diastereomers as measured by NMR: Rf = 0.60 (20% EtOAc/hexanes); 500 MHz 1H 
NMR (CDCb) 5 7.74-7.64 (m, 4H), 7.46-7.34 (m, 6H), 5.04 (dd, J  = 11.7, 4.9 Hz, 1H),
207
4.68-4.60 (m, 2H), 4.27 (ddd, J  = 12.2, 5.9, 5.9 Hz, 1H), 4.08 (ddd, J  = 12.2, 5.9, 5.9 Hz, 
1H), 3.52-3.42 (m, 1H), 3.14 (s, 3H), 2.73 (dd, J  = 14.6, 5.4, 1H), 2.64 (dd, J  = 14.6, 5.4 
Hz, 1H), 2.19 (dd, J  = 13.7, 6.4 Hz, 1H), 2.02 (s, 3H), 1.95 (dd, J  = 13.2, 6.8 Hz, 1H), 1.82­
1.77 (m, 2H), 1.55 (d, J  = 1.5 Hz, 2H), 1.44 (s, 9H), 1.08 (s, 9H), 1.04 (s, 9H), 0.91 (s, 3H), 
0.83 (s, 3H), 0.04 (s, 9H) ; 125 MHz 13C NMR (CDCI3) 5 197.8, 170.7, 144.4, 136.1,
136.0, 135.0, 130.0, 129.9, 129.8, 127.9(x2), 110.3, 104.9, 73.2, 68.8, 67.1, 66.4, 52.7,





dimethyltetrahydro-2#-pyran-2-yl) methyl)-4-methyl enetetrahydro-2#-pyran-2- 
yl)-2-methylbut-3-en-2-yl)-6-((2^,3^)-3-((benzyloxy) methoxy)-2-((4-methoxybenzyl) 
oxy)butyl)-2-methoxydihydro-2#-pyran-4(3#)-ylidene) acetate (2.70).31 To a stirring 
solution of aldehyde 2.25 (111 mg, 0.166 mmol, 1.0 equiv) and hydroxyallysilane 2.63 
(143 mg, 0.182 mmol, 1.1 equiv) in Et2O (4 mL) in a 15 ml rb flask at -78 °C, was added 
a solution of TMSOTf (0.9 M in Et2O, 150 |iL, 0.200 mmol, 1.2 equiv) dropwise via 
syringe down the side of the flask. Stirring continued for 1 h at -78° C, then the reaction
mixture was quenched by the addition of (z'Pr)2NEt (0.2 mL) followed by saturated aqueous 
NaHCO3 solution (3.0 mL). The reaction mixture was allowed to then reach rt. The phases 
were separated and the aqueous phase was extracted with Et2O (3 x 5 mL). The organic 
phases were combined, dried over Na2SO4, and concentrated under reduced pressure. 
Purification was accomplished by flash column chromatography using a 3.0 x 22.0 cm 
silica gel column, eluting with 25% EtOAc/hexanes, collecting 8 mL fractions. The 
product containing fractions (21-48) were combined and concentrated under reduced 
pressure to yield pyran 2.70 (124 mg, 55%) as a clear oil: Rf = 0.43 (30 % EtOAc/hexanes); 
500 MHz 1H NMR (CDCb) 5 7.70-7.65 (m, 4H), 7.46-7.30 (m, 11H), 7.18-7.23 (m, 2H),
6.86-6.82 (m, 2H), 6.00 (dd, J  = 16.1, 1.5 Hz, 1H), 5.89 (s, 1H), 5.45 (s, 1H), 5.39-5.31 
(m, 1H), 4.95 (dd, J  = 11.7, 5.4 Hz, 1H), 4.85 (d, J  = 2.0 Hz, 2H), 4.70 (s, 1H), 4.67 (s, 
2H), 4.61(d, J  = 10.7 Hz, 1H), 4.42 (d, J  = 10.7 Hz, 1H), 4.28-4.22 (m, 1H), 4.15-4.00 (m, 
2H), 3.88 (ddd, J  = 9.6, 4.4, 2.0 Hz, 1H), 3.79 (s, 3H), 3.69 (s, 3H), 3.66-3.61 (m, 1H), 
3.51-3.44 (m, 1H), 3.34-3.35 (m, 1H), 3.24 (s, 3H), 3.22-3.14 (m, 1H), 2.94 (s, 3H), 2.73­
2.69 (m, 2H), 2.38-2.10 (m, 3H), 2.06 (s, 3H), 2.04-2.x 02 (m, 2H), 1.99 (s, 3H), 1.96-1.79 
(m, 5H), 1.76-1.62 (m, 4H), 1.45 (s, 9H), 1.22 (d, J  = 6.3 Hz, 3H), 1.11 (s, 3H), 1.10 (s, 
3H), 1.03 (s, 9H), 0.88 (s, 3H), 0.83 (s, 3H); 125 MHz 13C NMR (CDCb) 5 198.2, 170.7,
169.4, 166.7, 159.4, 152.6, 144.7, 138.1, 137.8, 136.2, 136.0, 134.4, 133.7, 130.7, 130.0,
129.9, 129.5 (x2), 128.7, 128.0, 127.9, 127.8 (x2), 126.5, 117.2, 114.0 (x2), 104.1, 102.8,
93.6, 78.6, 77.4, 74.8, 74.4, 73.8, 72.5, 72.1, 68.5, 66.1, 55.5, 53.2, 51.5, 51.3, 48.5, 48.2,




Experimental Procedures and Analytical Data for Macrolactone 2.79
Me Me
(R)-4-((2S,4S,6S)- 4-acetoxy- 6-methoxy-5,5-dimethyl-6-(2-oxoethyl)tetra 
hydro-2#-pyran-2-yl)-3-((terf-butyldiphenylsilyl)oxy) butanoic acid (2.71). To a
stirring solution of thioester 2.16 (175 mg, 0.266 mmol, 1.0 equiv) in THF/H2O (5:1, 3 
mL) in a 15 ml rb flask at rt, was added #-bromosuccidimide (142 mg, 3.0 equiv) in a 
single portion. TLC analysis after 2 h indicated complete consumption of the thioester 
starting material. The mixture was quenched by the addition of saturated aqueous Na2S2O3 
solution (5 mL) and diluted with EtOAc (5 mL). The layers were separated and the aqueous 
layer was extracted with EtOAc (3 x 5 mL). The combined organic layers were dried over 
Na2SO4, filtered, and concentrated under reduced pressure. Purification was accomplished 
by flash column chromatography using a 2.0 x 8.0 cm silica gel column, eluting with 3% 
MeOH/17% EtOAc/hexanes, collecting 4 mL fractions. The product containing fractions 
(25-48) were combined and concentrated under reduced pressure to yield acid 2.71 (135 
mg, 87%) as a white foam: Rf = 0.50 (5:4:1 hexanes: EtOAc: MeOH); [«]2,0 = +21.0 (c =
1.0, CHCls); 500 MHz 1H NMR (CDCb) 5 9.65 (t, J  = 3.4 Hz, 1H), 7.72-7.62 (m, 4H), 
7.48-7.34 (m, 6H), 5.02 (dd, J  = 11.7, 4.9 Hz, 1H), 4.23 (dddd, J  = 6.4, 6.4, 4.8, 4.8 1H),
3.40 (dddd, J  = 11.7, 7.3, 3.9, 3.9 Hz, 1H), 2.99 (s, 3H), 2.60 (dd, J  = 10.7, 4.9 Hz, 1H), 
2.55 (t, J  = 3.4 Hz, 2H), 2.03 (s, 3H), 1.83 (ddd, J  = 14.7, 7.8, 7.8 Hz, 1H), 1.60 (ddd, J  =
14.2, 3.9, 3.9 Hz, 1H), 1.03 (s, 9H), 0.91 (s, 3H), 0.84 (s, 3H); 125 MHz 13C NMR (CDCb)
5 201.3, 176.8, 170.6, 136.0, 135.9, 133.4, 130.1, 130.0, 127.9, 104.1, 72.8, 69.0, 66.6,
48.7, 48.8, 45.8, 43.4, 43.1, 42.0, 32.9, 27.0, 21.3, 20.8, 19.4, 17.5. 125 MHz DEPT 13C 
NMR (CDCb) CH3 5 48.7, 27.0, 21.3, 20.8, 17.5; CH2 5 45.8, 43.4, 43.1, 32.9; CH 5
201.3, 136.0, 135.9, 130.1, 130.0, 127.9, 72.8, 69.0, 66.6; CH0 5 176.8, 170.7, 133.8,
133.4, 104.1, 42.0, 19.4; IR (neat) 2944, 2858, 1724, 1473, 1428, 1367, 1389, 1029 cm-1; 






silyl)oxy)butanoic acid (2.67). A 5 ml rb flask, was charged with N,N'-((1S,2S)-1,2- 
diphenylethane-1,2-diyl)bis(4-methylbenzenesulfon amide) (147 mg, 0.282 mmol, 3.0 
equiv) and heated to 90 °C under 0.2 mm Hg vacuum. After 18 h, the dry powder was 
cooled to rt, and the flask was flushed with Ar. CH2Cl2 (2 mL) was added via syringe and 
the suspension was cooled to 0 °C. Boron tribromide (27 |iL, 0.282 mmol, 3.0 equiv) was 
added dropwise via syringe and the mixture was then stirred for 1 h at rt. The solvent was 
removed under high vacuum and the flask was purged with Ar. A mixture of trimethyl(2- 
((tributylstannyl )methyl) allyl)silane (118 mg, 0.282 mmol, 3.0 equiv) and 2,6-di-tert- 
butyl-4-methylpyridine (58 mg, 0.282 mmol, 3.0 equiv) in CH2O 2 (1.5 mL + 0.5 mL rinse) 
was added via cannula. Stirring continued for 16 h under Ar.
To a stirring solution of aldehyde 2.71 (55 mg, 0.094 mmol, 1.0 equiv) and CH2O 2 (5 
mL) at -78 °C in a 15 ml rb flask, was added the previously prepared solution of (4S,5S)-
4,5- diphenyl-1,3-ditosyl-2-(2-((tri methyl silyl)methyl) allyl)-1,3,2-diazaborolidine 
dropwise via cannula. TLC analysis after 3 h at -78 °C indicated complete consumption of 
the aldehyde starting material. The mixture was quenched by the addition of pH 4 aqueous 
buffer (5 mL), then diluted with EtOAc (5 mL). The layers were separated and the aqueous 
layer was extracted with EtOAc (3 x 100 mL). The organic phases were combined, dried 
over Na2SO4 and concentrated by about 3/4 the volume under reduced pressure. Et2O/ 
hexanes (15 mL of 2:1) was added, #,^-((1S,2S)-1,2-diphenylethane-1,2-diyl)bis(4- 
methylbenzenesulfonamide) was recovered via filtration, and the solid was washed with 
copious amounts of 2:1 Et2O/hexanes. The filtrate was concentrated under reduced 
pressure and purification was accomplished by flash column chromatography using a 1.0 
x 10.0 cm silica gel column, eluting with 20% acetone/ hexanes, collecting 4 mL fractions. 
The product containing fractions (9-45) were combined and concentrated under reduced 
pressure to yield silane 2.67 (55 mg, 71%) as a colorless oil and as a 6:1 mixture of 
diastereomers as measured by NMR: Rf = 0.42 (5:4:1 hexanes: EtOAc: MeOH); [«]2,0 = 
+14.6 (c = 0.6, CHCb); 500 MHz 1H NMR (CDCb) 5 7.71-7.61 (m, 4H), 7.46-7.33 (m, 
6H), 5.10 (dd, J  = 11.7, 4.9 Hz, 1H), 4.64 (s, 1H), 4.61 (s, 1H), 4.26 (dddd, J  = 5.9, 5.9,
5.9, 5.9 1H), 4.08-4.02 (m, 1H), 3.64-3.56 (m, 1H), 2.94 (s, 3H), 2.57 (dd, J  = 15.1, 5.4 
Hz, 1H), 2.54 (dd, J  = 15.1, 6.8 Hz, 1H), 2.20 (dd, J  = 13.7, 5.9 Hz, 1H), 2.03 (s, 3H), 1.92 
(dd, J  = 13.7, 7.3 Hz, 1H), 1.88-1.83 (m, 1H), 1.79 (d, J  = 3.9 Hz, 1H), 1.68-1.48 (m, 4H), 
1.40-1.28 (m, 3H), 1.04 (s, 9H), 0.93 (s, 6H), 0.03 (s, 9H); 125 MHz 13C NMR (CDCb) 
5 170.8, 144.2, 136.0, 135.9, 133.8, 130.0, 127.9, 127.8, 110.4, 104.8, 73.3, 68.3, 67.4,
212
66.3, 49.1, 48.0, 46.0, 44.0, 42.5, 42.1, 39.4, 33.0, 28.5, 28.0, 27.1, 27.0, 21.4, 20.4, 19.4,
17.6, 13.8, -1.2; 125 MHz DEPT 13C NMR (CDCI3) CH3 5 49.0, 27.1, 21.4, 20.4, 17.6,
13.8, -1.2; CH2 5 110.4, 46.0, 44.0, 39.4, 33.0, 28.5, 28.0; CH 5 136.0, 135.9, 130.0, 127.9,
127.8, 73.3, 68.3, 67.4, 66.3; CH0 5 170.8, 144.2, 133.8, 104.8, 48.0, 42.5, 42.1, 19.4; IR 
(neat) 3071, 2905, 2855, 1739, 1633, 1432, 1420, 1252, 1106, 1112, 1071, 1034, 846, 711, 





butyldiphenylsilyl)oxy)butanoic acid (2.72).38 To a stirring solution of alcohol 2.67 (40 
mg, 0.056 mmol, 1.0 equiv), imidazole (19 mg, 0.280 mmol, 5.0 equiv), and CH2O 2 (1 
mL) in a 10 ml rb flask at 0 °C, was added TESCl (28 ^L, 0.168 mmol, 3.0 equiv) dropwise 
via syringe. TLC analysis after 2 h indicated complete consumption of the alcohol starting 
material. The mixture was quenched by the addition of saturated aqueous NaHCO3 
solution (5 mL) and diluted with EtOAc (10 mL). The layers were separated and the 
aqueous layer was extracted with EtOAc (3 x 10 mL). The combined organic layers were 
dried over Na2SO4, filtered, and concentrated under reduced pressure. Purification was 
accomplished by flash column chromatography using a 2.0 x 10.0 cm silica gel column, 
eluting with 20% EtOAc/hexanes, collecting 4 mL fractions. The product containing
fractions (14-45) were combined and concentrated under reduced pressure to yield TES 
ether 2.72 (44 mg, 95%) as clear oil: Rf = 0.56 (1:3:6 MeOH: EtOAc: hexanes); [«]2,0 = 
+19.1 (c = 0.6, CHCb); 500 MHz 1H NMR (CDCb) 5 7.74-7.62 (m, 4H), 7.48-7.34 (m, 
6H), 4.97 (dd, J  = 11.7, 4.9 Hz, 1H), 4.63 (s, 1H), 4.59 (s, 1H), 4.17-4.11 (m, 2H), 3.26 
(dddd, J  = 9.3, 6.4, 6.4, 2.9 1H), 2.95 (s, 3H), 2.68 (dd, J  = 15.1, 3.9 Hz, 1H), 2.54 (dd, J  
= 15.1, 7.3 Hz, 1H), 2.13 (dd, J  = 13.7, 5.9 Hz, 1H), 2.02 (s, 3H), 1.90-1.82 (m, 2H), 1.72 
(dd, J  = 16.1, 7.3 Hz, 1H), 1.56 (ddd, J  = 13.7, 5.9, 3.4 Hz, 1H), 1.50 (d, J  = 9.8 Hz, 1H), 
1.30 (ddd, J  = 12.2, 4.9, 2.9 Hz, 1H), 1.03 (s, 9H), 0.95 (t, J  = 7.8 Hz, 9H), 0.90 (s, 3H), 
0.89 (s, 3H), 0.59 (q, J  = 8.3 Hz, 6H), 0.03 (s, 9H); 125 MHz 13C NMR (CDCb) 
5 176.1, 170.8, 144.4, 136.1, 136.0, 133.8, 133.3, 130.1, 130.0, 127.9, 127.9, 127.9, 110.8,
104.5, 74.1, 69.0, 68.4, 65.6, 48.6, 48.4, 43.4, 42.6, 42.0, 39.8, 32.7, 27.0, 21.4, 20.9, 19.4,
17.2, 7.3, 5.7, -1.2; 125 MHz DEPT 13C NMR (CDCb) CH3 5 48.6, 27.0, 21.4, 20.9, 17.4; 
CH2 5 110.8, 48.4, 43.4, 42.6, 39.8, 32.7, 5.7; CH 5 136.1, 136.0, 130.1, 130.0, 127.9,
74.1, 69.0, 68.4, 65.6; CH0 5 176.1, 170.8, 144.4, 133.8, 133.3, 104.5, 42.0, 19.4, 7.3, - 
1.2; IR (neat) 3078, 2955, 2887, 1743, 1718, 1622, 1472, 1395, 1364, 1250, 1106, 1081, 









pyran-2-yl)-3-((terf-butyldiphenylsilyl)oxy) butanoate (2.79). To a stirring mixture of 
acid 2.72 (16 mg, 0.019 mmol, 1.2 equiv), Et3N (16 |iL, 0.116 mmol, 6.0 equiv), and 
toluene (2 mL) in a 10 mL round bottom flask at 0 °C, was added 2,4,6-trichlorobenzoyl 
chloride (9 ^L, 0.059 mmol, 3.0 equiv) dropwise via syringe. The reaction was allowed to 
proceed for 4 h at rt, after which time TLC analysis indicated complete consumption of the 
acid starting material. To a stirring mixture of this anhydride at 0 °C, was added a solution 
of alcohol 2.68 (9 mg, 0.016 mmol, 1.0 equiv) and DMAP (7 mg, 0.058 mmol, 3.0 equiv) 
in toluene (0.5 mL) dropwise via cannula. An additional toluene (0.2 mL) was used twice 
to rinse the remaining the alcohol residue from the flask via cannula. The reaction was 
allowed to proceed for 1 h at rt, after which time TLC analysis indicated complete 
consumption of the alcohol starting material. Purification was accomplished by directly 
loading the suspension onto a 1.0 x 5.0 cm silica gel flash column, rinsing with toluene, 
then eluting with 10% EtOAc/hexanes, collecting 4 mL fractions. The product containing
216
fractions (10-20) were combined and concentrated under reduced pressure to yield ester 
2.73 (18 mg, 82%) as a white foam: Rf = 0.45 (30% EtOAc/hexanes); 500 MHz 1H NMR 
(CDCb) 5 9.53 (d, J  = 7.8 Hz, 1H), 7.74-7.64 (m, 5H), 7.45-7.28 (m, 11H), 5.96-5.88 (m, 
2H), 5.37 (dd, J  = 5.9, 2.0 Hz, 1H), 4.98 (dd, J  = 11.7, 4.9 Hz, 1H), 4.83 (s, 1H), 4.66 (s, 
2H), 4.62 (s, 1H), 4.57 (s, 1H), 4.25-4.09 (m, 2H), 3.89 (dddd, J  = 10.3, 6.4, 6.4 Hz, 1H),
3.89 (dd, J  = 11.3, 11.3 Hz, 1H), 3.70 (s, 3H), 3.38-3.31 (m, 1H), 3.25 (s, 3H), 2.96 (s, 
3H), 2.54-2.46 (m, 2H), 2.27(t, J  = 11.7 Hz, 1H), 2.04 (s, 3H), 1.89 (s, 3H), 1.99-1.96 (m, 
1H), 1.75-1.60 (m, 2H), 1.55-1.44 (m, 2H), 1.30-1.22 (m, 5H), 1.20 (s, 3H), 1.19 (s, 3H),
1.00 (s, 9H), 0.94 (t, J  = 4.9 Hz, 9H), 0.90 (s, 3H), 0.86 (s, 3H), 0.58 (q, J  = 7.8 Hz, 6H), 
0.03 (s, 9H); 125 MHz 13C NMR (CDCb) 5 194.9, 170.7, 168.9, 167.1, 166.5, 137.9,
136.1, 136.0, 134.1, 133.6, 130.0, 129.9, 128.7, 128.0, 127.9, 127.8, 127.7, 126.8, 118.7,
110.8, 104.3, 102.6, 93.7, 74.1, 73.0, 71.8, 71.4, 69.8, 68.8, 68.7, 68.3, 65.3, 51.7, 51.5,
48.7, 48.4, 47.3, 43.5, 42.6, 42.0, 39.8, 35.8, 32.7, 32.1, 29.9, 27.5, 27.0, 24.1, 21.8, 21.5,





((benzyloxy)methoxy)butan-2-yl 4-((2S, 4S,6S)-4-acetoxy-6-((S)-2-hydroxy-4- 
((trimethylsilyl)methyl)pent-4-en-1-yl)-6-meth oxy-5,5-dimethyltetrahydro-2#- 
pyran-2-yl)-3-((tert-butyldiphenylsilyl)oxy) butanoate (2.74). To aldehyde 2.73 (12 mg,
0.010 mmol, 1.0 equiv) in a 4 mL vial, was added a solution of PPTS (0.1 M in EtOH, 20 
|iL, 0.002 mmol, 0.2 equiv) via syringe and the vial was sealed with a Teflon cap. TLC 
analysis after 12 h indicated complete consumption of the aldehyde starting material. The 
solution was brought to dryness under a steady stream of N2, dissolved in MeOH (1 mL), 
and stirred for 5 h. The mixture was quenched by the addition of saturated aqueous 
NaHCO3 solution (1 mL), then diluted with CH2Cl2 (10 mL) and H2O (10 mL). The layers 
were separated and the aqueous layer was extracted with CH2Cl2 (3 x 10 mL). The 
combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced 
pressure. Purification was accomplished by flash column chromatography using a 1.0 x
4.0 cm silica gel column, eluting with 10% EtOAc/hexanes, collecting 4 mL fractions. The 
product containing fractions (10-15) were combined and concentrated under reduced 
pressure to yield dimethyl acetal 2.74 (8 mg, 70%) as a clear oil: Rf = 0.53 (30% 
EtOAc/hexanes); 500 MHz 1H NMR (CDCb) 5 7.72-7.66 (m, 5H), 7.46-7.28 (m, 10H),
6.18 (d, J  = 16.1 Hz, 1H), 5.89 (s, 1H), 5.39-5.25 (m, 2H), 5.09 (dd, J  = 11.7, 4.9 Hz, 1H),
4.80 (s, 1H), 4.72-4.58 (m, 3H), 4.25 (ddd, J  = 11.4, 5.8, 5.8 Hz, 1H), 4.08 (ddd, J  = 12.5,
6.5. 6.5 Hz, 1H), 3.94-3.88 (m, 2H), 3.78 (dd, J  = 9.8, 9.8 Hz, 1H), 3.69 (s, 3H), 3.67-3.60 
(m, 1H), 3.53-3.44 (m, 1H), 3.28 (s, 3H), 3.26 (s, 3H), 3.00 (s, 3H), 2.60-2.40 (m, 3H),
2.28 (t, J  = 13.7 Hz, 1H), 2.23-2.14 (m, 1H), 2.04 (s, 3H), 1.99-1.82 (m, 3H), 1.75-1.50 
(m, 7H), 1.27 (s, 3H), 1.15 (d, J  = 6.4 Hz, 3H), 1.12 (s, 3H), 1.09 (s, 3H), 1.02 (s, 9H), 
0.93 (s, 3H), 0.85 (s, 3H), 0.04 (s, 9H); 125 MHz 13C NMR (CDCb) 5 170.7, 170.7, 169.5,
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166.7, 152.0, 144.5, 143.0, 138.0, 136.1, 136.0, 133.9, 133.6, 130.1, 128.6, 128.0, 127.9,
127.9, 121.6, 117.7, 110.3, 105.0, 104.3, 102.7, 93.7, 73.4, 73.3, 72.1, 71.9, 69.8, 68.3,
67.7, 67.3, 66.0, 64.2, 52.8, 51.5, 51.3, 51.4, 49.2, 46.3, 46.2, 43.8, 42.5, 42.1, 39.5, 36.2,
33.1, 32.5, 32.1, 29.9, 27.1, 24.7, 23.3, 22.9, 21.5, 21.3, 20.6, 20.5, 19.4, 17.6, 15.9, 14.3, 
- 1 .2 .
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(E)-methyl 2-((2^,3^,6^)-3-acetoxy-6-((2^,3^) -3-((benzyloxy)methoxy)-2- 
hydroxybutyl)-2-hydroxy-2-((E)-2-methyl-5-oxopent -3-en-2-yl)dihydro-2#-pyran- 
4(3#)-ylidene)acetate (2.77). To a stirring solution of PMB ether 2.25 (444 mg, 0.660 
mmol, 1.0 equiv) and CH2O 2/H2O (99:1, 15 mL) at 0 °C in a 50 ml rb flask, was added 
DDQ (225 mg, 0.990 mmol, 1.5 equiv). TLC analysis after 2 h at 0 °C indicated complete 
consumption of the PMB ether starting material. The mixture was quenched by the 
addition of saturated aqueous NaHCO3 solution (25 mL). The layers were separated and 
the aqueous layer was extracted with EtOAc (3 x 25 mL). The combined organic layers 
were dried over Na2SO4, filtered, and concentrated under reduced pressure. Purification 
was accomplished by flash column chromatography using a 3.0 x 14.0 cm silica gel 
column, eluting with 20% EtOAc/Hexanes (300 mL) and 30% EtOAc/Hexanes, collecting 
8  mL fractions. The product containing fractions (30-60) were combined and concentrated 
under reduced pressure to yield the crude alcohol.
To a stirring solution of this crude product in CH3CN (15 mL) at 0 °C in a 50 mL 
plastic bottle, was added HF (48% in H2O, 2.2 mL) dropwise via plastic syringe. The 
reaction mixture was stirred for 2 h at rt. The reaction mixture was quenched by pipetting 
into a stirring mixture of saturated aqueous NaHCO3 solution (50 mL) and EtOAc (50 mL). 
The layers were separated and the aqueous layer was extracted with EtOAc (2 x 50 mL). 
The combined organic layers were dried over Na2SO4, filtered, and concentrated under 
reduced pressure. Purification was accomplished by flash column chromatography using 
a 3.0 x 12.0 cm silica gel column, eluting with 50% EtOAc/Hexanes, collecting 8  mL 
fractions. The product containing fractions (14-50) were combined and concentrated under 
reduced pressure to yield alcohol 2.77 (306 mg, 87%) as a foam: Rf = 0.46 (60% 
EtOAc/hexanes); [oc]2  = -24.1 (c = 0.9, CHCb); 500 MHz 1H NMR (CDCb) 5 9.50 (d, J  
= 7.8 Hz, 1H), 7.32-7.21 (m, 5H), 5.95 (d, J  = 2.0 Hz, 1H), 5.90 (dd, J  = 16.1, 7.8 Hz, 1H),
5.05 (s, 1H), 4.78 (d, J  = 6 .8  Hz, 1H), 4.73 (d, J  = 6 .8  Hz, 1H), 4.56 (d, J  = 2.9 Hz, 1H),
4.25 (brs, 1H), 4.14 (dddd, J  = 11.0, 11.0, 2.1, 2.1 Hz, 1H), 3.73 (ddd, J  = 8.3, 3.9, 2.4 Hz, 
1H), 3.63 (s, 3H), 3.60 (d, J  = 2.0 Hz, 1H), 3.55 (dddd, J  = 6.4, 6.4, 6.4, 6.4 Hz, 1H), 2.09­
1.94 (m, 2H), 1.78 (s, 3H), 1.70 (ddd, J  = 13.7, 10.8, 2.5 Hz, 1H), 1.17 (d, J  = 6.4 Hz, 3H),
1.06 (s, 3H), 1.04 (s, 3H); 125 MHz 13C NMR (CDCb) 5 194.9, 169.0, 166.5, 166.4, 150.2,
137.5, 128.0, 127.6, 121.0, 99.9, 93.8, 77.6, 72.9, 71.0, 70.0, 67.0, 51.5, 46.6, 39.0, 31.3,
23.3, 21.5, 20.0, 16.8; 125 MHz DEPT 13C NMR (CDCb) CH3 5 51.5, 23.3, 21.5, 20.0, 
16.5; CH2 5 93.8, 70.0, 39.0, 31.3; CH 5 194.6, 166.5, 128.7, 128.1, 128.0, 127.6, 121.0,
77.6, 72.9, 67.0; CH0 5 169.0, 166.4, 150.2, 137.5, 99.9, 46.6; IR (neat) 3466, 2978, 2947, 
1750, 1724, 1689, 1440, 1378, 1212, 1165, 1095, 1037 cm-1; HRMS (ESI) calcd for 





idene)-6- ((E)-2-methyl-5-oxopent-3-en-2-yl) tetra hydro- 2#-pyran-2-yl)-3- 
((benzyloxy)methoxy)butan-2-yl 4-((2^,4^,6^)- 4-acetoxy-6-methoxy-5,5-dimethyl-6- 
((^)-2-((triethylsilyl)oxy)-4-((trimethylsilyl) methyl)pent-4-en-1-yl)tetrahydro- 2H- 
pyran-2-yl)-3-((terf-butyldiphenylsilyl)oxy) butanoate (2.78). To a stirring mixture of 
acid 2.72 (73.2 mg, 0.080 mmol, 1.1 equiv), Et3N (67 |iL, 0.482 mmol, 6.0 equiv), and 
toluene (2 mL) in a 10 mL round bottom flask at 0 °C, was added 2,4,6-trichlorobenzoyl 
chloride (14 ^L, 0.089 mmol, 1.1 equiv) dropwise via syringe. The reaction was allowed 
to proceed for 3h at rt, after which time TLC analysis indicated complete consumption of 
the acid starting material. To a stirring mixture of this anhydride at 0 °C, was added a 
solution of alcohol 2.77 (43.2 mg, 0.089 mmol, 1.0 equiv) and DMAP (29.0 mg, 0.241 
mmol, 3.0 equiv) in toluene (0.5 mL) dropwise via cannula. An additional toluene (0.2 
mL) was used twice to rinse the remaining alcohol residue from the flask via cannula. The 
reaction was allowed to proceed for 1 h at rt, after which time TLC analysis indicated 
complete consumption of the alcohol starting material. Purification was accomplished by 
directly loading the suspension onto a 3.0 x 12.0 cm silica gel flash column, rinsing with 
toluene, then eluting with 10% EtOAc/hexanes, collecting 4 mL fractions. The product
containing fractions (30-63) were combined and concentrated under reduced pressure to 
yield ester 2.78 (82 mg, 76%) as a white foam: Rf = 0.39 (30% EtOAc/hexanes); [«]2,0 = 
+0.8 (c = 1.0, CHCb); 500 MHz 1H NMR (CDCb) 5 9.57 (d, J  = 7.8 Hz, 1H), 7.74-7.62 
(m, 5H), 7.45-7.28 (m, 11H), 6.00 (s, 1H), 5.97 (dd, J  = 16.1, 7.8 Hz, 1H), 5.31-5.25 (m, 
2H), 5.12 (s, 1H), 4.93 (dd, J  = 11.7, 4.9 Hz, 1H), 4.83 (d, J  = 7.3 Hz, 1H), 4.79 (d, J  =
7.3 Hz, 1H), 4.66 (s, 2H), 4.62 (brs, 1H), 4.57 (brs, 1H), 4.19-4.09 (m, 2H), 3.89 (dq, J  =
5.9, 4.4 Hz, 1H), 3.85-3.80 (m, 1H), 3.69 (d, J  = 1.5 Hz, 1H), 3.66 (s, 3H), 3.34-3.26 (m, 
1H), 3.12 (s, 1H), 3.01-2.97 (m, 2H), 2.94(s, 3H), 2.57 (d, J  = 5.9 Hz, 2H), 2.05 (s, 3H),
2.02 (s, 3H), 1.99-1.96 (m, 1H), 1.88-1.86 (m, 2H), 1.56-1.44 (m, 2H), 1.30-1.22 (m, 5H), 
1.19 (s, 3H), 1.16 (s, 3H), 0.99 (s, 9H), 0.93 (t, J  = 4.9 Hz, 9H), 0.88 (s, 3H), 0.86 (s, 3H), 
0.56 (q, J  = 7.8 Hz, 6 H), 0.03 (s, 9H); 125 MHz 13C NMR (CDCb) 5 194.9, 172.4, 170.8,
169.0, 166.6, 166.5, 150.3, 144.5, 138.0, 136.2, 136.0, 134.1, 133.6, 130.0, 129.9, 128.7,
128.6, 128.0, 127.9, 127.8, 127.6, 121.2, 110.3, 99.6, 93.5, 74.2, 73.8, 72.9, 72.8, 69.9,
68.4, 68.0, 66.4, 65.2, 52.1, 51.4, 48.7, 48.4, 46.0, 43.5, 42.4, 42.0, 39.8, 36.7, 32.5, 31.0,
29.9, 27.5, 27.0, 23.2, 21.6, 21.4, 20.9, 20.2, 19.4, 17.2, 16.4, 7.3, 7.2, 5.7, -1.2; 125 MHz 
DEPT 13C NMR (CDCb) CH3 5 51.4, 48.4, 27.0 ,23.2, 21.6, 21.4, 20.9, 20.2, 17.2, 17.2,
16.4, 7.3, - 1 .2 ; CH2 5 110.3, 93.5, 69.9, 6 8 .0 , 48.7, 43.5, 42.4, 39.8, 32.5, 31.0, 27.5, 5.7; 
CH 5 194.9, 166.6, 136.2, 136.0, 130.0, 129.9, 128.7, 128.6, 128.0, 127.9, 127.8, 127.6,
1 2 1 .2 , 74.2, 73.8, 72.9, 72.8, 68.4, 66.4, 65.2; CH0 5 172.4, 170.8, 169.0, 166.5, 150.3,
133.6, 99.6, 52.1, 46.0, 42.0, 36.7, 29.9, 19.4, 7.2; IR (neat) 3472, 2956, 2887, 1746, 1693, 
1475, 1370. 1247, 1106, 1044, 880, 842, 706 cm-1; HRMS (ESI) calcd for C73H n 0NaO 17Sb 






tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-ene-12, 25-diyl diacetate (2.79). To 
aldehyde 2.78 (51 mg, 0.038 mmol, 1.0 equiv) in a 4 mL vial, was added a solution of 
PPTS (4 mM in EtOH, 1.9 mL, 0.008 mmol, 0.2 equiv) via syringe and the vial was sealed 
with a Teflon cap. TLC analysis after 14 h indicated complete consumption of the aldehyde 
starting material. The solution was brought to dryness under a steady stream of N 2, the 
residue was dissolved in MeOH (2 mL), and the resulting mixture was stirred for 5 h. The 
mixture was quenched by the addition of saturated aqueous NaHCO3 solution (1 mL), then 
diluted with CH2Q 2 (15 mL) and H2O (15 mL). The layers were separated and the aqueous 
layer was extracted with CH2Cl2 (3 x 15 mL). The combined organic layers were dried 
over Na2SO4, filtered, and concentrated under reduced pressure. Purification was 
accomplished by flash column chromatography using a 1 .0  x 8 . 0  cm silica gel column, 
eluting with 10% EtOAc/hexanes, collecting 4 mL fractions. The product containing 
fractions (15-45) were combined and concentrated under reduced pressure to yield 
bryopyran 2.79 (35 mg, 80%) as a white foam: Rf = 0.43 (30% EtOAc/hexanes); [«]2,0 =
+21.2 (c = 1.0, CHCb); 500 MHz 1H NMR (CDCb) 5 7.75-7.56 (m, 5H), 7.45-7.26 (m, 
11H), 6.01 (d, J  = 1.7 Hz, 1H), 5.97 (d, J  = 16.1 Hz, 1H), 5.52 (dd, J  = 15.9, 7.2 Hz, 1H),
5.26-5.19 (m, 2H), 5.12 (s, 1H), 4.82 (s, 1H), 4.81 (s, 1H), 4.65-4.58 (m, 2H), 4.54 (d, J  =
6.9 Hz, 1H), 4.51 (d, J  = 6.7 Hz, 1H), 4.48 (d, J  = 11.5 Hz, 1H), 3.99 (ddd, J  = 10.4, 7.5,
1.7 Hz, 1H), 3.90 (ddd, J  = 11.3, 8.1, 1.8 Hz, 1H), 3.71 (s, 3H), 3.65-3.59 (m, 2H), 3.54 
(ddd, J  = 10.6, 8.4, 1.4 Hz, 1H), 2.73 (s, 3H), 2.65 (dd, J  = 17.4, 3.4 Hz, 1H), 2.61 (s, 3H),
2.25 (dd, J  = 17.5, 9.9 Hz, 1H), 2.18-2.09 (m, 2H), 2.07 (s, 3H), 2.05 (s, 3H), 2.03-1.92 
(m, 2H), 1.71 (dd, J  = 7.8, 5.0 Hz, 2H), 1.67-1.59 (m, 2H), 1.56-1.50 (m, 2H), 1.44 (dd, J  
= 13.6, 10.3 Hz, 1H), 1.32-1.24 (m, 2H), 1.18 (s, 3H), 1.05 (d, J  = 6.4 Hz, 3H), 1.01 (s, 
9H), 1.00 (s, 3H), 0.94 (s, 6 H), 0.83 (s, 6 H); 125 MHz 13C NMR (CDCb) 5 171.0, 170.2,
169.4, 167.0, 151.2, 145.0, 138.0, 136.0, 135.8, 135.0, 135.3, 135.0, 134.3, 134.3, 134.2,
129.9, 129.8, 128.7, 128.1, 128.0, 127.9, 127.8, 120.2, 108.9, 103.0, 97.9, 93.8, 78.4, 74.4,
74.3, 73.1, 71.6, 69.7, 67.3, 65.0, 64.5, 51.4, 48.1, 45.4, 45.1, 42.7, 41.8, 41.5, 40.7, 39.8,
36.6, 33.7, 31.3, 29.9, 27.2, 24.3, 21.6, 21.5, 20.5, 20.1, 19.5, 17.5, 16.7, 14.3; 125 MHz 
DEPT 13C NMR (CDCb) CH3 5 51.4, 48.1, 27.2, 24.3, 21.6, 21.5, 20.5, 20.1, 16.7; CH2 
5 108.9, 130.0, 93.8, 69.7, 45.4, 42.7, 41.5, 40.7, 39.8, 36.6, 33.7, 31.3, 29.9; CH 5 136.0,
135.8, 135.3, 134.3, 134.2, 129.9, 129.8, 128.7, 128.1, 128.0, 127.9, 127.8, 120.2, 78.4,
74.4, 74.3, 74.3, 73.1, 71.6, 67.3, 65.0, 64.5; CH0 5 171.0, 170.2, 169.4, 167.0, 151.2,
145.0, 138.0, 135.0, 134.3, 129.8, 97.9, 45.1, 41.8, 19.5, 14.3; IR (neat) 3500, 3134, 3070, 
2954, 2858, 1759, 1672, 1587, 1513, 1463, 1442, 1240, 1177, 1046, 946, 822, 778, 706 
cm-1; HRMS (ESI) calcd for C64Hs6NaO 16Si (M+Na) 1161.5583, found 1161.5577.
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oxoethylidene)tetrahydro-2#-pyran-3-yl hex-5-ynoate (2.81). To a stirring solution of 
the TBS ether 2.49 (100 mg, 0.119 mmol, 1.0 equiv) in THF (3 mL) at rt in a plastic bottle, 
was added HF*py (20% in pyridine, 0.6 mL). TLC analysis after 6 h at rt indicated 
complete consumption of the TBS ether starting material. The mixture was quenched by 
pipetting into a stirring mixture of saturated aqueous NaHCO3 solution (30 mL) and EtOAc 
(30 mL). The layers were separated and the aqueous layer was extracted with EtOAc (2 x 
30 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated 
under reduced pressure. Purification was accomplished by flash column chromatography 
using a 2 x 17 cm silica gel column, eluting with 40% EtOAc/hexanes, collecting 8 mL 
fractions. The product containing fractions (15-24) were combined and concentrated under 
reduced pressure to yield alcohol 2.81 (80 mg, 93%) as a white foam: Rf = 0.30 (50% 
EtOAc/hexanes); [«]^0 = -3.1 (c = 1.1, CHCb); 500 MHz 1H NMR (CDCb) 5 7.40-7.18 
(m, 7H), 6.86-6.82 (m, 2H), 5.99 (d, J  = 15.6 Hz, 1H), 5.89 (s, 1H), 5.38 (dt, J  = 16.0, 6.3 
Hz, 1H), 5.45 (s, 1H), 4.86 (d, J  = 3.0 Hz, 2H), 4.68 (s, 2H), 4.62 (d, J  = 9.0 Hz, 1H), 4.42 
(d, J  = 10.7 Hz, 1H), ), 4.15 (dddd, J  = 11.1, 6.3, 6.3, 6.3 Hz, 1H), 4.10-4.01 (m, 2H), 3.91 
(ddd, J  = 9.6, 4.2, 1.5 Hz, 1H), 3.79 (s, 3H), 3.70 (s, 3H), 3.47 (dd, J  = 15.9, 2.1 Hz, 1H),
3.23 (s, 3H), 2.46 (t, J  = 7.8 Hz, 2H), 2.38-2.30 (m, 1H), 2.27 (dd, J  = 6.5, 2.6 Hz, 1H),
2.00 (dd, J  = 2.6, 2.6 Hz, 1H), 1.93 (ddd, J  = 14.2, 10.0, 1.5 Hz, 1H), 1.87-1.80 (m, 2H), 
1.74 (ddd, J  = 12.7, 9.8, 1.9 Hz, 1H), 1.22 (d, J  = 6.9 Hz, 3H), 1.13 (s, 3H), 1.10 (s, 3H); 
125 MHz 13C NMR (CDCI3) 5 171.7, 166.8, 159.4, 152.4, 139.7, 138.0, 130.6, 129.8,
129.5, 128.7, 128.0, 127.9, 125.1, 117.5, 114.0, 102.7, 93.5, 83.2, 76.7, 72.3, 71.9, 69.6,
68.6, 64.3, 55.4, 51.5, 46.2, 36.3, 33.2, 29.9, 24.2, 24.1, 23.3, 17.9; DEPT 13C NMR 
(CDCI3) CH3 5 55.4, 51.5, 24.2, 24.1; CH2 5 93.5, 71.9, 69.6, 64.3, 36.3, 33.2, 29.9, 23.3, 
17.9; CH 5 139.7, 129.8, 129.5, 128.7, 128.0, 127.9, 125.1, 117.7, 114.0, 83.2, 76.7, 72.3, 
69.7; CH0 5 171.7, 166.8, 159.4, 152.4, 138.0, 130.6, 102.7, 68.7, 46.2; IR (neat) 3496, 
3292, 2935, 1740, 1719, 1664, 1612, 1514, 1455, 1436, 1382, 1248, 1153, 1105, 1040, 




pyran-3-yl hex-5-ynoate (2.82). To a stirring solution of the allylic alcohol 2.81 (77 mg, 
0.106 mmol, 1.0 equiv) in benzene (2 mL) at rt in a 10 ml rb flask, was added activated 
MnO2 (267 mg, 3.1 mmol, 30.0 equiv). TLC analysis after 3 h indicated complete 
consumption of the allylic alcohol starting material. The reaction mixture was filtered over 
a pad (5.0 x 0.5 cm) of Celite®, washing with copious amounts of Et2O, and concentrated
under reduced pressure to give the crude aldehyde that was taken directly onto the next 
reaction without further purification.
To a stirring solution of the crude aldehyde in H2O ( 1 0 0  ^L) and CH2Q 2 (2 mL) at 
0 °C in a 10 ml rb flask, was added DDQ (47 mg, 0.206 mmol, 1.9 equiv). The reaction 
mixture was stirred for 4 h at 0 °C. The reaction mixture was quenched by transfer into a 
25 mL separatory funnel that contained a mixture of a saturated NaHCO3 solution (5 mL) 
and CH2Cl2 (5 mL). The aqueous layer was extracted with CH2Cl2 (2 x 5 mL), dried over 
Na2SO4, filtered, and concentrated under reduced pressure. Purification was accomplished 
by flash column chromatography using a 2 x 14 cm silica gel column, eluting with 20% 
EtOAc/hexanes, collecting 8  mL fractions. The product containing fractions (51-69) were 
combined and concentrated under reduced pressure to yield alcohol 2.82 (49 mg, 77%) as 
a white foam: Rf = 0.46 (50% EtOAc/hexanes); [«]“  = -15.0 (c = 1.0, CHCb); 500 MHz 
1H NMR (CDCb) 5 9.50 (d, J  = 7.6 Hz, 1H), 7.34-7.19 (m, 6 H), 5.88 (dd, J  = 15.6, 7.5 Hz, 
1H), 5.83 (s, 1H), 5.40 (s, 1H), 4.60 (ABq, J  = 11.7 Hz, Av = 24.2 Hz, 2H), 4.23-7.15 (m, 
1H), 3.82-3.75 (m, 1H), 3.63 (s, 3H), 3.58 (ddd, J  = 12.4, 6.2, 6.2 Hz, 1H), 3.45 (dd, J  =
15.6, 1.5 Hz, 1H), 3.37 (s, 3H), 2.68 (s, 1H), 2.36-2.11 (m, 5H), 1.93 (dd, J  = 2.8, 2.8 Hz, 
1H), 1.76-1.61 (m, 4H), 1.21 (d, J  = 6.0 Hz, 3H), 1.13 (s, 3H), 1.10 (s, 3H); 125 MHz 13C 
NMR (CDCb) 5 194.8, 171.2, 167.1, 166.5, 151.6, 137.5, 128.7, 128.0, 126.9, 117.9,
102.5, 94.0, 82.9, 78.3, 77.3, 71.7, 71.1, 70.1, 69.9, 6 8 .6 , 51.7, 51.5, 47.6, 39.8, 33.0, 32.9,
24.1, 23.2, 22.0, 17.8, 17.0; DEPT 13C NMR (CDCb) CH3 5 51.7, 51.5, 24.1, 22.0, 17.0; 
CH2 5 94.0, 70.1, 39.8, 33.0, 32.9, 23.2, 17.8; CH 5 194.8, 167.1, 128.7, 128.0, 126.9,
117.9, 78.2, 71.7, 71.1, 69.9, 6 8 .6 ; CH0 5 171.7, 166.8, 159.4, 152.4, 138.0, 130.6, 102.7,
68.7, 46.2; IR (neat) 3543, 3292, 2948, 1738, 1715, 1682, 1633, 1471, 1435, 1385, 1338,
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1038, 937, 744, 698 cm-1; HRMS (ESI) calcd for CssH44NaO 10 (M+Na) 623.2832, found 
623.2851.
(2S,3S,6SE)-6-((2R,3R)-2-(((R)-4-((2S,4S,6S) -4-acetoxy- 6-methoxy -5,5- 
dimethyl -6-((S)-2- ((triethylsilyl)oxy)-4-((tri methylsilyl)methyl)pent-4-en-1-yl) 
tetrahydro-2#-pyran-2-yl)-3- ((terf-butyldiphenyl silyl)oxy)butanoyl) oxy)-3- 
((benzyloxy) methoxy) butyl)-2-hydroxy -4-(2-methoxy-2-oxoethylidene)-2-((E)- 2- 
methyl-5-oxopent-3-en-2-yl)tetrahydro-2#- pyran-3-yl hex-5-ynoate (2.83). To a 
stirring solution of methyl ketal 2.82 (35 mg, 0.058 mmol, 1.0 equiv) in CH3CN/H2O (4:1,
1.5 mL) at 0 °C in a 5 mL plastic bottle, was added HF (48% in H2O, 150 |iL) dropwise 
via plastic syringe. TLC analysis after 6 h at rt indicated complete consumption of the 
ketal starting material. The reaction mixture was quenched by pipetting into a stirring 
mixture of saturated aqueous NaHCO3 solution (10 mL) and EtOAc (15 mL). The layers 
were separated and the aqueous layer was extracted with EtOAc (2 x 15 mL). The 
combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced 
pressure to give the crude hemiketal that was taken directly onto the next reaction without 
further purification.
Me Me
Separately, to a stirring solution of acid 2.72 (51 mg, 0.062 mmol, 1.1 equiv), Et3N 
(40 |iL, 0.280 mmol, 5.0 equiv), and toluene (1 mL) in a 10 mL round bottom flask at 0 
°C, was added 2,4,6-trichlorobenzoyl chloride (10 ^L, 0.062 mmol, 1.0 equiv) via syringe. 
The reaction was allowed to proceed for 4 h at rt, after which time TLC analysis indicated 
complete consumption of the acid starting material. To this stirring mixture of anhydride 
at 0 °C, was added a solution of crude alcohol and DMAP (7 mg, 0.058 mmol, 3.0 equiv) 
in toluene (0.5 mL) dropwise via cannula. Additional toluene (0.2 mL) was used twice to 
rinse the remaining alcohol residue from the flask via cannula. The reaction was allowed 
to proceed for 1 h at rt. Purification was accomplished by directly loading the suspension 
onto a 2  x 1 2  cm silica gel flash column, rinsing with toluene, then eluting with 2 0 % 
EtOAc/hexanes, collecting 4 mL fractions. The product containing fractions (60-78) were 
combined and concentrated under reduced pressure to yield ester 2.83 (55 mg, 70%) as a 
white foam: Rf = 0.32 (30% EtOAc/hexanes); [«]“  = -6.2 (c = 1.0, CHCb); 500 MHz 1H 
NMR (CDCb) 5 9.57 (d, J  = 7.9 Hz, 1H), 7.71-7.64 (m, 5H), 7.45-7.28 (m, 11H), 6.00 (s, 
1H), 5.98 (dd, J  = 16.5, 8.1 Hz, 1H), 5.28 (ddd, J  = 9.2, 3.9, 2.2 Hz, 1H), 5.14 (s, 1H), 4.93 
(dd, J  = 11.8, 4.8 Hz, 1H), 4.82 (ABq, J  = 7.0 Hz, Av = 21.7 Hz, 2H), 4.65 (s, 2H), 4.61 
(s, 1H), 4.57 (s, 1H), 4.20-4.08 (m, 2H), 3.92-3.86 (m, 1H), 3.86-3.78 (m, 1H), 3.35-3.26 
(m, 1H), 3.19 (s, 1H), 3.00-2.95 (m, 2H), 2.93 (s, 3H), 2.58 (d, J  = 5.5 Hz, 2H), 2.32-2.23 
(m, 1H), 2.21-2.16 (m, 2H), 2.12-2.04 (m, 1H), 2.02 (s, 3H), 1.98 (t, J  = 2.6 Hz, 1H), 1.94­
1.66 (m, 5H), 1.57-1.45 (m, 2H), 1.30-1.25 (m, 3H), 1.23 (d, J  = 6.3 Hz, 3H), 1.18 (s, 3H), 
1.16 (s, 3H), 0.98 (s, 9H), 0.93 (t, J  = 5.0 Hz, 9H), 0.88 (s, 3H), 0.86 (s, 3H), 0.64-0.54 (m, 
6 H), 0.04 (s, 9H); 125 MHz 13C NMR (CDCb) 5 194.8, 172.4, 171.2, 170.8, 166.5, 150.2,
137.8, 136.0, 134.1, 133.5, 130.0, 129.9, 128.7, 128.0, 127.9, 127.8, 127.7, 121.2, 110.8,
228
104.3, 99.7, 93.5, 83.0, 74.2, 73.7, 73.0, 72.8, 69.8, 68.4, 68.0, 66.4, 65.2, 51.4, 48.7, 48.4,
45.9, 43.5, 42.4, 42.0, 39.8, 36.7, 33.2, 31.1, 29.9, 27.5, 27.0, 23.2, 23.1, 21.4, 20.9, 20.3,
19.4, 17.8, 17.2, 16.3, 7.3, 5.6, -1.2; 125 MHz DEPT 13C NMR (CDCI3) CH3 5 51.4, 48.4,
27.0, 23.2, 21.4, 20.9, 20.3, 17.2, 16.3, 7.3, -1.2; CH2 5 110.8, 93.5, 69.8, 48.7, 43.5, 42.4,
39.8, 36.7, 33.2, 31.1, 29.9, 27.5, 23.2, 17.8, 5.6; CH 5 194.8, 166.5, 136.2, 136.0, 130.0,
129.9, 128.7, 128.0, 127.9, 127.8, 121.2, 74.2, 73.7, 73.0, 72.8, 69.8, 68.4, 68.0, 66.4, 65.2; 
CH0 5 172.4, 171.2, 170.8, 150.2, 144.5, 137.8, 134.1, 133.5, 104.2, 99.7, 83.0, 45.9, 42.0,
25.1, 19.4; IR (neat) 3479, 3306, 2951, 2733, 1738, 1732, 1688, 1633, 1471, 1455, 1385, 
1246, 1042, 855, 739, 702, 613 cm-1; HRMS (ESI) calcd for C73Hn0NaOnSi3 (M+Na) 
1417.7262, found 1417.7255.
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(3S,7R,8E,11S,12S, 13E,15S,17R, 21R,23S,25S)-25 -acetoxy- 17-((R) -1- 
((benzyloxy)methoxy)ethyl) -21-((tert-butyl diphenylsilyl)oxy) -11-hydroxy -1- 
methoxy-13-(2-methoxy-2-oxoethylidene)-10,10,26 ,26-tetramethyl-5-methylene-19- 
oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13’7.111’15] nonacos-8-en-12-yl hex-5-ynoate
(2.80). To aldehyde 2.83 (25 mg, 0.018 mmol, 1.0 equiv) in EtOH (1 mL) in a 4 mL vial, 
was added PPTS (1.8 mg, 0.007 mmol, 0.4 equiv). TLC analysis after stirring for 16 h
indicated complete consumption of the aldehyde starting material. The solution was 
brought to dryness under a steady stream of N 2, dissolved in MeOH (1 mL), and stirred for 
5 h. The mixture was quenched by the addition of saturated aqueous NaHCO3 solution (1 
mL), then diluted with CH2Cl2 (10 mL) and H2O (10 mL). The layers were separated and 
the aqueous layer was extracted with CH2Cl2 (3 x 10 mL). The combined organic layers 
were dried over Na2SO4, filtered, and concentrated under reduced pressure. Purification 
was accomplished by flash column chromatography using a 1 x 1 0  cm silica gel column, 
eluting with 15% EtOAc/hexanes, collecting 4 mL fractions. The product containing 
fractions (7-26) were combined and concentrated under reduced pressure to yield 
bryopyran 2.80 (14.6 mg, 70%) as a white foam: Rf = 0.34 (30% EtOAc/hexanes); [«]2,0 = 
+8.1 (c = 0.5, CHCb); 500 MHz 1H NMR (CDCb) 5 7.69-7.57 (m, 5H), 7.41-7.29 (m, 
11H), 6.01 (d, J  = 2.1 Hz, 1H), 5.97 (s, 1H), 5.52 (dd, J  = 16.3, 7.6 Hz, 1H), 5.26-5.19 (m, 
2H), 5.14 (s, 1H), 4.96-4.93 (m, 1H), 4.84-4.80 (m, 1H), 4.65-4.58 (m, 1H), 4.53 (ABq, J  
= 7.0 Hz, Av = 25.6 Hz, 2H), 4.49 (ABq, J  = 7.0 Hz, Av = 18.9 Hz, 2H), 3.99 (ddd, J  =
10.8, 7.4, 1.5 Hz, 1H), 3.93-3.87 (m, 1H), 3.71 (s, 3H), 3.65-3.59 (m, 2H), 3.57-3.51 (m, 
1H), 2.73 (s, 3H), 2.66 (dd, J  = 17.6, 3.5 Hz, 1H), 2.47 (t, J  = 7.6 Hz, 2H), 2.26 (dd, J  =
7.1, 2.9 Hz, 1H), 2.24 (dd, J  = 6.9, 2.6 Hz, 1H), 2.16-2.09 (m, 2H), 2.05 (s, 3H), 2.02-1.95 
(m, 3H), 1.92-1.81 (m, 3H), 1.75-1.60 (m, 3H), 1.57-1.51 (m, 2H), 1.45 (dd, J  = 13.5, 10.2 
Hz, 1H), 1.32-1.24 (m, 1H), 1.18 (s, 3H), 1.06 (d, J  = 6.3 Hz, 3H), 1.02 (s, 9H), 0.94 (s, 
6 H), 0.83 (s, 6 H); 125 MHz 13C NMR (CDCb) 5 171.6, 171.1, 170.3, 167.0, 151.2, 144.9,
137.9, 135.9, 135.8, 135.4, 135.0, 134.3, 134.0, 129.9, 129.8, 128.7, 128.1, 128.0, 127.9,
127.8, 120.3, 109.0, 103.0, 98.0, 93.8, 83.2, 78.5, 74.5, 74.4, 73.1, 71.6, 69.7, 69.6, 67.2,
65.0, 64.5, 51.5, 48.2, 45.4, 45.1, 42.7, 41.8, 41.4, 40.7, 39.9, 36.6, 33.3, 31.3, 29.9, 27.0,
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24.4, 23.4, 21.6, 20.5, 20.0, 19.6, 17.9, 16.7; 125 MHz DEPT 13C NMR (CDCI3) CH3 5
51.5, 48.2, 27.0, 24.2, 21.6, 20.0, 17.5, 16.7; CH2 5 109.0, 93.8, 69.7, 45.4, 42.7, 41.4,
40.7, 39.9, 36.6, 33.3, 31.3, 29.9, 23.4, 17.9; CH 5 135.9, 135.8, 135.4, 134.0, 129.9, 129.8,
128.7, 128.1, 128.0, 127.9, 127.8, 120.3, 78.5, 77.4, 74.5, 74.4, 73.1, 71.6, 67.2, 65.0, 64.5; 
CH0 5 171.6, 171.1, 170.3, 167.0, 151.2, 144.9, 137.9, 135.0, 134.3, 103.0, 98.0, 83.2, 45.1,
41.8, 19.6; IR (neat) 3508, 3309, 2930, 1738, 1667, 1633, 1471, 1455, 1385, 1246, 1154, 
1111, 852, 742, 702, 622 cm-1; HRMS (ESI) calcd for C68H90NaO 16Si (M+Na) 1213.5896, 
found 1213.5896.
231
(3S,7R,8E,11S,12S,13E,15S,17R,21R ,23R,25S) -25-acetoxy -1,11,21- 
trihydroxy-17 -((R)-1-hydroxyethyl) -13-(2-methoxy-2-oxoethylidene) -10,10,26,26- 
tetramethyl-5- methylene- 19-oxo-18,27,28,29-tetraoxa tetracyclo[21.3.1.13,7.111,15] 
nonacos-8-en-12-yl hex-5-ynoate (2.84). To a stirring solution of the BPS ether 2.80 (6.9 
mg, 0.0058 mmol, 1.0 equiv) in THF (0.5 mL) in a 4 mL plastic bottle, was added HF*py 
(20 % in pyridine, 0.1 mL). TLC analysis after 85 h at rt indicated complete consumption 
of the BPS ether starting material. The mixture was quenched by pipetting into a stirring 
mixture of saturated aqueous NaHCO3 solution (5 mL) and EtOAc (5 mL). The layers
were separated and the aqueous layer was extracted with EtOAc (3 x 5 mL). The combined 
organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure 
to give crude alcohol that was taken directly onto the next reaction without further 
purification.
To a stirring solution of the crude BOM ether in CH3CN/ H2O (25:1, 1 mL) in a 4 
mL vial, was added LiBF4 (22 mg, 0.232 mmol, 40.0 equiv). TLC analysis after stirring at 
80 °C for 18 h indicated complete consumption of the starting material. The reaction 
mixture was cooled to rt, quenched by the addition of saturated aqueous NaHCO3 solution 
(2 mL) and diluted with Et2O (5 mL). The layers were separated and the aqueous layer was 
extracted with Et2O (3 x 5 mL). The combined organic layers were dried over Na2SO4, 
filtered, and concentrated under reduced pressure. Purification was accomplished by flash 
column chromatography using a 0.5 x 4 cm silica gel column, eluting with 60% 
EtOAc/hexanes, collecting 1 mL fractions. The product containing fractions (7-12) were 
combined and concentrated under reduced pressure to yield bryopyran 2.84 (3.1 mg, 66%) 
as a clear film: Rf = 0.30 (60% EtOAc/hexanes); [«]“  = +1.1 (c = 0.8, CHCb); 500 MHz 
1H NMR (CDCb) 5 5.98 (s, 1H), 5.31 (dd, J  = 15.6, 8.5 Hz, 1H), 5.27 (s, 1H), 5.21 (ddd, 
J  = 12.0, 5.5, 2.8 Hz, 1H), 5.16 (dd, J  = 12.0, 4.9 Hz, 1H), 5.14 (s, 1H), 4.76 (d, J  = 7.4 
Hz, 1H), 4.31-4.23 (m, 1H), 4.22-4.14 (m, 1H), 4.03 (tt, J  = 11.0, 1.8 Hz, 1H), 3.85-3.79 
(m, 1H), 3.73-3.70 (m, 1H), 3.68 (s, 3H), 3.67-3.62 (m, 1H), 3.45 (dd, J  = 14.7, 7.4 Hz, 
1H), 2.51-2.41 (m, 2H), 2.27 (dd, J  = 6.9, 2.1 Hz, 1H), 2.25 (dd, J  = 6.9, 2.4 Hz, 1H), 2.16­
1.89 (m, 17H), 1.87-1.72 (m, 6H), 1.23 (d, J  = 7.5 Hz, 3H), 1.16 (s, 3H), 1.00 (s, 6H), 0.95 
(s, 3H); 125 MHz 13C NMR (CDCb) 5 172.5, 171.6, 171.0, 167.2, 151.8, 143.6, 138.8,
130.1, 120.0, 109.2, 102.1, 99.1, 83.2, 80.3, 77.4, 74.9, 73.9, 73.0, 72.2, 70.4, 69.6, 68.7,
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66.0, 64.9, 51.3, 45.0, 42.8, 42.7, 42.2, 40.1, 36.0, 33.4, 31.4, 29.9, 24.9, 23.5, 21.4, 21.2,
20.0, 18.0, 17.0; 125 MHz DEPT 13C NMR (CDCI3) CH3 5 51.3, 24.9, 21.4, 21.2, 20.0, 
17.0; CH2 5 109.2, 42.8, 42.2, 40.1, 36.0, 33.6, 33.4, 31.4, 29.9, 23.5, 18.0; CH 5 138.8,
130.1, 120.0, 80.3, 77.4, 74.9, 73.9, 73.0, 72.2, 70.4, 69.6, 66.0, 64.9; CH0 5 171.6, 172.5,
171.6, 171.0, 167.2, 151.8, 143.6, 102.1, 99.1, 83.2, 68.7, 45.0,; IR (neat) 3466, 330, 2919, 
2852, 2335, 1738, 1715, 1682, 1668, 1634, 1557, 1520, 1455, 1372, 1260, 1096, 802, 757, 
667 cm-1; HRMS (ESI) calcd for C43H ,2NaO 15 (M+Na) 841.3986, found 841.3997.
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7-(3-(4-(4-(((3S,7JR ,8 E ,m , 12S,13E,15S,17R,21R,23R,25S) -25-acetoxy-
1,11,21- trihydroxy- 17-((R)-1-hydroxy ethyl)-13-(2-methoxy-2-oxoethylidene)-
10,10,26,26-tetramethyl-5-methylene-19-oxo-18,27,28,29-tetraoxatetracyclo 
[21.3.1.13,7.111,15]nonacos-8-en-12-yl)oxy)-4-oxobutyl)-1H-1,2,3-triazol-1-yl)propyl) - 
5,5- difluoro- 1,3-dimethyl- 5H- dipyrrolo[1,2-c:2',1'-/j [1,3,2]diazaborinin-4-ium-5- 
uide (Merle 45). To a stirring solution of alkyne 2.84 (1.8 mg, 0.0022 mmol, 1.0 equiv) 
and THF (0.6 mL) in a 4 mL reaction vial, was added freshly distilled (/Pr)2NEt (2 |iL,
0.011 mmol, 5.0 equiv) and copper(I) iodide (2.1 mg, 0.011 mmol, 5.0 equiv). Azide 2.47 
(1.8 mg, 0.0066 mmol, 3.0 equiv) was added to the suspension, the reaction vial, was
sealed, and the mixture was allowed to stir at 70 °C for 18 h. The reaction suspension was 
cooled to rt, filtered over a pad (4.0 x 0.5 cm) of Celite®, washed with copious amounts of 
Et2O, and concentrated under reduced pressure. Purification was accomplished by flash 
column chromatography using a 0.5 x 4 cm silica gel column, eluting with 1% 
MeOH/CH2Cl2, collecting 1 mL fractions. The product containing fractions (6-11) were 
combined and concentrated under reduced pressure to yield Merle 45 (2.0 mg, 80%) as a 
white foam: Rf = 0.37 (5% MeOH/ CH2Ch); [a]^ = +4 (c = 0.05, CHCb); 500 MHz 1H 
NMR (CDCb) 5 7.34 (s, 1H), 7.10 (s, 1H), 6.89 (d, J  = 3.7 Hz, 1H), 6.26 (d, J  = 3.7 Hz, 
1H), 6.14 (s, 1H), 5.98 (s, 1H), 5.77 (d, J  = 15.8 Hz, 1H), 5.30 (dd, J  = 15.8, 8.5 Hz, 1H),
5.24 (s, 1H), 5.20 (ddd, J  = 11.5, 5.3, 2.5 Hz, 1H), 5.16 (dd, J  = 11.7, 4.6 Hz, 1H), 5.13 (s, 
1H), 4.75 (d, J  = 8.0 Hz, 1H), 4.40 (d, J  = 7.4 Hz, 1H), 4.29-4.13 (m, 2H), 4.05-3.98 (m, 
1H), 3.84-3.76 (m, 1H), 3.71-3.68 (m, 1H), 3.67 (s, 3H), 3.66-3.60 (m, 1H), 3.48 (dd, J  =
13.7, 6.7 Hz, 1H), 3.03 (d, J  = 7.1 Hz, 1H), 3.01 (d, J  = 7.5 Hz, 1H), 2.77-2.70 (m, 2H), 
2.57 (s, 3H), 2.52-2.32 (m, 9H), 2.26 (s, 3H), 2.13-1.88 (m, 17H), 1.86-1.73 (m, 1H), 1.23 
(d, J  = 3.3 Hz, 3H), 1.12 (s, 3H), 1.00 (s, 6 H), 0.96 (s, 3H); 125 MHz 13C NMR (CDCb) 
5 172.5, 171.9, 171.0, 167.2, 160.7, 157.0, 151.9, 147.1, 144.3, 143.6, 138.8, 135.4, 130.0,
128.4, 124.0, 121.3, 119.9, 116.9, 109.2, 102.1, 99.1, 80.2, 74.5, 73.9, 73.0, 72.2, 70.4,
68.7, 66.1, 65.9, 64.9, 51.3, 49.9, 45.0, 42.6, 42.1, 34.1, 33.6, 32.1, 30.1, 29.9, 25.0, 24.9,
24.6, 22.9, 21.4, 20.0, 17.0, 15.5, 15.2, 11.6; 125 MHz DEPT 13C NMR (CDCb) CH3 5
51.3, 24.9, 21.4, 2 0 .0 , 17.0, 15.5, 15.2, 1 1 .6 ; CH2 5 109.2, 66.1, 49.9, 42.6, 42.1, 41.3,
40.1, 34.1, 33.6, 32.1, 30.1, 29.9, 25.9, 24.6, 22.9; CH 5 138.8, 130.0, 128.4, 124.0, 121.3,
120.7, 119.9, 116.9, 80.2, 74.5, 73.9, 73.0, 72.2, 70.4, 68.7, 65.9, 64.9; CH0 5 172.5 171.9,
171.0, 167.2, 160.7, 157.0, 151.9, 147.1, 144.3, 143.6, 135.4, 130.0, 128.4, 102.1, 99.1,
234
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45.0,; IR (neat) 3362, 2919, 2851, 1738, 1715, 1667, 1633, 1537, 1454, 1372, 1258, 1088, 
798 cm-1; HRMS (ESI) calcd for C5?H78BF2N 5NaO 15 (M+Na) 1144.5453, found 
1144.5479.
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CHAPTER 3
THE SYNTHESIS OF THE CHROMENO[3,4-6]PYRROLE CORE.
Introduction
Fused pyrrolidine and chromene derivatives are common structural motifs of many 
natural products.1 The chromenopyrrole core does not appear in any natural products to 
date, but has potential therapeutic use as a dopamine receptor antagonist. The 3,4-fused 
chromenopyrrole core has 3 different constitutional isomers as shown in Figure 3.1A, 
where the nitrogen atom is placed at different positions in the pyrrole ring. The synthesis 
and biological effects of each isomer have been studied. Examples of biologically 
significant compounds containing the chromenopyrrole core are shown in Figure 3.1B. 
Methoctramin, a chromeno[4,3-6]pyrrole, is an antagonist of the muscarinic acetylcholine 
receptor (mAChR)2 and has shown selectivity for the M2 mAChR subtypes of the 
muscarinic receptors. Fiduxosin is an ala-adrenoreceptor antagonist, which is selective for 
this specific isozyme and is being developed for the treatment of benign prostatic 
hyperplasia (BPH).3 This drug contains a chromeno[3,4-c]pyrrole as part of its structure. 
Approaches to construct the 3,4-fused chromenopyrrole core are evaluated in the following 
sections.
A common way to construct chromeno[4,3-6]pyrrole ring systems is a [3 + 2] 
cycloaddition. An example of this methodology starts with the condensation of aldehyde 
3.1 with 2-(methylamino)acetic acid and after sonication, an azomethine ylide reacts with 
the olefin to produce the tricyclic core 3.2.4 This reaction works beautifully with a variety
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Figure 3.1. Constitutional Isomers of Chromenopyrroles (A) and 
Biologically Significant Chromenopyrroles (B)
of similar substrates. The Snider group also applied a similar 1,3-dipolar cycloaddition 
reaction (Figure 3.2) to the construction of this core that was used as a model for the 
pyrroloquinoline core during their studies toward the total synthesis of martinellic acid.5 
This reaction works well giving exclusively the cis-fused system 3.4.
More recently, chromeno[4,3-6]pyrrolone derivatives have been made using a 
radical addition-cyclization-elimination reaction (Figure 3.3). The synthesis of these 
tricyclic lactams start from the allylation of phenol 3.5 with K2CO3 and ethyl 4-bromobut- 
2-enoate to produce a,P-unsaturated ester 3.6. The resulting oxime was refluxed in benzene 
with AIBN and BmSnH, giving the cis (26 %) 3.7 and trans (24 %) 3.8 isomers, in a total 
of 50% yield. This reaction is tolerant to different substitution on the aromatic ring 
providing similar yields. Even though the yields are low, this method provides a concise 
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Figure 3.3. Synthesis of Chromeno [4,3-6] pyrrolone
The chromeno[4,3-c]pyrrole core has only been studied in a handful of peer 
reviewed articles6 and is patented in various accounts.7 Studies have shown that this 
particular motif is a selective dopamine D3 receptor antagonist potentially useful in treating 
psychotic disorders without neurological and endocrine side effects. Like the previously 
described synthesis of chromeno[4,3-6]pyrroline, a [3 + 2] cycloaddition was applied by 
the Lavielle group to construct the pyrrole of the chromeno[4,3-c]pyrrole system (Figure
3.4, part A). The synthesis began with an intermolecular 1,3-dipolar cycloaddition of the 
activated double bond of (E)-methyl 3-(2-methoxyphenyl)acrylate with an azomethine 
ylide to give the cis pyrrolidine 3.10. The methyl ester was then reduced with LAH and the 
methyl group was removed to give diol 3.11. A Mitsunobu reaction using DEAD and PPh3 
would complete the chromeno[4,3-6]pyrroline ring system 3.12. During Abbott’s process 
scale synthesis of Fiduxosin, an asymmetric [3+2] cycloaddition is utilized to install the 
pyrrolidyl ring system (Figure 3.4, part B).8 The cycloaddition uses the ylide derived from 
3.14, which reacts with coumarin 3.13 in the presence of a catalytic amount of TFA to give 
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Figure 3.4. Synthesis of Chromeno [3,4-c] pyrrole Core by 
Lavielle (A) and Abbott (B)
using crystallization, giving high enantiomeric purity with an overall yield of 43% of 
chromenopyrroline 3.15. Reduction of the lactone, followed by a methanol quench gave 
diol 3.16. Mesylation of the primary alcohol, displacement of the mesylate with the phenol, 
and removal of the chiral axillary gave chromeno[4,3-c]pyrrole 3.17. This synthesis 
improves the Lavielle group’s synthesis by applying an intermolecular asymmetric 1,3- 
dipolar cycloaddition providing process scale amounts of 3.17.
The Previous Synthetic Approaches 
In 1970, the Oppolzer group reported the first example of the synthesis of a 
chromeno[3,4-6]pyrrole core.9 This paper focused on the development of a 1,3-dipolar 
cycloaddition of nitrones and olefins to construct isoxazolidines. The route is shown in 
Figure 3.5A and does not contain all necessary reagents and yields, because they were not 
diclosed in the paper. The synthesis starts with the addition of phenol 3.18 into 
oxiranemethanol to give diol 3.19. Oxidative cleavage followed by condensation with 
methyl hydroxylamine gave nitrone 3.20. Upon heating the nitrone, a [3+2] cycloaddition 
with an a,P-unsaturated ester takes place to provide the cis isoxazolidine 3.21. The ethyl 
ester is then reduced and the resulting alcohol tosylated to produce tosyl ester 3.22. 
Subjecting the isoxazolidine to hydrogenation conditions breaks the N-O bond, the 
resulting free amine then displaces the -O Ts affording chromeno[3,4-6]pyrrole 3.23.
The chromeno[3,4-6]pyrrole core was patented in 1996 by Novo Nordisk 
pharmaceuticals as a D3 dopamine receptor selective ligand.10 Studies have shown that the 
D3 receptor is involved in neuropsychiatric disorders such as schizophrenia, drug 
addiction, depression and Parkinson’s disease.11 An example of the synthesis of a 
chromeno[3,4-6]pyrrole analog is given in the patent and is shown in Figure 3.5B. The 
synthesis starts from chromanone 3.24, which could be constructed in 4 steps following a 
literature procedure.12 The condensation of the ketone 3.24 with propylamine provided 
enamine 3.25. Formation of the pyrrolidine ring was accomplished by the reaction of 
enamine 3.25 with 1-bromo-chloroethane under basic conditions to provide tricyclic core 
3.26. The enamine was reduced using Adam’s catalyst, followed by the isolation of 































Figure 3.5. Oppolzer's (A) and Novo Nordisk's Design (B)
Results and Discussion 
Collaboration between the Keck group and Cephalon pharmaceuticals began in 
2008. One of the projects was to design and synthesize chromeno[3,4-6]pyrrole since there 
were very few published examples of its core construction. The Keck group was told very 
little about the biological significance of this scaffold, only that it would be used as a PKC 
modulator. 2 different routes were explored and are shown in the following sections.
The Construction of the Chromeno[3,4-&]pyrrole Core (Route I)
The chromeno[3,4-6]pyrrole system 3.29 was envisioned to be constructed through 
an intramolecular stannyl radical mediated addition cyclization reaction from oxime/ester 
3.30 (Figure 3.6, part A). This reaction would construct both the six and five fused ring of 
the tricyclic core. The cyclization precursor 3.30 would be synthesized from 2- 
hydroxybenzaldehyde using a Horner-Wadsworth-Emmons and alkylation reactions from 
commercially available phenol 3.31.
The synthesis started with the alkylation of phenol 3.31 with allyl bromide in the 
presence of K2CO3 . The aldehyde 3.32 is then transformed into the a,P-unsaturated ester 
using ethyl 2-(diethoxyphosphoryl)acetate and sodium hydride to provide 3.33 as an 18:1 
mixture of geometric isomers. The terminal olefin was cleaved using ozonolysis and the 
resulting aldehyde was converted to oxime ether 3.35. An intramolecular radical 
cyclization reaction was expected between oxime ether and a,P-unsaturated ester using the 
tributyl stannyl radical generated from Bu3SnH and AIBN. This reaction would form the 
C3-C4 bond and the resulting free amine would add into the ester to provide the fused 


























Figure 3.7. Intramolecular Radical Cyclization
the 1,4- reduction product 3.36 with no evidence of the desired compound 3.29. Similar 
results were observed when 3.35 was subjected to samarium(II) diiodide conditions. With 
these unfortunate observations, a tactical change was needed to construct the 
chromeno[3,4-b]pyrrole system.
The Construction of the Chromeno[3,4-&]pyrrole Core (Route II)
The chromeno[3,4-6]pyrrole ring system 3.28 was envisioned to be constructed by 
an intramolecular radical or Heck cyclization, as shown in Figure 3.8. The aryl iodide 3.37 
would be formed by a Mitsunobu etherfication between 2-iodophenol and 2- 
hydroxymethyl-3-pyrroline 3.39. This retrosynthetic plan allows interchanging of the 
phenol coupling partner providing diversification on the benzene ring.
Formation of the chromeno[3,4-6]pyrrole ring system began using a previously 
developed procedure to 2-hydroxymethyl-3-pyrroline 3.39 (Figure 3.9, part A).13 The
cyclization / \  & |
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Figure 3.9. 2-hydoxymethyl-3-pyrroline (A) and Mitsunobu Coupling (B)
sequence started with the esterification of commercially available trans-4-hydroxy-L- 
proline, which was achieved using thionyl chloride and methanol to give the methyl ester. 
The pyrrolidine amine was BOC protected using BOC2O to afford compound 3.42 in 86 % 
yield over 2 steps. The secondary alcohol was mesylated using MsCl and catalytic DMAP. 
Displacement of the mesylate with phenylselenide using diphenylselenide/NaBH4 afforded 
the phenylselenide intermediate 3.44. Oxidation of the phenylselenide with hydrogen 
peroxide and pyridine gave the phenylselenoxide which underwent syn-elimination to give
the olefin 3.45 as a single regioisomer in 74 % yield over 2 steps. Reduction of the ester 
with LAH in Et2O afforded the desired precursor alcohol 3.39.
2-hydroxymethyl-3-pyrroline was combined with either 2-iodophenol or 4-bromo- 
2-iodophenol using a Mitsunobu-type reaction providing 3.47 and 3.48 in good yields. The 
phenol 3.46 was made by the treatment of 4-bromophenol with NaI, NaOH, and NaOCl in 
methanol (Figure 3.9, part B).14
After producing the tethered aryl iodide 3.47, 2 types of cyclization reactions were 
investigated. First, a samarium mediated 6-exo-trig cyclization to give the chromeno[3,4- 
b]pyrrole ring system was explored.15 The cis fused ring system is expected based on 
previous observation.16 Unfortunately, the reduction of the alkyl iodide 3.47 with samarium 
(II) iodide in THF/HMPA produced both the desired product 3.49 and reduced product 
3.50 in almost equal amounts (Figure 3.10, part A). After a failed attempt using 
samarium(II) diiodide, a Heck coupling was explored. The Heck cyclization did not occur 
using common conditions with Pd(OAc)2, Et3N, PPh3, and DMF at 100°C. In the literature, 
a methodology was developed for the intermolecular coupling of 2,5-dihydropyrroles and 
aryl iodides using Pd(OAc)2, Ag2CO3, P(o-tol)3, and (iPr)2NEt as single regioisomers.
Applying these conditions to 3.47, the intramolecular Heck cyclization of 3.47 gave 
the desired chromeno[3,4-b]pyrrole core 3.51 (Figure 3.10, part B). A single olefin 
regioisomer was observed in accordance with previous reported results. Additionally, these 
conditions tolerated a bromide in the 4-position allowing further functionalization giving 
chromeno[3,4-b]pyrrole 3.52 on a gram scale. Further manipulations of 3.54 were explored 
(Figure 3.10, part C). The reduction of the enamine functionality was accomplished using 
Adams catalyst and H2 in acetone to selectively give 3.53 without compromising the aryl
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Figure 3.10. Samarium Mediated (A), Heck Cyclization (B), and 
Reduction/Deprotection (C)
bromide. The last step in this sequence was the removal of the BOC protecting group using 
TFA in CH2Cl2 to provide amine 3.54.
After the synthesis of the chromeno[3,4-b]pyrrole core 3.52, its structure was 
further confirmed by X-ray crystallographic analysis. This heavy atom X-ray crystal 
structure verified the absolute configuration at the cis ring fusion. Crystals of 3.52 were 
monoclinic having all dimensions of a = 7.4043(2) A, b = 5.55780(10) A, c = 18.9203(6) 
A, space group of P21. The ORTEP diagram of this structure is shown in Figure 3.11.
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Figure 3.11. Structure of 3.52 by X-ray Analysis 
Conclusion
In conclusion, this sequence demonstrated a viable route for a multigram synthesis 
of the biologically useful intermediate 3.52. This synthesis includes the incorporation of 
stereochemistry starting from the cheap commercially available starting material trans-4- 
hydroxy-L-proline. The Heck cyclization provided a robust method to construct the 
chromeno[3,4-b]pyrrole core. The versatility of this synthesis allows the preparation of 
various analogs by incorporating different substituents on the phenol coupling partner. This 
system can be further diversified independently at the amine position.
Experimental Section 
General Experimental Procedures, Materials, and Instrumentation
Solvents were purified according to the guidelines in Purification o f Common 
Laboratory Chemicals (Perrin, Armarego, and Perrin, Pergamon: Oxford, 1966).1 N,N- 
diisopropylethylamine, HMPA, pyridine, Et3N, EtOAc, and CH2Cl2 were distilled from
CaH2 . All other reagents were used without further purification. Yields were calculated 
for material judged homogenous by thin phase chromatography and nuclear magnetic 
resonance (NMR). Thin layer chromatography was performed on Merck Kieselgel 60 A 
F254 plates or Silicycle 60A F254 eluting with the solvent indicated, visualized by a 254 nm 
UV lamp, and stained with an ethenolic solution of 12-molybdophosphoric acid, 4- 
anisaldehyde, or an aqueous potassium permanganate solution. Flash column 
chromatography was performed with Silicycle flash silica gel 40 -  63 |im slurry packed 
with hexanes in glass columns. Glassware for reactions was oven dried at 125 °C and 
cooled under a dry nitrogen atmosphere prior to use. Liquid reagents and solvents were 
introduced by oven dried syringes through septum-sealed flasks under a nitrogen 
atmosphere. Nuclear magnetic resonance spectra were acquired at 500 MHz for 1H and 
125 MHz for 13C. Chemical shifts for proton nuclear magnetic resonance (1H NMR) 
spectra are reported in parts per million relative to the signal residual CDCl3 at 7.27 ppm. 
Chemicals shifts for carbon nuclear magnetic resonance (13C NMR and DEPT) spectra are 
reported in parts per million relative to the center line of the CDCb triplet at 77.23 ppm. 
Chemical shifts of the unprotonated carbons (‘C’) for DEPT spectra were obtained by 
comparison with the 13C NMR spectrum. The abbreviations s, d, dd, ddd, dddd, dq, t, and 
m stand for the resonance multiplicity singlet; doublet; doublet of doublets; doublet of 
doublet of doublets; doublet of doublet; of doublet of doublets; doublet of quartet; triplet; 
and multiplet, respectively. Optical rotations (Na D line) were obtained using a microcell 
with 1 dm path length. Specific rotations ([a]*0, Unit: °cm2/g) are based on the equation a 
= (1 0 0 a )/( lc ) and are reported as unitless numbers where the concentration c was in g/l00 
mL and the path length l was in decimeters. Mass spectrometry was performed at the mass
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spectrometry facility of the Department of Chemistry at The University of Utah on a double 
focusing high resolution mass spectrometer. Elemental analyses were performed by an 
out-of-house commercial analytical laboratory. Compounds were named using ChemDraw
11.0.1.
Experimental Procedures and Analytical Data for 3.39 and 3.46
The compounds 3.42, 3.43, 3.45, and 2.39 were previously prepared and are 
reported in the literature.13 The synthesis of pyrrole 2.39 was repeated on a larger scale to 
assess these for use in the present work. The procedure to compounds 3.42 and 3.45 were 
altered by purification using recrystallization instead of flash chromatography. Compound 
3.46 was also previously prepared and are reported in the literature.14 The experimental 
procedure and analytical data for pyrrole 2.39 and aryl iodide 3.46 are reproduced here for 




(3.42).13 To a stirring solution of trans-4-hydroxy-L-proline (50.3 g, 383 mmol, 1.0 equiv) 
in MeOH (480 mL) in a 1 L rb flask at 0 °C, was added SOCh (33.5 mL, 460 mmol, 1.2 
equiv). The reaction was stirred for 2 h at 0 °C, then for 2 h at reflux. The solution was 
cooled to rt and concentrated under reduced pressure. The crude ester was taken directly 
onto the next reaction without further purification.
To a stirring solution of this ester in CH2Q 2 (1.0 L) in a 2 L rb flask at 0 °C, was 
added Et3N (162 mL, 1.15 mol, 3.0 equiv). Stirring was continued for 5 min, and a solution 
of Boc2O (100 g, 460 mmol, 1.2 equiv) in CH2Q 2 (200 mL) was then added to the reaction 
mixture over 1.5 h via an addition funnel. The reaction was allowed to proceed for 15 h at 
rt. The organic phase was washed with aqueous NaHSO3 solution (2 x 600 mL of 1N), 
with aqueous citric acid solution (600 mL of 10%), and with brine (600 mL), then dried 
over MgSO4, filtered, and concentrated under reduced pressure. Purification was 
accomplished by recrystallization in EtOAc/hexanes. The resulting white solid was filtered 
and washed with ice cold hexanes to afford 3.42 (80.6 g, 86%). Analytical data: 1.3:1.0 
mixture of rotamers; Rf = 0.21 (50% EtOAc/hexanes); mp 92°-94°; 500 MHz 1H NMR 
(CDCb) 5 4.53-4.48 (br s, 1H), 4.45 (t, J  = 7.8 Hz, 1H, minor), 4.40 (t, J  = 7.1 Hz, 1H 
major), 3.75 (s, 3H, minor), 3.73 (s, 3H, major), 3.66 (d, J  = 3.9 Hz, 1H, minor), 3.63 (d, J  
= 3.9 Hz, 1H major), 3.56 (d, J  = 11.7 Hz, 1H, major), 3.46 (d, J  = 11.7 Hz, 1H minor), 
2.35-2.22 (m, 1H), 2.14-2.04 (m, 1H), 1.46 (s, 9H, minor), 1.42 (s, 9H, major); 125 MHz 
13C NMR (CDCb) 5 174.0 (major), 173.8 (minor), 154.9 (minor), 154.3 (major), 
80.7(major), 80.6 (minor), 70.3 (minor), 69.6 (major), 58.3 (major), 57.8 (minor), 55.0 
(minor), 54.9 (major), 52.6 (minor), 52.4 (major), 39.4 (major), 38.7 (minor), 28.7 (minor),
28.5 (major); 125 MHz DEPT 13C NMR (CDCb) CH3 5 52.5 (minor), 52.3 (major), 28.6 
(minor), 28.5 (major); CH2 5 54.9 (minor), 54.8 (major), 39.3 (major), 38.7 (minor); CH 5
70.3 (minor), 69.5 (major), 58.2 (major), 57.7 (minor); CH0 5 174.0 (major), 173.8 





(2»S,4^)-1-tert-butyl 2-methyl 4-(methylsulfonyloxy)pyrrolidine-1,2- 
dicarboxylate (3.43).13 To a stirring solution of alcohol 3.42 (39.6 g, 161 mmol, 1.0 equiv) 
in CH2Cl2 (500 mL) in a 1 L rb at 0 °C, were added DMAP (5.90 g, 48.0 mmol, 0.3 equiv) 
and Et3N (45.0 mL, 323 mmol, 2.0 equiv), followed by a solution of MsCl (25.0 mL, 323 
mmol, 2.0 equiv) in CH2Q 2 (40 mL) over 30 min via an addition funnel. TLC analysis 
after stirring at rt for 3 h indicated complete consumption of the starting material. The 
organic phase was washed with H2O (200 mL), with aqueous KHSO4 solution (200 mL of 
10%), with aqueous saturated NaHCO3 solution (200 mL), and brine (200 mL), then dried 
over MgSO4, filtered, and concentrated under reduced pressure. Purification was 
accomplished by recrystallization in EtOAc/hexanes. The resulting white solid was filtered 
and washed with ice cold hexanes to afford 3.43 (43.0 g, 82%). Analytical data: 1.0:1.7 
mixture of rotamers; Rf = 0.29 (50% EtOAc/hexanes); mp 105°-108°; 500 MHz 1H NMR 
(CDCb) 5 5.20-5.35 (m, 1H), 4.48 (t, J  = 7.8 Hz, 1H, minor), 4.41 (t, J  = 8.3 Hz, 1H major), 
3.86 (m, 1H, minor), 3.85 (m, 1H, major), 3.82-3.73 (m, 4H), 3.06 (s, 3H), 2.71-2.63 (m, 
1H, major), 2.61-2.54 (m, 1H, minor), 1.47 (s, 9H, minor), 1.43 (s, 9H, major); 125 MHz 
13C NMR (CDCb) 5 172.9 (major), 172.6 (minor), 154.1 (minor), 153.5 (major), 81.0, 78.5 
(minor), 78.2 (major), 57.6 (major), 57.3 (minor), 52.7, 52.5 (minor), 52.4 (major), 38.9 
(major), 38.8 (minor), 37.6 (major), 36.5 (minor), 28.5 (minor), 28.3 (major); 125 MHz 
DEPT 13C NMR (CDCb) CH3 5 52.6 (minor), 52.5 (major), 38.9, 28.5 (minor), 28.4 
(major); CH2 5 52.7 (minor), 52.4 (major), 37.6 (major), 36.5 (minor); CH 5 78.5 (minor),
78.2 (major), 57.6 (major), 57.3 (minor); CH0 5 172.9 (major), 172.6 (minor), 154.1 
(minor), 153.5 (major), 81.0.
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((»£)-1-tert-butyl 2-methyl 1H-pyrrole-1,2(2H,5H)-dicarboxylate (3.45).13 To a
stirring solution of mesylate 3.43 (43.0 g, 133 mmol, 1.0 equiv) in MeOH (450 mL) in a 1 
L rb flask at 0 °C, was added diphenyl diselenide (24.9 g, 79.9 mmol, 0.6 equiv). Stirring 
was continued for 5 min, and NaBH4 (6.60 g, 173 mmol, 1.3 equiv) was added in 4 large 
portions over 20 min. TLC analysis after stirring at reflux for 12 h indicated complete 
consumption of the starting material. The reaction mixture was quenched by pouring the 
mixture into a 2 L Erlenmeyer flask containing a stirring solution of H2O (500 mL) and 
CH2Cl2 (500 mL). The phases were separated and the organic phase was washed with H2O 
(2 x 100 mL), with aqueous HCl solution (2 x 100 mL of 1N), and with brine (100 mL). 
The organic phase was dried over MgSO4, filtered, and concentrated under reduced 
pressure. The crude selenide was taken directly onto the next reaction without further 
purification.
To a stirring solution of this selenide in CH2O 2 (450 mL, 0.3M) in a 1 L rb flask at 
0 °C, was added pyridine (15.0 mL, 186 mmol, 1.4 equiv), followed by a solution of 
aqueous H2O2 solution (23.0 mL of 30%, 200 mmol, 1.5 equiv) over 30 min via an addition 
funnel. TLC analysis after stirring at rt for 2 h indicated complete consumption of the 
starting material. The organic phase was washed with aqueous citric acid solution (150
mL of 10%), with aqueous saturated Na2SO3 solution (150 mL), and with brine (150 mL), 
then dried over MgSO4, filtered, and concentrated under reduced pressure. Purification 
was accomplished by flash column chromatography eluting with 5% and 10% 
EtOAc/hexanes to afford 3.45 (22.5 g, 74%) as a clear liquid. Analytical data: 1.0:1.6 
mixture of rotamers; Rf = 0.37 (30% EtOAc/hexanes); 500 MHz 1H NMR (CDCb) 5 6.00 
(dddd, J  = 4.4, 2.5, 2.5, 2.5 Hz, 1H, major), 5.95 (dddd, J  = 3.9, 2.0, 2.0, 2.0 Hz, 1H, 
minor), 5.76 (dddd, J  = 4.4, 2.5, 2.5, 2.5 Hz, 1H, minor), 5.72 (dddd, J  = 4.4, 2.4, 2.4, 2.4 
Hz, 1H, major), 5.26 (dddd, J  = 4.5, 2.4, 2.4, 2.4 Hz, 1H, minor), 4.97 (dddd, J  = 4.9, 2.4,
2.4, 2.4 Hz, 1H, major), 4.30-4.15 (m, 2H), 3.75 (s, 3H, minor), 3.74 (s, 3H, major), 1.49 
(s, 9H, minor), 1.44 (s, 9H, major); 125 MHz 13C NMR (CDCb) 5 171.1 (major), 170.8 
(minor), 153.9 (minor), 153.4 (major), 124.8 (minor), 124.7 (major), 80.2 (major), 80.1 
(minor), 6 6 . 6  (major), 66.3 (minor), 53.6 (minor), 53.3 (major), 52.3 (minor), 52.2 (major),
28.5 (minor), 28.3 (major); 125 MHz DEPT 13C NMR (CDCb) CH3 5 52.2, 28.5 (minor),
28.4 (major); CH2 5 53.6 (minor), 53.4 (major); CH 5 129.5 (minor), 129.4 (major), 124.8 
(minor), 124.7 (major), 66.7 (major), 66.3 (minor); CH0 5 171.1 (major), 170.8 (minor), 




(3.39).13 To a stirring solution of ester 3.45 (22.5 g, 99.1 mmol, 1.0 equiv) in ether (500 
mL) in a 1 L rb flask at 0° C, was added lithium aluminum hydride (4.10 g, 109 mmol,
1.10 equiv) in five portions over 30 mins. TLC analysis after stirring at rt for 1 h indicated 
complete consumption of the starting material. The reaction mixture was quenched by the
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addition of H2O (5 mL), with aqueous NaOH solution (5 mL of 15%), and then with an 
additional amount of H2O (15 mL). Stirring was continued for 1 h at rt. The solution was 
dried over MgSO4, filtered, and concentrated under reduced pressure. Purification was 
accomplished by flash column chromatography using 25% EtOAc/hexanes providing the 
alcohol 3.39 (15.8 g, 80%) as a clear liquid. Analytical data: 1.0:1.6 mixture of rotamers; 
Rf = 0.30 (30% EtOAc/hexanes); 500 MHz 1H NMR (CDCb) 5 5.97-5.90 (m, 1H, minor), 
5.84-5.79 (m, 1H, major), 5.72-5.67 (m, 1H, minor), 5.62 (m, 1H, major), 4.78-4.72 (m, 
1H, major), 4.66 (d, J  = 9.3 Hz, 1H), 4.65-4.57 (m, 1H, minor), 4.22-4.16 (m, 1H, major),
4.10 (ddd, J  = 5.37, 1.95, 1.95 Hz, 1H, major), 4.07 (ddd, J  = 4.88, 1.95, 1.95, Hz, 1H, 
minor), 3.97 (t, J  = 10.7 Hz, 1H), 3.69-3.62 (m, 1H, minor), 3.57 (ddd, J  = 11.5, 7.3, 1.7, 
1H, major), 1.51 (s, 9H, minor), 1.50 (s, 9H, major); 125 MHz 13C NMR (CDCb) 5 156.6,
127.8 (minor), 127.3 (minor), 127.0 (major), 126.9 (major), 80.7 (major), 80.4 (minor),
67.8 (minor), 67.2 (major), 66.4 (minor), 64.6 (minor), 54.4 (major), 54.3 (minor), 28.7; 
125 MHz DEPT 13C NMR (CDCb) CH3 5 28.6; CH2 5 67.2 (major), 64.6 (minor), 54.4 
(major), 54.2 (minor); CH 5 127.7 (minor), 127.3 (minor), 127.0 (major), 126.9 (major),
67.7 (major), 66.4 (minor); CH0 5 156.6, 80.7 (major), 80.4 (minor).
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4-bromo-2-iodophenol (3.46).14 To a stirring solution of 4-bromophenol (30. 8  g, 
179 mmol, 1.0 equiv) in 7:5 MeOH/H2O (600 mL) in a 2 L rb flask at 0 °C, was added Nal 
(26.4 g, 179 mmol, 1.0 equiv) and NaOH (7.20 g, 179 mmol, 1.0 equiv). Stirring was 
continued for 5 min, and an aqueous NaOCl solution (223 mL of 6 %, 170 mmol, 1.0 equiv)
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was then added to the reaction mixture over 30 min via an addition funnel. TLC analysis 
after stirring at rt for 1 h indicated complete consumption of the starting material. The 
reaction mixture was quenched by the addition of saturated aqueous Na2S2O3 solution (50 
mL), and aqueous KH2PO4 solution (300 mL of 10%). The resulting mixture was diluted 
with 80% EtOAc/hexanes (3 x 300 mL), the phases were separated, and the aqueous phase 
was extracted with 80% EtOAc/hexanes (2 x 300 mL). The organic phases were combined, 
dried over MgSO4, and concentrated under reduced pressure. Purification was 
accomplished by flash column chromatography eluting with 5% CH^Ch/hexanes to 
provide phenol 3.46 (37.8 g, 71%) as a white solid: Rf = 0.36 (50% CH2Ch/hexanes); mp 
70°-72°; 500 MHz 1H NMR (CDCb) 5 7.77 (d, J  =2.4 Hz, 1H), 7.36 (dd, J  = 8.4, 2.4 Hz, 
1H), 6.89 (d, J  = 8.9 Hz, 1H), 5.25 (s, 1H); 125 MHz 13C NMR (CDCb) 5 154.5, 140.1,
133.4, 116.6, 113.4, 86.5.
Experimental Procedures and Analytical Data Toward for 3.52 amd 3.54
(S)-tert-butyl 2-((2-iodophenoxy) methyl)-2,5- dihydro-lH- pyrrole-1- 
carboxylate (3.47). To a stirring solution of alcohol 3.39 (360 mg, 1.81 mmol, 1.0 equiv) 
in THF (9 mL) in a 25 ml rb flask, was added 2-iodophenol (438 mg, 1.99 mmol, 1.1 equiv)
diisopropyl azodicarboxylate (0.72 mL, 3.62 mmol, 2.00 equiv) was added dropwise. TLC 
analysis after stirring at rt for 5 h indicated complete consumption of the starting material. 
The reaction mixture was quenched by transfer into a 250 mL separatory or funnel that
and PPh3 (711 mg, 2.71 mmol, 1.5 equiv). The resulting solution was cooled to 0 °C and
contained a mixture of a 50 % EtOAc/hexanes (25 mL) and with aqueous NaOH solution 
(20 mL of 15%). The aqueous phase was extracted with 50% EtOAc/hexanes (2 x 25 mL). 
The combined organic phases were dried over MgSO4, filtered, and concentrated under 
reduced pressure. Purification was accomplished by flash column chromatography eluting 
with 5%, 10%, and 20% EtOAc/hexanes providing a mixture of product 3.47 (450 mg, 
62%) as a colorless oil. Analytical data: 1.0:1.2 mixture of rotamers; Rf = 0.75 (25% 
EtOAc/hexanes); [«]“  = -205 (c = 1.0, CHCb); 500 MHz 1H NMR (CDCb) 5 7.77 (d, J  
= 7.8 Hz, 1H, minor), 7.74 (d, J  = 7.7 Hz, 1H, major), 7.32-7.24 (m, 1H), 6.88 (d, J  = 8.3 
Hz, 1H, major), 6.82 (d, J  = 7.8 Hz, 1H, minor), 6.71 (ddd, J  = 15.9, 8.8, 7.7 Hz, 1H), 6.05­
5.88 (m, 2H), 4.92-4.86 (m, 1H, major), 4.85-4.78 (m, 1H, minor), 4.38-4.31 (m, 1H, 
major), 4.31-4.28 (m, 1H, minor), 4.24-4.14 (m, 2H, major), 3.95 (dd, J  = 7.3, 7.3 Hz, 1H, 
minor), 1.50 (s, 9H, minor), 1.48 (s, 9H, major); 125 MHz 13C NMR (CDCb) 5 157.4,
154.5 (major), 154.2(minor), 139.7 (minor), 139.5 (major), 129.7 (major), 129.6 (minor),
128.3 (minor), 128.1 (major), 127.3 (minor), 127.2 (major), 122.9 (minor), 122.7 (major),
112.5 (major), 112.3 (minor), 86.8 (minor), 86.5 (major), 80.3 (minor), 79.9 (major), 70.4 
(minor), 69.1 (major), 63.4 (major), 63.1 (minor), 54.4 (major), 54.1 (minor), 28.8; 125 
MHz DEPT 13C NMR (CDCb) CH3 5 28.8; CH2 5 70.4 (minor), 69.1 (major), 54.4 (major),
54.2 (minor); CH 5 139.7 (minor), 139.5 (major), 129.7 (major), 129.6 (minor), 128.3 
(minor), 128.2 (major), 127.3 (minor), 127.2 (major), 112.5 (major), 112.3 (minor), 63.4 
(major), 63.1 (minor); CH0 5 157.4, 154.5 (major), 154.2 (minor), 86.8 (minor), 86.5 
(major), 80.3 (minor), 79.9 (major); IR (neat) 2974, 2865, 1694, 1475, 1398, 1250, 1173, 




(S)-tert-butyl 2-((4-bromo- 2-iodophenoxy) methyl)-2,5-dihydro-1H-pyrrole- 
1-carboxylate (3.48). To a stirring solution of alcohol 3.39 (8.30 g, 41.7 mmol, 1.0 equiv.) 
in THF (300 mL) in a 500 mL rb flask at 0 °C, were added phenol 3.46 (24.9 g, 83.5 mmol,
2.0 equiv) and PPh3 (14.2 g, 54.3 mmol, 1.3 equiv), followed by diisopropyl 
azodicarboxylate (10.8 mL, 54.3 mmol, 1.3 equiv) dropwise. TLC analysis after stirring 
at rt for 5 h indicated complete consumption of the starting material. The reaction mixture 
was quenched by transfer into a 1 L separatory funnel that contained a mixture of a 50 % 
EtOAc/hexanes (250 mL) and with aqueous NaOH solution (200 mL of 15%). The layers 
were separated and the aqueous layer was extracted with 50% EtOAc/hexanes (2 x 250 
mL). The organic phases were combined, dried over MgSO4, filtered, and concentrated 
under reduced pressure. Purification was accomplished by flash column chromatography 
eluting with 5%, 10%, and 20% EtOAc/hexanes providing a mixture of product 3.48 (18.2 
g, 94%) as a colorless oil. Analytical data: 1.0:1.3 mixture of rotamers; Rf = 0.48 (25% 
EtOAc/hexanes); [afD0 = -168 (c = 1.0, CHCb); 500 MHz 1H NMR (CDCb) 5 7.86 (d, J  
= 2.4 Hz, 1H, minor), 7.84 (d, J  = 2.4 Hz, 1H, major), 7.39 (dd, J  = 1.9, 7.6 Hz, 1H, minor), 
7.37 (dd, J  = 2.4, 8.8 Hz, 1H, major), 6.75 (d, J  = 8.8 Hz, 1H, major), 6.75 (d, J  = 8.8 Hz, 
1H, minor), 5.98-5.96 (m, 1H), 5.95-5.94 (m, 1H, minor), 5.93-5.89 (m, 1H, major), 4.90­
4.84 (m, 1H, major), 4.83-4.78 (m, 1H, minor), 4.35-4.27 (m, 2H), 4.23-4.13 (m, 2H), 3.95 
(dd, J  = 8.8, 6.9 Hz, 1H, minor), 1.49 (s, 9H, minor), 1.48 (s, 9H, major); 125 MHz 13C 
NMR (CDCb) 5 156.9, 154.5 (minor), 141.5 (minor), 141.2 (major), 132.4 (major), 131.4 
(minor), 128.0 (minor), 120.0 (major), 127.6 (minor), 127.5 (major), 113.6 (minor), 113.5
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(minor), 113.3, 87.3 (major), 80.4 (minor), 80.1 (major), 70.6 (minor), 69.4 (major), 63.4 
(major), 63.1 (minor), 54.4 (major), 54.2 (minor), 28.9 (minor), 28.8 (major); 125 MHz 
DEPT 13C NMR (CDCb) CH3 5 28.9 (minor), 28.8 (major); CH2 5 70.7 (minor), 69.4 
(major), 54.4 (major), 54.2 (minor); CH 5 141.5 (minor), 141.2 (major), 132.4 (major),
132.4 (minor), 128.0 (major), 127.6 (minor), 127.5 (major), 113.6 (major), 113.4 (minor),
63.4 (major), 63.1 (minor); CH0 5 159.9, 154.5 (major), 154.2 (minor), 113.3, 87.6 (minor),
87.3 (major), 80.4 (minor), 80.1 (major); IR (neat) 3081, 2974, 2929, 2905, 2866, 1693, 
1626, 1561, 1459, 1399, 1332, 1279, 1247, 1173, 1124, 1039, 872, 802, 772, 716 cm-1; 
HRMS (ESI) calcd for C^H^NOsNaBr! (M+Na): 501.9491, found: 501.9502.
(3a»V,9b^)-tert-butyl 1,3a,4,9b-tetrahydrochromeno [3,4-b]pyrrole -3(2H)- 
carboxylatee (3.49). To a stirring solution of Sml2 (0.1 M solution in THF, 5.3 mL, 0.5 
mmol, 3.0 equiv)17 in a 25 ml rb flask, was added HMPA (0.4 mL, 2.5 mmol, 14.0 equiv). 
A solution of aryl iodide 3.47 (70 mg, 0.18 mmol, 1.0 equiv), ffiuOH (0.50 ^L, 0.53 mmol,
3.0 equiv), and THF (1 mL) was added dropwise via cannula, and rinsed with THF (2 x 
0.25 mL). After 30 min, additional Sml2 (0.1M solution in THF, 5.3 mL, 0.5 mmol, 3.0 
equiv) and HMPA (0.4 mL, 2.5 mmol, 14.0 equiv) were added and the deep purple color 
persisted. TLC analysis showed consumption of the starting material after 6 h. The 
reaction mixture was quenched by transfer into a 250 mL separatory funnel that contained 
a mixture of a CH2O 2 (50 mL) and pH 7 aqueous NaKPO4 solution (20 mL). The organic 
phase was washed with H2O (2 x 30 mL), brine (25 mL), dried over Na2SO4, filtered, and
NBoc
concentrated under reduced pressure. Purification was accomplished by flash column 
chromatography using 10% EtOAc/hexanes provides the tricyclic 3.49 (23 mg, 48%) and 
dehalogenated 3.50 (25 mg, 52%) as clear liquids. Analytical data: 2.0:1.0 mixture of 
rotamers; Rf = 0.31 (15% EtOAc/hexanes); [a]2D0 = -114.5 (c = 1.0, CHCb); 500 MHz 1H 
NMR (CDCb) 5 7.22-7.08 (m, 2H), 7.00-6.85 (m, 2H), 4.43-4.31 (m, 1H), 4.23-4.14 (m, 
1H, minor), 4.12-4.03 (m, 1H, major), 3.72 (ddd, J  = 9.3, 9.3, 9.3 Hz, 1H, minor), 3.58 
(ddd, J  = 10.3, 10.3, 10.3 Hz, 1H, major), 3.53-3.33 (m, 3H), 2.52-2.35 (m, 1H), 2.01 
(dddd, J  = 20.5, 19.7, 9.8, 9.8 Hz, 1H), 1.51 (s, 9H, major), 1.49 (s, 9H, minor); 125 MHz 
13C NMR (CDCb) 5 173.2, 154.9 (minor), 154.5 (major), 129.7 (major), 129,6 (minor),
127.8 (major), 127.7 (minor), 124.3 (minor), 124.4 (major), 121.6 (major), 121.4 (minor),
117.2 (minor), 117.2 (major), 80.2 (major), 79.9 (minor), 65.2 (major), 55.0 (minor), 53.6 
(minor), 53.3 (major), 45.7 (minor), 45.2 (major), 38.3 (major), 37.3 (minor), 33.5 (minor),
33.5 (major), 28.9; 125 MHz DEPT 13C NMR (CDCb) CH3 5 28.6; CH2 5 65.1 (major),
64.8 (minor), 45.5 (minor), 45.1 (major), 33.3 (minor), 32.4 (major); CH 5 129.6 (major),
129.5 (minor), 127.7 (major), 127.6 (minor), 121.4 (major), 121.3 (minor), 117.2 (minor),
117.0 (major), 53.5 (major), 53.1 (major), 38.0 (major), 37.2 (minor); CH0 5 173.2, 154.9 
(minor), 154.5 (major), 124.4 (major), 80.2 (major), 79.9 (minor); IR (neat) 2974, 2878, 
1693, 1583, 1489, 1455, 1394, 1231, 1176, 1122, 1044, 900, 758 cm-1; HRMS (ESI) calcd 




(3.50). Analytical data: 1.2:1.0 mixture of rotamers; Rf = 0.38 (15% EtOAc/hexanes); 
[a]2° = -195 (c = 1.0, CHCls); 500 MHz 1H NMR (CDCb) 5 7.32-7.22 (m, 2H), 7.00-6.88 
(m, 3H), 5.96-5.84 (m, 2H), 4.91-4.72 (m, 1H), 4.42-4.14 (m, 2H), 4.12-3.90 (m, 2H),
3.90 (ddd, J  = 7.8, 7.8, 7.8 Hz, 1H, minor), 1.50 (s, 9H, major), 1.48 (s, 9H, minor); 125 
MHz 13C NMR (CDCb) 5 159.0 (major), 1548.9 (minor), 154.4 (major), 154.2 (minor),
129.5 (major), 129.5 (minor), 128.3, 126.9 (major), 126.6 (minor), 121.0 (major), 120.8 
(minor), 114.9 (minor), 114.7 (major), 80.2 (minor), 79.7 (major), 69.5 (major), 68.4 
(minor), 63.6 (minor), 63.2 (major), 54.1 (minor), 53.9 (major), 28.7; 125 MHz DEPT 13C 
NMR (CDCb) CH3 5 28.7; CH2 5 69.5(major), 68.2 (minor), 54.2 (minor), 53.9 (major); 
CH 5 129.5 (major), 129.5 (minor), 128.3, 126.9 (major), 126.6 (minor), 121.0 (major),
1 2 0 . 8  (minor), 114.9 (minor), 114.7 (major), 63.5 (minor), 63.2 (major); CH0 5 159.0 
(major), 158.9 (minor), 154.4 (major), 154.2 (minor), 87.2 (minor), 79.7 (major); IR (neat) 
2975, 2867, 1697, 1599, 1497, 1396, 1246, 1173, 1109, 1040, 754, 692 cm-1; HRMS (ESI) 
calcd for C16H21NO3N  (M+Na): 298.1419, found: 298.1419.
(3a»S,9b»y)-terf-butyl 3a,4-dihydrochromeno[3,4-6]pyrrole-3(9b#)-carboxylate
(3.51). To a stirring solution of aryl iodide 3.47 (75 mg, 0.19 mmol, 1.0 equiv) in DMF (2 
mL), was added (z'Pr)2NEt (130 ^L, 0.75 mmol, 4.0 equiv) in a 10 ml rb flask. N 2 gas was
bubbled through the resulting solution for 1 h. Ag2CO3 (10 mg, 0.04 mmol, 0.2 equiv), tri- 
o-tolylphosphine (11 mg, 0.04 mmol, 0.2 equiv) and palladium(II) acetate (4 mg, 0.02 
mmol, 0.1 equiv) were added in one portion. TLC analysis after stirring at 90 °C for 26 h 
indicated complete consumption of the starting material. The mixture was cooled to rt then 
filtered through a small plug of Celite and washed with copious amounts of EtOAc. The 
organic phase was diluted with H 2O (10 mL), then the phases were separated and the 
aqueous phase was extracted with 20% EtOAc/hexanes (3 x 20 mL). The combined 
organic phases were dried over MgSO4, filtered, and concentrated under reduced pressure. 
Purification was accomplished by flash column chromatography eluting with 10% 
EtOAc/hexanes providing the pure tricyclic 3.51 as a colorless oil (41 mg, 80%). 
Analytical data: 1.0:1.3 mixture of rotamers; Rf = 0.38 (15% EtOAc/hexanes); [«]2,0 = -
115.0 (c = 1.0, CHCb); 500 MHz 1H NMR (CDCb) 5 7.24-7.08 (m, 2H), 6.98 (dd, J  =
13.7, 6.4 Hz, 1H), 6.91 (dd, J  = 13.7, 6.4 Hz, 1H), 6.64-6.60 (m, 1H, minor), 6.48-6.44 (m,
1H, major), 5.20-5.16 (m, 1H, minor), 5.08-4.02 (m, 1H, major), 4.62 (ddd, J  = 15.6, 10.3,
5.4 Hz, 1H), 4.58-4.50 (m, 1H, minor), 4.36 (d, J  = 9.7 Hz, 1H, minor), 4.30 (d, J  = 4.4 
Hz, 1H, major), 4.21 (dd, J  = 10.8, 4.4 Hz, 1H, major), 4.20-4.12 (m, 1H), 3.83 (dd, J  =
9.8, 9.8 Hz, 1H, minor), 1.57 (s, 9H, minor), 1.50 (s, 9H, major); 125 MHz 13C NMR 
(CDCb) 5 156.0 (major), 155.9 (minor), 129.4 (major), 129.3 (minor), 129.2 (major), 129.1 
(minor), 127.7, 124.7, 123.9, 122.3, 118.0 (major), 117.7 (minor), 112.2 (minor), 111.9 
(major), 81.2, 65.3 (major), 64.8 (major), 56.4 (major), 55.5 (major), 42.9 (minor), 41.9 
(major), 28.7; 125 MHz DEPT 13C NMR (CDCb) CH3 5 28.7; CH2 5 65.3 (major), 64.8 
(major); CH 5 129.4 (major), 129.3 (minor), 129.2 (major), 129.1 (minor), 127.7, 118.0 
(major), 117.7 (minor), 112.2 (minor), 111.9 (major), 56.4 (major), 55.5 (major), 42.9
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(minor), 41.9 (major); CH0 5 156.0 (major), 155.9 (minor), 127.7, 126.4 (minor), 124.7,
123.9, 81.2; IR (neat) 2979, 2937, 2878, 1715, 1470, 1350, 1270, 1240, 1180, 1104, 1091 
cm-1; Anal. Calcd for C 16H 18NO3 : C, 70.31; H, 7.01; N, 5.12; O, 17.56. Found: C, 69.60; 
H, 5.08;N, 3 .83 ;O, 3.82.
(3&S,9b»V)-tert-butyl 8-bromo-3a,4- dihydrochromeno [3,4-b]pyrrole-3(9bH)- 
carboxylate (3.52). To a stirring solution of aryl iodide 3.48 (15.2 g, 32.8 mmol, 1.0 equiv) 
in DMF (330 mL), was added (/Pr)2NEt (22.9 mL, 131 mmol, 4.0 equiv) in a 1 L rb flask. 
N 2 gas was bubbled through the resulting solution for 1 h. Ag2CO3 (1.80 g, 6.60 mmol,
0.2 equiv), tri-o-tolylphosphine (2.00 g, 6.60 mmol, 0.2 equiv) and palladium(II) acetate 
(0.70 g, 3.30 mmol, 0.1 equiv) were added in one portion. TLC analysis after stirring at 
90 °C for 90 h indicated complete consumption of the starting material. The mixture was 
cooled to rt then filtered through a small plug of Celite and washed with copious amounts 
of EtOAc. The organic phase was diluted with H 2O (500 mL), then the phases were 
separated and the aqueous phase was extracted with 25% EtOAc/hexanes (2 x 250 mL). 
The combined organic phases were dried over MgSO4, filtered, and concentrated under 
reduced pressure. Purification was accomplished by flash column chromatography eluting 
with 2%, 5%, and 10% EtOAc/hexanes providing the pure tricyclic 3.52 as a white solid 
(7.6 g, 70%). Analytical data: 1.0:1.3 mixture of rotamers; Rf = 0.36 (10%
EtOAc/hexanes); mp 83°-84°; [«]^0 = -81.2 (c = 1.1, CHCb); 500 MHz 1H NMR (CDCb) 
5 7.30 (d, J  = 11.2 Hz, 1H), 7.23 (d, J  = 8.3 Hz, 1H), 6.80 (d, J  = 8.8 Hz, 1H), 6.64-6.60
Br NBoc
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(m, 1H, minor), 6.54-6.45 (m, 1H, major), 5.19-5.10 (m, 1H, minor), 5.08-4.96 (m, 1H, 
major), 4.61 (ddd, J  = 14.8, 10.1, 4.8 Hz, 1H), 4.56-4.48 (m, 1H, minor), 4.33 (d, J  = 8.8 
Hz, 1H, minor), 4.25 (d, J  = 9.8 Hz, 1H, major), 4.24-4.10 (m, 2H), 3.83 (dd, J  = 9.8, 9.8 
Hz, 1H, minor), 1.57 (s, 9H, minor), 1.50 (s, 9H, major); 125 MHz 13C NMR (CDCb) 5
155.4 (major), 155.0 (minor), 151.8, 132.1 (minor), 131.9 (major), 130.9 (minor), 130.8 
(major), 130.1 (major), 129.8 (minor), 127.1 (major), 126.4 (minor), 122.0 (major), 119.8 
(minor), 114.5, 111.5 (minor), 111.2 (major), 87.7 (minor), 81.7 (major), 65.6 (major), 56.3 
(major), 55.4 (major), 44.0 (minor), 42.0 (major), 28.9; 125 MHz DEPT 13C NMR (CDCb) 
CH3 5 28.9; CH2 5 65.9 (major), 65.5 (minor); CH 5 132.4 (minor), 132.3 (major), 131.2,
130.0 (major), 130.2 (minor), 120.3 (major), 120.1 (minor), 111.8 (minor), 111.6 (major),
56.6 (major), 55.8 (minor), 43.4 (minor), 42.3 (major); CH0 5 155.4 (major), 155.0 (minor),
151.8, 127.1 (major), 126.4 (minor), 114.5, 87.7 (minor), 81.6 (major); IR (neat) 2975, 
2933, 2875, 1704, 1482, 1384, 1256, 1232, 1167, 1136, 1082 cm-1; HRMS (ESI) calcd for 
C 16H 18NO3NaBr (M+Na): 374.0368, found: 374.0370; Anal. Calcd for C 16H 18NO3Br: C, 
54.56; H, 5.15; N, 3.98. Found: C, 54.28; H, 5.13; N, 3.86.
(3&S,9b»V)- tert-butyl-8- bromo-1,3a,4,9b- tetrahydrochromeno[3,4-b] pyrrole- 
3(2H)-carboxylate (3.53). To a stirring solution of enamine 3.52 (1.02 g, 2.90 mmol, 1.0 
equiv) in acetone (30 mL) in a 50 mL 3 -necked rb flask, was added platinum oxide (33 
mg, 0.15 mmol, 0.05 equiv). The reaction flask was equipped with a hydrogen balloon. 
After 6 h at rt, the reaction mixture was filtered over a pad of Celite, and then washed with
Br NBoc
copious amounts of acetone. Purification was accomplished by flash column 
chromatography eluting with 10% EtOAc/hexanes providing reduced product 3.53 (0.98 
g, 96 %) as a white solid: Analytical data: 1.0:1.3 mixture of rotamers; Rf = 0.22 (10 % 
EtOAc/hexanes); mp 109°-110°; [a]2  = -160.0 (c = 1.1, CDCb); ); 500 MHz 1H NMR 
(CDCb) 5 7.29 (s,1H), 7.23 (d, J  = 8.3 Hz, 1H), 6.80 (d, J  = 8.8 Hz, 1H), 4.41-4.28 (m, 
1H), 4.19-4.11 (m, 1H, minor), 4.09-4.01 (m, 1H, major), 3.72 (ddd, J  = 10.3, 10.3, 10.3 
Hz, 1H, minor ), 3.57 (ddd, J  = 9.8, 9.8, 9.8 Hz, 1H, major), 3.50-3.28 (m, 3H), 2.46-2.33 
(m, 1H), 1.90 (dddd, J  = 18.3, 9.1, 9.1, 9.1 Hz, 1H), 1.51 (s, 9H, major), 1.49 (s, 9H, 
minor); 125 MHz 13C NMR (CDCb) 5 154.6 (minor), 154.4 (major), 154.0 (minor), 153.6 
(major), 132.2 (major), 132.1 (minor), 130.7 (major), 130.6 (minor), 126.7 (minor), 126.6 
(major), 119.1 (minor), 119.0 (major), 113.5 (major), 113.4 (minor), 80.2 (major), 79.9 
(minor), 65.2 (major), 65.0 (minor), 53.2 (minor), 52.9 (major), 45.5 (minor), 45.1 (major),
38.0 (major), 37.1 (minor), 33.3 (minor), 32.3 (major), 28.7; 125 MHz DEPT 13C NMR 
(CDCl3) CH3 5 28.7; CH2 5 65.3 (major), 65.1 (minor), 45.6 (minor), 45.2 (major), 33.3 
(minor), 32.4 (major); CH 5 132.3 (major), 132.2 (minor), 130.8 (major), 130.7 (minor),
119.2 (minor), 119.1 (major), 53.3 (minor), 53.0 (major), 38.0 (major), 37.2 (minor); CH0 
5 154.6 (minor), 154.4 (major), 154.0 (minor), 153.6 (major), 126.7 (minor),126.6 (major),
113.5 (major), 113.4 (minor), 80.2 (major), 79.9 (minor); IR (neat) 2975, 2878, 1695, 
1482, 1397, 1255, 1233, 1173, 1125, 1031 cm-1; Anal. Calcd for C^H^NOsBr: C, 54.25;




To a stirring solution of carbamate 3.53 (178 mg, 0.51 mmol, 1.0 equiv) in CH2O 2 (5 mL) 
in a 25 mL rb flask at 0 °C, was added trifluoroacetic acid (0.19 mL, 2.53 mmol, 5.0 equiv) 
dropwise. TLC analysis after stirring at rt for 6 h indicated complete consumption of the 
starting material. The reaction mixture was quenched by the slow addition of saturated 
aqueous NaHCO3 solution (5 mL) and diluted with CH2Cl2 (5 mL). The layers were 
separated and the aqueous layer was extracted with CH2Q 2 (2 x 5 mL). The organic phases 
were combined, dried over MgSO4, filtered, and concentrated under reduced pressure. 
Purification was accomplished by flash column chromatography eluting with 10% 
MeOH/CH2Cl2 providing deprotected product 3.54 (120 mg, 94%) as a white solid. 
Analytical data: Rf = 0.37 (10 % MeOH/ CH2O 2); mp 55°-56°; [a fD0 = -153.8 (c = 1.1, 
CDCb); ); 500 MHz 1H NMR (CDCb) 5 7.30 (dd, J  = 2.4, 1.0 Hz, 1H), 7.20 (dd, J  = 9.3,
2.5 Hz, 1H), 6.75 (d, J  = 8.8 Hz, 1H), 4.03 (dd, J  = 11.2, 3.4 Hz, 1H), 3.88 (dd, J  = 11.2,
6.3 Hz, 1H), 3.60-3.50 (m, 1H), 3.33 (ddd, J  = 7.3 7.3, 7.3 Hz, 1H), 3.09-2.95 (m, 2H ), 
2.41 (dddd, J  = 12.7, 7.8, 7.8, 4.9 Hz, 1H), 1.93 (br s, 1H), 1.83 (dddd, J  = 12.7, 7.3, 7.3,
7.3 Hz, 1H); 125 MHz 13C NMR (CDCb) 5 154.1, 132.9, 130.5, 129.1, 119.4, 113.9, 67.9,
55.5, 46.1, 38.7, 35.6; 125 MHz DEPT 13C NMR (CDCb) CH2 5 67.9, 46.1, 35.6; CH 5
132.9, 130.5, 119.4, 55.5, 38.7; CH0 5 154.1, 129.1, 113.9; IR (neat) 2957, 2916, 2871, 
1644, 1555, 1480, 1405, 1253, 1227, 1025, 815 cm-1; HRMS (ESI) calcd for 
CnHoNOsNaBr (M+Na): 254.0181, found: 254.0190; Anal. Calcd for C^H^NOsBr: C, 
51.99; H, 4.76; N, 5.51. Found: C, 51.87; H, 4.66; N, 5.42.
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APPENDIX A
1H, 13C, AND DEPT SPECTRA FOR CHAPTER 1
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u J laJj w y
i—i—i—I—i—r
4
1 1 1 1 1
2 1





13C NMR (125 MHz, CDCb)




DEPT NMR (125 MHz, CDCb)
i I i I i i | I i i i I i i i i | I I i ! I m i i — m — m — | i i i i | i i i — m —  i i i i |— m — m — [ i ■ i i |—  i i | i i i i | — tt -— n----------n— rp — rn — n— | I i i i | i i I i | i I i : | i
220 200 180 160 140 120 100 80 60 40 20 0 ppm
2.16.1
*H NMR (500 MHz, CDCb)







13C NMR (125 MHz, CDCb)
t i i i | i i i i | i i i i | i i i i | i i i ! | i i i i | i i i i | i i i i | i i i i | i i i i | i i i i | i i i i | i r
200 180 160 140 120 100
______ j!____________  ■ : .JI________________
1 | I I I I | I I I I | I I I 1 | I I I I | I I I I | I I I I | I I I I | I ! I I | I I I I | I I I I |
80 60 40 20 ppm
363
2.16.2
*H NMR (500 MHz, CDCb)
1
1—I—I--i------------------1—I—I—I—I—I-------------------- 1—I—I






13C NMR (125 MHz, CDCb)
I 'I I I | I I I I | I I I I | I I I I | i i i | i i i i | i i i r
180 160
I "I '| "I I I 'I I I I I T—|—r_T—|—T~|—[—[—I—I—f—
140 120 1002 0 0
80 60 40 20 ppm
365
2.16.3
*H NMR (500 MHz, CDCb)
aJu





13C NMR (125 MHz, CDCb)
________ _ ____________________________IULL L ....i ___________
T I I I | I I I I | I I I I | I I I I | I I I I | I I I I | I I I I | I I ! I | I I I I | I I I I | HI I I | I I I I | I I T
200 180 160 140 120 100
..... ... .... I__ ___ -_________ _________________________
i  pn i i i | i i i r - ] i i i i | i i i i | i i i i | i i i i | i i i i | i n  i | i i i i | i i i i |




*H NMR (500 MHz, CDCb)
10 9







13C NMR (125 MHz, CDCb)
i— —  i i i
200
l i i i i I i i i i I i i i I i i i i l i i i i | i
180 160 140











13C NMR (125 MHz, CDCb)
i I i i | i i i i | I i i i | I i i i | i i i i | i i i i | i i i I | i i ! I | i i i i | i i i i | n  i i | i i i i | i i i r
200 180 160 140 120 100
Lwlw*
T rn  "| r i I i | i I I i | i i h -|" i ■ i i i | riT T-p" n -|--[—i~ r -'i—i-|' i i i |
80 60 40 20 ppm
PMBO OH O
2.16.6







13C NMR (125 MHz, CDCb)
YfMWw ihU1
i i i i | i i i i | i i i i | i i i i | i i i i | i i i i | i i i r
200 180 160
I I | I I I I | II I I | ! I I I | I I I I |
140 120 100
I i i r i "| t  i I i | i i i i | i i i i | i t  t  i |  i r r  t \ t  i i | i i i  t ~\ (—(—|—T- 1 i i i ; |






*H NMR (500 MHz, CDCb)
374
2.16.7
13C NMR (125 MHz, CDCb)
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'HNM R (500 MHz, CDCb)
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DEPT NMR (125 MHz, CDCb)
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Merle 45 
13C NMR (125 MHz, CDCb)
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APPENDIX C
1H, 13C, DEPT SPECTRA AND CRYSTAL STRUCTURE REPORT
FOR CHAPTER 3
'HNM R (500 MHz, CDCb)
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DEPT NMR (125 MHz, CDCb)
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DEPT NMR (125 MHz, CDCb)
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DEPT NMR (125 MHz, CDCb)
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Completeness to theta = 27.87° 
Absorption correction 
Max. and min. transmission 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on F2 
Final R indices [I>2sigma(I)]
R indices (all data)
Absolute structure parameter 
Extinction coefficient 










a = 7.4043(2) A 
b = 5.55780(10) A 






0.45 x 0.43 x 0.10 mm3 
2.75 to 27.87°.
-9<=h<=9, -7<=k<=6, -24<=l<=24 
3178
3178 [R(int) = 0.0000]
98.8 %
Multi-scan 
0.7774 and 0.3817 
Full-matrix least-squares on F2 
3178/ 1 / 264 
1.019
R1 = 0.0394, wR2 = 0.0933 
R1 = 0.0432, wR2 = 0.0958 
0.015(11)
0.017(3)
1.061 and -0.854 e.A-3 about 0.805 A from
469
Table C.2. Atomic coordinates ( x 104) and equivalent isotropic displacement parameters 
(A2x 103)
x y z U(eq)
Br(1) 7989(1) 9890(1) 10005(1) 43(1)
O(1) 5744(3) -1461(5) 13607(2) 29(1)
O(2) 2737(3) -501(5) 13496(1) 19(1)
O(4) 9048(3) 4155(5) 12690(1) 23(1)
N(1) 4651(4) 982(6) 12730(2) 21(1)
C(2) 6439(4) 1563(7) 12463(2) 20(1)
C(3) 7419(5) 3248(7) 12980(2) 22(1)
C(5) 8749(4) 5424(6) 12075(2) 18(1)
C(6) 9983(5) 7211(7) 11917(2) 23(1)
C(7) 9773(5) 8546(7) 11308(2) 24(1)
C(8) 8295(5) 8045(7) 10854(2) 26(1)
C(9) 7076(5) 6280(7) 10994(2) 23(1)
C(10) 7271(4) 4919(8) 11612(2) 19(1)
C(11) 5983(5) 2896(7) 11756(2) 21(1)
C(12) 4024(5) 3595(8) 11845(2) 24(1)
C(13) 3330(4) 2396(7) 12375(2) 21(1)
C(14) 4465(4) -443(7) 13312(2) 20(1)
C(15) 2205(4) -1892(6) 14120(2) 18(1)
C(16) 202(5) -1345(8) 14141(2) 24(1)
C(17) 2524(5) -4540(6) 14002(2) 24(1)
C(18) 3214(6) -969(8) 14782(2) 26(1)
470



























































































































Table C.4. Anisotropic displacement parameters (A2x 103)for 3.52.
U11 U22 U33 U23 U 13 U 12
Br(1) 41(1) 59(1) 28(1) 21(1) 3(1) -3(1)
O(1) 19(1) 25(1) 44(2) 15(1) 3(1) 8(1)
O(2) 15(1) 20(1) 23(1) 8(1) 3(1) 1(1)
O(4) 16(1) 26(2) 27(1) 7(1) -4(1) 1(1)
N(1) 14(1) 22(2) 26(2) 6(1) 3(1) 5(1)
C(2) 15(1) 17(2) 29(2) -1(1) 7(1) 3(1)
C(3) 21(2) 24(2) 21(2) 8(1) 3(1) 2(2)
C(5) 16(1) 20(2) 19(1) 3(1) 3(1) 3(1)
C(6) 18(2) 23(2) 27(2) -5(1) 2(1) -2(1)
C(7) 22(2) 24(2) 25(2) 3(1) 6(1) -2(2)
C(8) 23(2) 33(2) 21(2) 5(2) 3(1) 7(2)
C(9) 18(2) 33(2) 19(2) 0(1) 2(1) -1(2)
C(10) 16(1) 22(2) 19(1) -5(2) 2(1) 2(2)
C(11) 18(2) 28(2) 17(2) -5(1) 3(1) -5(1)
C(12) 17(2) 35(2) 19(2) 3(2) -3(1) -2(2)
C(13) 14(1) 28(2) 20(2) 0(1) -1(1) 2(1)
C(14) 19(1) 14(2) 28(2) 4(1) 3(1) 2(1)
C(15) 19(2) 18(2) 17(2) 4(1) 2(1) -1(1)
C(16) 17(2) 29(2) 25(2) 2(2) 2(1) -1(2)
C(17) 29(2) 17(2) 26(2) 0(1) -1(1) -1(1)
C(18) 30(2) 25(2) 22(2) -3(1) -5(2) 1(2)
475
Table C.5. Hydrogen coordinates ( x 104) and isotropic displacement parameters (A2x 
103) for 3.52.
x y z U(eq)
H(7) 10540(50) 9730(100) 11204(18) 18(8)
H(2) 7080(40) -10(100) 12383(18) 18(8)
H(3B) 6720(50) 4540(90) 13110(20) 23(10)
H(17C) 2070(50) -5510(90) 14410(20) 22(10)
H(12) 3420(60) 4640(110) 11550(20) 35(11)
H(17A) 3700(60) -4830(110) 13990(20) 34(12)
H(17B) 1880(50) -4900(110) 13610(20) 31(11)
H(11) 6100(60) 1710(90) 11330(20) 31(12)
H(3A) 7800(60) 2440(90) 13400(20) 24(11)
H(6) 10950(70) 7670(90) 12230(30) 33(12)
H(16A) -260(60) -2190(90) 14540(20) 27(11)
H(18B) 2640(70) -1610(100) 15210(30) 39(14)
H(16C) 40(60) 380(110) 14200(20) 28(12)
H(13) 2090(60) 2490(90) 12580(20) 26(11)
H(18C) 2990(70) 810(100) 14880(30) 29(14)
H(9) 6140(90) 5900(120) 10750(30) 70(20)
H(18A) 4410(80) -1220(110) 14810(30) 54(17)
H(16B) -420(60) -1980(90) 13740(30) 27(12)
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j j__
I | I I I I | I I  I I | I I I I | I I I I  | I I I  I | I I I I | I I I I | I I I I | I I I ! | I I I I  | I I !  I | 1 I I I I  i I





DEPT NMR (125 MHz, CDCb)
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DEPT NMR (125 MHz, CDCb)
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